gene_symbol,uniprot_id,protein_name,sequence,pmids,dois,citation_titles,reviewed
GHR,P10912,Growth hormone receptor,MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP,,,"Growth hormone receptor and serum binding protein: purification, cloning and expression.; Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism.; Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor gene transcript.; Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein.; A membrane-fixed, truncated isoform of the human growth hormone receptor.; A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein.; Comparing of nucleotide sequences of alternatively spliced region of mammalian growth hormone receptor genes.; Functional characterization of the alternatively spliced, placental human growth hormone receptor.; Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution.; The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain.; Identification of a region critical for proteolysis of the human growth hormone receptor.; SOCS2 negatively regulates growth hormone action in vitro and in vivo.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels.; Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).; Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands.; Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.; Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9-A resolution.; Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase.; Laron dwarfism and mutations of the growth hormone-receptor gene.; Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome.; Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome.; Lack of hormone binding in COS-7 cells expressing a mutated growth hormone receptor found in Laron dwarfism.; A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization.; Mutations of the growth hormone receptor in children with idiopathic short stature.; Nine novel growth hormone receptor gene mutations in patients with Laron syndrome.; A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue.; Growth hormone receptor mutations in children with idiopathic short stature.; Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation.; Growth hormone receptor variant (L526I) modifies plasma HDL cholesterol phenotype in familial hypercholesterolemia: intra-familial association study in an eight-generation hyperlipidemic kindred.; The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of the GH receptor causing Laron syndrome: suppression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration.",False
GHRH,P01286,Somatoliberin,MPLWVFFFVILTLSNSSHCSPPPPLTLRMRRYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLGRQVDSMWAEQKQMELESILVALLQKHSRNSQG,,,"Cloning and sequence analysis of cDNA for the precursor of human growth hormone-releasing factor, somatocrinin.; Gene encoding human growth hormone-releasing factor precursor: structure, sequence, and chromosomal assignment.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor.; Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.; Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats.; N-terminome analysis of the human mitochondrial proteome.; Solution conformations of human growth hormone releasing factor: comparison of the restrained molecular dynamics and distance geometry methods for a system without long-range distance data.; Solution structure of human growth hormone releasing factor. Combined use of circular dichroism and nuclear magnetic resonance spectroscopy.; Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.",False
SHC1,P29353,SHC-transforming protein 1,MDLLPPKPKYNPLRNESLSSLEEGASGSTPPEELPSPSASSLGPILPPLPGDDSPTTLCSFFPRMSNLRLANPAGGRPGSKGEPGRAADDGEGIVGAAMPDSGPLPLLQDMNKLSGGGGRRTRVEGGQLGGEEWTRHGSFVNKPTRGWLHPNDKVMGPGVSYLVRYMGCVEVLQSMRALDFNTRTQVTREAISLVCEAVPGAKGATRRRKPCSRPLSSILGRSNLKFAGMPITLTVSTSSLNLMAADCKQIIANHHMQSISFASGGDPDTAEYVAYVAKDPVNQRACHILECPEGLAQDVISTIGQAFELRFKQYLRNPPKLVTPHDRMAGFDGSAWDEEEEEPPDHQYYNDFPGKEPPLGGVVDMRLREGAAPGAARPTAPNAQTPSHLGATLPVGQPVGGDPEVRKQMPPPPPCPGRELFDDPSYVNVQNLDKARQAVGGAGPPNPAINGSAPRDLFDMKPFEDALRVPPPPQSVSMAEQLRGEPWFHGKLSRREAEALLQLNGDFLVRESTTTPGQYVLTGLQSGQPKHLLLVDPEGVVRTKDHRFESVSHLISYHMDNHLPIISAGSELCLQQPVERKL,,,"A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.; Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway.; Characterization of human SHC p66 cDNA and its processed pseudogene mapping to Xq12-q13.1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Direct interaction between Shc and the platelet-derived growth factor beta-receptor.; Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses.; Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.; Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains.; Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.; Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation.; The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions.; Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors.; Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes.; Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src.; Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation.; Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation.; Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein.; Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase.; Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events.; A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.; Ligand discrimination in signaling through an ErbB4 receptor homodimer.; The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells.; Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.; The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter.; EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis.; TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.; Signal transduction via the stem cell factor receptor/c-Kit.; Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells.; Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.; Tyrosine phosphoproteomics of fibroblast growth factor signaling: a role for insulin receptor substrate-4.; A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria.; Serine and threonine phosphorylation of the low density lipoprotein receptor-related protein by protein kinase Calpha regulates endocytosis and association with adaptor molecules.; Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation.; Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.; A quantitative atlas of mitotic phosphorylation.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Copine-III interacts with ErbB2 and promotes tumor cell migration.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Role of herpes simplex virus VP11/12 tyrosine-based motifs in binding and activation of the Src family kinase Lck and recruitment of p85, Grb2, and Shc.; Temporal regulation of EGF signalling networks by the scaffold protein Shc1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; PEAK1 Y635 phosphorylation regulates cell migration through association with Tensin3 and integrins.; Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data.; Structure and ligand recognition of the phosphotyrosine binding domain of Shc.; Solution structure of the Shc SH2 domain complexed with a tyrosine-phosphorylated peptide from the T-cell receptor.",False
POU1F1,P28069,Pituitary-specific positive transcription factor 1,MSCQAFTSADTFIPLNSDASATLPLIMHHSAAECLPVSNHATNVMSTATGLHYSVPSCHYGNQPSTYGVMAGSLTPCLYKFPDHTLSHGFPPIHQPLLAEDPTAADFKQELRRKSKLVEEPIDMDSPEIRELEKFANEFKVRRIKLGYTQTNVGEALAAVHGSEFSQTTICRFENLQLSFKNACKLKAILSKWLEEAEQVGALYNEKVGANERKRKRRTTISIAAKDALERHFGEQNKPSSQEIMRMAEELNLEKEVVRVWFCNRRQREKRVKTSLNQSLFSISKEHLECR,,,"Cloning of the human cDNA for transcription factor Pit-1.; Nucleotide sequence of the complementary DNA for human Pit-1/GHF-1.; The structure and the chromosomal location of the human PIT1 gene.; A novel pituitary transcription factor is produced by alternative splicing of the human GHF-1/PIT-1 gene.; Characterization of the gene encoding human pituitary-specific transcription factor, Pit-1.; A 'hot spot' in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates.; The 9aaTAD Activation Domains in the Yamanaka Transcription Factors Oct4, Sox2, Myc, and Klf4.; Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency.; A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency.; Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia.; Cloning of a human GHF-1/Pit-1 cDNA variant.; A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.; Central hypothyroidism reveals compound heterozygous mutations in the Pit-1 gene.; Pro239Ser: a novel recessive mutation of the Pit-1 gene in seven Middle Eastern children with growth hormone, prolactin, and thyrotropin deficiency.; Combined pituitary hormone deficiency caused by compound heterozygosity for two novel mutations in the POU domain of the PIT1/POU1F1 gene.; Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency.; Identification and functional analysis of the novel S179R POU1F1 mutation associated with combined pituitary hormone deficiency.; Two novel mutations in the POU1F1 gene generate null alleles through different mechanisms leading to c ombined pituitary hormone deficiency.; Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD.",False
PROP1,O75360,Homeobox protein prophet of Pit-1,MEAERRRQAEKPKKGRVGSNLLPERHPATGTPTTTVDSSAPPCRRLPGAGGGRSRFSPQGGQRGRPHSRRRHRTTFSPVQLEQLESAFGRNQYPDIWARESLARDTGLSEARIQVWFQNRRAKQRKQERSLLQPLAHLSPAAFSSFLPESTACPYSYAAPPPPVTCFPHPYSHALPSQPSTGGAFALSHQSEDWYPTLHPAPAGHLPCPPPPPMLPLSLEPSKSWN,,,"Human Prop-1: cloning, mapping, genomic structure. Mutations in familial combined pituitary hormone deficiency.; Mutations in PROP1 cause familial combined pituitary hormone deficiency.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg-->Cys at codon 120 (R120C).; Combined pituitary hormone deficiency caused by a novel mutation of a highly conserved residue (F88S) in the homeodomain of PROP-1.; PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency.; Familial combined pituitary hormone deficiency due to a novel mutation R99Q in the hot spot region of Prophet of Pit-1 presenting as constitutional growth delay.; A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies.; Molecular analysis of novel PROP1 mutations associated with combined pituitary hormone deficiency (CPHD).",False
TP53,P04637,Cellular tumor antigen p53,MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD,,,"Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.; Characterization of the human p53 gene.; Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.; Molecular basis for heterogeneity of the human p53 protein.; A variation in the structure of the protein-coding region of the human p53 gene.; p53 is frequently mutated in Burkitt's lymphoma cell lines.; Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.; Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.; p53 isoforms can regulate p53 transcriptional activity.; P53 genomic sequence. Corrections and polymorphism.; Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8.; Identification of a tumor-rejection antigen recognized by HLA-B46 restricted CTL.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.; Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.; Study on the effect of tumor suppressor gene p53 in arsenism patients.; Detection of P53 gene mutations and serum p53 antibodies associated with cigarette smoking.; Mutation detection utilizing a novel PCR approach for amplification of the p53 gene from microdissected tissue: application to archival tumor samples.; Bcl6 and P53 gene mutations in tonsillar B cells.; Arginine methylation regulates the p53 response.; Allelic variant in intron 9 of TP53 gene.; The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.; The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.; Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.; The tumor suppressor p53 is bound to RNA by a stable covalent linkage.; Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen.; The human tumour suppressor gene p53 is alternatively spliced in normal cells.; Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.; p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.; Regulation of CAK kinase activity by p53.; Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.; Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15.; A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain.; Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.; Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.; Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry.; The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.; The function of PML in p53-dependent apoptosis.; p53 is involved in the p120E4F-mediated growth arrest.; The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein.; Zinc binding and redox control of p53 structure and function.; Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line.; hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.; p53 amino acids 339-346 represent the minimal p53 repression domain.; Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3.; Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.; SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.; Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes.; A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.; Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.; Differential effect of ik3-1/cables on p53- and p73-induced cell death.; Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.; Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.; Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.; p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.; Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305.; The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.; TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.; Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination.; iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.; Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).; Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.; Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.; The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle.; Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression.; A dynamic role of HAUSP in the p53-Mdm2 pathway.; Regulation of human p53 activity and cell localization by alternative splicing.; Regulation of p53 activity through lysine methylation.; A new effector pathway links ATM kinase with the DNA damage response.; Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.; A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73.; NIR is a novel INHAT repressor that modulates the transcriptional activity of p53.; Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif.; Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.; WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.; AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.; LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.; The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines.; Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon.; Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage.; Acetylation of the p53 DNA-binding domain regulates apoptosis induction.; Repression of p53 activity by Smyd2-mediated methylation.; Critical role for Daxx in regulating Mdm2.; Structural basis for the methylation site specificity of SET7/9.; Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression.; PRAK is essential for ras-induced senescence and tumor suppression.; Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation.; Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'.; A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.; SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53.; Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9.; Nine-amino-acid transactivation domain: establishment and prediction utilities.; CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation.; The notch regulator MAML1 interacts with p53 and functions as a coactivator.; Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death.; Dynamic regulation of p53 subnuclear localization and senescence by MORC3.; DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.; p53 is regulated by the lysine demethylase LSD1.; Modulation of p53 function by SET8-mediated methylation at lysine 382.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53.; Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes.; NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.; Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.; Hbo1 Links p53-dependent stress signaling to DNA replication licensing.; Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.; Plk1-mediated phosphorylation of Topors regulates p53 stability.; MSL2 promotes Mdm2-independent cytoplasmic localization of p53.; MTA1 coregulator regulates p53 stability and function.; Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein.; Two mammalian MOF complexes regulate transcription activation by distinct mechanisms.; JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation.; Trim24 targets endogenous p53 for degradation.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; TAF6delta orchestrates an apoptotic transcriptome profile and interacts functionally with p53.; USP10 regulates p53 localization and stability by deubiquitinating p53.; A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response.; Isoform specific phosphorylation of p53 by protein kinase CK1.; p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.; Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.; G9a and Glp methylate lysine 373 in the tumor suppressor p53.; G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis.; BRD7 is a candidate tumour suppressor gene required for p53 function.; RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.; Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence.; Initial characterization of the human central proteome.; NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor.; E3 ubiquitin ligase Hades negatively regulates the exonuclear function of p53.; Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression.; Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.; A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.; A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation.; p53 opens the mitochondrial permeability transition pore to trigger necrosis.; The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest.; Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses.; ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis.; PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53.; p53 regulates Period2 expression and the circadian clock.; MOZ increases p53 acetylation and premature senescence through its complex formation with PML.; Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.; S100A4 interacts with p53 in the nucleus and promotes p53 degradation.; DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected].; Disruption of FAT10-MAD2 binding inhibits tumor progression.; Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 activity through ATP synthase.; Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.; RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.; PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.; SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.; LACE1 interacts with p53 and mediates its mitochondrial translocation and apoptosis.; DDX3 localizes to the centrosome and prevents multipolar mitosis by epigenetically and translationally modulating p53 expression.; USP3 stabilizes p53 protein through its deubiquitinase activity.; DAZAP2 acts as specifier of the p53 response to DNA damage.; De novo mutations activating germline TP53 in an inherited bone-marrow-failure syndrome.; A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity.; Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6-deficient mice.; VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.; Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains.; The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an inhibitor of p53 signaling during viral reactivation.; ZNF768 links oncogenic RAS to cellular senescence.; Ser392 phosphorylation modulated a switch between p53 and transcriptional condensates.; Phase separation of p53 induced by its unstructured basic region and prevented by oncogenic mutations in tetramerization domain.; Phosphorylation and specific DNA improved the incorporation ability of p53 into functional condensates.; Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis.; High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.; Solution structure of the tetrameric minimum transforming domain of p53.; Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.; Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.; Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.; Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.; Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.; Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.; Structural basis of DNA recognition by p53 tetramers.; Molecular recognition of p53 and MDM2 by USP7/HAUSP.; Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.; The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression.; p53: at the crossroads of molecular carcinogenesis and risk assessment.; p53 mutations in human cancers.; Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses.; Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.; Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution.; Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.; Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.; Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core.; Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.; Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs.; Structure Determination of the Transactivation Domain of p53 in Complex with S100A4Using Annexin A2 as a Crystallization Chaperone.; Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population.; A germ line mutation in exon 5 of the p53 gene in an extended cancer family.; Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.; Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.; Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.; Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.; Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.; p53 mutations in colorectal cancer.; Frequent mutation of the p53 gene in human esophageal cancer.; Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors.; p53 gene mutations in Barrett's epithelium and esophageal cancer.; Mutational hotspot in the p53 gene in human hepatocellular carcinomas.; Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.; Frequent p53 mutations in head and neck cancer.; Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.; The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma.; A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.; p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.; An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.; p53 alterations in human squamous cell carcinomas and carcinoma cell lines.; The incidence of p53 mutations increases with progression of head and neck cancer.; Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors.; Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.; A temperature-sensitive mutant of human p53.; Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.; Germline mutations in the TP53 gene.; An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.; Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.; Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer.; Drastic genetic instability of tumors and normal tissues in Turcot syndrome.; Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample.; A germline missense mutation R337C in exon 10 of the human p53 gene.; Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.; p53 and human cancer: the first ten thousand mutations.; An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.; Investigations on a clinically and functionally unusual and novel germline p53 mutation.; The consensus coding sequences of human breast and colorectal cancers.; Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas.; Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.; DBC1 functions as a tumor suppressor by regulating p53 stability.; Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle Progression through Def Recruitment of Calpain3.",False
TERT,O14746,Telomerase reverse transcriptase,MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD,,,"hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.; Telomerase catalytic subunit homologs from fission yeast and human.; Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT).; Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.; Differential alternative splicing expressions of telomerase reverse transcriptase in gastrointestinal cell lines.; Sequence of a BAC carrying the entire hTERT gene.; The DNA sequence and comparative analysis of human chromosome 5.; Regulated expression of telomerase activity in human T lymphocyte development and activation.; Human telomerase contains evolutionarily conserved catalytic and structural subunits.; Reconstitution of human telomerase activity in vitro.; Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding.; Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.; Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707.; Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1 and reduces the telomere length.; Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells.; Immunohistochemical localization of hTERT protein in human tissues.; Nucleolin interacts with telomerase.; Functional organization of repeat addition processivity and DNA synthesis determinants in the human telomerase multimer.; Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT.; An anchor site-type defect in human telomerase that disrupts telomere length maintenance and cellular immortalization.; Telomerase with mutated catalytic motifs has dominant negative effects on telomerase activity and inhibits cell growth.; The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation.; Purification of human telomerase complexes identifies factors involved in telomerase biogenesis and telomere length regulation.; Characterization of physical and functional anchor site interactions in human telomerase.; The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity.; Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase.; Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway.; PML-IV functions as a negative regulator of telomerase by interacting with TERT.; Telomerase modulates Wnt signalling by association with target gene chromatin.; Human telomerase reverse transcriptase (hTERT) Q169 is essential for telomerase function in vitro and in vivo.; A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis.; Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo.; The DEAH-box RNA helicase RHAU binds an intramolecular RNA G-quadruplex in TERC and associates with telomerase holoenzyme.; The AAA-ATPase NVL2 is a telomerase component essential for holoenzyme assembly.; Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation.; Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.; HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex.; TERT promoter mutations in familial and sporadic melanoma.; ATF7 mediates TNF-alpha-induced telomere shortening.; Crystal structure of HLA-A*2402 complexed with a telomerase peptide.; Cryo-EM structure of substrate-bound human telomerase holoenzyme.; Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.; Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia.; Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita.; Coronary artery disease and a functional polymorphism of hTERT.; Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation.; Mutations in telomerase catalytic protein in Japanese children with aplastic anemia.; Functional characterization of natural telomerase mutations found in patients with hematologic disorders.; Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.; Telomerase mutations in families with idiopathic pulmonary fibrosis.; Adult-onset pulmonary fibrosis caused by mutations in telomerase.; Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene.; Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.; Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.; Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase.; Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells.; Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis.; Pulmonary fibrosis, bone marrow failure, and telomerase mutation.; FARSA mutations mimic phenylalanyl-tRNA synthetase deficiency caused by FARSB defects.",False
ATM,Q13315,Serine-protein kinase ATM,MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV,,,"The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species.; The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation.; Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; Mutations revealed by sequencing the 5' half of the gene for ataxia telangiectasia.; Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of ATM gene expression.; A single ataxia telangiectasia gene with a product similar to PI-3 kinase.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genomic organization of the ATM locus involved in ataxia-telangiectasia.; The product of the ATM gene is a 370-kDa nuclear phosphoprotein.; The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage.; Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms.; ATM gene product phosphorylates I kappa B-alpha.; Interaction between ATM protein and c-Abl in response to DNA damage.; Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.; ATM associates with and phosphorylates p53: mapping the region of interaction.; ATM binds to beta-adaptin in cytoplasmic vesicles.; Enhanced phosphorylation of p53 by ATM in response to DNA damage.; Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.; Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.; Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.; BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.; ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.; ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.; Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response.; ATM-dependent phosphorylation of nibrin in response to radiation exposure.; Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.; Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks.; ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses.; Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways.; Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein.; DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.; Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation.; Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response.; A new effector pathway links ATM kinase with the DNA damage response.; Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex.; The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR.; ATM-dependent phosphorylation of ATF2 is required for the DNA damage response.; Involvement of human MOF in ATM function.; Regulated degradation of replication-dependent histone mRNAs requires both ATR and Upf1.; A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM.; ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex.; Involvement of novel autophosphorylation sites in ATM activation.; ATMIN defines an NBS1-independent pathway of ATM signalling.; DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Single-stranded DNA-binding protein hSSB1 is critical for genomic stability.; A role for DEAD box 1 at DNA double-strand breaks.; Large-scale proteomics analysis of the human kinome.; ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.; A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability.; Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes.; Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.; Initial characterization of the human central proteome.; Protein phosphatase 5 is necessary for ATR-mediated DNA repair.; Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK catalytic subunit.; ATM protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell cycle control.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; ATM functions at the peroxisome to induce pexophagy in response to ROS.; ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1.; FBXW7 facilitates nonhomologous end-joining via K63-linked polyubiquitylation of XRCC4.; ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair pathway choice.; The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor suppressor FBXO31 and thereby prevents premature cellular senescence.; UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors.; UFL1 promotes histone H4 ufmylation and ATM activation.; Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks.; SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair.; Metabolic regulation of homologous recombination repair by MRE11 lactylation.; Structures of closed and open conformations of dimeric human ATM.; Structure of the human ATM kinase and mechanism of Nbs1 binding.; Mutations associated with variant phenotypes in ataxia-telangiectasia.; A high frequency of distinct ATM gene mutations in ataxia-telangiectasia.; ATM mutations in cancer families.; Exon-scanning mutation analysis of the ATM gene in patients with ataxia-telangiectasia.; New mutations in the ataxia telangiectasia gene.; Predominance of null mutations in ataxia-telangiectasia.; Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.; Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.; Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations.; ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer.; Genotype-phenotype relationships in ataxia-telangiectasia and variants.; Ataxia-telangiectasia without immunodeficiency: novel point mutations within and adjacent to the phosphatidylinositol 3-kinase-like domain.; Inactivation of the ATM gene in T-cell prolymphocytic leukemias.; Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays.; A double missense mutation in the ATM gene of a Dutch family with ataxia telangiectasia.; ATM mutations in patients with ataxia telangiectasia screened by a hierarchical strategy.; ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.; Ataxia-telangiectasia in the Japanese population: identification of R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being relatively common mutations.; ATM is usually rearranged in T-cell prolymphocytic leukaemia.; Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.; ATM mutations in B-cell chronic lymphocytic leukemia.; Rapid and efficient ATM mutation detection by fluorescent chemical cleavage of mismatch: identification of four novel mutations.; Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer.; Characterization of ATM gene mutations in 66 ataxia telangiectasia families.; New mutations, polymorphisms, and rare variants in the ATM gene detected by a novel SSCP strategy.; Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.; Missense mutations at ATM gene and cancer risk.; Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients.; Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity.; Mantle cell lymphoma is characterized by inactivation of the ATM gene.; ATM mutations in Finnish breast cancer patients.; Patterns of somatic mutation in human cancer genomes.; ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.; Modeling ATM mutant proteins from missense changes confirms retained kinase activity.; Next-generation sequencing in familial breast cancer patients from Lebanon.; Molecular and functional characterization of a cohort of Spanish patients with ataxia-telangiectasia.; Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.",False
PLAU,P00749,Urokinase-type plasminogen activator,MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKLLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL,,,"Cloning and expression of the gene for pro-urokinase in Escherichia coli.; Molecular cloning, sequencing, and expression in Escherichia coli of human preprourokinase cDNA.; Molecular cloning of cDNA coding for human preprourokinase.; The human urokinase-plasminogen activator gene and its promoter.; Cloning of human full-length CDSs in BD Creator(TM) System Donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure.; Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.; Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA.; The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain.; Human low-molecular-weight urinary urokinase. Partial characterization and preliminary sequence data of the two polypeptide chains.; The complete amino acid sequence of low molecular mass urokinase from human urine.; Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3.; Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.; Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility.; A urokinase receptor-associated protein with specific collagen binding properties.; The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.; The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.; Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.; Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.; Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.; Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1.; TMPRSS4 induces cancer cell invasion through pro-uPA processing.; Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR.; Sequential 1H NMR assignments and secondary structure of the kringle domain from urokinase.; Solution structure of the kringle domain from urokinase-type plasminogen activator.; The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.; (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.; Structure of human urokinase plasminogen activator in complex with its receptor.; Detection of polymorphisms in the human urokinase-type plasminogen activator gene.; Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.; DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.",False
ERCC2,P18074,General transcription and DNA repair factor IIH helicase subunit XPD,MKLNVDGLLVYFPYDYIYPEQFSYMRELKRTLDAKGHGVLEMPSGTGKTVSLLALIMAYQRAYPLEVTKLIYCSRTVPEIEKVIEELRKLLNFYEKQEGEKLPFLGLALSSRKNLCIHPEVTPLRFGKDVDGKCHSLTASYVRAQYQHDTSLPHCRFYEEFDAHGREVPLPAGIYNLDDLKALGRRQGWCPYFLARYSILHANVVVYSYHYLLDPKIADLVSKELARKAVVVFDEAHNIDNVCIDSMSVNLTRRTLDRCQGNLETLQKTVLRIKETDEQRLRDEYRRLVEGLREASAARETDAHLANPVLPDEVLQEAVPGSIRTAEHFLGFLRRLLEYVKWRLRVQHVVQESPPAFLSGLAQRVCIQRKPLRFCAERLRSLLHTLEITDLADFSPLTLLANFATLVSTYAKGFTIIIEPFDDRTPTIANPILHFSCMDASLAIKPVFERFQSVIITSGTLSPLDIYPKILDFHPVTMATFTMTLARVCLCPMIIGRGNDQVAISSKFETREDIAVIRNYGNLLLEMSAVVPDGIVAFFTSYQYMESTVASWYEQGILENIQRNKLLFIETQDGAETSVALEKYQEACENGRGAILLSVARGKVSEGIDFVHHYGRAVIMFGVPYVYTQSRILKARLEYLRDQFQIRENDFLTFDAMRHAAQCVGRAIRGKTDYGLMVFADKRFARGDKRGKLPRWIQEHLTDANLNLTVDEGVQVAKYFLRQMAQPFHREDQLGLSLLSLEQLESEETLKRIEQIAQQL,,,"ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3.; Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Correction of Xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene.; Human Xeroderma pigmentosum group D gene encodes a DNA helicase.; The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.; Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes.; Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH.; Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7.; Selective regulation of vitamin D receptor-responsive genes by TFIIH.; Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair.; Identification and Herc5-mediated ISGylation of novel target proteins.; MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity.; MMXD, a TFIIH-independent XPD-MMS19 protein complex involved in chromosome segregation.; Initial characterization of the human central proteome.; MMS19 links cytoplasmic iron-sulfur cluster assembly to DNA metabolism.; DNA quality control by a lesion sensor pocket of the xeroderma pigmentosum group D helicase subunit of TFIIH.; Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins.; Human CIA2A-FAM96A and CIA2B-FAM96B Integrate Iron Homeostasis and Maturation of Different Subsets of Cytosolic-Nuclear Iron-Sulfur Proteins.; IOP1 protein is an external component of the human cytosolic iron-sulfur cluster assembly (CIA) machinery and functions in the MMS19 protein-dependent CIA pathway.; Near-atomic resolution visualization of human transcription promoter opening.; Structural basis of TFIIH activation for nucleotide excision repair.; Structures of mammalian RNA polymerase II pre-initiation complexes.; Structural and mutational analysis of the xeroderma pigmentosum group D (XPD) gene.; Mutations in the xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy.; Molecular and cellular analysis of the DNA repair defect in a patient in xeroderma pigmentosum complementation group D who has the clinical features of xeroderma pigmentosum and Cockayne syndrome.; Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D.; Defects in the DNA repair and transcription gene ERCC2(XPD) in trichothiodystrophy.; Mutations in the XPD gene leading to Xeroderma pigmentosum symptoms.; DNA repair characteristics and mutations in the ERCC2 DNA repair and transcription gene in a trichothiodystrophy patient.; Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene.; Analysis of mutations in the XPD gene in Italian patients with trichothiodystrophy: site of mutation correlates with repair deficiency, but gene dosage appears to determine clinical severity.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy.; Associations between ercc2 polymorphisms and gliomas.; Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.; XPD exon 10 and 23 polymorphisms and DNA repair in human skin in situ.; The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases.; Two individuals with features of both xeroderma pigmentosum and trichothiodystrophy highlight the complexity of the clinical outcomes of mutations in the XPD gene.; A temperature-sensitive disorder in basal transcription and DNA repair in humans.",False
ERCC8,Q13216,DNA excision repair protein ERCC-8,MLGFLSARQTGLEDPLRLRRAESTRRVLGLELNKDRDVERIHGGGINTLDIEPVEGRYMLSGGSDGVIVLYDLENSSRQSYYTCKAVCSIGRDHPDVHRYSVETVQWYPHDTGMFTSSSFDKTLKVWDTNTLQTADVFNFEETVYSHHMSPVSTKHCLVAVGTRGPKVQLCDLKSGSCSHILQGHRQEILAVSWSPRYDYILATASADSRVKLWDVRRASGCLITLDQHNGKKSQAVESANTAHNGKVNGLCFTSDGLHLLTVGTDNRMRLWNSSNGENTLVNYGKVCNNSKKGLKFTVSCGCSSEFVFVPYGSTIAVYTVYSGEQITMLKGHYKTVDCCVFQSNFQELYSGSRDCNILAWVPSLYEPVPDDDETTTKSQLNPAFEDAWSSSDEEG,,,"The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage.; CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome.; Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo.; Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair.; The C-terminal Region and SUMOylation of Cockayne Syndrome Group B Protein Play Critical Roles in Transcription-coupled Nucleotide Excision Repair.; CSA and CSB play a role in the response to DNA breaks.; Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair.; The cooperative action of CSB, CSA, and UVSSA target TFIIH to DNA damage-stalled RNA polymerase II.; Transcription-coupled DNA-protein crosslink repair by CSB and CRL4CSA-mediated degradation.; Transcription-coupled repair of DNA-protein cross-links depends on CSA and CSB.; The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.; Structural basis of human transcription-DNA repair coupling.; Structural basis for RNA polymerase II ubiquitylation and inactivation in transcription-coupled repair.; CKN1 (MIM 216400): mutations in Cockayne syndrome type A and a new common polymorphism.; Characterisation of novel mutations in Cockayne syndrome type A and xeroderma pigmentosum group C subjects.; A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage.; High carriers frequency of an apparently ancient founder mutation p.Tyr322X in the ERCC8 gene responsible for Cockayne syndrome among Christian Arabs in Northern Israel.; Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome.",False
WRN,Q14191,Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN,MSEKKLETTAQQRKCPEWMNVQNKRCAVEERKACVRKSVFEDDLPFLEFTGSIVYSYDASDCSFLSEDISMSLSDGDVVGFDMEWPPLYNRGKLGKVALIQLCVSESKCYLFHVSSMSVFPQGLKMLLENKAVKKAGVGIEGDQWKLLRDFDIKLKNFVELTDVANKKLKCTETWSLNSLVKHLLGKQLLKDKSIRCSNWSKFPLTEDQKLYAATDAYAGFIIYRNLEILDDTVQRFAINKEEEILLSDMNKQLTSISEEVMDLAKHLPHAFSKLENPRRVSILLKDISENLYSLRRMIIGSTNIETELRPSNNLNLLSFEDSTTGGVQQKQIREHEVLIHVEDETWDPTLDHLAKHDGEDVLGNKVERKEDGFEDGVEDNKLKENMERACLMSLDITEHELQILEQQSQEEYLSDIAYKSTEHLSPNDNENDTSYVIESDEDLEMEMLKHLSPNDNENDTSYVIESDEDLEMEMLKSLENLNSGTVEPTHSKCLKMERNLGLPTKEEEEDDENEANEGEEDDDKDFLWPAPNEEQVTCLKMYFGHSSFKPVQWKVIHSVLEERRDNVAVMATGYGKSLCFQYPPVYVGKIGLVISPLISLMEDQVLQLKMSNIPACFLGSAQSENVLTDIKLGKYRIVYVTPEYCSGNMGLLQQLEADIGITLIAVDEAHCISEWGHDFRDSFRKLGSLKTALPMVPIVALTATASSSIREDIVRCLNLRNPQITCTGFDRPNLYLEVRRKTGNILQDLQPFLVKTSSHWEFEGPTIIYCPSRKMTQQVTGELRKLNLSCGTYHAGMSFSTRKDIHHRFVRDEIQCVIATIAFGMGINKADIRQVIHYGAPKDMESYYQEIGRAGRDGLQSSCHVLWAPADINLNRHLLTEIRNEKFRLYKLKMMAKMEKYLHSSRCRRQIILSHFEDKQVQKASLGIMGTEKCCDNCRSRLDHCYSMDDSEDTSWDFGPQAFKLLSAVDILGEKFGIGLPILFLRGSNSQRLADQYRRHSLFGTGKDQTESWWKAFSRQLITEGFLVEVSRYNKFMKICALTKKGRNWLHKANTESQSLILQANEELCPKKLLLPSSKTVSSGTKEHCYNQVPVELSTEKKSNLEKLYSYKPCDKISSGSNISKKSIMVQSPEKAYSSSQPVISAQEQETQIVLYGKLVEARQKHANKMDVPPAILATNKILVDMAKMRPTTVENVKRIDGVSEGKAAMLAPLLEVIKHFCQTNSVQTDLFSSTKPQEEQKTSLVAKNKICTLSQSMAITYSLFQEKKMPLKSIAESRILPLMTIGMHLSQAVKAGCPLDLERAGLTPEVQKIIADVIRNPPVNSDMSKISLIRMLVPENIDTYLIHMAIEILKHGPDSGLQPSCDVNKRRCFPGSEEICSSSKRSKEEVGINTETSSAERKRRLPVWFAKGSDTSKKLMDKTKRGGLFS,,,"Positional cloning of the Werner's syndrome gene.; Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.; Genomic structure of the human Werner's gene and cloning of the mouse homolog.; DNA sequence and analysis of human chromosome 8.; The Werner syndrome protein is a DNA helicase.; DNA helicase activity in Werner's syndrome gene product synthesized in a baculovirus system.; Characterization of Werner syndrome protein DNA helicase activity: directionality, substrate dependence and stimulation by replication protein A.; Nucleolar localization of the Werner syndrome protein in human cells.; Evolution of the RECQ family of helicases: a Drosophila homolog, Dmblm, is similar to the human Bloom syndrome gene.; Human werner syndrome DNA helicase unwinds tetrahelical structures of the fragile X syndrome repeat sequence d(CGG)n.; Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer.; A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities.; Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation.; The exonucleolytic and endonucleolytic cleavage activities of human exonuclease 1 are stimulated by an interaction with the carboxyl-terminal region of the Werner syndrome protein.; Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the SUV3 gene results in mouse embryonic lethality.; Werner syndrome protein interacts functionally with translesion DNA polymerases.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; The Werner syndrome protein binds replication fork and Holliday junction DNAs as an oligomer.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; WRN helicase promotes repair of DNA double-strand breaks caused by aberrant mismatch repair of chromium-DNA adducts.; The Werner syndrome helicase/exonuclease processes mobile D-loops through branch migration and degradation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Initial characterization of the human central proteome.; Promyelocytic leukemia protein interacts with werner syndrome helicase and regulates double-strand break repair in gamma-irradiation-induced DNA damage responses.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Solution structure of a multifunctional DNA- and protein-binding motif of human Werner syndrome protein.; WRN exonuclease structure and molecular mechanism imply an editing role in DNA end processing.; WRN mutations in Werner syndrome.; Solution structure of the helicase and RNase D C-terminal domain in Werner syndrome ATP-dependent helicase.; Crystal structure of the HRDC domain of human Werner syndrome protein, WRN.; Structural basis for DNA strand separation by the unconventional winged-helix domain of RecQ helicase WRN.; Ligand binding characteristics of the Ku80 von Willebrand domain.; Structure of the helicase core of Werner helicase, a key target in microsatellite instability cancers.; Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population.; Werner syndrome: characterization of mutations in the WRN gene in an affected family.; RECQL5 plays co-operative and complementary roles with WRN syndrome helicase.; The 1396del A mutation and a missense mutation or a rare polymorphism of the WRN gene detected in a French Werner family with a severe phenotype and a case of an unusual vulvar cancer.; Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians.; The Werner syndrome gene and global sequence variation.; The spectrum of WRN mutations in Werner syndrome patients.; The consensus coding sequences of human breast and colorectal cancers.; DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.",False
LMNA,P02545,Prelamin-A/C,METPSQRRATRSGAQASSTPLSPTRITRLQEKEDLQELNDRLAVYIDRVRSLETENAGLRLRITESEEVVSREVSGIKAAYEAELGDARKTLDSVAKERARLQLELSKVREEFKELKARNTKKEGDLIAAQARLKDLEALLNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKKQLQDEMLRRVDAENRLQTMKEELDFQKNIYSEELRETKRRHETRLVEIDNGKQREFESRLADALQELRAQHEDQVEQYKKELEKTYSAKLDNARQSAERNSNLVGAAHEELQQSRIRIDSLSAQLSQLQKQLAAKEAKLRDLEDSLARERDTSRRLLAEKEREMAEMRARMQQQLDEYQELLDIKLALDMEIHAYRKLLEGEEERLRLSPSPTSQRSRGRASSHSSQTQGGGSVTKKRKLESTESRSSFSQHARTSGRVAVEEVDEEGKFVRLRNKSNEDQSMGNWQIKRQNGDDPLLTYRFPPKFTLKAGQVVTIWAAGAGATHSPPTDLVWKAQNTWGCGNSLRTALINSTGEEVAMRKLVRSVTVVEDDEDEDGDDLLHHHHGSHCSSSGDPAEYNLRSRTVLCGTCGQPADKASASGSGAQVGGPISSGSSASSVTVTRSYRSVGGSGGGSFGDNLVTRSYLLGNSSPRTQSPQNCSIM,,,"Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins.; cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins.; In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients.; The progerin allele of lamin A disrupts chromatin organization.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; An alternative splicing product of the lamin A/C gene lacks exon 10.; Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis.; Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C.; The processing pathway of prelamin A.; In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease.; Antigens recognized by autologous antibody in patients with renal-cell carcinoma.; Prenylated prelamin A interacts with Narf, a novel nuclear protein.; Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein.; Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.; LEM2 is a novel MAN1-related inner nuclear membrane protein associated with A-type lamins.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra.; Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Emerin-prelamin A interplay in human fibroblasts.; The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Increased plasticity of the nuclear envelope and hypermobility of telomeres due to the loss of A-type lamins.; Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.; Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging.; Mammalian SUN protein interaction networks at the inner nuclear membrane and their role in laminopathy disease processes.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Identification of a novel muscle enriched A-type Lamin interacting protein (MLIP).; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.; LMNA-associated cardiocutaneous progeria: An inherited autosomal dominant premature aging syndrome with late onset.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model.; Myotonic dystrophy protein kinase is critical for nuclear envelope integrity.; Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation.; Matrix elasticity regulates lamin-A,C phosphorylation and turnover with feedback to actomyosin.; Interphase phosphorylation of lamin A.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; The active site of O-GlcNAc transferase imposes constraints on substrate sequence.; N-terminome analysis of the human mitochondrial proteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Intersectin goes nuclear: secret life of an endocytic protein.; Inner nuclear membrane protein TMEM201 maintains endothelial cell migration and angiogenesis by interacting with the LINC complex.; ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei.; DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A/C.; Structure of the globular tail of nuclear lamin.; The Ig-like structure of the C-terminal domain of lamin A/C, mutated in muscular dystrophies, cardiomyopathy, and partial lipodystrophy.; Crystal structure of the human lamin A coil 2B dimer: implications for the head-to-tail association of nuclear lamins.; Structural basis for lamin assembly at the molecular level.; Beta-strand-mediated dimeric formation of the Ig-like domains of human lamin A/C and B1.; Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy.; Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.; Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C.; Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy.; Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene.; Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy.; Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B).; LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.; Autosomal dominant Emery-Dreifuss dystrophy due to mutations in rod domain of the lamin A/C gene.; Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy.; Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease.; Properties of lamin A mutants found in Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial lipodystrophy.; A missense mutation in the exon 8 of lamin A/C gene in a Japanese case of autosomal dominant limb-girdle muscular dystrophy and cardiac conduction block.; A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation.; Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse.; Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C.; Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene.; Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease.; Identification of lamin A/C (LMNA) gene mutations in Korean patients with autosomal dominant Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy 1B.; Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy.; Frequent low penetrance mutations in the Lamin A/C gene, causing Emery Dreifuss muscular dystrophy.; Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation.; Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype.; Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.; A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy.; LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090).; Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations.; Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes.; LMNA mutations in atypical Werner's syndrome.; Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study.; Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations.; A novel mutation, Ser143Pro, in the lamin A/C gene is common in Finnish patients with familial dilated cardiomyopathy.; Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy.; Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes.; Homozygous missense mutation in the lamin A/C gene causes autosomal recessive Hutchinson-Gilford progeria syndrome.; A new mutation of the lamin A/C gene leading to autosomal dominant axonal neuropathy, muscular dystrophy, cardiac disease, and leuconychia.; Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations.; p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria.; Gene symbol: LMNA. Disease: cardiomyopathy, dilated, with conduction defect 1.; A novel homozygous Ala529Val LMNA mutation in Turkish patients with mandibuloacral dysplasia.; Lamin A N-terminal phosphorylation is associated with myoblast activation: impairment in Emery-Dreifuss muscular dystrophy.; A homozygous mutation in the lamin A/C gene associated with a novel syndrome of arthropathy, tendinous calcinosis, and progeroid features.; Collagen expression in fibroblasts with a novel LMNA mutation.; Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).; Mutations of the LMNA gene can mimic autosomal dominant proximal spinal muscular atrophy.; New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome.; De novo LMNA mutations cause a new form of congenital muscular dystrophy.; Heart-hand syndrome of Slovenian type: a new kind of laminopathy.; The nucleoskeleton protein IFFO1 immobilizes broken DNA and suppresses chromosome translocation during tumorigenesis.; Ovarian failure and dilated cardiomyopathy due to a novel lamin mutation.; Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation.; Dilated cardiomyopathy with profound segmental wall motion abnormalities and ventricular arrhythmia caused by the R541C mutation in the LMNA gene.; Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy.; LMNA mutation in progeroid syndrome in association with strokes.; Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations.; High prevalence of laminopathies among patients with metabolic syndrome.; Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel mutation (R225Q) in the lamin A/C gene identified by exome sequencing.; Mutations in LMNA modulate the lamin A--Nesprin-2 interaction and cause LINC complex alterations.; LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.; Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population.",False
IGF1R,P08069,Insulin-like growth factor 1 receptor,MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC,,,"Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.; Insulin-like growth factor I receptor gene structure.; Analysis of the DNA sequence and duplication history of human chromosome 15.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Analysis of the human type I insulin-like growth factor receptor promoter region.; Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification.; A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.; Interaction of the alpha beta dimers of the insulin-like growth factor I receptor is required for receptor autophosphorylation.; Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity.; Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3).; Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.; Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting.; 14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor.; Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues.; Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.; beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor.; The IGF-I receptor in cancer research.; Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis.; Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor.; Autophosphorylation of the insulin-like growth factor I receptor cytoplasmic domain.; Mechanism of STAT3 activation by insulin-like growth factor I receptor.; Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.; Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.; RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix.; Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).; Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.; Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.; {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.; JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3.; Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant.; The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis.; The insulin-like growth factor 1 receptor in cancer: old focus, new future.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.; Large-scale proteomics analysis of the human kinome.; Development and validation of a method for profiling post-translational modification activities using protein microarrays.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation.; Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.; mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.; Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.; IGF1R is an entry receptor for respiratory syncytial virus.; Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor.; Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.; Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation.; Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.; Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution.; Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).; Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.; Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.; Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.; Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.; Allosteric IGF-1R Inhibitors.; Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.; Design of potent IGF1-R inhibitors related to bis-azaindoles.; Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.; Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.; IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.; Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation.; Patterns of somatic mutation in human cancer genomes.; Three novel IGF1R mutations in microcephalic patients with prenatal and postnatal growth impairment.",False
TXN,P10599,Thioredoxin,MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV,,,"Cloning and expression of a cDNA for human thioredoxin.; ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction.; Isolation and characterization of human thioredoxin-encoding genes.; Cloning, purification and characterization of human lens thioredoxin.; Cloning and sequencing of thioredoxin cDNA from human brain.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; An alternative splice variant of human thioredoxin.; Characterization of a thioredoxin-related surface protein.; Identification of a thioredoxin-related protein associated with plasma membranes.; Human thioredoxin reactivity-structure/function relationship.; Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway.; AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1.; Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation.; S-nitrosation of thioredoxin in the nitrogen monoxide/superoxide system activates apoptosis signal-regulating kinase 1.; Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine.; Cross-reactivity and 1.4-A crystal structure of Malassezia sympodialis thioredoxin (Mala s 13), a member of a new pan-allergen family.; Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells.; Auto- and cross-reactivity to thioredoxin allergens in allergic bronchopulmonary aspergillosis.; Abnormal proteins in primary breast cancer tissues from 25 Sudanese patients.; Salmonella type III secretion effector SlrP is an E3 ubiquitin ligase for mammalian thioredoxin.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; A proton nuclear magnetic resonance assignment and secondary structure determination of recombinant human thioredoxin.; High-resolution three-dimensional structure of reduced recombinant human thioredoxin in solution.; The high-resolution three-dimensional solution structures of the oxidized and reduced states of human thioredoxin.; Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B.; The solution structure of human thioredoxin complexed with its target from Ref-1 reveals peptide chain reversal.; Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.; Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant.; Buried S-nitrosocysteine revealed in crystal structures of human thioredoxin.",False
KL,Q9UEF7,Klotho,MPASAPPRRPRPPPPSLSLLLVLLGLGGRRLRAEPGDGAQTWARFSRPPAPEAAGLFQGTFPDGFLWAVGSAAYQTEGGWQQHGKGASIWDTFTHHPLAPPGDSRNASLPLGAPSPLQPATGDVASDSYNNVFRDTEALRELGVTHYRFSISWARVLPNGSAGVPNREGLRYYRRLLERLRELGVQPVVTLYHWDLPQRLQDAYGGWANRALADHFRDYAELCFRHFGGQVKYWITIDNPYVVAWHGYATGRLAPGIRGSPRLGYLVAHNLLLAHAKVWHLYNTSFRPTQGGQVSIALSSHWINPRRMTDHSIKECQKSLDFVLGWFAKPVFIDGDYPESMKNNLSSILPDFTESEKKFIKGTADFFALCFGPTLSFQLLDPHMKFRQLESPNLRQLLSWIDLEFNHPQIFIVENGWFVSGTTKRDDAKYMYYLKKFIMETLKAIKLDGVDVIGYTAWSLMDGFEWHRGYSIRRGLFYVDFLSQDKMLLPKSSALFYQKLIEKNGFPPLPENQPLEGTFPCDFAWGVVDNYIQVDTTLSQFTDLNVYLWDVHHSKRLIKVDGVVTKKRKSYCVDFAAIQPQIALLQEMHVTHFRFSLDWALILPLGNQSQVNHTILQYYRCMASELVRVNITPVVALWQPMAPNQGLPRLLARQGAWENPYTALAFAEYARLCFQELGHHVKLWITMNEPYTRNMTYSAGHNLLKAHALAWHVYNEKFRHAQNGKISIALQADWIEPACPFSQKDKEVAERVLEFDIGWLAEPIFGSGDYPWVMRDWLNQRNNFLLPYFTEDEKKLIQGTFDFLALSHYTTILVDSEKEDPIKYNDYLEVQEMTDITWLNSPSQVAVVPWGLRKVLNWLKFKYGDLPMYIISNGIDDGLHAEDDQLRVYYMQNYINEALKAHILDGINLCGYFAYSFNDRTAPRFGLYRYAADQFEPKASMKHYRKIIDSNGFPGPETLERFCPEEFTVCTECSFFHTRKSLLAFIAFLFFASIISLSLIFYYSKKGRRSYK,,,"Mutation of the mouse klotho gene leads to a syndrome resembling ageing.; Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein.; The DNA sequence and analysis of human chromosome 13.; Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys.; Molecular cloning and expression of a novel klotho-related protein.; Severely reduced production of klotho in human chronic renal failure kidney.; Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane.; Association of human aging with a functional variant of klotho.; Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity.; The consensus coding sequences of human breast and colorectal cancers.; A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.",False
E2F1,Q01094,Transcription factor E2F1,MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF,,,"A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.; Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties.; Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F.; Structure and partial genomic sequence of the human E2F1 gene.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression.; A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity.; Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein.; Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase.; Differential regulation of E2F transactivation by cyclin/cdk2 complexes.; Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.; P53 and E2F-1 cooperate to mediate apoptosis.; Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription.; Phosphorylation of E2F-1 by cyclin A-cdk2.; Specific regulation of E2F family members by cyclin-dependent kinases.; A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer.; Regulation of E2F1 activity by acetylation.; E2F transcriptional activation requires TRRAP and GCN5 cofactors.; Regulation of E2F1 by BRCT domain-containing protein TopBP1.; Chk2 activates E2F-1 in response to DNA damage.; Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.; EAPP, a novel E2F binding protein that modulates E2F-dependent transcription.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Glycogen synthase kinase-3beta binds to E2F1 and regulates its transcriptional activity.; Regulation of E2F1 function by the nuclear corepressor KAP1.; PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B.; Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.; Lysine methylation regulates E2F1-induced cell death.; Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription.; Mixed lineage leukemia 5 (MLL5) protein regulates cell cycle progression and E2F1-responsive gene expression via association with host cell factor-1 (HCF-1).; Phosphorylated E2F1 is stabilized by nuclear USP11 to drive Peg10 gene expression and activate lung epithelial cells.; Methylated DNMT1 and E2F1 are targeted for proteolysis by L3MBTL3 and CRL4-DCAF5 ubiquitin ligase.; Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.; Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation.",False
PTPN11,Q06124,Tyrosine-protein phosphatase non-receptor type 11,MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR,,,"Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3 with sequence similarity to the src-homology region 2.; Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew.; Cloning, expression and mutational analysis of SH-PTP2, human protein-tyrosine phosphatase.; A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains.; Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.; Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.; Activation of protein-tyrosine phosphatase SH-PTP2 by a tyrosine-based activation motif of a novel brain molecule.; A family of proteins that inhibit signalling through tyrosine kinase receptors.; Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.; Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors.; SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T-cell activation.; Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.; Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs.; Molecular cloning and characterization of SPAP1, an inhibitory receptor.; Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP.; Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family.; Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2-interacting transmembrane adaptor protein).; Identification of Fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cells.; The inhibitory potential of Fc receptor homolog 4 on memory B cells.; Signal transduction via the stem cell factor receptor/c-Kit.; Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes.; Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells.; ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.; FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection.; Identification of CLEC12B, an inhibitory receptor on myeloid cells.; Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase.; Regulation of RhoA-dependent ROCKII activation by Shp2.; An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.; GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, contributes to cellular transformation through the activation of extracellular signal-regulated kinase signaling.; A novel and critical role for tyrosine 663 in platelet endothelial cell adhesion molecule-1 trafficking and transendothelial migration.; FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell receptor-mediated signaling.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration.; Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.; Crystal structure of the tyrosine phosphatase SHP-2.; Large-scale structural analysis of the classical human protein tyrosine phosphatome.; Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).; Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.; PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.; Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.; PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.; PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.; PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.; Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.; Noonan syndrome with leukaemoid reaction and overproduction of catecholamines: a case report.; A novel PTPN11 mutation in LEOPARD syndrome.; Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.; Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.; Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.; Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome.; PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience.; Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome.; Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient.; A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.; Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.; PTPN11 gene mutations: linking the Gln510Glu mutation to the 'LEOPARD syndrome phenotype'.; Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive).; PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.; A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.; Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.; Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.",False
NFKB2,Q00653,Nuclear factor NF-kappa-B p100 subunit,MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH,,,"Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65.; A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site.; Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation.; Purification of the major histocompatibility complex class I transcription factor H2TF1. The full-length product of the nfkb2 gene.; The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers.; Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity.; Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor.; A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription.; The generation of nfkb2 p52: mechanism and efficiency.; Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences.; NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.; B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.; Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.; Structural and functional characterization of the promoter regions of the NFKB2 gene.; The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation.; Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase.; IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1-A resolution.; Solution structure of the death domain of nuclear factor NF-kappa-B p100.; Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency.; TRIM55 promotes noncanonical NF-kappaB signaling and B cell-mediated immune responses by coordinating p100 ubiquitination and processing.; Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies.",False
STAT5B,P51692,Signal transducer and activator of transcription 5B,MAVWIQAQQLQGEALHQMQALYGQHFPIEVRHYLSQWIESQAWDSVDLDNPQENIKATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQNTYDRCPMELVRCIRHILYNEQRLVREANNGSSPAGSLADAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFGPLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNDYSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRSDRRGAESVTEEKFTILFESQFSVGGNELVFQVKTLSLPVVVIVHGSQDNNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGRNYTFWQWFDGVMEVLKKHLKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSQERMFWNLMPFTTRDFSIRSLADRLGDLNYLIYVFPDRPKDEVYSKYYTPVPCESATAKAVDGYVKPQIKQVVPEFVNASADAGGGSATYMDQAPSPAVCPQAHYNMYPQNPDSVLDTDGDFDLEDTMDVARRVEELLGRPMDSQWIPHAQS,,,"Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone.; Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells.; The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specific STAT5B promoter.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of Stat 5B as a substrate of the insulin receptor.; Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling.; The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.; A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus.; Retraction.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain.; FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.; Signal transduction via the stem cell factor receptor/c-Kit.; Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta.; Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation.; Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b.; Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.; ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.; A novel role of CPEB3 in regulating EGFR gene transcription via association with Stat5b in neurons.; Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.; Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation.; Growth hormone insensitivity associated with a STAT5b mutation.; A Novel Missense Mutation in the SH2 Domain of the STAT5B Gene Results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease.",False
STAT3,P40763,Signal transducer and activator of transcription 3,MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM,,,"Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway.; Highly conserved amino-acid sequence between murine STAT3 and a revised human STAT3 sequence.; Methods for treating chronic kidney disease.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Requirement of serine phosphorylation for formation of STAT-promoter complexes.; Specific inhibition of Stat3 signal transduction by PIAS3.; Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation.; The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation.; Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.; Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation.; A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.; Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.; Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway.; Characterization of the signaling capacities of the novel gp130-like cytokine receptor.; IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression.; TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3.; Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.; STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen.; Physical and functional interactions between STAT3 and ZIP kinase.; Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.; Stat3 dimerization regulated by reversible acetylation of a single lysine residue.; Identification of STAT3 as a specific substrate of breast tumor kinase.; Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer.; leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3.; The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.; up-regulation of survivin by leptin/STAT3 signaling in MCF-7 cells.; Role for DYRK family kinases on regulation of apoptosis.; Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.; BART is essential for nuclear retention of STAT3.; The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.; Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.; Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.; Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity.; Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.; Human Cytomegalovirus Immediate-Early 1 Protein Rewires Upstream STAT3 to Downstream STAT1 Signaling Switching an IL6-Type to an IFNgamma-Like Response.; Lysyl oxidase 3 is a dual-specificity enzyme involved in STAT3 deacetylation and deacetylimination modulation.; TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity.; Salmonella Activation of STAT3 Signaling by SarA Effector Promotes Intracellular Replication and Production of IL-10.; Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.; PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.; Prohibitin 1 interacts with signal transducer and activator of transcription 3 in T-helper 17 cells.; The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis.; A double helical motif in OCIAD2 is essential for its localization, interactions and STAT3 activation.; Distinct roles of Brd2 and Brd4 in potentiating the transcriptional program for th17 cell differentiation.; STAT3 mutations in the hyper-IgE syndrome.; Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.; Signal transducer and activator of transcription 3 mutation with invasive eosinophilic disease.; Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.; Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.; Functional characterization of two new STAT3 mutations associated with hyper-IgE syndrome in a Mexican cohort.; STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.; Short stature in a boy with multiple early-onset autoimmune conditions due to a STAT3 activating mutation: could intracellular growth hormone signalling be compromised?; An activating mutation in STAT3 results in neonatal diabetes through reduced insulin synthesis.; Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome.; A novel gain-of-function STAT3 variant in infantile-onset diabetes associated with multiorgan autoimmunity.",False
STAT5A,P42229,Signal transducer and activator of transcription 5A,MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS,,,"Identification and purification of human Stat proteins activated in response to interleukin-2.; Cloning and characterization of a variant of human stat5a, missing a portion of the n-terminal region, with dominant negative effects on the growth of breast cancer cells and [beta]-casein gene expression.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus.; Retraction.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain.; STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA.; FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.; Signal transduction via the stem cell factor receptor/c-Kit.; The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.; Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation.; Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.; Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells.",False
NRG1,Q02297,"Pro-neuregulin-1, membrane-bound isoform",MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENVPMKVQNQEKAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV,,,"Identification of heregulin, a specific activator of p185erbB2.; Structural and functional aspects of the multiplicity of Neu differentiation factors.; Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system.; Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 8.; Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.; Neuregulin 1 and susceptibility to Schizophrenia.; Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.; Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.; Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.; Gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.; Gamma-heregulin: a fusion gene of DOC-4 and neuregulin-1 derived from a chromosome translocation.; Ligand discrimination in signaling through an ErbB4 receptor homodimer.; Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.; Solution structure of the epidermal growth factor-like domain of heregulin-alpha, a ligand for p180erbB-4.; High-resolution solution structure of the EGF-like domain of heregulin-alpha.",False
HDAC3,O15379,Histone deacetylase 3,MAKTVAYFYDPDVGNFHYGAGHPMKPHRLALTHSLVLHYGLYKKMIVFKPYQASQHDMCRFHSEDYIDFLQRVSPTNMQGFTKSLNAFNVGDDCPVFPGLFEFCSRYTGASLQGATQLNNKICDIAINWAGGLHHAKKFEASGFCYVNDIVIGILELLKYHPRVLYIDIDIHHGDGVQEAFYLTDRVMTVSFHKYGNYFFPGTGDMYEVGAESGRYYCLNVPLRDGIDDQSYKHLFQPVINQVVDFYQPTCIVLQCGADSLGCDRLGCFNLSIRGHGECVEYVKSFNIPLLVLGGGGYTVRNVARCWTYETSLLVEEAISEELPYSEYFEYFAPDFTLHPDVSTRIENQNSRQYLDQIRQTIFENLKMLNHAPSVQIHDVPADLLTYDRTDEADAEERGPEENYSRPEAPNEFYDGDHDNDKESDVEI,,,"Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.; Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family.; Characterization of a human RPD3 ortholog, HDAC3.; Genomic organization and chromosomal localization of the human histone deacetylase 3 gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation.; Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing.; Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.; Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.; The histone deacetylase-3 complex contains nuclear receptor corepressors.; Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo.; ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.; Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain.; The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase.; A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness.; Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3.; BCoR, a novel corepressor involved in BCL-6 repression.; The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2.; Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1.; Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene.; DACH1 inhibits transforming growth factor-beta signaling through binding Smad4.; Regulation of human SRY subcellular distribution by its acetylation/deacetylation.; Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.; Stat3 dimerization regulated by reversible acetylation of a single lysine residue.; INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription.; Transcription-dependent nucleolar cap localization and possible nuclear function of DExH RNA helicase RHAU.; NKAP is a transcriptional repressor of notch signaling and is required for T cell development.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; HDAC3 is negatively regulated by the nuclear protein DBC1.; Initial characterization of the human central proteome.; A BEN-domain-containing protein associates with heterochromatin and represses transcription.; Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes.; A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from oxidative stress through interaction with histone deacetylase 3.; Regulation of histone acetyltransferase TIP60 function by histone deacetylase 3.; Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription.; MicroRNA-10a is crucial for endothelial response to different flow patterns via interaction of retinoid acid receptors and histone deacetylases.; Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation pathway.; USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.; Dynamic crotonylation of EB1 by TIP60 ensures accurate spindle positioning in mitosis.; Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.; NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.; Structure of HDAC3 bound to co-repressor and inositol tetraphosphate.",False
GH1,P01241,Somatotropin,MATGSRTSLLLAFGLLCLPWLQEGSAFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF,,,"Molecular cloning and nucleotide sequence of the human growth hormone structural gene.; Human growth hormone: complementary DNA cloning and expression in bacteria.; Human growth hormone DNA sequence and mRNA structure: possible alternative splicing.; The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone.; The human growth hormone locus: nucleotide sequence, biology, and evolution.; A novel gene expressed in human pituitary.; Complex signatures of locus-specific selective pressures and gene conversion on human growth hormone/chorionic somatomammotropin genes.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Periplasmic production of correctly processed human growth hormone in Escherichia coli: natural and bacterial signal sequences are interchangeable.; Human pituitary growth hormone. XIX. The primary structure of the hormone.; Human pituitary growth hormone. 32. The primary structure of the hormone: revision.; Sequence comparison of human pituitary growth hormone, human chorionic somatomammotropin, and ovine pituitary growth and lactogenic hormones.; Revised primary structure for human growth hormone.; Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication.; The chemistry of the human lactogenic hormones.; The 20,000 molecular weight variant of human growth hormone. Preparation and some physical and chemical properties.; The 20,000-dalton variant of human growth hormone: location of the amino acid deletions.; Altered proteolytic cleavage of human growth hormone as a result of deamidation.; A new mutation causing inherited growth hormone deficiency: a compound heterozygote of a 6.7 kb deletion and a two base deletion in the third exon of the GH-1 gene.; Identification and characterization of phosphorylated proteins in the human pituitary.; Growth hormone heterogeneity in human pituitary and plasma.; Phosphoproteomic analysis of the human pituitary.; Prediction of the three-dimensional structure of human growth hormone.; Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.; The X-ray structure of a growth hormone-prolactin receptor complex.; The crystal-structure of wild-type growth-hormone at 2.5-A resolution.; Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9-A resolution.; Short stature caused by a mutant growth hormone.; Detection of growth hormone gene defects by dideoxy fingerprinting (ddF).; Biologically inactive growth hormone caused by an amino acid substitution.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Autosomal dominant GH deficiency due to an Arg183His GH-1 gene mutation: clinical and molecular evidence of impaired regulated GH secretion.; Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature.; A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway.; Short stature caused by a biologically inactive mutant growth hormone (GH-C53S).; Evaluation of the biological activity of a growth hormone (GH) mutant (R77C) and its impact on GH responsiveness and stature.",False
IL7R,P16871,Interleukin-7 receptor subunit alpha,MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ,,,"Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily.; Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter.; Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The Tetraspanin CD53 Regulates Early B Cell Development by Promoting IL-7R Signaling.; MARCH8 Mediates K27-Linked Polyubiquitination of IL-7 Receptor alpha to Negatively Regulate IL-7-Triggered T Cell Homeostasis.; Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.; A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency.; Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.",False
IGF1,P05019,Insulin-like growth factor 1,MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGKKGK,,,"Sequence of cDNA encoding human insulin-like growth factor I precursor.; Organization of the human genes for insulin-like growth factors I and II.; Complete characterization of the human IGF-I nucleotide sequence isolated from a newly constructed adult liver cDNA library.; Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides.; Two insulin-like growth factor I messenger RNAs are expressed in human liver.; A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells.; Complete nucleotide sequence of the high molecular weight human IGF-I mRNA.; Characterization of two cDNAs encoding insulin-like growth factor 1 (IGF-1) in the human fetal brain.; Characterization of insulin-like growth factor 1 in human primary brain tumors.; The finished DNA sequence of human chromosome 12.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Insulin-like growth factor II precursor gene organization in relation to insulin gene family.; The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin.; Location of disulphide bonds in human insulin-like growth factors (IGFs) synthesized by recombinant DNA technology.; The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.; The SRC homology 2 domain protein Shep1 plays an important role in the penetration of olfactory sensory axons into the forebrain.; Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I.; Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.; Insulin-like growth factor (IGF) signaling requires alphavbeta3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.; An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.; SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients.; Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors.; Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study.; 1H-NMR assignment and secondary structure of human insulin-like growth factor-I (IGF-I) in solution.; Structural basis for assembly and disassembly of the IGF/IGFBP/ALS ternary complex.; Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Genomic analysis of primordial dwarfism reveals novel disease genes.",False
IGF2,P01344,Insulin-like growth factor 2,MGIPMGKSMLVLLTFLAFASCCIAAYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRLRRGLPALLRARRGHVLAKELEAFREAKRHRPLIALPTQDPAHGGAPPEMASNRK,,,"Insulin-like growth factor II precursor gene organization in relation to insulin gene family.; Sequence of a cDNA clone encoding human preproinsulin-like growth factor II.; Isolation of an insulin-like growth factor II cDNA with a unique 5' untranslated region from human placenta.; Organization of the human genes for insulin-like growth factors I and II.; Tissue-specific expression of insulin-like growth factor II mRNAs with distinct 5' untranslated regions.; Human insulin-like growth factor I and II messenger RNA: isolation of complementary DNA and analysis of expression.; Nucleotide sequences of cDNAs encoding precursors of human insulin-like growth factor II (IGF-II) and an IGF-II variant.; Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: its identity with insulin-like growth factor II.; Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human.; Down-regulation of achaete-scute complex homolog 1 (ASCL1) in neuroblastoma cells induces up-regulation of insulin-like growth factor 2 (IGF2).; Large-scale cDNA transfection screening for genes related to cancer development and progression.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein.; A new 5'-non-coding region for human placental insulin-like growth factor II mRNA expression.; Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene.; Primary structure of human insulin-like growth factor II.; Structure and activity dependence of recombinant human insulin-like growth factor II on disulfide bond pairing.; Purification and characterization of insulin-like growth factor II (IGF II) and an IGF II variant from human placenta.; The identification of O-glycosylated precursors of insulin-like growth factor II.; Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males.; Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry.; Quantitative mass spectrometric immunoassay of insulin like growth factor 1.; Role of pro-IGF-II processing by proprotein convertase 4 in human placental development.; Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo.; Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.; Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): results from a large cohort of patients with SRS and SRS-like phenotypes.; Enrichment of glycopeptides for glycan structure and attachment site identification.; Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD.; LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.; Insulin-like growth factor-II: its role in metabolic and endocrine disease.; Paternally inherited IGF2 mutation and growth restriction.; Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.; Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors.; Solution structure of human insulin-like growth factor II; recognition sites for receptors and binding proteins.; Structure and functional analysis of the IGF-II/IGF2R interaction.; Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction.",False
INS,P01308,Insulin,MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN,,,"Sequence of the human insulin gene.; Genetic variation in the human insulin gene.; Nucleotide sequence of a cDNA clone encoding human preproinsulin.; Nucleotide sequence of human preproinsulin complementary DNA.; Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR.; Insulinomas and expression of an insulin splice variant.; Global haplotype diversity in the human insulin gene region.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Description of a novel RFLP diallelic polymorphism (-127 BsgI C/G) within the 5' region of insulin gene.; Amino-acid sequence of human insulin.; Studies on human proinsulin. Isolation and amino acid sequence of the human pancreatic C-peptide.; The amino acid sequence of the C-peptide of human proinsulin.; Total synthesis of human insulin under directed formation of the disulfide bonds.; Studies on polypeptides, IV. The synthesis of C-peptide of human proinsulin.; Synthesis of peptides with the properties of human proinsulin C peptides (hC peptide). 3. Synthesis of the sequences 14-17 and 9-13 of human proinsulin C peptides.; Synthesis of peptides with the properties of human proinsulin C peptides (hC peptide). I. Scheme for the synthesis and preparation of the sequence 28-31 of human proinsulin C peptide.; Studies on mutant human insulin genes: identification and sequence analysis of a gene encoding [SerB24]insulin.; Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution.; A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia.; Structurally abnormal insulin in a diabetic patient. Characterization of the mutant insulin A3 (Val-->Leu) isolated from the pancreas.; Two unrelated patients with familial hyperproinsulinemia due to a mutation substituting histidine for arginine at position 65 in the proinsulin molecule: identification of the mutation by direct sequencing of genomic deoxyribonucleic acid amplified by polymerase chain reaction.; Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia.; A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto).; Toward the solution structure of human insulin: sequential 2D 1H NMR assignment of a des-pentapeptide analogue and comparison with crystal structure.; Comparative 2D NMR studies of human insulin and des-pentapeptide insulin: sequential resonance assignment and implications for protein dynamics and receptor recognition.; Two-dimensional NMR studies of Des-(B26-B30)-insulin: sequence-specific resonance assignments and effects of solvent composition.; Three-dimensional solution structure of an insulin dimer. A study of the B9(Asp) mutant of human insulin using nuclear magnetic resonance, distance geometry and restrained molecular dynamics.; Paradoxical structure and function in a mutant human insulin associated with diabetes mellitus.; Solution structures of the R6 human insulin hexamer.; Insulin gene mutations as a cause of permanent neonatal diabetes.; Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.; Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes.; Further evidence that mutations in INS can be a rare cause of Maturity-Onset Diabetes of the Young (MODY).; Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young.",False
NGF,P01138,Beta-nerve growth factor,MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQAHWTKLQHSLDTALRRARSAPAAAIAARVAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNRTHRSKRSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA,,,"Human beta-nerve growth factor gene sequence highly homologous to that of mouse.; Sequence homology of human and mouse beta-NGF subunit genes.; cDNA sequence of human beta-NGF.; Cloning and sequencing of the gene for premature beta nerve growth factor.; Human-specific amino acid changes found in 103 protein-coding genes.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary.; The trk proto-oncogene encodes a receptor for nerve growth factor.; SorCS3 does not require propeptide cleavage to bind nerve growth factor.; Nerve growth factor inhibits metalloproteinase-disintegrins and blocks ectodomain shedding of platelet glycoprotein VI.; Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor.; Structure of nerve growth factor complexed with the shared neurotrophin receptor p75.; Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception.; A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy.; Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort.",False
IRS1,P35568,Insulin receptor substrate 1,MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ,,,"Human skeletal muscle insulin receptor substrate-1. Characterization of the cDNA, gene, and chromosomal localization.; Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The insulin receptor substrate (IRS-1) is a PEST protein that is susceptible to calpain degradation in vitro.; Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells.; Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.; Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains.; Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.; Src homology 3 domain-dependent interaction of Nck-2 with insulin receptor substrate-1.; Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2.; Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101).; ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.; Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase.; S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Subcellular localization of IRS-1 in IGF-I-mediated chondrogenic proliferation, differentiation and hypertrophy of bone marrow mesenchymal stem cells.; The double-stranded RNA-dependent protein kinase differentially regulates insulin receptor substrates 1 and 2 in HepG2 cells.; C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate 1 (IRS-1), regulating IRS-1 stability and muscle atrophy.; Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishevelled2.; Regulation of C1-Ten protein tyrosine phosphatase by p62/SQSTM1-mediated sequestration and degradation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Cellular phosphatase activity of C1-Ten/Tensin2 is controlled by Phosphatidylinositol-3,4,5-triphosphate binding through the C1-Ten/Tensin2 SH2 domain.; The E3 ligase TRAF4 Promotes IGF Signaling by Mediating Atypical Ubiquitination of IRS-1.; An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling.; The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction.; Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain.; Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1.; Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.; Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus.; Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus.; Novel allele of the insulin receptor substrate-1 bearing two non-conservative amino acid substitutions in a patient with noninsulin-dependent diabetes mellitus.; The Gly-->Arg(972) amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells.; The Arg(972) variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients.; Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance.; A novel T608R missense mutation in insulin receptor substrate-1 identified in a subject with type 2 diabetes impairs metabolic insulin signaling.; G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.; Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation.",False
PTPN1,P18031,Tyrosine-protein phosphatase non-receptor type 1,MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEPPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYGIESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLTAGAYLCYRFLFNSNT,,,"Cloning of a cDNA for a major human protein-tyrosine-phosphatase.; Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins.; Multi-site phosphorylation of the protein tyrosine phosphatase, PTP1B: identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation.; The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence.; Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor.; The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B.; Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; PTP1B regulates Eph receptor function and trafficking.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling.; Initial characterization of the human central proteome.; H2s-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A protein phosphatase network controls the temporal and spatial dynamics of differentiation commitment in human epidermis.; Crystal structure of human protein tyrosine phosphatase 1B.; Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design.; Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by X-ray crystallography.; Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics.; Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate.; Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B.; Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism.",False
IRS2,Q9Y4H2,Insulin receptor substrate 2,MASPPRHGPPGPASGDGPNLNNNNNNNNHSVRKCGYLRKQKHGHKRFFVLRGPGAGGDEATAGGGSAPQPPRLEYYESEKKWRSKAGAPKRVIALDCCLNINKRADAKHKYLIALYTKDEYFAVAAENEQEQEGWYRALTDLVSEGRAAAGDAPPAAAPAASCSASLPGALGGSAGAAGAEDSYGLVAPATAAYREVWQVNLKPKGLGQSKNLTGVYRLCLSARTIGFVKLNCEQPSVTLQLMNIRRCGHSDSFFFIEVGRSAVTGPGELWMQADDSVVAQNIHETILEAMKALKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQTGLVRRSRTDSLAATPPAAKCSSCRVRTASEGDGGAAAGAAAAGARPVSVAGSPLSPGPVRAPLSRSHTLSGGCGGRGSKVALLPAGGALQHSRSMSMPVAHSPPAATSPGSLSSSSGHGSGSYPPPPGPHPPLPHPLHHGPGQRPSSGSASASGSPSDPGFMSLDEYGSSPGDLRAFCSHRSNTPESIAETPPARDGGGGGEFYGYMTMDRPLSHCGRSYRRVSGDAAQDLDRGLRKRTYSLTTPARQRPVPQPSSASLDEYTLMRATFSGSAGRLCPSCPASSPKVAYHPYPEDYGDIEIGSHRSSSSNLGADDGYMPMTPGAALAGSGSGSCRSDDYMPMSPASVSAPKQILQPRAAAAAAAAVPSAGPAGPAPTSAAGRTFPASGGGYKASSPAESSPEDSGYMRMWCGSKLSMEHADGKLLPNGDYLNVSPSDAVTTGTPPDFFSAALHPGGEPLRGVPGCCYSSLPRSYKAPYTCGGDSDQYVLMSSPVGRILEEERLEPQATPGPSQAASAFGAGPTQPPHPVVPSPVRPSGGRPEGFLGQRGRAVRPTRLSLEGLPSLPSMHEYPLPPEPKSPGEYINIDFGEPGARLSPPAPPLLASAASSSSLLSASSPASSLGSGTPGTSSDSRQRSPLSDYMNLDFSSPKSPKPGAPSGHPVGSLDGLLSPEASSPYPPLPPRPSASPSSSLQPPPPPPAPGELYRLPPASAVATAQGPGAASSLSSDTGDNGDYTEMAFGVAATPPQPIAAPPKPEAARVASPTSGVKRLSLMEQVSGVEAFLQASQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSPSFAHNPKRHNSASVENVSLRKSSEGGVGVGPGGGDEPPTSPRQLQPAPPLAPQGRPWTPGQPGGLVGCPGSGGSPMRRETSAGFQNGLNYIAIDVREEPGLPPQPQPPPPPLPQPGDKSSWGRTRSLGGLISAVGVGSTGGGCGGPGPGALPPANTYASIDFLSHHLKEATIVKE,,,"14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain.; Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene.; Insulin receptor substrate 2 gene sequence.; The DNA sequence and analysis of human chromosome 13.; Two missense mutations in insulin receptor substrate 2 (G879S and G882A).; SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Phosphoproteome of resting human platelets.; A quantitative atlas of mitotic phosphorylation.; Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishevelled2.; Nedd4-induced monoubiquitination of IRS-2 enhances IGF signalling and mitogenic activity.; The Insulin Receptor Adaptor IRS2 is an APC/C Substrate That Promotes Cell Cycle Protein Expression and a Robust Spindle Assembly Checkpoint.; Complex haplotypes of IRS2 gene are associated with severe obesity and reveal heterogeneity in the effect of Gly1057Asp mutation.",False
AKT1,P31749,RAC-alpha serine/threonine-protein kinase,MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA,,,"Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily.; Isolation and characterization of the human AKT1 gene, identification of 13 single nucleotide polymorphisms (SNPs), and their lack of association with Type II diabetes.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families.; CREB is a regulatory target for the protein kinase Akt/PKB.; Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase.; Mechanism of activation of protein kinase B by insulin and IGF-1.; Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha.; Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B.; Phosphorylation and regulation of Raf by Akt (protein kinase B).; Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage.; The protooncogene TCL1 is an Akt kinase coactivator.; Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.; Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.; Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane.; A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain.; Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.; Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase.; Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.; Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1.; TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.; PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.; Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk.; PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion.; LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway.; Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase.; Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt.; PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt.; Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.; Akt/PKB regulates actin organization and cell motility via Girdin/APE.; The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells.; Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.; Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias.; A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.; Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Kinetic mechanism of AKT/PKB enzyme family.; Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.; The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1.; Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation.; Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells.; A quantitative atlas of mitotic phosphorylation.; The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt.; Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons.; The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin dynamics and thereby regulate cell migration.; The E3 ligase TRAF6 regulates Akt ubiquitination and activation.; Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt.; Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120.; Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation.; The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.; Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway.; Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by the IGF1-Akt Pathway.; Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.; Initial characterization of the human central proteome.; Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2.; Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt.; Microarray-assisted pathway analysis identifies MT1X & NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.; OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.; Signal transduction via the stem cell factor receptor/c-Kit.; The protein kinase B/Akt signalling pathway in human malignancy.; A novel human dynactin-associated protein, dynAP, promotes activation of Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of human cancer cells.; Akt signalling in health and disease.; Akt1 and Akt2: differentiating the aktion.; IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.; The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.; Akt is negatively regulated by the MULAN E3 ligase.; Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling.; CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.; MOZ increases p53 acetylation and premature senescence through its complex formation with PML.; BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.; Akt kinase-mediated checkpoint of cGAS DNA sensing pathway.; KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.; Regulation of serine-threonine kinase Akt activation by NAD+-dependent deacetylase SIRT7.; Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated phosphorylation.; Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth.; Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis.; Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.; The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.; Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175.; RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation.; High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate.; Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change.; Synthesis and structure based optimization of novel Akt inhibitors.; Discovery of pyrrolopyrimidine inhibitors of Akt.; Design of selective, ATP-competitive inhibitors of Akt.; Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.; Discovery and SAR of spirochromane Akt inhibitors.; A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.; Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.; A mosaic activating mutation in AKT1 associated with the Proteus syndrome.; Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.",False
PIK3CB,P42338,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLWKQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGEKLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEHEPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDEVSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAIEAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHGTELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTINPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQTNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKEILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPKLPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFLLERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLKTLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMDSKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYGCLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEEFTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFILTYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKDIQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS,,,"Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85.; Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma.; Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.; Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.; PTEN-deficient cancers depend on PIK3CB.; p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.; A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.; Initial characterization of the human central proteome.; Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.; A beta version of life: p110beta takes center stage.; Regulation and roles of PI3Kbeta, a major actor in platelet signaling and functions.",False
NGFR,P08138,Tumor necrosis factor receptor superfamily member 16,MGAGATGRAMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGISVDSQSLHDQQPHTQTASGQALKGDGGLYSSLPPAKREEVEKLLNGSAGDTWRHLAGELGYQPEHIDSFTHEACPVRALLASWATQDSATLDALLAALRRIQRADLVESLCSESTATSPV,,,"Expression and structure of the human NGF receptor.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A constitutive promoter directs expression of the nerve growth factor receptor gene.; TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction.; Association of the p75 neurotrophin receptor with TRAF6.; Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB activation.; The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor.; RanBPM is a novel binding protein for p75NTR.; LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.; O-linked oligosaccharide on the 75-kDa neurotrophin receptor.; Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth.; Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac.; p75NTR signal transduction suppressed by BFAR and p75NTR interactions.; p75 neurotrophin receptor is a clock gene that regulates oscillatory components of circadian and metabolic networks.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; SorCS2 regulates dopaminergic wiring and is processed into an apoptotic two-chain receptor in peripheral glia.; Structural basis of death domain signaling in the p75 neurotrophin receptor.",False
HRAS,P01112,GTPase HRas,MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS,,,"Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.; Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene.; Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.; Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mechanism of activation of a human oncogene.; Identification of the principal promoter sequence of the c-H-ras transforming oncogene: deletion analysis of the 5'-flanking region by focus formation assay.; Affinity labeling of c-H-ras p21 consensus elements with periodate-oxidized GDP and GTP.; Isolation of ras GTP-binding mutants using an in situ colony-binding assay.; Deletion mutants of Harvey ras p21 protein reveal the absolute requirement of at least two distant regions for GTP-binding and transforming activities.; All ras proteins are polyisoprenylated but only some are palmitoylated.; Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation.; Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation.; Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes.; A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction.; Functional consequences of monoglucosylation of Ha-Ras at effector domain amino acid threonine 35.; Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization.; RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a Ras/Rap1A-associating domain, is conserved between nematode and humans.; Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras.; Nedd4 regulates ubiquitination and stability of the guanine-nucleotide exchange factor CNrasGEF.; Diacylglycerol kinase zeta regulates Ras activation by a novel mechanism.; The complex of Arl2-GTP and PDE delta: from structure to function.; The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras.; A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.; Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.; DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras.; An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.; Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin.; Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation catalysed by Clostridium sordellii lethal toxin.; SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a.; Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.; Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF activation and Noonan syndrome.; Structural basis for SHOC2 modulation of RAS signalling.; Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase complex.; Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21.; Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation.; Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35-A resolution: implications for the mechanism of GTP hydrolysis.; Crystal structures at 2.2-A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP.; Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy.; The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.; The pre-hydrolysis state of p21(ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins.; The structural basis for the transition from Ras-GTP to Ras-GDP.; Structural and biochemical studies of p21Ras S-nitrosylation and nitric oxide-mediated guanine nucleotide exchange.; A newly designed microspectrofluorometer for kinetic studies on protein crystals in combination with x-ray diffraction.; Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf.; Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.; Structural insights into Ras regulation by SIN1.; The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma.; RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.; Germline mutations in HRAS proto-oncogene cause Costello syndrome.; HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.; Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.; Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome.; Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation.; Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype?; Severe neonatal manifestations of Costello syndrome.; Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.; Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.",False
MYC,P01106,Myc proto-oncogene protein,MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA,,,"The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.; Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.; Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29.; Nucleotide sequence of cloned cDNA of human c-myc oncogene.; Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.; Nucleotide sequence analysis of human c-myc locus, chicken homologue, and myelocytomatosis virus MC29 transforming gene reveals a highly conserved gene product.; Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.; Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon.; Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas.; A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas.; The pathogenesis of Burkitt's lymphoma.; DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.; Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.; Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-73 and Ser-77.; c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.; c-Raf kinase binds to N-terminal domain of c-Myc.; Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.; Six lysine residues on c-Myc are direct substrates for acetylation by p300.; c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.; PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; CIP2A inhibits PP2A in human malignancies.; Induction of pluripotent stem cells from adult human fibroblasts by defined factors.; Fbw7 and Usp28 regulate myc protein stability in response to DNA damage.; The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth.; Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer.; The ubiquitin-specific protease USP28 is required for MYC stability.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Tipping the balance: Cdk2 enables Myc to suppress senescence.; HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.; Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation.; Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis.; DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; tRNA synthetase counteracts c-Myc to develop functional vasculature.; The nucleolar protein GLTSCR2 is an upstream negative regulator of the oncogenic Nucleophosmin-MYC axis.; AMBRA1 and BECLIN 1 interplay in the crosstalk between autophagy and cell proliferation.; AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation.; The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting C-terminal degrons.; MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability.; Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.; The 9aaTAD Activation Domains in the Yamanaka Transcription Factors Oct4, Sox2, Myc, and Klf4.; Orphan quality control shapes network dynamics and gene expression.; Ribogenesis boosts controlled by HEATR1-MYC interplay promote transition into brain tumour growth.; Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.; A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia.",False
EGFR,P00533,Epidermal growth factor receptor,MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA,,,"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.; Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta.; A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor.; Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer.; Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.; Cloning of the cDNA for a short EGF receptor from human placenta.; Human and mouse alternative EGFR transcripts encoding only the extracellular domain of the receptor.; Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells.; Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells.; Isolation of an evolutionarily conserved epidermal growth factor receptor cDNA from human A431 carcinoma cells.; The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription.; Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis.; Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene.; Production of an epidermal growth factor receptor-related protein.; Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo.; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; Identification of residues in the nucleotide binding site of the epidermal growth factor receptor/kinase.; Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain.; Disulfide bond structure of human epidermal growth factor receptor.; ATP-stimulated interaction between epidermal growth factor receptor and supercoiled DNA.; Receptors for epidermal growth factor and other polypeptide mitogens.; Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation.; All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.; Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells.; Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor.; Interaction of ZPR1 with translation elongation factor-1alpha in proliferating cells.; Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor.; Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction.; Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.; Analysis of the glycosylation patterns of the extracellular domain of the epidermal growth factor receptor expressed in Chinese hamster ovary fibroblasts.; Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.; Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase.; Inhibition of the receptor-binding function of clathrin adaptor protein AP-2 by dominant-negative mutant mu2 subunit and its effects on endocytosis.; Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing adapter protein having similar binding and biological properties to Nck.; Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor.; RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation.; Characterization of glycosylation sites of the epidermal growth factor receptor.; Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.; LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.; Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.; The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome.; The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.; Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling.; Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.; Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications-comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR).; Functional implications of altered subcellular localization of PELP1 in breast cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Tyrosine phosphorylation controls PCNA function through protein stability.; Syntaxin 9 is enriched in skin hair follicle epithelium and interacts with the epidermal growth factor receptor.; The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus.; Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.; Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation.; A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells.; Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking.; Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.; GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, contributes to cellular transformation through the activation of extracellular signal-regulated kinase signaling.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; Large-scale proteomics analysis of the human kinome.; G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells.; ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.; COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport.; Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts.; A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.; Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation.; EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.; FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.; The Ankrd 13 family of UIM-bearing proteins regulates EGF receptor endocytosis from the plasma membrane.; Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression.; CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.; The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of the epidermal growth factor receptor.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin.; Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts.; EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer.; Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.; NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.; Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.; Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance.; Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells.; Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation pathway.; TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation.; ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.; CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR internalization and metabolism through recycling pathway.; Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.; Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.; EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.; A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.; Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.; A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor.; Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.; Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.; The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.; Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.; The juxtamembrane region of the EGF receptor functions as an activation domain.; Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases.; Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.; Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 peptide.; Structural flexibility regulates phosphopeptide-binding activity of the tyrosine kinase binding domain of Cbl-c.; High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.; EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.; Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.; Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.; Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.; Patterns of somatic mutation in human cancer genomes.; Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR.",False
ERBB2,P04626,Receptor tyrosine-protein kinase erbB-2,MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV,,,"Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.; Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.; NEDO human cDNA sequencing project focused on splicing variants.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.; Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism.; A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.; Amplification of a novel v-erbB-related gene in a human mammary carcinoma.; Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene.; ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.; Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.; Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.; Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.; Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2.; Memo mediates ErbB2-driven cell motility.; Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.; Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.; Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and patterning of the developing nervous system in vivo.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Brk is coamplified with ErbB2 to promote proliferation in breast cancer.; ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.; Copine-III interacts with ErbB2 and promotes tumor cell migration.; ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.; Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes.; Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced HSP90 isoforms and their conformationally restricted mutants.; Crystal structure and substrate specificity of PTPN12.; SORLA regulates endosomal trafficking and oncogenic fitness of HER2.; SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane.; SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line.; IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis.; Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.; Novel mode of ligand recognition by the Erbin PDZ domain.; Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2.; Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.; Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.; Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.; Structural basis for high-affinity HER2 receptor binding by an engineered protein.; Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.; Characterization of a new allele of the human ERBB2 gene by allele-specific competition hybridization.; Lung cancer: intragenic ERBB2 kinase mutations in tumours.; Patterns of somatic mutation in human cancer genomes.; Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.",False
INSR,P06213,Insulin receptor,MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNEECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECLGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQGCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGCTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETLEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQERNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFSDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWERQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQILKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAFPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSNPS,,,"The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.; Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.; Human insulin-receptor gene. Partial sequence and amplification of exons by polymerase chain reaction.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of the promoter region of the human insulin receptor gene. Evidence for promoter activity.; Characterization of the promoter region of the human insulin receptor gene.; Characterization of the promoter region and 3' end of the human insulin receptor gene.; Structural and functional analysis of the insulin receptor promoter.; Substructural analysis of the insulin receptor by microsequence analyses of limited tryptic fragments isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence or presence of dithiothreitol.; Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification.; Alternative splicing of human insulin receptor messenger RNA.; Functionally distinct insulin receptors generated by tissue-specific alternative splicing.; Molecular and clinical characterization of an insertional polymorphism of the insulin-receptor gene.; Studies on the autophosphorylation of the insulin receptor from human placenta. Analysis of the sites phosphorylated by two-dimensional peptide mapping.; Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor.; Partial amino acid sequence analyses of human placental insulin receptor.; Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity.; Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity.; Analysis of the order of autophosphorylation of human insulin receptor tyrosines 1158, 1162 and 1163.; Identification of a disulfide bridge connecting the alpha-subunits of the extracellular domain of the insulin receptor.; Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity.; Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor.; Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains.; Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.; Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting.; Identification of Stat 5B as a substrate of the insulin receptor.; Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells.; Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin.; Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues.; Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.; Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit.; Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on 'substrate-trapping' mutants.; Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2.; Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.; Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain.; Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14.; Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.; Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor.; Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP.; Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans.; Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling.; Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a negative regulator of insulin signaling in primary hepatocytes and liver.; Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant.; Critical nodes in signalling pathways: insights into insulin action.; Regulation of insulin receptor function.; A quantitative atlas of mitotic phosphorylation.; A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor alpha-chain C-terminal peptide and the site 1 insulin mimetic peptides.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; Large-scale proteomics analysis of the human kinome.; Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.; Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin.; mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.; MARCH1 regulates insulin sensitivity by controlling cell surface insulin receptor levels.; SORLA facilitates insulin receptor signaling in adipocytes and exacerbates obesity.; A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin.; An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling.; Crystal structure of the tyrosine kinase domain of the human insulin receptor.; Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.; Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism.; Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor.; Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor.; Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14.; Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.; Structure of the insulin receptor ectodomain reveals a folded-over conformation.; The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.; Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2.; Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.; Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.; Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.; Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.; Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists.; How insulin engages its primary binding site on the insulin receptor.; Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing.; Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance.; A leucine-to-proline mutation in the insulin receptor in a family with insulin resistance.; Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor.; A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance.; Substitution of lysine for asparagine at position 15 in the alpha-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding.; Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance.; Functional properties of a naturally occurring Trp1200-->Ser1200 mutation of the insulin receptor.; Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms.; Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles.; A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman.; Detection of mutations in insulin receptor gene by denaturing gradient gel electrophoresis.; NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene.; Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms.; An Arg for Gly substitution at position 31 in the insulin receptor, linked to insulin resistance, inhibits receptor processing and transport.; Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of insulin receptor observed in insulin resistant diabetes.; Methionine for valine substitution in exon 17 of the insulin receptor gene in a pedigree with familial NIDDM.; Ala1048-->Asp mutation in the kinase domain of insulin receptor causes defective kinase activity and insulin resistance.; Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli type, express normal insulin receptors.; A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance.; Substitution of Leu for Pro-193 in the insulin receptor in a patient with a genetic form of severe insulin resistance.; Substitution of glutamic acid for alanine 1135 in the putative 'catalytic loop' of the tyrosine kinase domain of the human insulin receptor. A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity.; Antibodies to the extracellular receptor domain restore the hormone-insensitive kinase and conformation of the mutant insulin receptor valine 382.; A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents.; Activation of glucose transport by a natural mutation in the human insulin receptor.; Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance.; Molecular scanning of the insulin receptor gene in syndromes of insulin resistance.; Functional properties of a heterozygous mutation (Arg1174-->Gln) in the tyrosine kinase domain of the insulin receptor from a type A insulin resistant patient.; A mutation in the insulin receptor that impairs proreceptor processing but not insulin binding.; Two naturally occurring mutations in the kinase domain of insulin receptor accelerate degradation of the insulin receptor and impair the kinase activity.; Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor gene in five sibs with familial insulin resistance.; Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.; Two mutations in the insulin receptor gene of a patient with leprechaunism: application to prenatal diagnosis.; In-frame exon 2 deletion in insulin receptor RNA in a family with extreme insulin resistance in association with defective insulin binding: a case report.; Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization.; The Val985Met insulin-receptor variant in the Danish Caucasian population: lack of associations with non-insulin-dependent diabetes mellitus or insulin resistance.; Identification of two novel insulin receptor mutations, Asp59Gly and Leu62Pro, in type A syndrome of extreme insulin resistance.; Four mutant alleles of the insulin receptor gene associated with genetic syndromes of extreme insulin resistance.; Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families.; Multiple molecular mechanisms of insulin receptor dysfunction in a patient with Donohue syndrome.; Progressive decline in insulin levels in Rabson-Mendenhall syndrome.; Identification of three novel mutations in the insulin receptor gene in type A insulin resistant patients.; Identification of novel C253Y missense and Y864X nonsense mutations in the insulin receptor gene in type A insulin-resistant patients.; An arginine to cysteine(252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events.; Genotype-phenotype correlation in inherited severe insulin resistance.; Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor that is unable to bind insulin and causes Donohue's syndrome in a human subject.; Identification and functional assessment of novel and known insulin receptor mutations in five patients with syndromes of severe insulin resistance.; A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene.; Functional characterization of a novel insulin receptor mutation contributing to Rabson-Mendenhall syndrome.; Patterns of somatic mutation in human cancer genomes.; A novel mutation of the insulin receptor gene in a preterm infant with Donohue syndrome and heart failure.; Two novel mutations identified in familial cases with Donohue syndrome.; Structural Basis and Genotype-Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance.",False
NCOR1,O75376,Nuclear receptor corepressor 1,MSSSGYPPNQGAFSTEQSRYPPHSVQYTFPNTRHQQEFAVPDYRSSHLEVSQASQLLQQQQQQQLRRRPSLLSEFHPGSDRPQERRTSYEPFHPGPSPVDHDSLESKRPRLEQVSDSHFQRVSAAVLPLVHPLPEGLRASADAKKDPAFGGKHEAPSSPISGQPCGDDQNASPSKLSKEELIQSMDRVDREIAKVEQQILKLKKKQQQLEEEAAKPPEPEKPVSPPPVEQKHRSIVQIIYDENRKKAEEAHKIFEGLGPKVELPLYNQPSDTKVYHENIKTNQVMRKKLILFFKRRNHARKQREQKICQRYDQLMEAWEKKVDRIENNPRRKAKESKTREYYEKQFPEIRKQREQQERFQRVGQRGAGLSATIARSEHEISEIIDGLSEQENNEKQMRQLSVIPPMMFDAEQRRVKFINMNGLMEDPMKVYKDRQFMNVWTDHEKEIFKDKFIQHPKNFGLIASYLERKSVPDCVLYYYLTKKNENYKALVRRNYGKRRGRNQQIARPSQEEKVEEKEEDKAEKTEKKEEEKKDEEEKDEKEDSKENTKEKDKIDGTAEETEEREQATPRGRKTANSQGRRKGRITRSMTNEAAAASAAAAAATEEPPPPLPPPPEPISTEPVETSRWTEEEMEVAKKGLVEHGRNWAAIAKMVGTKSEAQCKNFYFNYKRRHNLDNLLQQHKQKTSRKPREERDVSQCESVASTVSAQEDEDIEASNEEENPEDSEVEAVKPSEDSPENATSRGNTEPAVELEPTTETAPSTSPSLAVPSTKPAEDESVETQVNDSISAETAEQMDVDQQEHSAEEGSVCDPPPATKADSVDVEVRVPENHASKVEGDNTKERDLDRASEKVEPRDEDLVVAQQINAQRPEPQSDNDSSATCSADEDVDGEPERQRMFPMDSKPSLLNPTGSILVSSPLKPNPLDLPQLQHRAAVIPPMVSCTPCNIPIGTPVSGYALYQRHIKAMHESALLEEQRQRQEQIDLECRSSTSPCGTSKSPNREWEVLQPAPHQVITNLPEGVRLPTTRPTRPPPPLIPSSKTTVASEKPSFIMGGSISQGTPGTYLTSHNQASYTQETPKPSVGSISLGLPRQQESAKSATLPYIKQEEFSPRSQNSQPEGLLVRAQHEGVVRGTAGAIQEGSITRGTPTSKISVESIPSLRGSITQGTPALPQTGIPTEALVKGSISRMPIEDSSPEKGREEAASKGHVIYEGKSGHILSYDNIKNAREGTRSPRTAHEISLKRSYESVEGNIKQGMSMRESPVSAPLEGLICRALPRGSPHSDLKERTVLSGSIMQGTPRATTESFEDGLKYPKQIKRESPPIRAFEGAITKGKPYDGITTIKEMGRSIHEIPRQDILTQESRKTPEVVQSTRPIIEGSISQGTPIKFDNNSGQSAIKHNVKSLITGPSKLSRGMPPLEIVPENIKVVERGKYEDVKAGETVRSRHTSVVSSGPSVLRSTLHEAPKAQLSPGIYDDTSARRTPVSYQNTMSRGSPMMNRTSDVTISSNKSTNHERKSTLTPTQRESIPAKSPVPGVDPVVSHSPFDPHHRGSTAGEVYRSHLPTHLDPAMPFHRALDPAAAAYLFQRQLSPTPGYPSQYQLYAMENTRQTILNDYITSQQMQVNLRPDVARGLSPREQPLGLPYPATRGIIDLTNMPPTILVPHPGGTSTPPMDRITYIPGTQITFPPRPYNSASMSPGHPTHLAAAASAEREREREREKERERERIAAASSDLYLRPGSEQPGRPGSHGYVRSPSPSVRTQETMLQQRPSVFQGTNGTSVITPLDPTAQLRIMPLPAGGPSISQGLPASRYNTAADALAALVDAAASAPQMDVSKTKESKHEAARLEENLRSRSAAVSEQQQLEQKTLEVEKRSVQCLYTSSAFPSGKPQPHSSVVYSEAGKDKGPPPKSRYEEELRTRGKTTITAANFIDVIITRQIASDKDARERGSQSSDSSSSLSSHRYETPSDAIEVISPASSPAPPQEKLQTYQPEVVKANQAENDPTRQYEGPLHHYRPQQESPSPQQQLPPSSQAEGMGQVPRTHRLITLADHICQIITQDFARNQVSSQTPQQPPTSTFQNSPSALVSTPVRTKTSNRYSPESQAQSVHHQRPGSRVSPENLVDKSRGSRPGKSPERSHVSSEPYEPISPPQVPVVHEKQDSLLLLSQRGAEPAEQRNDARSPGSISYLPSFFTKLENTSPMVKSKKQEIFRKLNSSGGGDSDMAAAQPGTEIFNLPAVTTSGSVSSRGHSFADPASNLGLEDIIRKALMGSFDDKVEDHGVVMSQPMGVVPGTANTSVVTSGETRREEGDPSPHSGGVCKPKLISKSNSRKSKSPIPGQGYLGTERPSSVSSVHSEGDYHRQTPGWAWEDRPSSTGSTQFPYNPLTMRMLSSTPPTPIACAPSAVNQAAPHQQNRIWEREPAPLLSAQYETLSDSDD,,,"ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.; Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Localization of the human nuclear receptor co-repressor (hN-CoR) gene between the CMT1A and the SMS critical regions of chromosome 17p11.2.; Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar development.; A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1.; ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.; The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2.; The histone deacetylase 9 gene encodes multiple protein isoforms.; DACH1 inhibits transforming growth factor-beta signaling through binding Smad4.; N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso.; MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.; JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2).; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Regulation of P-TEFb elongation complex activity by CDK9 acetylation.; Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; FBI-1 functions as a novel AR co-repressor in prostate cancer cells.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Structural and functional analysis of the DEAF-1 and BS69 MYND domains.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Functional analyses of a novel missense and other mutations of the vitamin D receptor in association with alopecia.; Solution structure of the first SANT domain from human nuclear receptor corepressor 1.; A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor.",False
NBN,O60934,Nibrin,MWKLLPAAGPAGGEPYRLLTGVEYVVGRKNCAILIENDQSISRNHAVLTANFSVTNLSQTDEIPVLTLKDNSKYGTFVNEEKMQNGFSRTLKSGDGITFGVFGSKFRIEYEPLVACSSCLDVSGKTALNQAILQLGGFTVNNWTEECTHLVMVSVKVTIKTICALICGRPIVKPEYFTEFLKAVESKKQPPQIESFYPPLDEPSIGSKNVDLSGRQERKQIFKGKTFIFLNAKQHKKLSSAVVFGGGEARLITEENEEEHNFFLAPGTCVVDTGITNSQTLIPDCQKKWIQSIMDMLQRQGLRPIPEAEIGLAVIFMTTKNYCDPQGHPSTGLKTTTPGPSLSQGVSVDEKLMPSAPVNTTTYVADTESEQADTWDLSERPKEIKVSKMEQKFRMLSQDAPTVKESCKTSSNNNSMVSNTLAKMRIPNYQLSPTKLPSINKSKDRASQQQQTNSIRNYFQPSTKKRERDEENQEMSSCKSARIETSCSLLEQTQPATPSLWKNKEQHLSENEPVDTNSDNNLFTDTDLKSIVKNSASKSHAAEKLRSNKKREMDDVAIEDEVLEQLFKDTKPELEIDVKVQKQEEDVNVRKRPRMDIETNDTFSDEAVPESSKISQENEIGKKRELKEDSLWSAKEISNNDKLQDDSEMLPKKLLLTEFRSLVIKNSTSRNPSGINDDYGQLKNFKKFKKVTYPGAGKLPHIIGGSDLIAHHARKNTELEEWLRQEMEVQNQHAKEESLADDLFRYNPYLKRRR,,,"Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.; The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response.; Positional cloning of the gene for Nijmegen breakage syndrome.; Sequence analysis of an 800-kb genomic DNA region on chromosome 8q21 that contains the Nijmegen breakage syndrome gene, NBS1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The full-ORF clone resource of the German cDNA consortium.; Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11, and p95.; BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.; ATM-dependent phosphorylation of nibrin in response to radiation exposure.; Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.; ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.; ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.; Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres.; Distinct functional domains of nibrin mediate Mre11 binding, focus formation, and nuclear localization.; Recruitment of NBS1 into PML oncogenic domains via interaction with SP100 protein.; NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain.; Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex.; Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1.; ATM-dependent phosphorylation of ATF2 is required for the DNA damage response.; Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage.; Nbs1 is required for ATR-dependent phosphorylation events.; ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex.; The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control.; Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage.; Phosphorylation of SDT repeats in the MDC1 N terminus triggers retention of NBS1 at the DNA damage-modified chromatin.; Structure of a second BRCT domain identified in the nijmegen breakage syndrome protein Nbs1 and its function in an MDC1-dependent localization of Nbs1 to DNA damage sites.; MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Histone H2AX participates the DNA damage-induced ATM activation through interaction with NBS1.; A supramodular FHA/BRCT-repeat architecture mediates Nbs1 adaptor function in response to DNA damage.; N terminus of CtIP is critical for homologous recombination-mediated double-strand break repair.; SOSS complexes participate in the maintenance of genomic stability.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Physical interaction between the herpes simplex virus type 1 exonuclease, UL12, and the DNA double-strand break-sensing MRN complex.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The RING finger protein RNF8 ubiquitinates Nbs1 to promote DNA double-strand break repair by homologous recombination.; Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific domains.; Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Acetylation of histone H2AX at Lys 5 by the TIP60 histone acetyltransferase complex is essential for the dynamic binding of NBS1 to damaged chromatin.; MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex.; MRNIP/C5orf45 interacts with the MRN complex and contributes to the DNA damage response.; Nbs1 converts the human Mre11/Rad50 nuclease complex into an endo/exonuclease machine specific for protein-DNA adducts.; Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection.; Single-molecule imaging reveals how Mre11-Rad50-Nbs1 initiates DNA break repair.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; UFL1 promotes histone H4 ufmylation and ATM activation.; NBS1 promotes the endonuclease activity of the MRE11-RAD50 complex by sensing CtIP phosphorylation.; Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks.; MRE11-RAD50-NBS1 promotes Fanconi Anemia R-loop suppression at transcription-replication conflicts.; A conserved Ctp1/CtIP C-terminal peptide stimulates Mre11 endonuclease activity.; NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.; NBS1 phosphorylation status dictates repair choice of dysfunctional telomeres.; Structure of the human ATM kinase and mechanism of Nbs1 binding.; Cryo-EM structure of the Mre11-Rad50-Nbs1 complex reveals the molecular mechanism of scaffolding functions.; Mutations in the Nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL).; Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility.; Polymorphisms in DNA repair and metabolic genes in bladder cancer.; First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability.; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.",False
JUND,P17535,Transcription factor JunD,METPFYGDEALSGLGGGASGSGGSFASPGRLFPGAPPTAAAGSMMKKDALTLSLSEQVAAALKPAAAPPPTPLRADGAPSAAPPDGLLASPDLGLLKLASPELERLIIQSNGLVTTTPTSSQFLYPKVAASEEQEFAEGFVKALEDLHKQNQLGAGAAAAAAAAAAGGPSGTATGSAPPGELAPAAAAPEAPVYANLSSYAGGAGGAGGAATVAFAAEPVPFPPPPPPGALGPPRLAALKDEPQTVPDVPSFGESPPLSPIDMDTQERIKAERKRLRNRIAASKCRKRKLERISRLEEKVKTLKSQNTELASTASLLREQVAQLKQKVLSHVNSGCQLLPQHQVPAY,,,"Structure and function of human jun-D.; Isolation of human cDNA clones of jun-related genes, jun-B and jun-D.; Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.; A quantitative atlas of mitotic phosphorylation.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.; Activator Protein-1: redox switch controlling structure and DNA-binding.",False
IL2,P60568,Interleukin-2,MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT,,,"Cloning of interleukin 2 mRNAs from human tonsils.; Structure and expression of a cloned cDNA for human interleukin-2.; Molecular cloning of human interleukin 2 cDNA and its expression in E. coli.; Structure of the human interleukin 2 gene.; DNA sequence of the 5' flanking region of the human interleukin 2 gene: homologies with adult T-cell leukemia virus.; T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells.; Interleukin-2 transcripts in human and rodent brains: possible expression by astrocytes.; Sequence of interleukin-2 isolated from human placental poly A+ RNA: possible role in maintenance of fetal allograft.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Organization of the DNA regions flanking the human interleukin 2 gene.; Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells.; Structure-activity relationships of recombinant human interleukin 2.; Amino acid sequence and post-translational modification of human interleukin 2.; Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells.; Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked carbohydrate chains and their location within the polypeptide.; A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma.; Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.; Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.; Simultaneous dissection and comparison of IL-2 and IL-15 signaling pathways by global quantitative phosphoproteomics.; Three-dimensional structure of interleukin-2.; Unraveling the structure of IL-2.; Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments.; The interleukin-2 and interleukin-4 receptors studied by molecular modelling.; Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.; Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.",False
PDGFB,P01127,Platelet-derived growth factor subunit B,MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHGDPGEEDGAELDLNMTRSHSGGELESLARGRRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKTALKETLGA,,,"Transforming potential of human c-sis nucleotide sequences encoding platelet-derived growth factor.; Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis.; Nucleotide sequence of transforming human c-sis cDNA clones with homology to platelet-derived growth factor.; Oncogenic potential of the human platelet-derived growth factor transcriptional unit.; Structure and sequence of the human c-sis/platelet-derived growth factor 2 (SIS/PDGF2) transcriptional unit.; A genome annotation-driven approach to cloning the human ORFeome.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of human chromosome 22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A novel human c-sis mRNA species is transcribed from a promoter in c-sis intron 1 and contains the code for an alternative PDGF B-like protein.; Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.; Nucleotide sequence analysis identifies the human c-sis proto-oncogene as a structural gene for platelet-derived growth factor.; The human osteosarcoma cell line U-2 OS expresses a 3.8 kilobase mRNA which codes for the sequence of the PDGF-B chain.; Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus.; Human platelet-derived growth factor (PDGF): amino-terminal amino acid sequence.; The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor.; Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation.; Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF.; PDGF D, a novel protease-activated growth factor.; Dermatofibrosarcoma protuberans of breast.; The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.; Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members.; Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification.; KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state.; Role of platelet-derived growth factors in physiology and medicine.; Crystal structure of human platelet-derived growth factor BB.; Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex.; Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice.",False
EGF,P01133,Pro-epidermal growth factor,MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRIDTEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSGMAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAGSLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHISKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHPLAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNECAFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPLCFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASGPQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERANMDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQPRGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCDAKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVRLQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTCLALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGCSMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCSEGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHLREDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRSRRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGMGTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPPHQMELTQ,,,"Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The primary structure of human urogastrone.; The primary structure of human EGF produced by genetic engineering, studied by high-performance tandem mass spectrometry.; Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD.; Human epidermal growth factor. High resolution solution structure and comparison with human transforming growth factor alpha.; Neurotrophic actions of a novel molluscan epidermal growth factor.; Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.; Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling.; Crystal structure of human epidermal growth factor and its dimerization.; Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.; EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.; The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin.; Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.",False
IL2RG,P31785,Cytokine receptor common subunit gamma,MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET,,,"Cloning of the gamma chain of the human IL-2 receptor.; Characterization of the human interleukin-2 receptor gamma chain gene.; The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1.; IL2RG mRNA, nirs splice variant 2.; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4.; Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor.; Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.; The human T-cell leukemia/lymphotropic virus type 1 p12I proteins bind the interleukin-2 receptor beta and gammac chains and affects their expression on the cell surface.; IL-2 receptor signaling through the Shb adapter protein in T and NK cells.; Interleukin-15 enhances human neutrophil phagocytosis by a Syk-dependent mechanism: importance of the IL-15Ralpha chain.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; The interleukin-2 and interleukin-4 receptors studied by molecular modelling.; Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.; Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.; Interleukin-2 (IL-2) receptor gamma chain mutations in X-linked severe combined immunodeficiency disease result in the loss of high-affinity IL-2 receptor binding.; Detection of three nonsense mutations and one missense mutation in the interleukin-2 receptor gamma chain gene in SCIDX1 that differently affect the mRNA processing.; Impairment of ligand binding and growth signaling of mutant IL-2 receptor gamma-chains in patients with X-linked severe combined immunodeficiency.; Defective human interleukin 2 receptor gamma chain in an atypical X chromosome-linked severe combined immunodeficiency with peripheral T cells.; Two mutational hotspots in the interleukin-2 receptor gamma chain gene causing human X-linked severe combined immunodeficiency.; Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis.; Female germ line mosaicism as the origin of a unique IL-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency.; Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency.; Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.; B-cell-negative severe combined immunodeficiency associated with a common gamma chain mutation.; Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred.; An interleukin-2 receptor gamma chain mutation with normal thymus morphology.",False
FOS,P01100,Protein c-Fos,MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL,,,"Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Retrovirus-mediated gene transfer of a human c-fos cDNA into mouse bone marrow stromal cells.; Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers.; The basic region of Fos mediates specific DNA binding.; The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells.; Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription.; Molecular interpretation of ERK signal duration by immediate early gene products.; Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.; Ubc9 fusion-directed SUMOylation identifies constitutive and inducible SUMOylation.; N-Terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; The kinase c-Src and the phosphatase TC45 coordinately regulate c-Fos tyrosine phosphorylation and c-Fos phospholipid synthesis activation capacity.; Uncovering global SUMOylation signaling networks in a site-specific manner.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.",False
PDGFRB,P09619,Platelet-derived growth factor receptor beta,MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL,,,"Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class.; cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules.; Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity.; Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm.; Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes.; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins.; Independent expression of human alpha or beta platelet-derived growth factor receptor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways.; Functions of the major tyrosine phosphorylation site of the PDGF receptor beta subunit.; Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation.; Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor.; Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.; Identification of two C-terminal autophosphorylation sites in the PDGF beta-receptor: involvement in the interaction with phospholipase C-gamma.; Ligand-induced polyubiquitination of the platelet-derived growth factor beta-receptor.; GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit.; Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases.; Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor.; Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.; Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.; Shb is a ubiquitously expressed Src homology 2 protein.; Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors.; Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.; Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis.; APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.; Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1.; Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.; Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.; PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor.; Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.; Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.; HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).; p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.; Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase.; Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II.; Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation.; A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer.; Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration.; Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways.; Glyceollins inhibit platelet-derived growth factor-mediated human arterial smooth muscle cell proliferation and migration.; Direct interaction between Shc and the platelet-derived growth factor beta-receptor.; Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo.; A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome.; Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation.; Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification.; Signal transduction via platelet-derived growth factor receptors.; PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.; PDGF receptors as targets in tumor treatment.; Role of platelet-derived growth factors in physiology and medicine.; NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex.; Structural determinants of the Na+/H+ exchanger regulatory factor interaction with the beta 2 adrenergic and platelet-derived growth factor receptors.; Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex.; Patterns of somatic mutation in human cancer genomes.; Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.; A recurrent PDGFRB mutation causes familial infantile myofibromatosis.; Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification.; Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification.; A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.; Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions.",False
EPOR,P19235,Erythropoietin receptor,MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPVSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTHKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGLSDGPYSNPYENSLIPAAEPLPPSYVACS,,,"The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p.; Human erythropoietin receptor: cloning, expression, and biologic characterization.; Cloning of the human erythropoietin receptor gene.; The erythropoietin receptor gene: cloning and identification of multiple transcripts in an erythroid cell line OCIM1.; A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning of the gene encoding the human erythropoietin receptor.; Genomic organization of the human erythropoietin receptor gene.; Isolation of a cDNA encoding a potential soluble receptor for human erythropoietin.; Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation.; Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways.; Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family.; Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia.; Design and application of a cytokine-receptor-based interaction trap.; A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor.; Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation.; APS, an adaptor protein containing pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl.; Cloning and characterization of a family of proteins associated with Mpl.; RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development.; Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A.; An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.; Efficiency of signalling through cytokine receptors depends critically on receptor orientation.; Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin.; Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.; Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase.; Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.; Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia.; Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies.; Analysis of protein-coding genetic variation in 60,706 humans.",False
SST,P61278,Somatostatin,MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEPNQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC,,,"Human somatostatin I: sequence of the cDNA.; Sequence of the human somatostatin I gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin.",False
PRKCD,Q05655,Protein kinase C delta type,MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFDAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQYFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFVWGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED,,,"Molecular and biochemical characterization of a recombinant human PKC-delta family member.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Partial cDNA Sequence of human protein kinase C delta.; Functional analyses of mammalian protein kinase C isozymes in budding yeast and mammalian fibroblasts.; Identification of a novel antiapoptotic human protein kinase C delta isoform, PKCdeltaVIII in NT2 cells.; Identification of multiple, novel, protein kinase C-related gene products.; Regulation of human eosinophil NADPH oxidase activity: a central role for PKCdelta.; Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction.; Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by a C-terminal PRK2 fragment.; Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling.; Phospholipid scramblase 3 is the mitochondrial target of protein kinase C delta-induced apoptosis.; Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9.; Roles of tyrosine phosphorylation and cleavage of protein kinase Cdelta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis.; PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation.; Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling.; Novel phosphorylation site markers of protein kinase C delta activation.; Activation of acid sphingomyelinase by protein kinase Cdelta-mediated phosphorylation.; The localization of protein kinase Cdelta in different subcellular sites affects its proapoptotic and antiapoptotic functions and the activation of distinct downstream signaling pathways.; Protein kinase C delta is phosphorylated on five novel Ser/Thr sites following inducible overexpression in human colorectal cancer cells.; Phosphoproteome of resting human platelets.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Regulation of TNF-induced oxygen radical production in human neutrophils: role of delta-PKC.; Protein kinase C delta (PKC delta): activation mechanisms and functions.; Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death.; Initial characterization of the human central proteome.; PKC-delta and PKC-epsilon: Foes of the same family or strangers?; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Protein kinase cdelta in apoptosis: a brief overview.; B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C delta.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop.; Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs.; The C2 domain of PKCdelta is a phosphotyrosine binding domain.; Solution structure of the first phorbol esters/diacylglycerol binding domain of human protein kinase C, delta.",False
PPARA,Q07869,Peroxisome proliferator-activated receptor alpha,MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY,,,"cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor.; Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators.; Peroxisome proliferator-activated receptors: structures and function.; DNA-binding profiling of human hormone nuclear receptors via fluorescence correlation spectroscopy in a cell-free system.; Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.; A novel alternatively spliced peroxisome proliferator-activated receptor alpha.; A genome annotation-driven approach to cloning the human ORFeome.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of human chromosome 22.; Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat.; RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.; Regulation of peroxisome proliferator-activated receptor alpha-induced transactivation by the nuclear orphan receptor TAK1/TR4.; Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR.; Cloning and characterization of RAP250, a nuclear receptor coactivator.; Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.; Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha.; Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}.; SIRT4 represses peroxisome proliferator-activated receptor alpha activity to suppress hepatic fat oxidation.; MicroRNA-10a is crucial for endothelial response to different flow patterns via interaction of retinoid acid receptors and histone deacetylases.; Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.; Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.; Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha.; Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.; Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.; Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.; Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.; Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.",False
RET,P07949,Proto-oncogene tyrosine-protein kinase receptor Ret,MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS,,,"Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence.; Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.; ret transforming gene encodes a fusion protein homologous to tyrosine kinases.; Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy-termini due to alternative splicing.; PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.; RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.; Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium.; The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.; Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.; Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site.; Identification of RET autophosphorylation sites by mass spectrometry.; Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient.; The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.; The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.; Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.; Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.; CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation of ret signal transduction.; The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability.; Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3.; Large-scale proteomics analysis of the human kinome.; RETouching upon mechanoreceptors.; The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.; Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.; Functional role of the RET dependence receptor, GFRa co-receptors and ligands in the pituitary.; RET-mediated cell adhesion and migration require multiple integrin subunits.; Direct visualization of vesicle maturation and plasma membrane protein trafficking.; A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo.; RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons.; Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.; Sorting protein-related receptor SorLA controls regulated secretion of glial cell line-derived neurotrophic factor.; SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRalpha1 and RET.; Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15.; Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15.; GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.; GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.; The active site of O-GlcNAc transferase imposes constraints on substrate sequence.; Structure and chemical inhibition of the RET tyrosine kinase domain.; Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.; Mammal-restricted elements predispose human RET to folding impairment by HSCR mutations.; RET recognition of GDNF-GFRalpha1 ligand by a composite binding site promotes membrane-proximal self-association.; Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.; Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.; Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands.; Mutations in Hirschsprung disease: when does a mutation contribute to the phenotype.; Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease.; Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.; Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.; Heterogeneity and low detection rate of RET mutations in Hirschsprung disease.; Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.; Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests.; RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.; RET proto-oncogene mutations in French MEN 2A and FMTC families.; Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.; De-novo mutations of the RET proto-oncogene in Hirschsprung's disease.; A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.; Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.; Mutations of the RET proto-oncogene in Hirschsprung's disease.; Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.; Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.; Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A).; Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.; Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.; Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B.; A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.; RET mutations in exons 13 and 14 of FMTC patients.; Mutations in three genes are found associated with the development of Hirschsprung disease: RET, EDNRB and EDN3.; Prevalence and parental origin of de novo RET mutations in Hirschsprung's disease.; Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.; Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.; Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype.; RET in human development and oncogenesis.; A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A.; Frequency of RET mutations in long- and short-segment Hirschsprung disease.; Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting.; Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.; A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.; Mutation analysis of the RET, the endothelin-B receptor, and the endothelin-3 genes in sporadic cases of Hirschsprung's disease.; Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.; Germline mutation of RET codon 883 in two cases of de novo MEN 2B.; Mutations of the RET-GDNF signaling pathway in Ondine's curse.; Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.; Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B).; Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation.; Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A.; A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma.; A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.; Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.; Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease.; Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.; A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma.; A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene.; Japanese patients with sporadic Hirschsprung: mutation analysis of the receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin-3, glial cell line-derived neurotrophic factor and neurturin genes: a comparison with similar studies.; A RET double mutation in the germline of a kindred with FMTC.; A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?; RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.; A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.; Three novel mutations in the RET proto-oncogene.; Germ-line mutations in nonsyndromic pheochromocytoma.; Congenital central hypoventilation syndrome: a novel mutation of the RET gene in an isolated case.; Molecular analysis of congenital central hypoventilation syndrome.; The consensus coding sequences of human breast and colorectal cancers.; Patterns of somatic mutation in human cancer genomes.; Renal aplasia in humans is associated with RET mutations.; RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese patients.; Drug resistance profiles of mutations in the RET kinase domain.",False
PLCG2,P16885,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2",MSTTVNVDSLAEYEKSQIKRALELGTVMTVFSFRKSTPERRTVQVIMETRQVAWSKTADKIEGFLDIMEIKEIRPGKNSKDFERAKAVRQKEDCCFTILYGTQFVLSTLSLAADSKEDAVNWLSGLKILHQEAMNASTPTIIESWLRKQIYSVDQTRRNSISLRELKTILPLINFKVSSAKFLKDKFVEIGAHKDELSFEQFHLFYKKLMFEQQKSILDEFKKDSSVFILGNTDRPDASAVYLHDFQRFLIHEQQEHWAQDLNKVRERMTKFIDDTMRETAEPFLFVDEFLTYLFSRENSIWDEKYDAVDMQDMNNPLSHYWISSSHNTYLTGDQLRSESSPEAYIRCLRMGCRCIELDCWDGPDGKPVIYHGWTRTTKIKFDDVVQAIKDHAFVTSSFPVILSIEEHCSVEQQRHMAKAFKEVFGDLLLTKPTEASADQLPSPSQLREKIIIKHKKLGPRGDVDVNMEDKKDEHKQQGELYMWDSIDQKWTRHYCAIADAKLSFSDDIEQTMEEEVPQDIPPTELHFGEKWFHKKVEKRTSAEKLLQEYCMETGGKDGTFLVRESETFPNDYTLSFWRSGRVQHCRIRSTMEGGTLKYYLTDNLTFSSIYALIQHYRETHLRCAEFELRLTDPVPNPNPHESKPWYYDSLSRGEAEDMLMRIPRDGAFLIRKREGSDSYAITFRARGKVKHCRINRDGRHFVLGTSAYFESLVELVSYYEKHSLYRKMRLRYPVTPELLERYNMERDINSLYDVSRMYVDPSEINPSMPQRTVKALYDYKAKRSDELSFCRGALIHNVSKEPGGWWKGDYGTRIQQYFPSNYVEDISTADFEELEKQIIEDNPLGSLCRGILDLNTYNVVKAPQGKNQKSFVFILEPKQQGDPPVEFATDRVEELFEWFQSIREITWKIDTKENNMKYWEKNQSIAIELSDLVVYCKPTSKTKDNLENPDFREIRSFVETKADSIIRQKPVDLLKYNQKGLTRVYPKGQRVDSSNYDPFRLWLCGSQMVALNFQTADKYMQMNHALFSLNGRTGYVLQPESMRTEKYDPMPPESQRKILMTLTVKVLGARHLPKLGRSIACPFVEVEICGAEYDNNKFKTTVVNDNGLSPIWAPTQEKVTFEIYDPNLAFLRFVVYEEDMFSDPNFLAHATYPIKAVKSGFRSVPLKNGYSEDIELASLLVFCEMRPVLESEEELYSSCRQLRRRQEELNNQLFLYDTHQNLRNANRDALVKEFSVNENQLQLYQEKCNKRLREKRVSNSKFYS,,,"Complete cDNA encoding a putative phospholipase C from transformed human lymphocytes.; NovelFam3000 -- uncharacterized human protein domains conserved across model organisms.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling.; Activation of phospholipase Cgamma2 by tyrosine phosphorylation.; Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Initial characterization of the human central proteome.; Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis.; Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.; A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.; Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.",False
PEX5,P50542,Peroxisomal targeting signal 1 receptor,MAMRELVEAECGGANPLMKLAGHFTQDKALRQEGLRPGPWPPGAPASEAASKPLGVASEDELVAEFLQDQNAPLVSRAPQTFKMDDLLAEMQQIEQSNFRQAPQRAPGVADLALSENWAQEFLAAGDAVDVTQDYNETDWSQEFISEVTDPLSVSPARWAEEYLEQSEEKLWLGEPEGTATDRWYDEYHPEEDLQHTASDFVAKVDDPKLANSEFLKFVRQIGEGQVSLESGAGSGRAQAEQWAAEFIQQQGTSDAWVDQFTRPVNTSALDMEFERAKSAIESDVDFWDKLQAELEEMAKRDAEAHPWLSDYDDLTSATYDKGYQFEEENPLRDHPQPFEEGLRRLQEGDLPNAVLLFEAAVQQDPKHMEAWQYLGTTQAENEQELLAISALRRCLELKPDNQTALMALAVSFTNESLQRQACETLRDWLRYTPAYAHLVTPAEEGAGGAGLGPSKRILGSLLSDSLFLEVKELFLAAVRLDPTSIDPDVQCGLGVLFNLSGEYDKAVDCFTAALSVRPNDYLLWNKLGATLANGNQSEEAVAAYRRALELQPGYIRSRYNLGISCINLGAHREAVEHFLEALNMQRKSRGPRGEGGAMSENIWSTLRLALSMLGQSDAYGAADARDLSTLLTMFGLPQ,,,"Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders.; Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal disorders.; Identification and characterization of the putative human peroxisomal C-terminal targeting signal import receptor.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The finished DNA sequence of human chromosome 12.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; C-terminal tripeptide Ser-Asn-Leu (SNL) of human D-aspartate oxidase is a functional peroxisome-targeting signal.; An isoform of pex5p, the human PTS1 receptor, is required for the import of PTS2 proteins into peroxisomes.; PEX12 interacts with PEX5 and PEX10 and acts downstream of receptor docking in peroxisomal matrix protein import.; The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol.; The di-aromatic pentapeptide repeats of the human peroxisome import receptor PEX5 are separate high affinity binding sites for the peroxisomal membrane protein PEX14.; Domain mapping of human PEX5 reveals functional and structural similarities to Saccharomyces cerevisiae Pex18p and Pex21p.; PEX5 binds the PTS1 independently of Hsp70 and the peroxin PEX12.; Shuttling mechanism of peroxisome targeting signal type 1 receptor Pex5: ATP-independent import and ATP-dependent export.; Properties of the ubiquitin-pex5p thiol ester conjugate.; PEX5 protein binds monomeric catalase blocking its tetramerization and releases it upon binding the N-terminal domain of PEX14.; Identification of ubiquitin-specific protease 9X (USP9X) as a deubiquitinase acting on ubiquitin-peroxin 5 (PEX5) thioester conjugate.; AWP1/ZFAND6 functions in Pex5 export by interacting with cys-monoubiquitinated Pex5 and Pex6 AAA ATPase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Distinct modes of ubiquitination of peroxisome-targeting signal type 1 (PTS1) receptor Pex5p regulate PTS1 protein import.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; PEX5, the shuttling import receptor for peroxisomal matrix proteins, is a redox-sensitive protein.; Mechanistic insights into PTS2-mediated peroxisomal protein import: the co-receptor PEX5L drastically increases the interaction strength between the cargo protein and the receptor PEX7.; A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform.; ATM functions at the peroxisome to induce pexophagy in response to ROS.; PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation.; The peroxisomal matrix protein translocon is a large cavity-forming protein assembly into which PEX5 protein enters to release its cargo.; TRIM37, a novel E3 ligase for PEX5-mediated peroxisomal matrix protein import.; Peroxisomal monoubiquitinated PEX5 interacts with the AAA ATPases PEX1 and PEX6 and is unfolded during its dislocation into the cytosol.; A missense allele of PEX5 is responsible for the defective import of PTS2 cargo proteins into peroxisomes.; Peroxisomal targeting signal-1 recognition by the TPR domains of human PEX5.; Recognition of a functional peroxisome type 1 target by the dynamic import receptor Pex5p.; A previously unobserved conformation for the human Pex5p receptor suggests roles for intrinsic flexibility and rigid domain motions in ligand binding.; Structural basis for competitive interactions of Pex14 with the import receptors Pex5 and Pex19.; A novel Pex14 protein-interacting site of human Pex5 is critical for matrix protein import into peroxisomes.; Functional heterogeneity of C-terminal peroxisome targeting signal 1 in PEX5-defective patients.",False
TCF3,Q9HCS4,Transcription factor 7-like 1,MPQLGGGGGGGGGGSGGGGGSSAGAAGGGDDLGANDELIPFQDEGGEEQEPSSDSASAQRDLDEVKSSLVNESENQSSSSDSEAERRPQPVRDTFQKPRDYFAEVRRPQDSAFFKGPPYPGYPFLMIPDLSSPYLSNGPLSPGGARTYLQMKWPLLDVPSSATVKDTRSPSPAHLSNKVPVVQHPHHMHPLTPLITYSNDHFSPGSPPTHLSPEIDPKTGIPRPPHPSELSPYYPLSPGAVGQIPHPLGWLVPQQGQPMYSLPPGGFRHPYPALAMNASMSSLVSSRFSPHMVAPAHPGLPTSGIPHPAIVSPIVKQEPAPPSLSPAVSVKSPVTVKKEEEKKPHVKKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRKWHNLSREEQAKYYELARKERQLHSQLYPTWSARDNYGKKKKRKREKQLSQTQSQQQVQEAEGALASKSKKPCVQYLPPEKPCDSPASSHGSMLDSPATPSAALASPAAPAATHSEQAQPLSLTTKPETRAQLALHSAAFLSAKAAASSSGQMGSQPPLLSRPLPLGSMPTALLASPPSFPATLHAHQALPVLQAQPLSLVTKSAH,,,"Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A gene family of HMG-box transcription factors with homology to TCF-1.; Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium.; Dazap2 modulates transcription driven by the Wnt effector TCF-4.; The consensus coding sequences of human breast and colorectal cancers.",False
PARP1,P09874,Poly [ADP-ribose] polymerase 1,MAESSDKLYRVEYAKSGRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPHWYHFSCFWKVGHSIRHPDVEVDGFSELRWDDQQKVKKTAEAGGVTGKGQDGIGSKAEKTLGDFAAEYAKSNRSTCKGCMEKIEKGQVRLSKKMVDPEKPQLGMIDRWYHPGCFVKNREELGFRPEYSASQLKGFSLLATEDKEALKKQLPGVKSEGKRKGDEVDGVDEVAKKKSKKEKDKDSKLEKALKAQNDLIWNIKDELKKVCSTNDLKELLIFNKQQVPSGESAILDRVADGMVFGALLPCEECSGQLVFKSDAYYCTGDVTAWTKCMVKTQTPNRKEWVTPKEFREISYLKKLKVKKQDRIFPPETSASVAATPPPSTASAPAAVNSSASADKPLSNMKILTLGKLSRNKDEVKAMIEKLGGKLTGTANKASLCISTKKEVEKMNKKMEEVKEANIRVVSEDFLQDVSASTKSLQELFLAHILSPWGAEVKAEPVEVVAPRGKSGAALSKKSKGQVKEEGINKSEKRMKLTLKGGAAVDPDSGLEHSAHVLEKGGKVFSATLGLVDIVKGTNSYYKLQLLEDDKENRYWIFRSWGRVGTVIGSNKLEQMPSKEDAIEHFMKLYEEKTGNAWHSKNFTKYPKKFYPLEIDYGQDEEAVKKLTVNPGTKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTSLW,,,"Nucleotide sequence of a full-length cDNA for human fibroblast poly(ADP-ribose) polymerase.; Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence.; cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase.; Human nuclear NAD+ ADP-ribosyltransferase(polymerizing): organization of the gene.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human poly(ADP-ribose) polymerase gene. Cloning of the promoter region.; Characterization of a putative promoter region of the human poly(ADP-ribose) polymerase gene: structural similarity to that of the DNA polymerase beta gene.; Human pADPRT is involved in the regulation of its own gene.; Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells.; Isolation of a cDNA clone for human NAD+: protein ADP-ribosyltransferase.; Molecular cloning of cDNA for human poly(ADP-ribose) polymerase and expression of its gene during HL-60 cell differentiation.; The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA.; The zinc fingers of human poly(ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA.; Expression and site-directed mutagenesis of the catalytic domain of human poly(ADP-ribose)polymerase in Escherichia coli. Lysine 893 is critical for activity.; The human poly(ADP-ribose) polymerase nuclear localization signal is a bipartite element functionally separate from DNA binding and catalytic activity.; Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation. Evidence for active site similarities to the ADP-ribosylating toxins.; Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.; Random mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids involved in polymer branching.; Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis.; Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication.; Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7.; Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro.; NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1.; Aprataxin, a novel protein that protects against genotoxic stress.; Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis.; The poly(ADP-ribose) polymerase 1 interacts with Sry and modulates its biological functions.; A novel human AP endonuclease with conserved zinc-finger-like motifs involved in DNA strand break responses.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.; A quantitative atlas of mitotic phosphorylation.; Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes.; PARP-1 transcriptional activity is regulated by sumoylation upon heat shock.; Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications.; The metastasis efficiency modifier ribosomal RNA processing 1 homolog B (RRP1B) is a chromatin-associated factor.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.; The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Toward a unified nomenclature for mammalian ADP-ribosyltransferases.; Initial characterization of the human central proteome.; hPuf-A/KIAA0020 modulates PARP-1 cleavage upon genotoxic stress.; Poly(ADP-ribose)-dependent regulation of Snail1 protein stability.; Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling.; SIRT6 promotes DNA repair under stress by activating PARP1.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling.; Suppressive regulation of KSHV RTA with O-GlcNAcylation.; Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes.; Systematic analysis of protein pools, isoforms, and modifications affecting turnover and subcellular localization.; Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.; Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; ZNF365 promotes stalled replication forks recovery to maintain genome stability.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Family-wide analysis of poly(ADP-ribose) polymerase activity.; Uncovering global SUMOylation signaling networks in a site-specific manner.; PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.; HPF1/C4orf27 is a PARP-1-interacting protein that regulates PARP-1 ADP-ribosylation activity.; Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro.; ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling.; Serine ADP-ribosylation depends on HPF1.; A Poly-ADP-Ribose trigger releases the auto-inhibition of a chromatin remodeling oncogene.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Interplay of histone marks with serine ADP-ribosylation.; Comprehensive ADP-ribosylome analysis identifies tyrosine as an ADP-ribose acceptor site.; Nuclear cGAS suppresses DNA repair and promotes tumorigenesis.; PARP2 mediates branched poly ADP-ribosylation in response to DNA damage.; KHDC3L mutation causes recurrent pregnancy loss by inducing genomic instability of human early embryonic cells.; An HPF1/PARP1-based chemical biology strategy for exploring ADP-ribosylation.; JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in response to oxidative stress by recruiting PARP1 to DNA Breaks.; Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation.; Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.; PARP1 exhibits enhanced association and catalytic efficiency with gammaH2A.X-nucleosome.; Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage.; PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.; HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.; Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy.; PARP1-cGAS-NF-kappaB pathway of proinflammatory macrophage activation by extracellular vesicles released during Trypanosoma cruzi infection and Chagas disease.; Dual function of HPF1 in the modulation of PARP1 and PARP2 activities.; PARP1-mediated PARylation of TonEBP prevents R-loop-associated DNA damage.; HPF1 and nucleosomes mediate a dramatic switch in activity of PARP1 from polymerase to hydrolase.; Serine ADP-ribosylation marks nucleosomes for ALC1-dependent chromatin remodeling.; The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis.; CARM1 regulates replication fork speed and stress response by stimulating PARP1.; XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.; XRCC1 protects transcription from toxic PARP1 activity during DNA base excision repair.; Serine-linked PARP1 auto-modification controls PARP inhibitor response.; The regulatory landscape of the human HPF1- and ARH3-dependent ADP-ribosylome.; SPINDOC binds PARP1 to facilitate PARylation.; HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP-ribose modifications.; Multiple roles for PARP1 in ALC1-dependent nucleosome remodeling.; PARP1 is activated by membrane damage and is involved in membrane repair through poly(ADP-ribosyl)ation.; RECON syndrome is a genome instability disorder caused by mutations in the DNA helicase RECQL1.; SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage.; Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation.; Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS.; The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.; Poly(ADP-ribosylation) of P-TEFb by PARP1 disrupts phase separation to inhibit global transcription after DNA damage.; ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance.; Solution structure of the first ZF-PARP domain, of the BRCT domain and of the WGR domain of human poly(ADP-ribose)polymerase-1.; A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation.; Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity.; The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks.; Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.; Timeless interacts with PARP-1 to promote homologous recombination repair.; Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1.; PARP-1 activation requires local unfolding of an autoinhibitory domain.; NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains.; Structural basis for allosteric PARP-1 retention on DNA breaks.; Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.; The BRCT domain of PARP1 binds intact DNA and mediates intrastrand transfer.; HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones.; The consensus coding sequences of human breast and colorectal cancers.",False
BRCA1,P38398,Breast cancer type 1 susceptibility protein,MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY,,,"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.; Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.; Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa).; Localization of BRCA1 and a splice variant identifies the nuclear localization signal.; BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.; BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.; Characterization of a carboxy-terminal BRCA1 interacting protein.; RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination.; BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.; Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.; hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.; BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.; BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations.; Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.; Phosphorylation of serine 1387 in BRCA1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.; NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain.; SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint.; The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.; BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.; BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.; The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.; BRCA1-independent ubiquitination of FANCD2.; Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair.; BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair.; BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.; Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response.; Human claspin works with BRCA1 to both positively and negatively regulate cell proliferation.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.; BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.; ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.; Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation.; CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response.; CCDC98 targets BRCA1 to DNA damage sites.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.; Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.; A quantitative atlas of mitotic phosphorylation.; MERIT40 facilitates BRCA1 localization and DNA damage repair.; NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control.; MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.; PALB2 is an integral component of the BRCA complex required for homologous recombination repair.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Identification of DBC1 as a transcriptional repressor for BRCA1.; The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.; The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Protein phosphatase 5 is necessary for ATR-mediated DNA repair.; KIAA0101 interacts with BRCA1 and regulates centrosome number.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; EXD2 promotes homologous recombination by facilitating DNA end resection.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.; ZGRF1 promotes end resection of DNA homologous recombination via forming complex with BRCA1/EXO1.; Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.; Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.; Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.; Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.; Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.; Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.; Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.; Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.; Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1.; Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.; Preliminary crystallographic studies of BRCA1 BRCT-ABRAXAS complex.; Structure of BRCA1-BRCT/Abraxas complex reveals phosphorylation-dependent BRCT dimerization at DNA damage sites.; Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene.; BRCA1 mutations in primary breast and ovarian carcinomas.; Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.; Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.; A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.; BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.; Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.; Mutations in the BRCA1 gene in Japanese breast cancer patients.; A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.; Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.; High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.; The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.; Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.; Germline BRCA1 alterations in a population-based series of ovarian cancer cases.; Characterization of common BRCA1 and BRCA2 variants.; BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.; BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.; Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.; BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.; One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.; Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.; BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.; The consensus coding sequences of human breast and colorectal cancers.; A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.; Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.; Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.; A high-throughput functional complementation assay for classification of BRCA1 missense variants.; Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.; Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea.; Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.",False
PIN1,Q13526,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,MADEEKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNSSSGGKNGQGEPARVRCSHLLVKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAFSRGQMQKPFEDASFALRTGEMSGPVFTDSGIHIILRTE,,,"A human peptidyl-prolyl isomerase essential for regulation of mitosis.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a novel kinesin-related protein, KRMP1, as a target for mitotic peptidyl-prolyl isomerase Pin1.; Regulation of Raf-1 by direct feedback phosphorylation.; Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients.; Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1.; Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Nerve growth factor stimulates interaction of Cayman ataxia protein BNIP-H/Caytaxin with peptidyl-prolyl isomerase Pin1 in differentiating neurons.; Protein kinase-X interacts with Pin-1 and Polycystin-1 during mouse kidney development.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.; Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function.; Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Prolyl isomerase PIN1 regulates DNA double-strand break repair by counteracting DNA end resection.; Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.; Cullin3-KLHL15 ubiquitin ligase mediates CtIP protein turnover to fine-tune DNA-end resection.; The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.; Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent.",False
PTEN,P60484,"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN",MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV,,,"TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.; Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.; PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.; The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers.; Genomic sequence of PTEN/MMAC1.; Homo sapiens phosphatase and tensin homolog mRNA splicing variants.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.; The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.; The lipid phosphatase activity of PTEN is critical for its tumor suppressor function.; Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.; The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.; Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding.; Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase.; Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2.; Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity.; The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation.; Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.; Direct identification of PTEN phosphorylation sites.; Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein.; LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes.; Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases.; Physiological levels of PTEN control the size of the cellular Ins(1,3,4,5,6)P(5) pool.; The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity.; NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.; The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.; Rak functions as a tumor suppressor by regulating PTEN protein stability and function.; X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization.; Regulation of PTEN stability and activity by Plk3.; Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2.; Initial characterization of the human central proteome.; IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; A secreted PTEN phosphatase that enters cells to alter signaling and survival.; TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in human glomerular endothelial cells.; PTENalpha, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity.; A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.; The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by targeting PTEN degradation.; The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by ISGylating the phosphatase PTEN.; Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.; The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases.; Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis.; Somatic mutations of PTEN in glioblastoma multiforme.; Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.; Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.; Germline mutations in PTEN are present in Bannayan-Zonana syndrome.; Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.; Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in patients with Cowden disease.; The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1.; Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.; Novel mutation of the PTEN gene in an Italian Cowden's disease kindred.; Germline PTEN mutations in Cowden syndrome-like families.; PTEN germ-line mutations in juvenile polyposis coli.; Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene.; Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.; Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations.; PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.; Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.; Germline PTEN mutations in three families with Cowden syndrome.; Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers.; Identification of PTEN mutations in metastatic melanoma specimens.; PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.; A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association.; Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.; A novel germline mutation of PTEN associated with brain tumours of multiple lineages.; Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.; Germline mutation of the tumour suppressor PTEN in Proteus syndrome.; Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.; The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer.; Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities.; A germline PTEN mutation with manifestations of prenatal onset and verrucous epidermal nevus.; Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.; Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.; Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.; Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates Multiple Genetic Mechanisms.; Discovery and functional characterization of a neomorphic PTEN mutation.; The genomic landscape of benign and malignant thyroid tumors from individuals carrying germline PTEN variants is distinct from sporadic thyroid cancers.",False
CREBBP,Q92793,CREB-binding protein,MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLVPDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSPLSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSQTGPGICMNANFNQTHPGLLNSNSGHSLINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTLNPLGNNPMNIPAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPMSLGNVQLPQAPMGPRAASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTPPGMTPPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLGNHLEDRVNKFLRRQNHPEAGEVFVRVVASSDKTVEVKPGMKSRFVDSGEMSESFPYRTKALFAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDSIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKKEESTAASETTEGSQGDSKNAKKKNNKKTNKNKSSISRANKKKPSMPNVSNDLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDAFLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIKHKLRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYRVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMPGLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGPGGYPPAMQQQQRMQQHLPLQGSSMGQMAAQMGQLGQMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSPQTGSPHPGLAVTMASSIDQGHLGNPEQSAMLPQLNTPSRSALSSELSLVGDTTGDTLEKFVEGL,,,"MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).; Construction of a 1.2-Mb contig surrounding, and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3.; Preparation of a set of expression-ready clones of mammalian long cDNAs encoding large proteins by the ORF trap cloning method.; The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.; Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13).; A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.; An essential role for p300/CBP in the cellular response to hypoxia.; RNA helicase A mediates association of CBP with RNA polymerase II.; Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300.; Acetylation and modulation of erythroid Krueppel-like factor (EKLF) activity by interaction with histone acetyltransferases.; Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-binding protein.; Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.; Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.; The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors.; A new family of nuclear receptor coregulators that integrates nuclear receptor signaling through CBP.; Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation.; Requirement of two NFATc4 transactivation domains for CBP potentiation.; Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.; The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation.; Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.; A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression.; Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.; HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators.; Interaction between the hematopoietic Ets transcription factor Spi-B and the coactivator CREB-binding protein associated with negative cross-talk with c-Myb.; Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2.; Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase.; Interferon regulatory factor-2 regulates cell growth through its acetylation.; Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination.; P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain.; Histone acetyltransferase-dependent chromatin remodeling and the vascular clock.; Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86.; FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1).; The calcium-responsive transactivator recruits CREB binding protein to nuclear bodies.; Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity.; Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.; Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1.; An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Repression of RNA polymerase I upon stress is caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis.; Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced transcriptional responses.; Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.; DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes.; SIRT7 and the DEAD-box helicase DDX21 cooperate to resolve genomic R loops and safeguard genome stability.; RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP.; SIRT7-dependent deacetylation of fibrillarin controls histone H2A methylation and rRNA synthesis during the cell cycle.; Deubiquitinase OTUD3 regulates metabolism homeostasis in response to nutritional stresses.; Metabolic regulation of homologous recombination repair by MRE11 lactylation.; Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response.; Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.; NMR mapping of the HIV-1 Tat interaction surface of the KIX domain of the human coactivator CBP.; Histone recognition and large-scale structural analysis of the human bromodomain family.; Allosteric communication in the KIX domain proceeds through dynamic repacking of the hydrophobic core.; Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation.; Structural insights into acetylated-histone H4 recognition by the bromodomain-PHD finger module of human transcriptional coactivator CBP.; Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins.; Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.; Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP.; Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome.; Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.; Inheritance and variable expression in Rubinstein-Taybi syndrome.; Insights into genotype-phenotype correlations from CREBBP point mutation screening in a cohort of 46 Rubinstein-Taybi syndrome patients.; CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype.; Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.; Confirmation of a new phenotype in an individual with a variant in the last part of exon 30 of CREBBP.; Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.",False
HIF1A,Q16665,Hypoxia-inducible factor 1-alpha,MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTGHIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVSGIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKKEPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKILIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPRSPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIGTLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLGQSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN,,,"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.; Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway.; The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation.; Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes.; HIF1a sequence in the Quechua, a high altitude population.; Hypoxia-inducible factor-1 alpha variant isolated from human liver tissue.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; An essential role for p300/CBP in the cellular response to hypoxia.; Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension.; Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha.; Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.; Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300.; Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1.; Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.; Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.; Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha.; Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations.; Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.; Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7.; Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.; Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation.; FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.; Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.; S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity.; HIF-1 alpha protein as a target for S-nitrosation.; Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.; Sumoylation increases HIF-1alpha stability and its transcriptional activity.; Molecular cloning and characterization of the von Hippel-Lindau-like protein.; VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha.; Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha.; Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.; Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells.; SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity.; RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia.; RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.; HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.; Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling.; HIF-1 regulation: not so easy come, easy go.; Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth.; HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport.; Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1.; Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha.; Casein kinase 1 regulates human hypoxia-inducible factor HIF-1.; UBXN7 docks on neddylated cullin complexes using its UIM motif and causes HIF1alpha accumulation.; RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells.; Ubiquitin-specific protease 19 (USP19) regulates hypoxia-inducible factor 1alpha (HIF-1alpha) during hypoxia.; The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.; DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase.; In silico structural and functional characterization of the RSUME splice variants.; SIRT2 regulates tumour hypoxia response by promoting HIF-1alpha hydroxylation.; Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced HSP90 isoforms and their conformationally restricted mutants.; Myeloid translocation gene-16 co-repressor promotes degradation of hypoxia-inducible factor 1.; UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1alpha.; The vacuolar-ATPase complex and assembly factors, TMEM199 and CCDC115, control HIF1alpha prolyl hydroxylation by regulating cellular iron levels.; A pathogen-derived effector modulates host glucose metabolism by arginine GlcNAcylation of HIF-1alpha protein.; Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1alpha/Glycolysis-Dependent Axis.; A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence.; Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha.; Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.; Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response.; Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling.; Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.",False
UBB,P0CG47,Polyubiquitin-B,MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGC,,,"The human ubiquitin gene family: structure of a gene and pseudogenes from the Ub B subfamily.; Lineage-specific homogenization of the polyubiquitin gene among human and great apes.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man.; Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.; Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain.; Functional regulation of FEZ1 by the U-box-type ubiquitin ligase E4B contributes to neuritogenesis.; Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks.; The emerging complexity of protein ubiquitination.; Mutant ubiquitin (UBB(+1)) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3).; Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients.; Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain.; Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.; PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity.; Ubiquitin is phosphorylated by PINK1 to activate parkin.; Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis.; Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9.; Threonine ADP-ribosylation of ubiquitin by a bacterial effector family blocks host ubiquitination.; K29-linked ubiquitin signaling regulates proteotoxic stress response and cell cycle.; A Structure-Based Strategy for Engineering Selective Ubiquitin Variant Inhibitors of Skp1-Cul1-F-Box Ubiquitin Ligases.; K29-selective ubiquitin binding domain reveals structural basis of specificity and heterotypic nature of K29 polyubiquitin.; Assembly and specific recognition of K29- and K33-linked polyubiquitin.; Mechanism of phospho-ubiquitin-induced PARKIN activation.",False
RPA1,P27694,Replication protein A 70 kDa DNA-binding subunit,MVGQLSEGAIAAIMQKGDTNIKPILQVINIRPITTGNSPPRYRLLMSDGLNTLSSFMLATQLNPLVEEEQLSSNCVCQIHRFIVNTLKDGRRVVILMELEVLKSAEAVGVKIGNPVPYNEGLGQPQVAPPAPAASPAASSRPQPQNGSSGMGSTVSKAYGASKTFGKAAGPSLSHTSGGTQSKVVPIASLTPYQSKWTICARVTNKSQIRTWSNSRGEGKLFSLELVDESGEIRATAFNEQVDKFFPLIEVNKVYYFSKGTLKIANKQFTAVKNDYEMTFNNETSVMPCEDDHHLPTVQFDFTGIDDLENKSKDSLVDIIGICKSYEDATKITVRSNNREVAKRNIYLMDTSGKVVTATLWGEDADKFDGSRQPVLAIKGARVSDFGGRSLSVLSSSTIIANPDIPEAYKLRGWFDAEGQALDGVSISDLKSGGVGGSNTNWKTLYEVKSENLGQGDKPDYFSSVATVVYLRKENCMYQACPTQDCNKKVIDQQNGLYRCEKCDTEFPNFKYRMILSVNIADFQENQWVTCFQESAEAILGQNAAYLGELKDKNEQAFEEVFQNANFRSFIFRVRVKVETYNDESRIKATVMDVKPVDYREYGRRLVMSIRRSALM,,,"Characterization of a cDNA encoding the 70-kDa single-stranded DNA-binding subunit of human replication protein A and the role of the protein in DNA replication.; Type I human complement C2 deficiency. A 28-base pair gene deletion causes skipping of exon 6 during RNA splicing.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mammalian DNA nucleotide excision repair reconstituted with purified protein components.; RPA involvement in the damage-recognition and incision steps of nucleotide excision repair.; Rpa4, a homolog of the 34-kilodalton subunit of the replication protein A complex.; Role of protein-protein interactions in the function of replication protein A (RPA): RPA modulates the activity of DNA polymerase alpha by multiple mechanisms.; The evolutionarily conserved zinc finger motif in the largest subunit of human replication protein A is required for DNA replication and mismatch repair but not for nucleotide excision repair.; Replication protein A stimulates long patch DNA base excision repair.; Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA.; Interactions of human nucleotide excision repair protein XPA with DNA and RPA70 Delta C327: chemical shift mapping and 15N NMR relaxation studies.; Proteomic characterization of the human centrosome by protein correlation profiling.; Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes.; Sumoylation of the novel protein hRIPbeta is involved in replication protein A deposition in PML nuclear bodies.; FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.; RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells.; Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; An alternative form of replication protein a prevents viral replication in vitro.; Evidence for direct contact between the RPA3 subunit of the human replication protein A and single-stranded DNA.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; An alternative form of replication protein a expressed in normal human tissues supports DNA repair.; Regulation of DNA repair through desumoylation and sumoylation of replication protein A complex.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Human DNA helicase B (HDHB) binds to replication protein A and facilitates cellular recovery from replication stress.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; hPrimpol1/CCDC111 is a human DNA primase-polymerase required for the maintenance of genome integrity.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry.; PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress.; Human PrimPol is a highly error-prone polymerase regulated by single-stranded DNA binding proteins.; HELB is a feedback inhibitor of DNA end resection.; Ewing Tumor-associated Antigen 1 interacts with replication protein A to promote restart of stalled replication forks.; ETAA1 acts at stalled replication forks to maintain genome integrity.; Activation of the ATR kinase by the RPA-binding protein ETAA1.; RFWD3-dependent ubiquitination of RPA regulates repair at stalled replication forks.; A PARylation-phosphorylation cascade promotes TOPBP1 loading and RPA-RAD51 exchange in homologous recombination.; Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA.; Molecular basis for PrimPol recruitment to replication forks by RPA.; Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue.",False
BLM,P54132,RecQ-like DNA helicase BLM,MAAVPQNNLQEQLERHSARTLNNKLSLSKPKFSGFTFKKKTSSDNNVSVTNVSVAKTPVLRNKDVNVTEDFSFSEPLPNTTNQQRVKDFFKNAPAGQETQRGGSKSLLPDFLQTPKEVVCTTQNTPTVKKSRDTALKKLEFSSSPDSLSTINDWDDMDDFDTSETSKSFVTPPQSHFVRVSTAQKSKKGKRNFFKAQLYTTNTVKTDLPPPSSESEQIDLTEEQKDDSEWLSSDVICIDDGPIAEVHINEDAQESDSLKTHLEDERDNSEKKKNLEEAELHSTEKVPCIEFDDDDYDTDFVPPSPEEIISASSSSSKCLSTLKDLDTSDRKEDVLSTSKDLLSKPEKMSMQELNPETSTDCDARQISLQQQLIHVMEHICKLIDTIPDDKLKLLDCGNELLQQRNIRRKLLTEVDFNKSDASLLGSLWRYRPDSLDGPMEGDSCPTGNSMKELNFSHLPSNSVSPGDCLLTTTLGKTGFSATRKNLFERPLFNTHLQKSFVSSNWAETPRLGKKNESSYFPGNVLTSTAVKDQNKHTASINDLERETQPSYDIDNFDIDDFDDDDDWEDIMHNLAASKSSTAAYQPIKEGRPIKSVSERLSSAKTDCLPVSSTAQNINFSESIQNYTDKSAQNLASRNLKHERFQSLSFPHTKEMMKIFHKKFGLHNFRTNQLEAINAALLGEDCFILMPTGGGKSLCYQLPACVSPGVTVVISPLRSLIVDQVQKLTSLDIPATYLTGDKTDSEATNIYLQLSKKDPIIKLLYVTPEKICASNRLISTLENLYERKLLARFVIDEAHCVSQWGHDFRQDYKRMNMLRQKFPSVPVMALTATANPRVQKDILTQLKILRPQVFSMSFNRHNLKYYVLPKKPKKVAFDCLEWIRKHHPYDSGIIYCLSRRECDTMADTLQRDGLAALAYHAGLSDSARDEVQQKWINQDGCQVICATIAFGMGIDKPDVRFVIHASLPKSVEGYYQESGRAGRDGEISHCLLFYTYHDVTRLKRLIMMEKDGNHHTRETHFNNLYSMVHYCENITECRRIQLLAYFGENGFNPDFCKKHPDVSCDNCCKTKDYKTRDVTDDVKSIVRFVQEHSSSQGMRNIKHVGPSGRFTMNMLVDIFLGSKSAKIQSGIFGKGSAYSRHNAERLFKKLILDKILDEDLYINANDQAIAYVMLGNKAQTVLNGNLKVDFMETENSSSVKKQKALVAKVSQREEMVKKCLGELTEVCKSLGKVFGVHYFNIFNTVTLKKLAESLSSDPEVLLQIDGVTEDKLEKYGAEVISVLQKYSEWTSPAEDSSPGISLSSSRGPGRSAAEELDEEIPVSSHYFASKTRNERKRKKMPASQRSKRRKTASSGSKAKGGSATCRKISSKTKSSSIIGSSSASHTSQATSGANSKLGIMAPPKPINRPFLKPSYAFS,,,"The Bloom's syndrome gene product is homologous to RecQ helicases.; The Bloom's syndrome gene product is a 3'-5' DNA helicase.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; BLM (the causative gene of Bloom syndrome) protein translocation into the nucleus by a nuclear localization signal.; The Bloom's syndrome helicase unwinds G4 DNA.; BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.; BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks.; The BLM helicase is necessary for normal DNA double-strand break repair.; BLAP75, an essential component of Bloom's syndrome protein complexes that maintain genome integrity.; A double Holliday junction dissolvasome comprising BLM, topoisomerase III alpha, and BLAP75.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the SUV3 gene results in mouse embryonic lethality.; RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability.; BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome.; FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Scaffolding protein SPIDR/KIAA0146 connects the Bloom syndrome helicase with homologous recombination repair.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Vpu modulates DNA repair to suppress innate sensing and hyper-integration of HIV-1.; USP37 regulates DNA damage response through stabilizing and deubiquitinating BLM.; Structure and function of the regulatory HRDC domain from human Bloom syndrome protein.; Structure of the RecQ C-terminal domain of human Bloom syndrome protein.; Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.; Solution structure of the RecQ C-terminal domain of human Bloom syndrome protein.; Crystal structure of the Bloom's syndrome helicase indicates a role for the HRDC domain in conformational changes.; A helical bundle in the N-terminal domain of the BLM helicase mediates dimer and potentially hexamer formation.; Characterization of a new BLM mutation associated with a topoisomerase II alpha defect in a patient with Bloom's syndrome.; Identification of a novel BLM missense mutation (2706T>C) in a Moroccan patient with Bloom's syndrome.; Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry.",False
BCL2,P10415,Apoptosis regulator Bcl-2,MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK,,,"Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.; Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo.; Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.; Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma.; Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene.; DNA sequence and analysis of human chromosome 18.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas.; Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.; BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.; BAG-1 modulates the chaperone activity of Hsp70/Hsc70.; Conversion of Bcl-2 to a Bax-like death effector by caspases.; The p53-binding protein 53BP2 also interacts with Bcl2 and impedes cell cycle progression at G2/M.; Phosphorylation of Bcl2 and regulation of apoptosis.; BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.; PUMA induces the rapid apoptosis of colorectal cancer cells.; BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis.; The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38).; p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association.; BMRP is a Bcl-2 binding protein that induces apoptosis.; Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression.; Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1.; JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy.; Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2.; Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect.; Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells.; Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy.; Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.; Human Bop is a novel BH3-only member of the Bcl-2 protein family.; Mitochondrion-associated protein LRPPRC suppresses the initiation of basal levels of autophagy via enhancing Bcl-2 stability.; Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma.; Tom70 mediates Sendai virus-induced apoptosis on mitochondria.; N-terminome analysis of the human mitochondrial proteome.; Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis.; BAP31 regulates mitochondrial function via interaction with Tom40 within ER-mitochondria contact sites.; Toxoplasma gondii ROP17 promotes autophagy via the Bcl-2-Beclin 1 pathway.; Solution structure of the antiapoptotic protein bcl-2.; An inhibitor of Bcl-2 family proteins induces regression of solid tumours.; Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.",False
S100B,P04271,Protein S100-B,MSELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINNELSHFLEEIKEQEVVDKVMETLDNDGDGECDFQEFMAFVAMVTTACHEFFEHE,,,"Cloning and expression of the human S100 beta gene.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of human chromosome 21.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of human brain S100 protein fraction: amino acid sequence of S100 beta.; Purification, characterization and ion binding properties of human brain S100b protein.; Demonstration of heterodimer formation between S100B and S100A6 in the yeast two-hybrid system and human melanoma.; The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding.; The calcium-dependent interaction between S100B and the mitochondrial AAA ATPase ATAD3A and the role of this complex in the cytoplasmic processing of ATAD3A.; S100 proteins modulate protein phosphatase 5 function: a link between CA2+ signal transduction and protein dephosphorylation.; Regulation of the tubulin polymerization-promoting protein by Ca2+/S100 proteins.; A novel calcium-sensitive switch revealed by the structure of human S100B in the calcium-bound form.; A novel S100 target conformation is revealed by the solution structure of the Ca2+-S100B-TRTK-12 complex.; The crystal structures of human S100B in the zinc- and calcium-loaded state at three pH values reveal zinc ligand swapping.",False
VCP,P55072,Transitional endoplasmic reticulum ATPase,MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG,,,"Sequence analysis of a human P1 clone containing the XRCC9 DNA repair gene.; Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Valosin-containing protein, VCP, is a ubiquitous clathrin-binding protein.; A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.; Characterization of different mRNA types expressed in human brain.; A novel UBA and UBX domain protein that binds polyubiquitin and VCP and is a substrate for SAPKs.; Physical and functional interaction between dorfin and valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders.; A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol.; Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.; The ubiquitin-domain protein HERP forms a complex with components of the endoplasmic reticulum associated degradation pathway.; Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase.; Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane.; Multiprotein complexes that link dislocation, ubiquitination, and extraction of misfolded proteins from the endoplasmic reticulum membrane.; Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin.; Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation.; Characterization of erasin (UBXD2): a new ER protein that promotes ER-associated protein degradation.; Identification of SVIP as an endogenous inhibitor of endoplasmic reticulum-associated degradation.; The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Ubiquitin ligase Kf-1 is involved in the endoplasmic reticulum-associated degradation pathway.; Ubxd1 is a novel co-factor of the human p97 ATPase.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; UBXD1 binds p97 through two independent binding sites.; UBXD1 is a VCP-interacting protein that is involved in ER-associated degradation.; Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD.; The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover.; A ubiquitin ligase-associated chaperone holdase maintains polypeptides in soluble states for proteasome degradation.; Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations.; The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks.; The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks.; The tissue-specific Rep8/UBXD6 tethers p97 to the endoplasmic reticulum membrane for degradation of misfolded proteins.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; UBXN7 docks on neddylated cullin complexes using its UIM motif and causes HIF1alpha accumulation.; Ubiquitin-dependent intramembrane rhomboid protease promotes ERAD of membrane proteins.; Proliferating cell nuclear antigen (PCNA)-binding protein C1orf124 is a regulator of translesion synthesis.; STT3B-dependent posttranslational N-glycosylation as a surveillance system for secretory protein.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Lysine methylation of VCP by a member of a novel human protein methyltransferase family.; DVC1 (C1orf124) recruits the p97 protein segregase to sites of DNA damage.; DVC1 (C1orf124) is a DNA damage-targeting p97 adaptor that promotes ubiquitin-dependent responses to replication blocks.; Ubiquitination of the N-terminal region of caveolin-1 regulates endosomal sorting by the VCP/p97 AAA-ATPase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Signal-peptide-mediated translocation is regulated by a p97-AIRAPL complex.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB signaling.; UBXN2A regulates nicotinic receptor degradation by modulating the E3 ligase activity of CHIP.; Pre-emptive quality control protects the ER from protein overload via the proximity of ERAD components and SRP.; A non-canonical role of the p97 complex in RIG-I antiviral signaling.; Proteasomal degradation of preemptive quality control (pQC) substrates is mediated by an AIRAPL-p97 complex.; Systematic proteomics of the VCP-UBXD adaptor network identifies a role for UBXN10 in regulating ciliogenesis.; N-terminome analysis of the human mitochondrial proteome.; Chromatin-associated degradation is defined by UBXN-3/FAF1 to safeguard DNA replication fork progression.; Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.; Ankyrin repeat and zinc-finger domain-containing 1 mutations are associated with infantile-onset inflammatory bowel disease.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Physiological and pathophysiological characteristics of ataxin-3 isoforms.; LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.; TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.; Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner.; The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.; A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants.; Structure and function of the PLAA/Ufd3-p97/Cdc48 complex.; The structural and functional basis of the p97/valosin-containing protein (VCP)-interacting motif (VIM): mutually exclusive binding of cofactors to the N-terminal domain of p97.; Structural insights into the interaction of human p97 N-terminal domain and SHP motif in Derlin-1 rhomboid pseudoprotease.; Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.; Mutant valosin-containing protein causes a novel type of frontotemporal dementia.; Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene.; Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.; Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia.; VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD.; ZFAND1 recruits p97 and the 26S proteasome to promote the clearance of arsenite-induced stress granules.; A mitochondrial SCF-FBXL4 ubiquitin E3 ligase complex degrades BNIP3 and NIX to restrain mitophagy and prevent mitochondrial disease.; Two Australian families with inclusion-body myopathy, Paget's disease of bone and frontotemporal dementia: novel clinical and genetic findings.; Exome sequencing reveals VCP mutations as a cause of familial ALS.; A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.; Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation.; Nuclear inclusions mimicking poly(A)-binding protein nuclear 1 inclusions in a case of inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia with a novel mutation in the valosin-containing protein gene.; VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy.; Novel Variants in the VCP Gene Causing Multisystem Proteinopathy 1.",False
POLG,P54098,DNA polymerase subunit gamma-1,MSRLLWRKVAGATVGPGPVPAPGRWVSSSVPASDPSDGQRRRQQQQQQQQQQQQQPQQPQVLSSEGGQLRHNPLDIQMLSRGLHEQIFGQGGEMPGEAAVRRSVEHLQKHGLWGQPAVPLPDVELRLPPLYGDNLDQHFRLLAQKQSLPYLEAANLLLQAQLPPKPPAWAWAEGWTRYGPEGEAVPVAIPEERALVFDVEVCLAEGTCPTLAVAISPSAWYSWCSQRLVEERYSWTSQLSPADLIPLEVPTGASSPTQRDWQEQLVVGHNVSFDRAHIREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGKHKVQPPTKQGQKSQRKARRGPAISSWDWLDISSVNSLAEVHRLYVGGPPLEKEPRELFVKGTMKDIRENFQDLMQYCAQDVWATHEVFQQQLPLFLERCPHPVTLAGMLEMGVSYLPVNQNWERYLAEAQGTYEELQREMKKSLMDLANDACQLLSGERYKEDPWLWDLEWDLQEFKQKKAKKVKKEPATASKLPIEGAGAPGDPMDQEDLGPCSEEEEFQQDVMARACLQKLKGTTELLPKRPQHLPGHPGWYRKLCPRLDDPAWTPGPSLLSLQMRVTPKLMALTWDGFPLHYSERHGWGYLVPGRRDNLAKLPTGTTLESAGVVCPYRAIESLYRKHCLEQGKQQLMPQEAGLAEEFLLTDNSAIWQTVEELDYLEVEAEAKMENLRAAVPGQPLALTARGGPKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSCNVGSPFAKDFLPKMEDGTLQAGPGGASGPRALEINKMISFWRNAHKRISSQMVVWLPRSALPRAVIRHPDYDEEGLYGAILPQVVTAGTITRRAVEPTWLTASNARPDRVGSELKAMVQAPPGYTLVGADVDSQELWIAAVLGDAHFAGMHGCTAFGWMTLQGRKSRGTDLHSKTATTVGISREHAKIFNYGRIYGAGQPFAERLLMQFNHRLTQQEAAEKAQQMYAATKGLRWYRLSDEGEWLVRELNLPVDRTEGGWISLQDLRKVQRETARKSQWKKWEVVAERAWKGGTESEMFNKLESIATSDIPRTPVLGCCISRALEPSAVQEEFMTSRVNWVVQSSAVDYLHLMLVAMKWLFEEFAIDGRFCISIHDEVRYLVREEDRYRAALALQITNLLTRCMFAYKLGLNDLPQSVAFFSAVDIDRCLRKEVTMDCKTPSNPTGMERRYGIPQGEALDIYQIIELTKGSLEKRSQPGP,,,"Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma.; Mitochondrial DNA polymerases from yeast to man: a new family of polymerases.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase.; Identification of 5'-deoxyribose phosphate lyase activity in human DNA polymerase gamma and its role in mitochondrial base excision repair in vitro.; In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells.; Fidelity of nucleotide incorporation by human mitochondrial DNA polymerase.; Exonuclease proofreading by human mitochondrial DNA polymerase.; The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit.; DNA polymerase gamma, the mitochondrial replicase.; Reconstitution of a minimal mtDNA replisome in vitro.; The layered structure of human mitochondrial DNA nucleoids.; The exonuclease activity of DNA polymerase gamma is required for ligation during mitochondrial DNA replication.; N-terminome analysis of the human mitochondrial proteome.; Tetratricopeptide repeat domain 3 overexpression tends to form aggregates and inhibit ubiquitination and degradation of DNA polymerase gamma.; Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy.; Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations.; Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase.; Polgamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.; Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions.; Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia.; Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis.; Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.; Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy.; Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in POLG and C10orf2/Twinkle.; POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions.; Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO).; Patient homozygous for a recessive POLG mutation presents with features of MERRF.; Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia.; POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion.; Sequence analysis of familial PEO shows additional mutations associated with the 752C-->T and 3527C-->T changes in the POLG1 gene.; A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and parkinsonism.; Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study.; POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness.; POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement.; Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin.; POLG mutations and Alpers syndrome.; Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA.; Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome.; Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations.; Early-onset familial parkinsonism due to POLG mutations.; Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population.; Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene.; Molecular analysis of ANT1, TWINKLE and POLG in patients with multiple deletions or depletion of mitochondrial DNA by a dHPLC-based assay.; SANDO: two novel mutations in POLG1 gene.; Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism.; Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease.; Novel Twinkle (PEO1) gene mutations in Mendelian progressive external ophthalmoplegia.; Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion.; Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations.; Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes.; Genetic analysis of two Japanese families with progressive external ophthalmoplegia and parkinsonism.; Alpers syndrome with mutations in POLG: clinical and investigative features.; Mitochondrial DNA depletion syndrome causing liver failure.; PRICKLE2 mutations might not be involved in epilepsy.; The role of recessive inheritance in early-onset epileptic encephalopathies: a combined whole-exome sequencing and copy number study.",False
IGFBP3,P17936,Insulin-like growth factor-binding protein 3,MQRARPTLWAAALTLLVLLRGPPVARAGASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK,,,"Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein.; Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity.; Analysis of the primary structure of insulin-like growth factor binding protein-3 cDNA from Werner syndrome fibroblasts.; The DNA sequence of human chromosome 7.; Human chromosome 7: DNA sequence and biology.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia.; Purification from human cerebrospinal fluid of insulin-like growth factor binding proteins (IGFBPs). Isolation of IGFBP-2, an altered form of IGFBP-3 and a new IGFBP species.; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor.; Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis.; Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis.; Identification of insulin receptor substrate proteins as key molecules for the TbetaR-V/LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells.; Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; Enhancing the apoptotic potential of insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation.; Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.; A single kinase generates the majority of the secreted phosphoproteome.; The consensus coding sequences of human breast and colorectal cancers.; Humanin: a novel central regulator of peripheral insulin action.; Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis.; Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-beta.; Structural basis for assembly and disassembly of the IGF/IGFBP/ALS ternary complex.",False
HSP90AA1,P07900,Heat shock protein HSP 90-alpha,MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKEDKEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRNPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKNNIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKKCLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKDYCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSVKDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLEGDDDTSRMEEVD,,,"Nucleotide sequence of a full-length cDNA for 90 kDa heat-shock protein from human peripheral blood lymphocytes.; Molecular cloning of cDNA encoding a human heat-shock protein whose expression is induced by adenovirus type 12 E1A in HeLa cells.; Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein.; The HSP90 family of genes in the human genome: insights into their divergence and evolution.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 14.; Heat-shock proteins, Hsp84 and Hsp86, of mice and men: two related genes encode formerly identified tumour-specific transplantation antigens.; Cloning and analysis of a human 86-kDa heat-shock-protein-encoding gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The analysis of the genes reactive to monoclonal antibody, CE5.; Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II.; Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization.; S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities.; The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues.; The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo.; Mechanism of dimer formation of the 90-kDa heat-shock protein.; Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin.; Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90.; Antigens recognized by autologous antibody in patients with renal-cell carcinoma.; Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.; Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex.; A CD14-independent LPS receptor cluster.; Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70.; Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.; Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone.; Proteomic characterization of the human centrosome by protein correlation profiling.; SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.; Small glutamine-rich tetratricopeptide repeat-containing protein is composed of three structural units with distinct functions.; Human protein phosphatase 5 dissociates from heat-shock proteins and is proteolytically activated in response to arachidonic acid and the microtubule-depolymerizing drug nocodazole.; Molecular basis for TPR domain-mediated regulation of protein phosphatase 5.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Phosphoproteomic analysis of the human pituitary.; Conformational diversity in the TPR domain-mediated interaction of protein phosphatase 5 with Hsp90.; Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase.; Conserved conformational changes in the ATPase cycle of human Hsp90.; Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment.; Phosphoproteome of resting human platelets.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein.; Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.; Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.; Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.; The ATPase-dependent chaperoning activity of Hsp90a regulates thick filament formation and integration during skeletal muscle myofibrillogenesis.; Hsp90 is regulated by a switch point in the C-terminal domain.; Tom70 mediates activation of interferon regulatory factor 3 on mitochondria.; Stat1 mediates an auto-regulation of hsp90beta gene in heat shock response.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion.; Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through CHIP/Stub1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.; Hsp90, the concertmaster: tuning transcription.; Tom70 mediates Sendai virus-induced apoptosis on mitochondria.; C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.; Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced HSP90 isoforms and their conformationally restricted mutants.; N-terminome analysis of the human mitochondrial proteome.; Hsp90: Friends, clients and natural foes.; Review: The HSP90 molecular chaperone-an enigmatic ATPase.; The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.; IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis.; Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.; Proteasomal degradation of NOD2 by NLRP12 in monocytes promotes bacterial tolerance and colonization by enteropathogens.; Herpes Simplex Virus 1 Inhibits TANK-Binding Kinase 1 through Formation of the Us11-Hsp90 Complex.; Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.; In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis.; Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex.",False
NR3C1,P04150,Glucocorticoid receptor,MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK,,,"Primary structure and expression of a functional human glucocorticoid receptor cDNA.; The genomic structure of the human glucocorticoid receptor.; Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing.; A new transcript splice variant of the human glucocorticoid receptor: identification and tissue distribution of hGR Delta 313-338, an alternative exon 2 transactivation domain isoform.; Novel hyperactive glucocorticoid receptor isoform identified within a human population.; Alternative splicing within the DNA binding domain creates a novel isoform of the human glucocorticoid receptor.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification of a human glucocorticoid receptor gene promoter-binding protein. Production of polyclonal antibodies against the purified factor.; Human glucocorticoid receptor gene promotor-homologous down regulation.; Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product.; Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells.; Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans.; The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function.; The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U.; Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor.; Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.; A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity.; Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing.; Steroidogenic enzyme gene expression in the human heart.; A new family of nuclear receptor coregulators that integrates nuclear receptor signaling through CBP.; Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.; Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.; Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids.; High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids.; Molecular identification and characterization of A and B forms of the glucocorticoid receptor.; Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.; Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor.; Deciphering the phosphorylation 'code' of the glucocorticoid receptor in vivo.; Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.; The origin and functions of multiple human glucocorticoid receptor isoforms.; Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation.; Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes.; Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor.; HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b.; Functional interaction between the glucocorticoid receptor and GANP/MCM3AP.; GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles.; Glucocorticoid receptor phosphorylation differentially affects target gene expression.; A quantitative atlas of mitotic phosphorylation.; Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity.; Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.; Glucocorticoid receptor-beta and receptor-gamma exert dominant negative effect on gene repression but not on gene induction.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor.; The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress.; Cryptochromes mediate rhythmic repression of the glucocorticoid receptor.; Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity.; Determinants of the heightened activity of glucocorticoid receptor translational isoforms.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; Human Glucocorticoid Receptor beta (hGRbeta) Regulates Gluconeogenesis and Inflammation in Mouse Liver.; Glucocorticoid receptor interacts with PNRC2 in a ligand-dependent manner to recruit UPF1 for rapid mRNA degradation.; Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy.; The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.; Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Genome-wide Regulatory Roles of the C2H2-type Zinc Finger Protein ZNF764 on the Glucocorticoid Receptor.; UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.; Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition.; The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism.; Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance.; Cloning and expression of mutant glucocorticoid receptors from glucocorticoid-sensitive and -resistant human leukemic cells.; Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene.; A mutation of the glucocorticoid receptor in primary cortisol resistance.; Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes.; Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia.; Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance.; The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus.; Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking.; A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels.; Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene.; A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators.; Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men.; The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults.; A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity.; Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.; A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance.; A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.; Generalized glucocorticoid resistance accompanied with an adrenocortical adenoma and caused by a novel point mutation of human glucocorticoid receptor gene.; A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD.; A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.; A novel mutation of the hGR gene causing Chrousos syndrome.; Functional characterization of the hGRalphaT556I causing Chrousos syndrome.; Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance.; ARGLU1 is a transcriptional coactivator and splicing regulator important for stress hormone signaling and development.",False
EGR1,P18146,Early growth response protein 1,MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC,,,"cDNA sequence of the human cellular early growth response gene Egr-1.; A gene coding for a zinc finger protein is induced during 12-O-tetradecanoylphorbol-13-acetate-stimulated HL-60 cell differentiation.; Expression of a zinc finger gene in HTLV-I- and HTLV-II-transformed cells.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Snail associates with EGR-1 and SP-1 to upregulate transcriptional activation of p15INK4b.; Mature human neutrophils constitutively express the transcription factor EGR-1.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence.; Structural impact of complete CpG methylation within target DNA on specific complex formation of the inducible transcription factor Egr-1.",False
VEGFA,P15692,"Vascular endothelial growth factor A, long form",MTDRQTDTAPSPSYHLLPGRRRTVDAAASRGQGPEPAPGGGVEGVGARGVALKLFVQLLGCSRFGGAVVRAGEAEPSGAARSASSGREEPQPEEGEEEEEKEEERGPQWRLGARKPGSWTGEAAVCADSAPAARAPQALARASGRGGRVARRGAEESGPPHSPSRRGSASRAGPGRASETMNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR,,,"Vascular endothelial growth factor is a secreted angiogenic mitogen.; Vascular permeability factor, an endothelial cell mitogen related to PDGF.; The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.; The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.; AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.; VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix.; Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183.; Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability.; Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant.; VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.; Human cDNA for the vascular endothelial growth factor isoform VEGF165.; Human cDNA for vascular endothelial growth factor isoform VEGF121.; Cloning of vascular endothelial growth factor (VEGF) cDNA.; Cloning and identification of vascular endothelial growth factor isoform VEGF165.; Cloning and characterization of VEGF from LNCaP cells, a line of prostate cancer cells.; VEGF111, a new VEGF-A variant lacking exons 5, 6 and 7.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells.; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; Human vascular permeability factor. Isolation from U937 cells.; Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor.; A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon.; Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor.; New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation.; A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.; VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.; Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences.; Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis.; Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein.; Association of ATP1A1 and dear single-nucleotide polymorphism haplotypes with essential hypertension: sex-specific and haplotype-specific effects.; RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells.; CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase.; Corrigendum: CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase.; EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.; KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state.; N-VEGF, the Autoregulatory Arm of VEGF-A.; Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.; 1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor.; The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93-A resolution: multiple copy flexibility and receptor binding.; Crystal structure of the complex between VEGF and a receptor-blocking peptide.; Solution structure of the heparin-binding domain of vascular endothelial growth factor.",False
ABL1,P00519,Tyrosine-protein kinase ABL1,MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR,,,"Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.; Nucleotide sequence analysis of human abl and bcr-abl cDNAs.; Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia.; Homology between phosphotyrosine acceptor site of human c-abl and viral oncogene products.; Sequence analysis of the mutation at codon 834 and the sequence variation of codon 837 of c-abl gene.; N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.; Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity.; Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase.; Protein binding and signaling properties of RIN1 suggest a unique effector function.; Regulation of Rad51 function by c-Abl in response to DNA damage.; A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.; Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis.; The DNA-binding domain of human c-Abl tyrosine kinase promotes the interaction of a HMG chromosomal protein with DNA.; Regulation of cell death by the Abl tyrosine kinase.; Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.; Regulation of ionizing radiation-induced Rad52 nuclear foci formation by c-Abl-mediated phosphorylation.; c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage.; Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl.; c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14.; Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase.; Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases.; The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner.; Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.; The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to stimulate Fe65/amyloid precursor protein nuclear signaling.; Role of c-Abl in the DNA damage stress response.; RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration.; c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage.; JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; c-Abl acetylation by histone acetyltransferases regulates its nuclear-cytoplasmic localization.; Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.; Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor.; Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates proteasome degradation.; A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave formation.; c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration.; Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.; Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1.; Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components.; Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Emerging roles of Abl family tyrosine kinases in microbial pathogenesis.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases.; Large-scale proteomics analysis of the human kinome.; Unc119 protects from Shigella infection by inhibiting the Abl family kinases.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; c-Abl, Lamellipodin, and Ena/VASP proteins cooperate in dorsal ruffling of fibroblasts and axonal morphogenesis.; Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function.; ABL tyrosine kinases: evolution of function, regulation, and specificity.; Initial characterization of the human central proteome.; Tyrosine phosphorylation of a SNARE protein, Syntaxin 17: Implications for membrane trafficking in the early secretory pathway.; Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop.; Three-dimensional solution structure of the src homology 2 domain of c-abl.; Secondary structure of Src homology 2 domain of c-Abl by heteronuclear NMR spectroscopy in solution.; Homology modeling of the Abl-SH3 domain.; The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.; Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.; Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.; Structural basis for the autoinhibition of c-Abl tyrosine kinase.; Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.; Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.; A Src-like inactive conformation in the abl tyrosine kinase domain.; Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.; Crystallization by capillary counter-diffusion and structure determination of the N114A mutant of the SH3 domain of Abl tyrosine kinase complexed with a high-affinity peptide ligand.; Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.; A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain.; Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.; Patterns of somatic mutation in human cancer genomes.; Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations.",False
BRCA2,P51587,Breast cancer type 2 susceptibility protein,MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI,,,"Identification of the breast cancer susceptibility gene BRCA2.; The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.; The DNA sequence and analysis of human chromosome 13.; Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients.; Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.; Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.; Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin.; BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage.; Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour.; FANCD2 functions independently of BRCA2 and RAD51 associated homologous recombination in response to DNA damage.; CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.; WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.; Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.; DSS1 is required for the stability of BRCA2.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.; The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage.; PALB2 is an integral component of the BRCA complex required for homologous recombination repair.; Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA.; The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.; Purified human BRCA2 stimulates RAD51-mediated recombination.; BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2.; Homologous recombination proteins are associated with centrosomes and are required for mitotic stability.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.; Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.; Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombination-associated DNA synthesis at blocked replication forks.; BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2.; Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability.; Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.; HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis.; Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.; Structural basis for recruitment of BRCA2 by PALB2.; Mutations of the BRCA2 gene in ovarian carcinomas.; BRCA2 germline mutations in male breast cancer cases and breast cancer families.; BRCA2 mutations in primary breast and ovarian cancers.; Low incidence of BRCA2 mutations in breast carcinoma and other cancers.; Mutation analysis in the BRCA2 gene in primary breast cancers.; A low proportion of BRCA2 mutations in Finnish breast cancer families.; High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.; High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.; The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.; Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.; Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations.; Germline brca2 sequence variants in patients with ocular melanoma.; A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.; BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease.; BRCA2 germline mutations in male breast cancer patients in the Polish population.; An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD).; Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.; BRCA2 T2722R is a deleterious allele that causes exon skipping.; BRCA2 gene mutations in families with aggregations of breast and stomach cancers.; Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.; Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma.; Characterization of common BRCA1 and BRCA2 variants.; BRCA1 and BRCA2 in Indian breast cancer patients.; BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.; BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.; Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer.; Biallelic inactivation of BRCA2 in Fanconi anemia.; BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer.; Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.; Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer.; BRCA2 germline mutations in familial pancreatic carcinoma.; Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.; BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.; Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.; One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.; Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.; RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.; BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.; Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases.; A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.; Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.; Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.; A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.; A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.; Homozygous missense mutation in the LMAN2L gene segregates with intellectual disability in a large consanguineous Pakistani family.; BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?; Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.",False
TOP2A,P11388,DNA topoisomerase 2-alpha,MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF,,,"Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.; Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.; Structural organization of the human TOP2A and TOP2B genes.; Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Two differentially spliced forms of topoisomerase II alpha and beta mRNAs are conserved between birds and humans.; Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.; The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.; Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469.; Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.; RNA helicase A interacts with dsDNA and topoisomerase IIalpha.; Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra.; Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.; Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Use of divalent metal ions in the DNA cleavage reaction of human type II topoisomerases.; Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.; Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Metnase promotes restart and repair of stalled and collapsed replication forks.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity.; RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progression.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; DNA cleavage and opening reactions of human topoisomerase IIalpha are regulated via Mg2+-mediated dynamic bending of gate-DNA.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; GANP regulates recruitment of AID to immunoglobulin variable regions by modulating transcription and nucleosome occupancy.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the activity of topoisomerase II during productive infection.; The human RNA polymerase I structure reveals an HMG-like docking domain specific to metazoans.; Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase.; The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.; Structure of the N-terminal Gyrase B fragment in complex with ADPPi reveals rigid-body motion induced by ATP hydrolysis.; Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.; Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.",False
TOP2B,Q02880,DNA topoisomerase 2-beta,MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN,,,"Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.; Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.; Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.; Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.; Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells.; Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.; Human cells express two differentially spliced forms of topoisomerase II beta mRNA.; Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.; The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.; Mutagenesis of E477 or K505 in the B' domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage.; Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line.; Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Mutations in topoisomerase IIbeta result in a B cell immunodeficiency.; The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the activity of topoisomerase II during productive infection.; Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.; Global developmental delay and intellectual disability associated with a de novo TOP2B mutation.; Topoisomerase 2beta mutation impairs early B-cell development.; A de novo TOP2B variant associated with global developmental delay and autism spectrum disorder.; Inherited TOP2B Mutation: Possible Confirmation of Mutational Hotspots in the TOPRIM Domain.",False
NFKB1,P19838,Nuclear factor NF-kappa-B p105 subunit,MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPLEGKI,,,"The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.; Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs.; Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.; The complete exon-intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction.; Genome sequencing of the chromosome 4q region implicated in human hepatocellular carcinoma pathogenesis.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The precursor of NF-kappa B p50 has I kappa B-like functions.; A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene.; The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.; Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor.; Phosphorylation of p105 PEST sequence via a redox-insensitive pathway up-regulates processing of p50 NF-kappaB.; A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit.; Inhibition of NF-kappaB DNA binding by nitric oxide.; A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription.; Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome.; NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes.; TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105.; SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.; Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production.; RAC-3 is a NF-kappa B coactivator.; Inhibition of NF-kappaB by S-nitrosylation.; Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappa B.; 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit.; Direct phosphorylation of NF-kappa B1 p105 by the Ikappa B kinase complex on serine 927 is essential for signal-induced p105 proteolysis.; Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.; The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation.; Casper/c-FLIP is physically and functionally associated with NF-kappaB1 p105.; Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins.; Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10.; Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation.; Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability.; betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932.; Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB.; Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing.; ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability.; Leishmania major amastigotes induce p50/c-Rel NF-kappa B transcription factor in human macrophages: involvement in cytokine synthesis.; Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105.; A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.; Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH).; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Haploinsufficiency of the NF-kappaB1 Subunit p50 in Common Variable Immunodeficiency.; KPC1-mediated ubiquitination and proteasomal processing of NF-kappaB1 p105 to p50 restricts tumor growth.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structure of the NF-kappa B p50 homodimer bound to DNA.; Structure of an IkappaBalpha/NF-kappaB complex.; Solution structure of the death domain in human nuclear factor NF-kappa-B p105 subunit.",False
TOP1,P11387,DNA topoisomerase 1,MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF,,,"cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment.; Structure of the human type I DNA topoisomerase gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; Structural characterisation of the human DNA topoisomerase I gene promoter.; Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.; Monoclonal antibodies neutralizing mammalian DNA topoisomerase I activity.; Characterization of the 3' region of the human DNA topoisomerase I gene.; Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.; The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion.; Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Simian virus 40 DNA replication is dependent on an interaction between topoisomerase I and the C-terminal end of T antigen.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; Rhythmic binding of Topoisomerase I impacts on the transcription of Bmal1 and circadian period.; CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA Binding, and increases cellular camptothecin sensitivity.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.; A model for the mechanism of human topoisomerase I.; Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA.; 8-Oxoguanine rearranges the active site of human topoisomerase I.; The mechanism of topoisomerase I poisoning by a camptothecin analog.; Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.; The role of lysine 532 in the catalytic mechanism of human topoisomerase I.; Mechanisms of camptothecin resistance by human topoisomerase I mutations.; Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.; Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.; Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.; Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.; The consensus coding sequences of human breast and colorectal cancers.",False
RAD51,Q06609,DNA repair protein RAD51 homolog 1,MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD,,,"Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA.; Cloning and sequence of the human RecA-like gene cDNA.; Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH).; A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.; Identification of a novel human Rad51 variant that promotes DNA strand exchange.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Analysis of the DNA sequence and duplication history of human chromosome 15.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA.; Interaction of human recombination proteins Rad51 and Rad54.; A novel nucleic acid-binding protein that interacts with human rad51 recombinase.; RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein.; Regulation of Rad51 function by c-Abl in response to DNA damage.; A novel human Rad54 homologue, Rad54B, associates with Rad51.; Homologous DNA pairing by human recombination factors Rad51 and Rad54.; Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells.; Complex formation by the human Rad51B and Rad51C DNA repair proteins and their activities in vitro.; Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2.; Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51.; The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.; RAD51AP2, a novel vertebrate- and meiotic-specific protein, shares a conserved RAD51-interacting C-terminal domain with RAD51AP1/PIR51.; Single-stranded DNA-binding protein hSSB1 is critical for genomic stability.; Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C.; Physical interaction of RECQ5 helicase with RAD51 facilitates its anti-recombinase activity.; Discovery of a novel function for human Rad51: maintenance of the mitochondrial genome.; Regulation of DNA repair through desumoylation and sumoylation of replication protein A complex.; DNA polymerase POLN participates in cross-link repair and homologous recombination.; RecQL5 promotes genome stabilization through two parallel mechanisms--interacting with RNA polymerase II and acting as a helicase.; A PP4 phosphatase complex dephosphorylates RPA2 to facilitate DNA repair via homologous recombination.; Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.; Homologous recombination proteins are associated with centrosomes and are required for mitotic stability.; The role of human SWI5-MEI5 complex in homologous recombination repair.; hSWS1.SWSAP1 is an evolutionarily conserved complex required for efficient homologous recombination repair.; RAD51 haploinsufficiency causes congenital mirror movements in humans.; Inhibition of homologous recombination by the PCNA-interacting protein PARI.; Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; The MCM8-MCM9 complex promotes RAD51 recruitment at DNA damage sites to facilitate homologous recombination.; A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.; Single-molecule sorting reveals how ubiquitylation affects substrate recognition and activities of FBH1 helicase.; Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.; FIGNL1-containing protein complex is required for efficient homologous recombination repair.; Scaffolding protein SPIDR/KIAA0146 connects the Bloom syndrome helicase with homologous recombination repair.; A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination.; Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair.; The MMS22L-TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress.; TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.; Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability.; RFWD3-mediated ubiquitination promotes timely removal of both RPA and RAD51 from dna damage sites to facilitate homologous recombination.; ATAD5 promotes replication restart by regulating RAD51 and PCNA in response to replication stress.; The ZGRF1 Helicase Promotes Recombinational Repair of Replication-Blocking DNA Damage in Human Cells.; HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51.; GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer.; The N-terminal domain of the human Rad51 protein binds DNA: structure and a DNA binding surface as revealed by NMR.; Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.; Identification of Rad51 alteration in patients with bilateral breast cancer.; A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51.; Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.; Abnormal subcortical activity in congenital mirror movement disorder with RAD51 mutation.; Defining the genetic landscape of congenital mirror movements in 80 affected individuals.",False
UBE2I,P63279,SUMO-conjugating enzyme UBC9,MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS,,,"Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9.; Assignment of the gene for a ubiquitin-conjugating enzyme (UBE2I) to human chromosome band 16p13.3 by in situ hybridization.; Cloning, expression, and mapping of UBE2I, a novel gene encoding a human homologue of yeast ubiquitin-conjugating enzymes which are critical for regulating the cell cycle.; Poly(ADP-ribose) polymerase interacts with a novel human ubiquitin conjugating enzyme: hUbc9.; Mammalian ubiquitin-conjugating enzyme Ubc9 interacts with Rad51 recombination protein and localizes in synaptonemal complexes.; Two-hybrid interaction of a human UBC9 homolog with centromere proteins of Saccharomyces cerevisiae.; Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9.; Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect.; Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway.; Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription.; Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.; Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9.; Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.; Role of two residues proximal to the active site of Ubc9 in substrate recognition by the Ubc9.SUMO-1 thiolester complex.; The intracellular association of the nucleocapsid protein (NP) of hantaan virus (HTNV) with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9).; Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.; The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type.; Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for localization, sumoylation, and inhibition of monocyte differentiation.; Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.; A general approach for investigating enzymatic pathways and substrates for ubiquitin-like modifiers.; Ubc9 interacts with SOX4 and represses its transcriptional activity.; Functional interaction between human herpesvirus 6 immediate-early 2 protein and ubiquitin-conjugating enzyme 9 in the absence of sumoylation.; RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia.; Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SUMOylation enhances DNA methyltransferase 1 activity.; Sumoylation of forkhead L2 by Ubc9 is required for its activity as a transcriptional repressor of the steroidogenic acute regulatory gene.; SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle.; Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase UBC9 and likely interferes with polySUMOylation.; Initial characterization of the human central proteome.; SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.; Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.; The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest.; Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; A SUMO-dependent interaction between Senataxin and the exosome, disrupted in the neurodegenerative disease AOA2, targets the exosome to sites of transcription-induced DNA damage.; UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity.; In silico structural and functional characterization of the RSUME splice variants.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; N-terminome analysis of the human mitochondrial proteome.; The C-terminal Region and SUMOylation of Cockayne Syndrome Group B Protein Play Critical Roles in Transcription-coupled Nucleotide Excision Repair.; Transcription Factor hDREF Is a Novel SUMO E3 Ligase of Mi2alpha.; SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Sumoylation of the Carboxy-Terminal of Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 Attenuates Viral DNA Replication.; Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system.; Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1.; Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex.; Lysine activation and functional analysis of E2-mediated conjugation in the SUMO pathway.; Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction.; Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45.; Structure of Importin13-Ubc9 complex: nuclear import and release of a key regulator of sumoylation.; RWD domain as an E2 (Ubc9)-interaction module.; Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase.",False
TNF,P01375,Tumor necrosis factor,MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL,,,"Tandem arrangement of genes coding for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) in the human genome.; Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.; Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor.; Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization.; Molecular cloning of the complementary DNA for human tumor necrosis factor.; Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor.; Dense Alu clustering and a potential new member of the NF kappa B family within a 90 kilobase HLA class III segment.; A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC.; Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse.; Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.; Genome diversity in HLA: a new strategy for detection of genetic polymorphisms in expressed genes within the HLA class III and class I regions.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; O-glycosylated species of natural human tumor-necrosis factor-alpha.; Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells.; A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'.; Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.; Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues.; Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.; A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria.; Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity.; Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.; Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection.; SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production.; A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b.; Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL.; SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine.; Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis.; Tuberculosis in otherwise healthy adults with inherited TNF deficiency.; Structure of tumour necrosis factor.; The structure of tumour necrosis factor -- implications for biological function.; The structure of tumor necrosis factor-alpha at 2.6-A resolution. Implications for receptor binding.; Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2.; High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity.",False
PDPK1,O15530,3-phosphoinositide-dependent protein kinase 1,MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ,,,"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha.; 3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.; Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Homo sapiens protein coding cDNA.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B.; Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.; Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase.; Phosphorylation and activation of p70s6k by PDK1.; Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo.; A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans.; 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1.; p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1).; Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 (PDK1) and their role in regulating kinase activity.; Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3.; Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.; Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions.; Peroxisomal targeting as a tool for assaying protein-protein interactions in the living cell: cytokine-independent survival kinase (CISK) binds PDK-1 in vivo in a phosphorylation-dependent manner.; The adaptor protein Grb14 regulates the localization of 3-phosphoinositide-dependent kinase-1.; PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2.; PDK1, the master regulator of AGC kinase signal transduction.; 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling.; Regulation of transforming growth factor-beta signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein.; Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation.; Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling.; Role of the PH domain in regulating in vitro autophosphorylation events required for reconstitution of PDK1 catalytic activity.; 3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with Smad proteins.; Essential role of PDK1 in regulating endothelial cell migration.; The C-terminus of PRK2/PKNgamma is required for optimal activation by RhoA in a GTP-dependent manner.; TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.; Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways.; Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding.; The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.; IGF-I regulated phosphorylation and translocation of PDK-1 in neurons.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; PDK1 phosphorylation at Thr354 by murine protein serine/threonine kinase 38 contributes to the negative regulation of PDK1 activity.; Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master growth factor signaling kinase PDK1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.; Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding.; Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.; Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells.; Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.",False
CEBPA,P49715,CCAAT/enhancer-binding protein alpha,MESADFYEAEPRPPMSSHLQSPPHAPSSAAFGFPRGAGPAQPPAPPAAPEPLGGICEHETSIDISAYIDPAAFNDEFLADLFQHSRQQEKAKAAVGPTGGGGGGDFDYPGAPAGPGGAVMPGGAHGPPPGYGCAAAGYLDGRLEPLYERVGAPALRPLVIKQEPREEDEAKQLALAGLFPYQPPPPPPPSHPHPHPPPAHLAAPHLQFQIAHCGQTTMHLQPGHPTPPPTPVPSPHPAPALGAAGLPGPGSALKGLGAAHPDLRASGGSGAGKAKKSVDKNSNEYRVRRERNNIAVRKSRDKAKQRNVETQQKVLELTSDNDRLRKRVEQLSRELDTLRGIFRQLPESSLVKAMGNCA,,,"Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha).; Transcription factor C/EBP-alpha: novel sites of expression and cloning of the human gene.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter.; Ubinuclein, a novel nuclear protein interacting with cellular and viral transcription factors.; Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.; Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity.; CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle.; The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest.; Mutation of CEBPA in familial acute myeloid leukemia.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.; Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA transcription and cell size.; Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Molecular mechanism of CCAAT-enhancer binding protein recruitment by the TRIB1 pseudokinase.; Comparative Transcriptomic and Epigenomic Analyses Reveal New Regulators of Murine Brown Adipogenesis.; Structural basis for substrate selectivity of the E3 ligase COP1.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",False
CEBPB,P17676,CCAAT/enhancer-binding protein beta,MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC,,,"A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.; Large-scale cDNA transfection screening for genes related to cancer development and progression.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a transcriptional regulatory factor for human aromatase cytochrome P450 gene expression as nuclear factor interleukin-6 (NF-IL6), a member of the CCAAT/enhancer-binding protein family.; A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6.; Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser299.; Crystal structure of the CCAAT box/enhancer-binding protein beta activating transcription factor-4 basic leucine zipper heterodimer in the absence of DNA.; C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.; Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins.; MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma.; Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3.; Nine-amino-acid transactivation domain: establishment and prediction utilities.; G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Crosstalk between C/EBPbeta phosphorylation, arginine methylation, and SWI/SNF/Mediator implies an indexing transcription factor code.; Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma.; Uncovering global SUMOylation signaling networks in a site-specific manner.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; Transcriptional Regulation of Adipocyte Differentiation: A Central Role for CCAAT/Enhancer-binding Protein (C/EBP) beta.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Comparative Transcriptomic and Epigenomic Analyses Reveal New Regulators of Murine Brown Adipogenesis.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.; Mechanism of c-Myb-C/EBP beta cooperation from separated sites on a promoter.",False
MXI1,P50539,Max-interacting protein 1,MERVKMINVQRLLEAAEFLERRERECEHGYASSFPSMPSPRLQHSKPPRRLSRAQKHSSGSSNTSTANRSTHNELEKNRRAHLRLCLERLKVLIPLGPDCTRHTTLGLLNKAKAHIKKLEEAERKSQHQLENLEREQRFLKWRLEQLQGPQEMERIRMDSIGSTISSDRSDSEREEIEVDVESTEFSHGEVDNISTTSISDIDDHSSLPSIGSDEGYSSASVKLSFTS,,,"Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.; Genomic organization of human MXI1, a putative tumor suppressor gene.; Expression, regulation and polymorphism of the mxi1 genes.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas.; Mutation of the MXI1 gene in prostate cancer.",False
TGFB1,P01137,Transforming growth factor beta-1 proprotein,MPPSGLRLLPLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS,,,"Intron-exon structure of the human transforming growth factor-beta precursor gene.; Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and expression of the gene for human transforming growth factor-beta in Escherichia coli.; Recombinant human transforming growth factor-beta 1: expression by Chinese hamster ovary cells, isolation, and characterization.; Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines.; Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization.; Processing of transforming growth factor beta 1 precursor by human furin convertase.; Role for carbohydrate structures in TGF-beta 1 latency.; A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1.; Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1.; Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1.; Latent transforming growth factor-beta: structural features and mechanisms of activation.; Dermatopontin interacts with transforming growth factor beta and enhances its biological activity.; Differential gene expression of cultured human osteoblasts.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.; Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach.; Mechanisms for asporin function and regulation in articular cartilage.; Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.; Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg.; GARP regulates the bioavailability and activation of TGFbeta.; GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells.; Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1.; Initial characterization of the human central proteome.; Sustained induction of collagen synthesis by TGF-beta requires regulated intramembrane proteolysis of CREB3L1.; N-terminome analysis of the human mitochondrial proteome.; Functional consequence of fibulin-4 missense mutations associated with vascular and skeletal abnormalities and cutis laxa.; Syntenin regulates TGF-beta1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I receptor internalization.; PSG9 Stimulates Increase in FoxP3+ Regulatory T-Cells through the TGF-beta1 Pathway.; Regulation of the bioavailability of TGF-beta and TGF-beta-related proteins.; A milieu molecule for TGF-beta required for microglia function in the nervous system.; Human TGF-beta1 deficiency causes severe inflammatory bowel disease and encephalopathy.; TTC3 contributes to TGF-beta1-induced epithelial-mesenchymal transition and myofibroblast differentiation, potentially through SMURF2 ubiquitylation and degradation.; Transforming growth factor beta 1: NMR signal assignments of the recombinant protein expressed and isotopically enriched using Chinese hamster ovary cells.; Transforming growth factor beta 1: secondary structure as determined by heteronuclear magnetic resonance spectroscopy.; Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2.; Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily.; Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFbeta reveal structural plasticity of antibody-antigen interactions.; Force interacts with macromolecular structure in activation of TGF-beta.; Prodomain-growth factor swapping in the structure of pro-TGF-beta1.; Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women.; Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.; Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.; A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway.; Transforming growth factor-beta-1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.; A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro.; TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations.",False
ERCC6,Q03468,DNA excision repair protein ERCC-6,MPNEGIPHSSQTQEQDCLQSQPVSNNEEMAIKQESGGDGEVEEYLSFRSVGDGLSTSAVGCASAAPRRGPALLHIDRHQIQAVEPSAQALELQGLGVDVYDQDVLEQGVLQQVDNAIHEASRASQLVDVEKEYRSVLDDLTSCTTSLRQINKIIEQLSPQAATSRDINRKLDSVKRQKYNKEQQLKKITAKQKHLQAILGGAEVKIELDHASLEEDAEPGPSSLGSMLMPVQETAWEELIRTGQMTPFGTQIPQKQEKKPRKIMLNEASGFEKYLADQAKLSFERKKQGCNKRAARKAPAPVTPPAPVQNKNKPNKKARVLSKKEERLKKHIKKLQKRALQFQGKVGLPKARRPWESDMRPEAEGDSEGEESEYFPTEEEEEEEDDEVEGAEADLSGDGTDYELKPLPKGGKRQKKVPVQEIDDDFFPSSGEEAEAASVGEGGGGGRKVGRYRDDGDEDYYKQRLRRWNKLRLQDKEKRLKLEDDSEESDAEFDEGFKVPGFLFKKLFKYQQTGVRWLWELHCQQAGGILGDEMGLGKTIQIIAFLAGLSYSKIRTRGSNYRFEGLGPTVIVCPTTVMHQWVKEFHTWWPPFRVAILHETGSYTHKKEKLIRDVAHCHGILITSYSYIRLMQDDISRYDWHYVILDEGHKIRNPNAAVTLACKQFRTPHRIILSGSPMQNNLRELWSLFDFIFPGKLGTLPVFMEQFSVPITMGGYSNASPVQVKTAYKCACVLRDTINPYLLRRMKSDVKMSLSLPDKNEQVLFCRLTDEQHKVYQNFVDSKEVYRILNGEMQIFSGLIALRKICNHPDLFSGGPKNLKGLPDDELEEDQFGYWKRSGKMIVVESLLKIWHKQGQRVLLFSQSRQMLDILEVFLRAQKYTYLKMDGTTTIASRQPLITRYNEDTSIFVFLLTTRVGGLGVNLTGANRVVIYDPDWNPSTDTQARERAWRIGQKKQVTVYRLLTAGTIEEKIYHRQIFKQFLTNRVLKDPKQRRFFKSNDLYELFTLTSPDASQSTETSAIFAGTGSDVQTPKCHLKRRIQPAFGADHDVPKRKKFPASNISVNDATSSEEKSEAKGAEVNAVTSNRSDPLKDDPHMSSNVTSNDRLGEETNAVSGPEELSVISGNGECSNSSGTGKTSMPSGDESIDEKLGLSYKRERPSQAQTEAFWENKQMENNFYKHKSKTKHHSVAEEETLEKHLRPKQKPKNSKHCRDAKFEGTRIPHLVKKRRYQKQDSENKSEAKEQSNDDYVLEKLFKKSVGVHSVMKHDAIMDGASPDYVLVEAEANRVAQDALKALRLSRQRCLGAVSGVPTWTGHRGISGAPAGKKSRFGKKRNSNFSVQHPSSTSPTEKCQDGIMKKEGKDNVPEHFSGRAEDADSSSGPLASSSLLAKMRARNHLILPERLESESGHLQEASALLPTTEHDDLLVEMRNFIAFQAHTDGQASTREILQEFESKLSASQSCVFRELLRNLCTFHRTSGGEGIWKLKPEYC,,,"ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes.; Structure and expression of the excision repair gene ERCC6, involved in the human disorder Cockayne's syndrome group B.; The DNA sequence and comparative analysis of human chromosome 10.; Biochemical and biological characterization of wild-type and ATPase-deficient Cockayne syndrome B repair protein.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; Manitoba aboriginal kindred with original cerebro-oculo-facio-skeletal syndrome has a mutation in the Cockayne syndrome group B (CSB) gene.; Identical mutations in the CSB gene associated with either Cockayne syndrome or the DeSanctis-Cacchione variant of xeroderma pigmentosum.; Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome.; The Cockayne syndrome group B protein is a functional dimer.; The CSB protein actively wraps DNA.; Recognition of RNA polymerase II and transcription bubbles by XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne Syndrome.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome.; The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription.; Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Protein lysine methyltransferase G9a acts on non-histone targets.; An abundant evolutionarily conserved CSB-PiggyBac fusion protein expressed in Cockayne syndrome.; A quantitative atlas of mitotic phosphorylation.; A ubiquitin-binding domain in cockayne syndrome B required for transcription-coupled nucleotide excision repair.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The conserved Cockayne syndrome B-piggyBac fusion protein (CSB-PGBD3) affects DNA repair and induces both interferon-like and innate antiviral responses in CSB-null cells.; Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair.; UV-sensitive syndrome protein UVSSA recruits USP7 to regulate transcription-coupled repair.; Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; The cockayne syndrome B protein is essential for neuronal differentiation and neuritogenesis.; Cockayne syndrome group B protein regulates DNA double-strand break repair and checkpoint activation.; Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.; The C-terminal Region and SUMOylation of Cockayne Syndrome Group B Protein Play Critical Roles in Transcription-coupled Nucleotide Excision Repair.; Cockayne syndrome B protein regulates recruitment of the Elongin A ubiquitin ligase to sites of DNA damage.; ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair pathway choice.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; CSA and CSB play a role in the response to DNA breaks.; Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair.; The cooperative action of CSB, CSA, and UVSSA target TFIIH to DNA damage-stalled RNA polymerase II.; Transcription-coupled DNA-protein crosslink repair by CSB and CRL4CSA-mediated degradation.; Transcription-coupled repair of DNA-protein cross-links depends on CSA and CSB.; Structural basis of human transcription-DNA repair coupling.; Structural basis for RNA polymerase II ubiquitylation and inactivation in transcription-coupled repair.; Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome.; The consensus coding sequences of human breast and colorectal cancers.; DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.; Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome.",False
STK11,Q15831,Serine/threonine-protein kinase STK11,MEVVDPQQLGMFTEGELMSVGMDTFIHRIDSTEVIYQPRRKRAKLIGKYLMGDLLGEGSYGKVKEVLDSETLCRRAVKILKKKKLRRIPNGEANVKKEIQLLRRLRHKNVIQLVDVLYNEEKQKMYMVMEYCVCGMQEMLDSVPEKRFPVCQAHGYFCQLIDGLEYLHSQGIVHKDIKPGNLLLTTGGTLKISDLGVAEALHPFAADDTCRTSQGSPAFQPPEIANGLDTFSGFKVDIWSAGVTLYNITTGLYPFEGDNIYKLFENIGKGSYAIPGDCGPPLSDLLKGMLEYEPAKRFSIRQIRQHSWFRKKHPPAEAPVPIPPSPDTKDRWRSMTVVPYLEDLHGADEDEDLFDIEDDIIYTQDFTVPGQVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASSKIRRLSACKQQ,,,"Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.; Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Antigens recognized by autologous antibody in patients with renal-cell carcinoma.; Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain.; LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1.; The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death.; Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.; Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD.; MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm.; Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD.; LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.; Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene.; Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate.; LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes.; LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.; Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell growth arrest and p27(Kip1) induction.; LKB1 gene mutations in Japanese lung cancer patients.; LKB1 modulates lung cancer differentiation and metastasis.; Prevalence and specificity of LKB1 genetic alterations in lung cancers.; Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.; Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells.; Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells.; SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation.; Characterization of an alternative splice variant of LKB1.; Large-scale proteomics analysis of the human kinome.; Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas.; Initial characterization of the human central proteome.; A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation.; The role of LKB1 and AMPK in cellular responses to stress and damage.; LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.; The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK.; Integrin-binding protein nischarin interacts with tumor suppressor liver kinase B1 (LKB1) to regulate cell migration of breast epithelial cells.; Phosphorylation of serine 399 in LKB1 protein short form by protein kinase Czeta is required for its nucleocytoplasmic transport and consequent AMP-activated protein kinase (AMPK) activation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation.; Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.; Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.; Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors.; Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer.; STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer.; Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers syndrome.; Mutations of the STK11 gene in sporadic gastric carcinoma.; A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.; LKB1 somatic mutations in sporadic cancers.; Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families.; Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer.; Mutational analysis of STK11 gene in ovarian carcinomas.; Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas.; Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.; Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients.; Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix.; Patterns of somatic mutation in human cancer genomes.; A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome patient significantly diminished p53 activity.",False
EP300,Q09472,Histone acetyltransferase p300,MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLPDELINSTELGLTNGGDINQLQTSLGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSMVKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGMLAAGNGQGIMPNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRGPQPLKMGMMNNPNPYGSPYTQNPGQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGGMPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRQCNLPHCRTMKNVLNHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDCPVCLPLKNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQMPTQPQVQAKNQQNQQPGQSPQGMRPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINSQNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKLVQAIFPTPDPAALKDRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNAAGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMAQPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLAPSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSHIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPSIGAQQPPATTIPAPVPTPPAMPPGPQSQALHPPPRQTPTPPTTQLPQQVQPSLPAAPSADQPQQQPRSQQSTAASVPTPTAPLLPPQPATPLSQPAVSIEGQVSNPPSTSSTEVNSQAIAEKQPSQEVKMEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPAPGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNKKTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQAAATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICKQLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQQQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVTPPTPPQTAQPPLPGPPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMGMNPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQLQSGMPRPAMMSVAQHGQPLNMAPQPGLGQVGISPLKPGTVSQQALQNLLRTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRAAKYANSNPQPIPGQPGMPQGQPGLQPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQQPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMANHNQFQQPQGVGYPPQQQQRMQHHMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRLLQQQMGSPVQPNPMSPQQHMLPNQAQSPHLQGQQIPNSLSNQVRSPQPVPSPRPQSQPPHSSPSPRMQPQPSPHHVSPQTSSPHPGLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGASATDLGLSTDNSDLNSNLSQSTLDIH,,,"Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.; The DNA sequence of human chromosome 22.; MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).; Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP.; A transcriptional switch mediated by cofactor methylation.; A novel cofactor for p300 that regulates the p53 response.; The transcriptional coactivators p300 and CBP are histone acetyltransferases.; A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.; An essential role for p300/CBP in the cellular response to hypoxia.; Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300.; Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.; HIV-1 tat transcriptional activity is regulated by acetylation.; Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1.; Exogenous expression of a dominant negative RORalpha1 vector in muscle cells impairs differentiation: RORalpha1 directly interacts with p300 and myoD.; The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors.; A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation.; Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle.; A novel Rb- and p300-binding protein inhibits transactivation by MyoD.; Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator.; Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones.; Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein.; Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors.; Adenovirus DNA binding protein interacts with the SNF2-related CBP activator protein (SrCap) and inhibits SrCap-mediated transcription.; A TPR motif cofactor contributes to p300 activity in the p53 response.; The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation.; Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.; A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression.; Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.; Role of Deltex-1 as a transcriptional regulator downstream of the Notch receptor.; Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300.; Acetylation control of the retinoblastoma tumour-suppressor protein.; Interaction between the hematopoietic Ets transcription factor Spi-B and the coactivator CREB-binding protein associated with negative cross-talk with c-Myb.; Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2.; The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter.; Scaffold/matrix attachment region elements interact with a p300-scaffold attachment factor A complex and are bound by acetylated nucleosomes.; Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities.; Acetylation inactivates the transcriptional repressor BCL6.; p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.; Identification of a promoter-specific transcriptional activation domain at the C-terminus of the Wnt effector protein T-cell factor 4.; Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.; Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9.; Acetylated SP3 is a transcriptional activator.; P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain.; SATB1 makes a complex with p300 and represses gp91(phox) promoter activity.; P300 transcriptional repression is mediated by SUMO modification.; Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300.; Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.; Regulation of human SRY subcellular distribution by its acetylation/deacetylation.; Histone acetyltransferase-dependent chromatin remodeling and the vascular clock.; Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86.; Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53.; A new effector pathway links ATM kinase with the DNA damage response.; Regulation of the p300 HAT domain via a novel activation loop.; Orphan nuclear receptor small heterodimer partner, a novel corepressor for a basic helix-loop-helix transcription factor BETA2/neuroD.; Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.; Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.; STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen.; SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1.; p300 modulates ATF4 stability and transcriptional activity independently of its acetyltransferase domain.; The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription.; Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination.; Stat3 dimerization regulated by reversible acetylation of a single lysine residue.; BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes.; Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase.; The transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle-dependent manner.; Kinetic and mass spectrometric analysis of p300 histone acetyltransferase domain autoacetylation.; HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription.; Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription.; MTA1, a transcriptional activator of breast cancer amplified sequence 3.; Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal portion.; Concerted activation of the Mdm2 promoter by p72 RNA helicase and the coactivators p300 and P/CAF.; Lysine propionylation and butyrylation are novel post-translational modifications in histones.; Orphan receptor TR3 attenuates the p300-induced acetylation of retinoid X receptor-alpha.; Acetylation of Sirt2 by p300 attenuates its deacetylase activity.; PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.; A transcription cofactor required for the heat-shock response.; An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ.; The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain.; PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.; The SIRT2 deacetylase regulates autoacetylation of p300.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation.; p300-mediated acetylation stabilizes the Th-inducing POK factor.; Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes.; HDAC3 is negatively regulated by the nuclear protein DBC1.; Initial characterization of the human central proteome.; Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation.; Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Human ALKBH4 interacts with proteins associated with transcription.; Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer.; A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.; Kruppel-like factor 15 is critical for vascular inflammation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization.; Differential regulation of estrogen receptor alpha expression in breast cancer cells by metastasis-associated protein 1.; Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60.; Zinc finger protein 451 is a novel Smad corepressor in transforming growth factor-beta signaling.; Human Kruppel-related 3 (HKR3) is a novel transcription activator of alternate reading frame (ARF) gene.; Constitutive nuclear localization of an alternatively spliced sirtuin-2 isoform.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Modification of ASC1 by UFM1 is crucial for ERalpha transactivation and breast cancer development.; CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis.; Two ZNF509 (ZBTB49) isoforms induce cell-cycle arrest by activating transcription of p21/CDKN1A and RB upon exposure to genotoxic stress.; Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced transcriptional responses.; Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.; Intracellular crotonyl-CoA stimulates transcription through p300-catalyzed histone crotonylation.; PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection.; Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon.; Multisystem anomalies in severe combined immunodeficiency with mutant BCL11B.; DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes.; Heat shock factor 1 mediates latent HIV reactivation.; RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP.; p300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis.; Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme activity between gluconeogenic and anaplerotic reactions.; Leucine signals to mTORC1 via its metabolite acetyl-coenzyme A.; Metabolic regulation of gene expression by histone lactylation.; Leucine regulates autophagy via acetylation of the mTORC1 component raptor.; Acetyl-methyllysine marks chromatin at active transcription start sites.; Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.; Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.; The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.; Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.; Histone recognition and large-scale structural analysis of the human bromodomain family.; Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation.; Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues.; Mutations truncating the EP300 acetylase in human cancers.; Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.; Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia.; Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.",False
APTX,Q7Z2E3,Aprataxin,MSNVNLSVSDFWRVMMRVCWLVRQDSRHQRIRLPHLEAVVIGRGPETKITDKKCSRQQVQLKAECNKGYVKVKQVGVNPTSIDSVVIGKDQEVKLQPGQVLHMVNELYPYIVEFEEEAKNPGLETHRKRKRSGNSDSIERDAAQEAEAGTGLEPGSNSGQCSVPLKKGKDAPIKKESLGHWSQGLKISMQDPKMQVYKDEQVVVIKDKYPKARYHWLVLPWTSISSLKAVAREHLELLKHMHTVGEKVIVDFAGSSKLRFRLGYHAIPSMSHVHLHVISQDFDSPCLKNKKHWNSFNTEYFLESQAVIEMVQEAGRVTVRDGMPELLKLPLRCHECQQLLPSIPQLKEHLRKHWTQ,,,"Novel splice variants increase molecular diversity of aprataxin, the gene responsible for early-onset ataxia with ocular motor apraxia and hypoalbuminemia.; Identification of FHA-HIT as a novel nuclear protein involved in cell-cycle regulation.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mutations in the APTX gene.; Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene.; The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin.; Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein.; The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4.; Aprataxin, a novel protein that protects against genotoxic stress.; Nucleolar localization of aprataxin is dependent on interaction with nucleolin and on active ribosomal DNA transcription.; Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities.; The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates.; Actions of aprataxin in multiple DNA repair pathways.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response.; Aprataxin resolves adenylated RNA-DNA junctions to maintain genome integrity.; Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations.; Phenotypic variability of aprataxin gene mutations.; Cerebellar ataxia with oculomotor apRAxia type 1: clinical and genetic studies.; Very late onset in ataxia oculomotor apraxia type I.; Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation.",False
PML,P29590,Protein PML,MEPAPARSPRPQQDPARPQEPTMPPPETPSEGRQPSPSPSPTERAPASEEEFQFLRCQQCQAEAKCPKLLPCLHTLCSGCLEASGMQCPICQAPWPLGADTPALDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEAHQWFLKHEARPLAELRNQSVREFLDGTRKTNNIFCSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHSELKCDISAEIQQRQEELDAMTQALQEQDSAFGAVHAQMHAAVGQLGRARAETEELIRERVRQVVAHVRAQERELLEAVDARYQRDYEEMASRLGRLDAVLQRIRTGSALVQRMKCYASDQEVLDMHGFLRQALCRLRQEEPQSLQAAVRTDGFDEFKVRLQDLSSCITQGKDAAVSKKASPEAASTPRDPIDVDLPEEAERVKAQVQALGLAEAQPMAVVQSVPGAHPVPVYAFSIKGPSYGEDVSNTTTAQKRKCSQTQCPRKVIKMESEEGKEARLARSSPEQPRPSTSKAVSPPHLDGPPSPRSPVIGSEVFLPNSNHVASGAGEAEERVVVISSSEDSDAENSSSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS,,,"The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.; Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.; Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins.; Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.; The tripartite motif family identifies cell compartments.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Homo sapiens protein coding cDNA.; Analysis of the DNA sequence and duplication history of human chromosome 15.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants.; Cytogenetics, FISH and RT-PCR analysis of acute promyelocytic leukemia: structure of the fusion point in a case lacking classic t(15;17) translocation.; Identification of three major sentrinization sites in PML.; Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML.; An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm.; Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.; A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.; Role of SUMO-1-modified PML in nuclear body formation.; Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis.; Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.; The function of PML in p53-dependent apoptosis.; PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.; PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.; The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.; PML protein isoforms and the RBCC/TRIM motif.; Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.; SUMO-1 protease-1 regulates gene transcription through PML.; PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.; Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies.; The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.; PML colocalizes with and stabilizes the DNA damage response protein TopBP1.; The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome.; Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells.; Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein.; The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle.; PML regulates p53 stability by sequestering Mdm2 to the nucleolus.; PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein.; Cytoplasmic PML function in TGF-beta signalling.; Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for localization, sumoylation, and inhibition of monocyte differentiation.; Characterization of endogenous human promyelocytic leukemia isoforms.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR.; Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.; The mechanisms of PML-nuclear body formation.; Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein.; Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.; Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection.; The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.; RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.; Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus.; The eIF4E RNA regulon promotes the Akt signaling pathway.; A role for cytoplasmic PML in cellular resistance to viral infection.; A quantitative atlas of mitotic phosphorylation.; Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus.; PML-IV functions as a negative regulator of telomerase by interacting with TERT.; PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Two-step colocalization of MORC3 with PML nuclear bodies.; Resistance to rabies virus infection conferred by the PMLIV isoform.; Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies.; SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML.; Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.; Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.; Initial characterization of the human central proteome.; Promyelocytic leukemia protein interacts with werner syndrome helicase and regulates double-strand break repair in gamma-irradiation-induced DNA damage responses.; A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.; The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.; The nuclear bodies inside out: PML conquers the cytoplasm.; Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.; PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication.; Role of promyelocytic leukemia protein in host antiviral defense.; Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies.; The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.; The role of PML in the nervous system.; SUMO E3 ligase activity of TRIM proteins.; Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against Varicella-Zoster virus.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.; MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.; Role of the promyelocytic leukaemia protein in cell death regulation.; Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence.; PML regulates PER2 nuclear localization and circadian function.; Post-translational modifications of PML: consequences and implications.; Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.; Moloney murine leukemia virus integrase and reverse transcriptase interact with PML proteins.; Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha).; Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.; The role of PML ubiquitination in human malignancies.; PML promotes MHC class II gene expression by stabilizing the class II transactivator.; A metabolic prosurvival role for PML in breast cancer.; Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation.; TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.; The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.; Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.; PML tumor suppressor protein is required for HCV production.; Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.; The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription.; MOZ increases p53 acetylation and premature senescence through its complex formation with PML.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.; SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.; HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.; The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.; 3C protease of enterovirus 71 cleaves promyelocytic leukemia protein and impairs PML-NBs production.; The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.; The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML.",False
GSK3B,P49841,Glycogen synthase kinase-3 beta,MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST,,,"Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter.; Radiation hybrid mapping of genes in the lithium-sensitive wnt signaling pathway.; Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.; Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.; Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling.; Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.; Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.; Human dynamin-like protein interacts with the glycogen synthase kinase 3beta.; Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.; Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase.; Cloning and characterization of a novel human ninein protein that interacts with the glycogen synthase kinase 3beta.; Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.; A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation.; Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction.; Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules.; Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.; Characterization of two non-testis-specific CABYR variants that bind to GSK3beta with a proline-rich extensin-like domain.; Wnt-dependent regulation of the E-cadherin repressor snail.; GSKIP is homologous to the axin GSK3beta interaction domain and functions as a negative regulator of GSK3beta.; Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions.; Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock.; Glycogen synthase kinase-3beta binds to E2F1 and regulates its transcriptional activity.; Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex.; Identification of an antiapoptotic protein complex at death receptors.; Importance of autophosphorylation at Ser186 in the A-loop of salt inducible kinase 1 for its sustained kinase activity.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts.; A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation.; GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth.; Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing.; Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.; ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.; Glycogen synthase kinase-3: properties, functions, and regulation.; The role of GSK3 in glucose homeostasis and the development of insulin resistance.; Glycogen synthase kinase 3: more than a namesake.; Glycogen synthase kinase 3beta interaction protein functions as an A-kinase anchoring protein.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease.; ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor.; Glycogen synthase kinase 3? (GSK3?) modulates antiviral activity of zinc-finger antiviral protein (ZAP).; GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy.; ARTD10 substrate identification on protein microarrays: regulation of GSK3beta by mono-ADP-ribosylation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3beta resulting in the stabilization of MYCN in human neuroblastomas.; HN1 negatively influences the beta-catenin/E-cadherin interaction, and contributes to migration in prostate cells.; GSKIP- and GSK3-mediated anchoring strengthens cAMP/PKA/Drp1 axis signaling in the regulation of mitochondrial elongation.; Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.; The A-Kinase Anchoring Protein (AKAP) Glycogen Synthase Kinase 3beta Interaction Protein (GSKIP) Regulates beta-Catenin through Its Interactions with Both Protein Kinase A (PKA) and GSK3beta.; Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and colorectal tumorigenesis.; Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating the stability and activity of BMAL1 and CLOCK.; Phosphorylated E2F1 is stabilized by nuclear USP11 to drive Peg10 gene expression and activate lung epithelial cells.; FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development.; SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.; Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of autophagosome maturation and lipid metabolism.; LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.; A catenin of the plakophilin-subfamily, Pkp3, responds to canonical-Wnt pathway components and signals.; GSK3beta palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2-STAT3 axis.; Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition.; The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation.; Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex.",False
HTT,P31645,Sodium-dependent serotonin transporter,METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTRHSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIMAWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPETPTEIPCGDIRLNAV,,,"Isolation of a cDNA encoding the human brain serotonin transporter.; Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.; Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter.; Molecular characterization and intracellular regulation of the human serotonin transporter in Caco-2 cells.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Molecular cloning, expression and characterization of a bovine serotonin transporter.; Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter.; Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2.; Plasma serotonin levels and the platelet serotonin transporter.; Serotonin transporter phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with obsessive compulsive disorder.; Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter.; The cellular distribution of serotonin transporter is impeded on serotonin-altered vimentin network.; Retraction: The Cellular Distribution of Serotonin Transporter Is Impeded on Serotonin-Altered Vimentin Network.; Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans.; A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport.; Tyrosine phosphorylation of the human serotonin transporter: a role in the transporter stability and function.; Electrogenic Binding of Intracellular Cations Defines a Kinetic Decision Point in the Transport Cycle of the Human Serotonin Transporter.; X-ray structures and mechanism of the human serotonin transporter.; Illumination of serotonin transporter mechanism and role of the allosteric site.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype.; A human serotonin transporter mutation causes constitutive activation of transport activity.; Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.; Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits.; Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors.; Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence.; Enhanced activity of human serotonin transporter variants associated with autism.; Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function.",False
PRKCA,P17252,Protein kinase C alpha type,MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV,,,"Sequence of human protein kinase C alpha.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Phorbol diester-induced alterations in the expression of protein kinase C isozymes and their mRNAs. Analysis in wild-type and phorbol diester-resistant HL-60 cell clones.; Homo sapiens protein kinase C alpha 5-flanking sequence.; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis.; Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a murine macrophage cell line.; Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis.; Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide.; Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression.; Inhibition of protein kinase Calpha prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo.; Centaurin-alpha(1) associates with and is phosphorylated by isoforms of protein kinase C.; Direct demonstration of involvement of protein kinase Calpha in the Ca2+-induced platelet aggregation.; Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T.; Signal transduction via the stem cell factor receptor/c-Kit.; Protein kinase Calpha phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells.; The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and GluR2 as interacting ligands.; Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility.; Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase.; Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor.; Phosphoproteome of resting human platelets.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Phosphorylation of activation transcription factor-2 at serine 121 by protein kinase c controls c-Jun-mediated activation of transcription.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; mTORC2 targets AGC kinases through Sin1-dependent recruitment.; Initial characterization of the human central proteome.; Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1.; Protein kinase C alpha (PKC alpha): regulation and biological function.; Protein kinase Calpha: disease regulator and therapeutic target.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.; Rare deleterious PARD3 variants in the aPKC-binding region are implicated in the pathogenesis of human cranial neural tube defects via disrupting apical tight junction formation.; LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates experimental autoimmune encephalomyelitis.; PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain.; Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.; Solution structure of the second phorbol esters/diacylglycerol binding domain of human protein kinase C alpha type.; Patterns of somatic mutation in human cancer genomes.",False
SSTR3,P32745,Somatostatin receptor type 3,MDMLHPSSVSTTSEPENASSAWPPDATLGNVSAGPSPAGLAVSGVLIPLVYLVVCVVGLLGNSLVIYVVLRHTASPSVTNVYILNLALADELFMLGLPFLAAQNALSYWPFGSLMCRLVMAVDGINQFTSIFCLTVMSVDRYLAVVHPTRSARWRTAPVARTVSAAVWVASAVVVLPVVVFSGVPRGMSTCHMQWPEPAAAWRAGFIIYTAALGFFGPLLVICLCYLLIVVKVRSAGRRVWAPSCQRRRRSERRVTRMVVAVVALFVLCWMPFYVLNIVNVVCPLPEEPAFFGLYFLVVALPYANSCANPILYGFLSYRFKQGFRRVLLRPSRRVRSQEPTVGPPEKTEEEDEEEEDGEESREGGKGKEMNGRVSQITQPGTSGQERPPSRVASKEQQLLPQEASTGEKSSTMRISYL,,,"Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase.; A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides.; The human somatostatin receptor subtype 3 contains an upstream exon in the 5'-untranslated region: functional promoter studies.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; A genome annotation-driven approach to cloning the human ORFeome.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of human chromosome 22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).",False
HELLS,Q9NRZ9,Lymphoid-specific helicase,MPAERPAGSGGSEAPAMVEQLDTAVITPAMLEEEEQLEAAGLERERKMLEKARMSWDRESTEIRYRRLQHLLEKSNIYSKFLLTKMEQQQLEEQKKKEKLERKKESLKVKKGKNSIDASEEKPVMRKKRGREDESYNISEVMSKEEILSVAKKNKKENEDENSSSTNLCVEDLQKNKDSNSIIKDRLSETVRQNTKFFFDPVRKCNGQPVPFQQPKHFTGGVMRWYQVEGMEWLRMLWENGINGILADEMGLGKTVQCIATIALMIQRGVPGPFLVCGPLSTLPNWMAEFKRFTPDIPTMLYHGTQEERQKLVRNIYKRKGTLQIHPVVITSFEIAMRDRNALQHCYWKYLIVDEGHRIKNMKCRLIRELKRFNADNKLLLTGTPLQNNLSELWSLLNFLLPDVFDDLKSFESWFDITSLSETAEDIIAKEREQNVLHMLHQILTPFLLRRLKSDVALEVPPKREVVVYAPLSKKQEIFYTAIVNRTIANMFGSSEKETIELSPTGRPKRRTRKSINYSKIDDFPNELEKLISQIQPEVDRERAVVEVNIPVESEVNLKLQNIMMLLRKCCNHPYLIEYPIDPVTQEFKIDEELVTNSGKFLILDRMLPELKKRGHKVLLFSQMTSMLDILMDYCHLRDFNFSRLDGSMSYSEREKNMHSFNTDPEVFIFLVSTRAGGLGINLTAADTVIIYDSDWNPQSDLQAQDRCHRIGQTKPVVVYRLVTANTIDQKIVERAAAKRKLEKLIIHKNHFKGGQSGLNLSKNFLDPKELMELLKSRDYEREIKGSREKVISDKDLELLLDRSDLIDQMNASGPIKEKMGIFKILENSEDSSPECLF,,,"Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia.; Tumor-specific exon creation of the HELLS/SMARCA6 gene in non-small cell lung cancer.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Neuroblastoma oligo-capping cDNA project: toward the understanding of the genesis and biology of neuroblastoma.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome.; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.",False
APOC3,P02656,Apolipoprotein C-III,MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA,,,"Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes.; Isolation and DNA sequence of full-length cDNA for human preapolipoprotein CIII.; Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles.; Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance.; The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Amino acid sequence of human plasma apolipoprotein C-III from normolipidemic subjects.; The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.; An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?; Enrichment of glycopeptides for glycan structure and attachment site identification.; Initial characterization of the human central proteome.; Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production.; Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structure and dynamics of human apolipoprotein CIII.; Molecular cloning of a human apoC-III variant: Thr 74-->Ala 74 mutation prevents O-glycosylation.; Apolipoprotein C-III(Lys-58-->Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.",False
EEF2,P13639,Elongation factor 2,MVNFTVDQIRAIMDKKANIRNMSVIAHVDHGKSTLTDSLVCKAGIIASARAGETRFTDTRKDEQERCITIKSTAISLFYELSENDLNFIKQSKDGAGFLINLIDSPGHVDFSSEVTAALRVTDGALVVVDCVSGVCVQTETVLRQAIAERIKPVLMMNKMDRALLELQLEPEELYQTFQRIVENVNVIISTYGEGESGPMGNIMIDPVLGTVGFGSGLHGWAFTLKQFAEMYVAKFAAKGEGQLGPAERAKKVEDMMKKLWGDRYFDPANGKFSKSATSPEGKKLPRTFCQLILDPIFKVFDAIMNFKKEETAKLIEKLDIKLDSEDKDKEGKPLLKAVMRRWLPAGDALLQMITIHLPSPVTAQKYRCELLYEGPPDDEAAMGIKSCDPKGPLMMYISKMVPTSDKGRFYAFGRVFSGLVSTGLKVRIMGPNYTPGKKEDLYLKPIQRTILMMGRYVEPIEDVPCGNIVGLVGVDQFLVKTGTITTFEHAHNMRVMKFSVSPVVRVAVEAKNPADLPKLVEGLKRLAKSDPMVQCIIEESGEHIIAGAGELHLEICLKDLEEDHACIPIKKSDPVVSYRETVSEESNVLCLSKSPNKHNRLYMKARPFPDGLAEDIDKGEVSARQELKQRARYLAEKYEWDVAEARKIWCFGPDGTGPNILTDITKGVQYLNEIKDSVVAGFQWATKEGALCEENMRGVRFDVHDVTLHADAIHRGGGQIIPTARRCLYASVLTAQPRLMEPIYLVEIQCPEQVVGGIYGVLNRKRGHVFEESQVAGTPMFVVKAYLPVNESFGFTADLRSNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETRKRKGLKEGIPALDNFLDKL,,,"Complete sequence of the coding region of human elongation factor 2 (EF-2) by enzymatic amplification of cDNA from human ovarian granulosa cells.; Construction of a plasmid containing the complete coding region of human elongation factor 2.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and sequence analysis of a cDNA from human ovarian granulosa cells encoding the C-terminal part of human elongation factor 2.; Proteomic characterization of the human centrosome by protein correlation profiling.; Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Site-specific mutagenesis of the histidine precursor of diphthamide in the human elongation factor-2 gene confers resistance to diphtheria toxin.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SMG-8 and SMG-9, two novel subunits of the SMG-1 complex, regulate remodeling of the mRNA surveillance complex during nonsense-mediated mRNA decay.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase.; C-terminal Src kinase (Csk)-mediated phosphorylation of eukaryotic elongation factor 2 (eEF2) promotes proteolytic cleavage and nuclear translocation of eEF2.; Identification and characterization of a novel evolutionarily conserved lysine-specific methyltransferase targeting eukaryotic translation elongation factor 2 (eEF2).; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Homodimerization of RBPMS2 through a new RRM-interaction motif is necessary to control smooth muscle plasticity.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; Functional dynamics within the human ribosome regulate the rate of active protein synthesis.; N-terminome analysis of the human mitochondrial proteome.; Evidence for a negative cooperativity between eIF5A and eEF2 on binding to the ribosome.; Structures of translationally inactive mammalian ribosomes.; Structures of the human and Drosophila 80S ribosome.; Structure and function of yeast Lso2 and human CCDC124 bound to hibernating ribosomes.; A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult.",False
ERCC3,P19447,General transcription and DNA repair factor IIH helicase/translocase subunit XPB,MGKRDRADRDKKKSRKRHYEDEEDDEEDAPGNDPQEAVPSAAGKQVDESGTKVDEYGAKDYRLQMPLKDDHTSRPLWVAPDGHIFLEAFSPVYKYAQDFLVAIAEPVCRPTHVHEYKLTAYSLYAAVSVGLQTSDITEYLRKLSKTGVPDGIMQFIKLCTVSYGKVKLVLKHNRYFVESCHPDVIQHLLQDPVIRECRLRNSEGEATELITETFTSKSAISKTAESSGGPSTSRVTDPQGKSDIPMDLFDFYEQMDKDEEEEEETQTVSFEVKQEMIEELQKRCIHLEYPLLAEYDFRNDSVNPDINIDLKPTAVLRPYQEKSLRKMFGNGRARSGVIVLPCGAGKSLVGVTAACTVRKRCLVLGNSAVSVEQWKAQFKMWSTIDDSQICRFTSDAKDKPIGCSVAISTYSMLGHTTKRSWEAERVMEWLKTQEWGLMILDEVHTIPAKMFRRVLTIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAIKTKKRILLYTMNPNKFRACQFLIKFHERRNDKIIVFADNVFALKEYAIRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGDTSFDLPEANVLIQISSHGGSRRQEAQRLGRVLRAKKGMVAEEYNAFFYSLVSQDTQEMAYSTKRQRFLVDQGYSFKVITKLAGMEEEDLAFSTKEEQQQLLQKVLAATDLDAEEEVVAGEFGSRSSQASRRFGTMSSMSGADDTVYMEYHSSRSKAPSKHVHPLFKRFRK,,,"Molecular cloning and biological characterization of the human excision repair gene ERCC-3.; A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders Xeroderma pigmentosum and Cockayne's syndrome.; Structure and expression of the human XPBC/ERCC-3 gene involved in DNA repair disorders xeroderma pigmentosum and Cockayne's syndrome.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor.; Correction of xeroderma pigmentosum repair defect by basal transcription factor BTF2 (TFIIH).; The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.; A 3' --> 5' XPB helicase defect in repair/transcription factor TFIIH of xeroderma pigmentosum group B affects both DNA repair and transcription.; Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes.; Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7.; The FBP interacting repressor targets TFIIH to inhibit activated transcription.; Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum.; Phosphorylation of XPB helicase regulates TFIIH nucleotide excision repair activity.; Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Functional interplay between TFIIH and KAT2A regulates higher-order chromatin structure and class II gene expression.; Structure of the C-terminal half of human XPB helicase and the impact of the disease-causing mutation XP11BE.; Near-atomic resolution visualization of human transcription promoter opening.; Structural basis of TFIIH activation for nucleotide excision repair.; Structures of mammalian RNA polymerase II pre-initiation complexes.; Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3.; A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy.; Identification of four single nucleotide polymorphisms in DNA repair genes: XPA and XPB (ERCC3) in Polish population.; Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome.; The consensus coding sequences of human breast and colorectal cancers.",False
TERF1,P54274,Telomeric repeat-binding factor 1,MAEDVSSAAPSPRGCADGRDADPTEEQMAETERNDEEQFECQELLECQVQVGAPEEEEEEEEDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRNSAEAIIHGLSSLTACQLRTIYICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIEKEHDKLHEEIQNLIKIQAIAVCMENGNFKEAEEVFERIFGDPNSHMPFKSKLLMIISQKDTFHSFFQHFSYNHMMEKIKSYVNYVLSEKSSTFLMKAAAKVVESKRTRTITSQDKPSGNDVEMETEANLDTRKSVSDKQSAVTESSEGTVSLLRSHKNLFLSKLQHGTQQQDLNKKERRVGTPQSTKKKKESRRATESRIPVSKSQPVTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKLKLISSDSED,,,"A human telomeric protein.; Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2.; Characterization and cell cycle regulation of the related human telomeric proteins Pin2 and TRF1 suggest a role in mitosis.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The telobox, a Myb-related telomeric DNA binding motif found in proteins from yeast, plants and human.; Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks.; Involvement of the telomeric protein Pin2/TRF1 in the regulation of the mitotic spindle.; Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres.; POT1 as a terminal transducer of TRF1 telomere length control.; TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres.; Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins.; Shelterin: the protein complex that shapes and safeguards human telomeres.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Ubiquitin ligase RLIM modulates telomere length homeostasis through a proteolysis of TRF1.; GNL3L stabilizes the TRF1 complex and promotes mitotic transition.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome.; The 68-kDa telomeric repeat binding factor 1 (TRF1)-associated protein (TAP68) interacts with and recruits TRF1 to the spindle pole during mitosis.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Solution structure of the DNA-binding domain of human telomeric protein, hTRF1.; Solution structure of a telomeric DNA complex of human TRF1.; Structure of the TRFH dimerization domain of the human telomeric proteins TRF1 and TRF2.; How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA: a view from high-resolution crystal structures.; A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins.; Structural basis of selective ubiquitination of TRF1 by SCFFbx4.",False
PRKDC,P78527,DNA-dependent protein kinase catalytic subunit,MAGSGAGVRCSLLRLQETLSAADRCGAALAGHQLIRGLGQECVLSSSPAVLALQTSLVFSRDFGLLVFVRKSLNSIEFRECREEILKFLCIFLEKMGQKIAPYSVEIKNTCTSVYTKDRAAKCKIPALDLLIKLLQTFRSSRLMDEFKIGELFSKFYGELALKKKIPDTVLEKVYELLGLLGEVHPSEMINNAENLFRAFLGELKTQMTSAVREPKLPVLAGCLKGLSSLLCNFTKSMEEDPQTSREIFNFVLKAIRPQIDLKRYAVPSAGLRLFALHASQFSTCLLDNYVSLFEVLLKWCAHTNVELKKAALSALESFLKQVSNMVAKNAEMHKNKLQYFMEQFYGIIRNVDSNNKELSIAIRGYGLFAGPCKVINAKDVDFMYVELIQRCKQMFLTQTDTGDDRVYQMPSFLQSVASVLLYLDTVPEVYTPVLEHLVVMQIDSFPQYSPKMQLVCCRAIVKVFLALAAKGPVLRNCISTVVHQGLIRICSKPVVLPKGPESESEDHRASGEVRTGKWKVPTYKDYVDLFRHLLSSDQMMDSILADEAFFSVNSSSESLNHLLYDEFVKSVLKIVEKLDLTLEIQTVGEQENGDEAPGVWMIPTSDPAANLHPAKPKDFSAFINLVEFCREILPEKQAEFFEPWVYSFSYELILQSTRLPLISGFYKLLSITVRNAKKIKYFEGVSPKSLKHSPEDPEKYSCFALFVKFGKEVAVKMKQYKDELLASCLTFLLSLPHNIIELDVRAYVPALQMAFKLGLSYTPLAEVGLNALEEWSIYIDRHVMQPYYKDILPCLDGYLKTSALSDETKNNWEVSALSRAAQKGFNKVVLKHLKKTKNLSSNEAISLEEIRIRVVQMLGSLGGQINKNLLTVTSSDEMMKSYVAWDREKRLSFAVPFREMKPVIFLDVFLPRVTELALTASDRQTKVAACELLHSMVMFMLGKATQMPEGGQGAPPMYQLYKRTFPVLLRLACDVDQVTRQLYEPLVMQLIHWFTNNKKFESQDTVALLEAILDGIVDPVDSTLRDFCGRCIREFLKWSIKQITPQQQEKSPVNTKSLFKRLYSLALHPNAFKRLGASLAFNNIYREFREEESLVEQFVFEALVIYMESLALAHADEKSLGTIQQCCDAIDHLCRIIEKKHVSLNKAKKRRLPRGFPPSASLCLLDLVKWLLAHCGRPQTECRHKSIELFYKFVPLLPGNRSPNLWLKDVLKEEGVSFLINTFEGGGCGQPSGILAQPTLLYLRGPFSLQATLCWLDLLLAALECYNTFIGERTVGALQVLGTEAQSSLLKAVAFFLESIAMHDIIAAEKCFGTGAAGNRTSPQEGERYNYSKCTVVVRIMEFTTTLLNTSPEGWKLLKKDLCNTHLMRVLVQTLCEPASIGFNIGDVQVMAHLPDVCVNLMKALKMSPYKDILETHLREKITAQSIEELCAVNLYGPDAQVDRSRLAAVVSACKQLHRAGLLHNILPSQSTDLHHSVGTELLSLVYKGIAPGDERQCLPSLDLSCKQLASGLLELAFAFGGLCERLVSLLLNPAVLSTASLGSSQGSVIHFSHGEYFYSLFSETINTELLKNLDLAVLELMQSSVDNTKMVSAVLNGMLDQSFRERANQKHQGLKLATTILQHWKKCDSWWAKDSPLETKMAVLALLAKILQIDSSVSFNTSHGSFPEVFTTYISLLADTKLDLHLKGQAVTLLPFFTSLTGGSLEELRRVLEQLIVAHFPMQSREFPPGTPRFNNYVDCMKKFLDALELSQSPMLLELMTEVLCREQQHVMEELFQSSFRRIARRGSCVTQVGLLESVYEMFRKDDPRLSFTRQSFVDRSLLTLLWHCSLDALREFFSTIVVDAIDVLKSRFTKLNESTFDTQITKKMGYYKILDVMYSRLPKDDVHAKESKINQVFHGSCITEGNELTKTLIKLCYDAFTENMAGENQLLERRRLYHCAAYNCAISVICCVFNELKFYQGFLFSEKPEKNLLIFENLIDLKRRYNFPVEVEVPMERKKKYIEIRKEAREAANGDSDGPSYMSSLSYLADSTLSEEMSQFDFSTGVQSYSYSSQDPRPATGRFRRREQRDPTVHDDVLELEMDELNRHECMAPLTALVKHMHRSLGPPQGEEDSVPRDLPSWMKFLHGKLGNPIVPLNIRLFLAKLVINTEEVFRPYAKHWLSPLLQLAASENNGGEGIHYMVVEIVATILSWTGLATPTGVPKDEVLANRLLNFLMKHVFHPKRAVFRHNLEIIKTLVECWKDCLSIPYRLIFEKFSGKDPNSKDNSVGIQLLGIVMANDLPPYDPQCGIQSSEYFQALVNNMSFVRYKEVYAAAAEVLGLILRYVMERKNILEESLCELVAKQLKQHQNTMEDKFIVCLNKVTKSFPPLADRFMNAVFFLLPKFHGVLKTLCLEVVLCRVEGMTELYFQLKSKDFVQVMRHRDDERQKVCLDIIYKMMPKLKPVELRELLNPVVEFVSHPSTTCREQMYNILMWIHDNYRDPESETDNDSQEIFKLAKDVLIQGLIDENPGLQLIIRNFWSHETRLPSNTLDRLLALNSLYSPKIEVHFLSLATNFLLEMTSMSPDYPNPMFEHPLSECEFQEYTIDSDWRFRSTVLTPMFVETQASQGTLQTRTQEGSLSARWPVAGQIRATQQQHDFTLTQTADGRSSFDWLTGSSTDPLVDHTSPSSDSLLFAHKRSERLQRAPLKSVGPDFGKKRLGLPGDEVDNKVKGAAGRTDLLRLRRRFMRDQEKLSLMYARKGVAEQKREKEIKSELKMKQDAQVVLYRSYRHGDLPDIQIKHSSLITPLQAVAQRDPIIAKQLFSSLFSGILKEMDKFKTLSEKNNITQKLLQDFNRFLNTTFSFFPPFVSCIQDISCQHAALLSLDPAAVSAGCLASLQQPVGIRLLEEALLRLLPAELPAKRVRGKARLPPDVLRWVELAKLYRSIGEYDVLRGIFTSEIGTKQITQSALLAEARSDYSEAAKQYDEALNKQDWVDGEPTEAEKDFWELASLDCYNHLAEWKSLEYCSTASIDSENPPDLNKIWSEPFYQETYLPYMIRSKLKLLLQGEADQSLLTFIDKAMHGELQKAILELHYSQELSLLYLLQDDVDRAKYYIQNGIQSFMQNYSSIDVLLHQSRLTKLQSVQALTEIQEFISFISKQGNLSSQVPLKRLLNTWTNRYPDAKMDPMNIWDDIITNRCFFLSKIEEKLTPLPEDNSMNVDQDGDPSDRMEVQEQEEDISSLIRSCKFSMKMKMIDSARKQNNFSLAMKLLKELHKESKTRDDWLVSWVQSYCRLSHCRSRSQGCSEQVLTVLKTVSLLDENNVSSYLSKNILAFRDQNILLGTTYRIIANALSSEPACLAEIEEDKARRILELSGSSSEDSEKVIAGLYQRAFQHLSEAVQAAEEEAQPPSWSCGPAAGVIDAYMTLADFCDQQLRKEEENASVIDSAELQAYPALVVEKMLKALKLNSNEARLKFPRLLQIIERYPEETLSLMTKEISSVPCWQFISWISHMVALLDKDQAVAVQHSVEEITDNYPQAIVYPFIISSESYSFKDTSTGHKNKEFVARIKSKLDQGGVIQDFINALDQLSNPELLFKDWSNDVRAELAKTPVNKKNIEKMYERMYAALGDPKAPGLGAFRRKFIQTFGKEFDKHFGKGGSKLLRMKLSDFNDITNMLLLKMNKDSKPPGNLKECSPWMSDFKVEFLRNELEIPGQYDGRGKPLPEYHVRIAGFDERVTVMASLRRPKRIIIRGHDEREHPFLVKGGEDLRQDQRVEQLFQVMNGILAQDSACSQRALQLRTYSVVPMTSRLGLIEWLENTVTLKDLLLNTMSQEEKAAYLSDPRAPPCEYKDWLTKMSGKHDVGAYMLMYKGANRTETVTSFRKRESKVPADLLKRAFVRMSTSPEAFLALRSHFASSHALICISHWILGIGDRHLNNFMVAMETGGVIGIDFGHAFGSATQFLPVPELMPFRLTRQFINLMLPMKETGLMYSIMVHALRAFRSDPGLLTNTMDVFVKEPSFDWKNFEQKMLKKGGSWIQEINVAEKNWYPRQKICYAKRKLAGANPAVITCDELLLGHEKAPAFRDYVAVARGSKDHNIRAQEPESGLSEETQVKCLMDQATDPNILGRTWEGWEPWM,,,"DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.; Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J.; MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are close neighbours located on chromosome 8q12-->q13.; Gene for the catalytic subunit of the human DNA-activated protein kinase maps to the site of the XRCC7 gene on chromosome 8.; Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases.; Sequence of the 3' segment (exons 70-86) of PRKDC, the gene for human DNA-PKcs.; The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues.; A DNA-activated protein kinase from HeLa cell nuclei.; DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.; The carboxyl-terminal transactivation domain of human serum response factor contains DNA-activated protein kinase phosphorylation sites.; c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro; definition of the minimal kinase recognition motif.; CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent protein kinase in the holoenzyme.; Alternate splice-site utilization in the gene for the catalytic subunit of the DNA-activated protein kinase, DNA-PKcs.; DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.; Interaction between DNA-dependent protein kinase and a novel protein, KIP.; Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions.; Mapping of amino acid residues in the p34 subunit of human single-stranded DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 kinase in vitro.; Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.; DNA end-independent activation of DNA-PK mediated via association with the DNA-binding protein C1D.; DNA-dependent protein kinase interacts with antigen receptor response element binding proteins NF90 and NF45.; DNA-dependent protein kinase: DNA binding and activation in the absence of Ku.; DNA-dependent protein kinase phosphorylation sites in Ku 70/80 heterodimer.; Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro.; Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase.; Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination.; Defining interactions between DNA-PK and ligase IV/XRCC4.; Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks.; Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation.; Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation.; Down-regulation of histone H2B by DNA-dependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1.; DNA-PK phosphorylation sites in XRCC4 are not required for survival after radiation or for V(D)J recombination.; DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner.; Identification of DNA-PKcs phosphorylation sites in XRCC4 and effects of mutations at these sites on DNA end joining in a cell-free system.; Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase.; DNA-PK and ATM phosphorylation sites in XLF/Cernunnos are not required for repair of DNA double strand breaks.; In cellulo phosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA damage.; In cellulo phosphorylation of DNA double-strand break repair protein XRCC4 on Ser260 by DNA-PK.; Functional and biochemical dissection of the structure-specific nuclease ARTEMIS.; The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes the catalytic core for V(D)J recombination.; A biochemically defined system for mammalian nonhomologous DNA end joining.; Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response.; DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent manner.; DNA-PKcs function regulated specifically by protein phosphatase 5.; DNA-PK is responsible for enhanced phosphorylation of histone H2AX under hypertonic conditions.; Artemis deficiency confers a DNA double-strand break repair defect and Artemis phosphorylation status is altered by DNA damage and cell cycle progression.; The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and gaps.; Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage.; The life and death of DNA-PK.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability.; Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes.; Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK catalytic subunit.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Systematic analysis of protein pools, isoforms, and modifications affecting turnover and subcellular localization.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage.; DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1.; XLS (c9orf142) is a new component of mammalian DNA double-stranded break repair.; Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation.; Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway.; N-terminome analysis of the human mitochondrial proteome.; DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.; HEXIM1 and NEAT1 Long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response.; The histone chaperones ASF1 and CAF-1 promote MMS22L-TONSL-mediated Rad51 loading onto ssDNA during homologous recombination in human cells.; DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis.; DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity.; TIP60 K430 SUMOylation attenuates its interaction with DNA-PKcs in S-phase cells: Facilitating homologous recombination and emerging target for cancer therapy.; Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS.; Cryo-EM of NHEJ supercomplexes provides insights into DNA repair.; Structural basis of long-range to short-range synaptic transition in NHEJ.; Patterns of somatic mutation in human cancer genomes.; PRKDC mutations in a SCID patient with profound neurological abnormalities.",False
CAT,Q6IB77,Glycine N-acyltransferase,MMLPLQGAQMLQMLEKSLRKSLPASLKVYGTVFHINHGNPFNLKAVVDKWPDFNTVVVCPQEQDMTDDLDHYTNTYQIYSKDPQNCQEFLGSPELINWKQHLQIQSSQPSLNEAIQNLAAIKSFKVKQTQRILYMAAETAKELTPFLLKSKILSPNGGKPKAINQEMFKLSSMDVTHAHLVNKFWHFGGNERSQRFIERCIQTFPTCCLLGPEGTPVCWDLMDQTGEMRMAGTLPEYRLHGLVTYVIYSHAQKLGKLGFPVYSHVDYSNEAMQKMSYTLQHVPIPRSWNQWNCVPL,,,"The utilization of alanine, glutamic acid, and serine as amino acid substrates for glycine N-acyltransferase.; Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma.; Human HRP-1(CLP).; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Purification to homogeneity of mitochondrial acyl CoA:glycine N-acyltransferase from human liver.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.",False
ERCC5,P28715,DNA excision repair protein ERCC-5,MGVQGLWKLLECSGRQVSPEALEGKILAVDISIWLNQALKGVRDRHGNSIENPHLLTLFHRLCKLLFFRIRPIFVFDGDAPLLKKQTLVKRRQRKDLASSDSRKTTEKLLKTFLKRQAIKTAFRSKRDEALPSLTQVRRENDLYVLPPLQEEEKHSSEEEDEKEWQERMNQKQALQEEFFHNPQAIDIESEDFSSLPPEVKHEILTDMKEFTKRRRTLFEAMPEESDDFSQYQLKGLLKKNYLNQHIEHVQKEMNQQHSGHIRRQYEDEGGFLKEVESRRVVSEDTSHYILIKGIQAKTVAEVDSESLPSSSKMHGMSFDVKSSPCEKLKTEKEPDATPPSPRTLLAMQAALLGSSSEEELESENRRQARGRNAPAAVDEGSISPRTLSAIKRALDDDEDVKVCAGDDVQTGGPGAEEMRINSSTENSDEGLKVRDGKGIPFTATLASSSVNSAEEHVASTNEGREPTDSVPKEQMSLVHVGTEAFPISDESMIKDRKDRLPLESAVVRHSDAPGLPNGRELTPASPTCTNSVSKNETHAEVLEQQNELCPYESKFDSSLLSSDDETKCKPNSASEVIGPVSLQETSSIVSVPSEAVDNVENVVSFNAKEHENFLETIQEQQTTESAGQDLISIPKAVEPMEIDSEESESDGSFIEVQSVISDEELQAEFPETSKPPSEQGEEELVGTREGEAPAESESLLRDNSERDDVDGEPQEAEKDAEDSLHEWQDINLEELETLESNLLAQQNSLKAQKQQQERIAATVTGQMFLESQELLRLFGIPYIQAPMEAEAQCAILDLTDQTSGTITDDSDIWLFGARHVYRNFFNKNKFVEYYQYVDFHNQLGLDRNKLINLAYLLGSDYTEGIPTVGCVTAMEILNEFPGHGLEPLLKFSEWWHEAQKNPKIRPNPHDTKVKKKLRTLQLTPGFPNPAVAEAYLKPVVDDSKGSFLWGKPDLDKIREFCQRYFGWNRTKTDESLFPVLKQLDAQQTQLRIDSFFRLAQQEKEDAKRIKSQRLNRAVTCMLRKEKEAAASEIEAVSVAMEKEFELLDKAKGKTQKRGITNTLEESSSLKRKRLSDSKGKNTCGGFLGETCLSESSDGSSSEDAESSSLMNVQRRTAAKEPKTSASDSQNSVKEAPVKNGGATTSSSSDSDDDGGKEKMVLVTARSVFGKKRRKLRRARGRKRKT,,,"Complementation of the DNA repair defect in Xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2.; An ERCC5 gene with homology to yeast RAD2 is involved in group G Xeroderma pigmentosum.; Human ERCC5 cDNA-cosmid complementation for excision repair and bipartite amino acid domains conserved with RAD proteins of Saccharomyces cerevisiae and Schizosaccharomyces pombe.; The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The human gene for Xeroderma pigmentosum complementation group G (XPG) maps to 13q33 by fluorescence in situ hybridization.; Isolation of active recombinant XPG protein, a human DNA repair endonuclease.; XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair.; Human Xeroderma pigmentosum group G gene encodes a DNA endonuclease.; XPG protein has a structure-specific endonuclease activity.; The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21.; Nucleotide excision repair 3' endonuclease XPG stimulates the activity of base excision repair enzyme thymine glycol DNA glycosylase.; The XPG story.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; Recognition of RNA polymerase II and transcription bubbles by XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne Syndrome.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability.; Structural basis of TFIIH activation for nucleotide excision repair.; Structural and Calorimetric Studies Demonstrate that Xeroderma Pigmentosum Type G (XPG) Can Be Imported to the Nucleus by a Classical Nuclear Import Pathway via a Monopartite NLS Sequence.; The crystal structure of human XPG, the xeroderma pigmentosum group G endonuclease, provides insight into nucleotide excision DNA repair.; Human XPG nuclease structure, assembly, and activities with insights for neurodegeneration and cancer from pathogenic mutations.; A novel homozygous ERCC5 truncating mutation in a family with prenatal arthrogryposis--further evidence of genotype-phenotype correlation.; Mutations that disable the DNA repair gene XPG in a Xeroderma pigmentosum group G patient.; A common mutational pattern in Cockayne syndrome patients from Xeroderma pigmentosum group G: implications for a second XPG function.; Xeroderma pigmentosum group G with severe neurological involvement and features of Cockayne syndrome in infancy.; The founding members of xeroderma pigmentosum group G produce XPG protein with severely impaired endonuclease activity.; Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum group G patients.; Novel XPG (ERCC5) mutations affect DNA repair and cell survival after ultraviolet but not oxidative stress.; TPP2 mutation associated with sterile brain inflammation mimicking MS.",False
AR,P10275,Androgen receptor,MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ,,,"The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate.; Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.; Characterization and expression of a cDNA encoding the human androgen receptor.; Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity.; Specific region in hormone binding domain is essential for hormone binding and trans-activation by human androgen receptor.; Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance.; Androgen receptor function is modulated by the tissue-specific AR45 variant.; A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The N-terminal domain of the human androgen receptor is encoded by one, large exon.; Molecular cloning of human and rat complementary DNA encoding androgen receptors.; Cloning, structure and expression of a cDNA encoding the human androgen receptor.; Structural organization of the human androgen receptor gene.; A point mutation in the second zinc finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptor-positive androgen resistance.; Cloning of human androgen receptor complementary DNA and localization to the X chromosome.; Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics.; Trinucleotide repeat polymorphism in the androgen receptor gene (AR).; Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.; The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.; PQBP-1, a novel polyglutamine tract binding protein, inhibits transcription activation by Brn-2 and affects cell survival.; Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.; Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription.; The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator.; PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression.; Androgen receptor interacts with a novel MYST protein, HBO1.; Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).; RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor.; Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor.; Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.; hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci.; The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway.; The retinoblastoma protein-associated transcription repressor RBaK interacts with the androgen receptor and enhances its transcriptional activity.; DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex.; Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling.; Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors.; hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes.; Regulation of androgen receptor activity by tyrosine phosphorylation.; Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells.; PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.; The zinc finger protein Ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer.; RanBP10 acts as a novel coactivator for the androgen receptor.; Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.; TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.; Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.; ZIP kinase plays a crucial role in androgen receptor-mediated transcription.; TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells.; Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.; The single-macro domain protein LRP16 is an essential cofactor of androgen receptor.; CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.; The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling.; Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.; MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.; FBI-1 functions as a novel AR co-repressor in prostate cancer cells.; Cryptochromes mediate rhythmic repression of the glucocorticoid receptor.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors.; CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2.; ARID4A and ARID4B regulate male fertility, a functional link to the AR and RB pathways.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.; Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.; Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.; The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.; Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.; Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.; Interaction between the androgen receptor and a segment of its corepressor SHP.; Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.; Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.; Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12.; A surface on the androgen receptor that allosterically regulates coactivator binding.; Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.; Androgen resistance due to mutation of the androgen receptor.; Molecular genetics of human androgen insensitivity.; Mutations of androgen receptor gene in androgen insensitivity syndromes.; The androgen receptor gene mutations database.; Androgen receptor mutations.; The androgen receptor gene mutations database.; The androgen receptor gene mutations database: 2012 update.; A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.; Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity.; Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg-->Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function.; A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance.; Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy.; Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.; Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen insensitivity with different receptor phenotypes.; Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome.; A unique point mutation in the androgen receptor gene in a family with complete androgen insensitivity syndrome.; Point mutation in the steroid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome (CAIS).; Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome.; A single amino acid substitution (Met-786-->Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome.; Immunoreactive androgen receptor expression in subjects with androgen resistance.; Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene.; The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.; Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance.; Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique.; A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome.; Androgen receptor gene mutations in human prostate cancer.; Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation.; A new mutation within the deoxyribonucleic acid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome.; An exonic point mutation creates a MaeIII site in the androgen receptor gene of a family with complete androgen insensitivity syndrome.; Androgen receptor gene mutation in male breast cancer.; A single-base substitution in exon 6 of the androgen receptor gene causing complete androgen insensitivity: the mutated receptor fails to transactivate but binds to DNA in vitro.; A single amino acid substitution (Gly743 --> Val) in the steroid-binding domain of the human androgen receptor leads to Reifenstein syndrome.; Single strand conformation polymorphism analysis of androgen receptor gene mutations in patients with androgen insensitivity syndromes: application for diagnosis, genetic counseling, and therapy.; Mutations of the androgen receptor gene identified in perineal hypospadias.; Complete androgen insensitivity syndrome associated with a de novo mutation of the androgen receptor gene detected by single strand conformation polymorphism.; Androgen receptor gene mutations in human prostate cancer.; Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes.; Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.; Androgen receptor (AR) gene mutations in 6 families with androgen insensitivity syndrome (Abstract #114).; Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer.; Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer.; Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.; Molecular prenatal diagnosis of partial androgen insensitivity syndrome based on the Hind III polymorphism of the androgen receptor gene.; Molecular prenatal exclusion of familial partial androgen insensitivity (Reifenstein syndrome).; Single amino acid substitution (840Arg-->His) in the hormone-binding domain of the androgen receptor leads to incomplete androgen insensitivity syndrome associated with a thermolabile androgen receptor.; Molecular characterization of the androgen receptor gene in boys with hypospadias.; Partial androgen insensitivity (PAIS) in a large eskimo kindred caused by a delD690 mutation in the androgen receptor (AR) gene (Abstract #244).; Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor.; Detection of point mutations in the androgen receptor gene using non-isotopic single strand conformation polymorphism analysis.; Two mutations causing complete androgen insensitivity: a frame-shift in the steroid binding domain and a Cys-->Phe substitution in the second zinc finger of the androgen receptor.; Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome.; An androgen receptor mutation causing androgen resistance in undervirilized male syndrome.; Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance.; Amino acid substitutions in the hormone-binding domain of the human androgen receptor alter the stability of the hormone receptor complex.; Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene.; A practical approach to the detection of androgen receptor gene mutations and pedigree analysis in families with X-linked androgen insensitivity.; A frame-shift mutation of the androgen receptor gene in a patient with receptor-negative complete testicular feminization: comparison with a single base substitution in a receptor-reduced incomplete form.; Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men.; Genetic counselling in complete androgen insensitivity syndrome: trinucleotide repeat polymorphisms, single-strand conformation polymorphism and direct detection of two novel mutations in the androgen receptor gene.; Androgen receptor defects: historical, clinical, and molecular perspectives.; Characterization of alternative amino acid substitutions at arginine 830 of the androgen receptor that cause complete androgen insensitivity in three families.; Leu-676-Pro mutation of the androgen receptor causes complete androgen insensitivity syndrome in a large Hutterite kindred.; Human androgen insensitivity due to point mutations encoding amino acid substitutions in the androgen receptor steroid-binding domain.; Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.; Mutations of the androgen receptor coding sequence are infrequent in patients with isolated hypospadias.; Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol.; A single amino acid exchange abolishes dimerization of the androgen receptor and causes Reifenstein syndrome.; Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.; The clinical and molecular spectrum of androgen insensitivity syndromes.; Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.; Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene.; Rapid detection of a mutation hot-spot in the human androgen receptor.; Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome.; Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-->Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels.; A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene causes complete androgen resistance.; Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene.; A novel missense mutation in the amino-terminal domain of the human androgen receptor gene in a family with partial androgen insensitivity syndrome causes reduced efficiency of protein translation.; Molecular basis of androgen insensitivity.; Androgen receptor gene mutations are rarely associated with isolated penile hypospadias.; Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations.; Androgen insensitivity syndrome due to new mutations in the DNA-binding domain of the androgen receptor.; Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis.; Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.; Germ-line and somatic mosaicism in the androgen insensitivity syndrome: implications for genetic counseling.; Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.; Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome.; Molecular analysis of androgen resistance syndromes in Egyptian patients.; Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene.; Mutations of the androgen receptor gene in patients with complete androgen insensitivity.; Genetic alterations of androgen receptor gene in Japanese human prostate cancer.; Androgen receptor gene mutations in prostate cancer.; DNA analysis of the androgen receptor gene in two cases with complete androgen insensitivity syndrome.; Etiologic classification of severe hypospadias: implications for prognosis and management.; Complete androgen insensitivity syndrome. Molecular characterization in two Chinese women.; Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome.; Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome.; Molecular analysis of the androgen receptor gene in 4 patients with complete androgen insensitivity.; Mutations of androgen receptor gene in Brazilian patients with male pseudohermaphroditism.; Analysis of the transactivation domain of the androgen receptor in patients with male infertility.; Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding.; One additional mutation at exon A amplifies thermolability of androgen receptor in a case with complete androgen insensitivity syndrome.; Functional characterisation of mutations in the ligand-binding domain of the androgen receptor gene in patients with androgen insensitivity syndrome.; A new missense substitution at a mutational hot spot of the androgen receptor in siblings with complete androgen insensitivity syndrome.; An androgen receptor gene mutation (A645D) in a boy with a normal phenotype.; Single amino acid substitution in the hormone-binding domain of the androgen receptor in a family with complete androgen insensitivity syndrome (CAIS).; Response to androgen treatment in a patient with partial androgen insensitivity and a mutation in the deoxyribonucleic acid-binding domain of the androgen receptor.; Trafficking of androgen receptor mutants fused to green fluorescent protein: a new investigation of partial androgen insensitivity syndrome.; Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation.; Inherited and de novo androgen receptor gene mutations: investigation of single-case families.; Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.; A new point mutation of the androgen receptor gene in a patient with partial androgen resistance and severe oligozoospermia.; Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.; Update of the androgen receptor gene mutations database.; A novel point mutation (R840S) in the androgen receptor in a Brazilian family with partial androgen insensitivity syndrome.; Analysis of exon 1 mutations in the androgen receptor gene.; Androgen receptor gene mutations in 46,XY females with germ cell tumours.; A case of complete testicular feminization: laparoscopic orchiectomy and analysis of androgen receptor gene mutation.; Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.; Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions.; Androgen receptor gene mutations in hormone-refractory prostate cancer.; Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.; Directed pharmacological therapy of ambiguous genitalia due to an androgen receptor gene mutation.; An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity.; A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1.; Clinical and molecular spectrum of somatic mosaicism in androgen insensitivity syndrome.; Point mutations in the steroid-binding domain of the androgen receptor gene of five Japanese patients with androgen insensitivity syndrome.; Screening for mutations in candidate genes for hypospadias.; Androgen receptor mutations in prostate cancer.; Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome.; Significance of mutations in the androgen receptor gene in males with idiopathic infertility.; Eight novel mutations of the androgen receptor gene in patients with androgen insensitivity syndrome.; Polymorphism of the androgen receptor gene is associated with male pattern baldness.; Characterization of a novel receptor mutation A->T at exon 4 in complete androgen insensitivity syndrome and a carrier sibling via bidirectional polymorphism sequence analysis.; Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene.; Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.; A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy.; Concordance of phenotypic expression and gender identity in a large kindred with a mutation in the androgen receptor.; Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.; AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children with a clinical diagnosis of androgen insensitivity.; Analysis of protein-coding genetic variation in 60,706 humans.; Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males.",False
GTF2H2,Q13888,General transcription factor IIH subunit 2,MDEEPERTKRWEGGYERTWEILKEDESGSLKATIEDILFKAKRKRVFEHHGQVRLGMMRHLYVVVDGSRTMEDQDLKPNRLTCTLKLLEYFVEEYFDQNPISQIGIIVTKSKRAEKLTELSGNPRKHITSLKKAVDMTCHGEPSLYNSLSIAMQTLKHMPGHTSREVLIIFSSLTTCDPSNIYDLIKTLKAAKIRVSVIGLSAEVRVCTVLARETGGTYHVILDESHYKELLTHHVSPPPASSSSECSLIRMGFPQHTIASLSDQDAKPSFSMAHLDGNTEPGLTLGGYFCPQCRAKYCELPVECKICGLTLVSAPHLARSYHHLFPLDAFQEIPLEEYNGERFCYGCQGELKDQHVYVCAVCQNVFCVDCDVFVHDSLHCCPGCIHKIPAPSGV,,,"p44 and p34 subunits of the BTF2/TFIIH transcription factor have homologies with SSL1, a yeast protein involved in DNA repair.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A provisional transcript map of the spinal muscular atrophy (SMA) critical region.; Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP.; Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7.; Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes.; A role of the C-terminal part of p44 in the promoter escape activity of transcription factor IIH.; Varicella-zoster virus IE63 protein represses the basal transcription machinery by disorganizing the pre-initiation complex.; Initial characterization of the human central proteome.; Near-atomic resolution visualization of human transcription promoter opening.; Structural basis of TFIIH activation for nucleotide excision repair.; Structures of mammalian RNA polymerase II pre-initiation complexes.; A multicopy transcription-repair gene, BTF2p44, maps to the SMA region and demonstrates SMA associated deletions.",False
XRCC5,P13010,X-ray repair cross-complementing protein 5,MVRSGNKAAVVLCMDVGFTMSNSIPGIESPFEQAKKVITMFVQRQVFAENKDEIALVLFGTDGTDNPLSGGDQYQNITVHRHLMLPDFDLLEDIESKIQPGSQQADFLDALIVSMDVIQHETIGKKFEKRHIEIFTDLSSRFSKSQLDIIIHSLKKCDISLQFFLPFSLGKEDGSGDRGDGPFRLGGHGPSFPLKGITEQQKEGLEIVKMVMISLEGEDGLDEIYSFSESLRKLCVFKKIERHSIHWPCRLTIGSNLSIRIAAYKSILQERVKKTWTVVDAKTLKKEDIQKETVYCLNDDDETEVLKEDIIQGFRYGSDIVPFSKVDEEQMKYKSEGKCFSVLGFCKSSQVQRRFFMGNQVLKVFAARDDEAAAVALSSLIHALDDLDMVAIVRYAYDKRANPQVGVAFPHIKHNYECLVYVQLPFMEDLRQYMFSSLKNSKKYAPTEAQLNAVDALIDSMSLAKKDEKTDTLEDLFPTTKIPNPRFQRLFQCLLHRALHPREPLPPIQQHIWNMLNPPAEVTTKSQIPLSKIKTLFPLIEAKKKDQVTAQEIFQDNHEDGPTAKKLKTEQGGAHFSVSSLAEGSVTSVGSVNPAENFRVLVKQKKASFEEASNQLINHIEQFLDTNETPYFMKSIDCIRAFREEAIKFSEEQRFNNFLKALQEKVEIKQLNHFWEIVVQDGITLITKEEASGSSVTAEEAKKFLAPKDKPSGDTAAVFEEGGDVDDLLDMI,,,"cDNA-derived amino acid sequence of the 86-kDa subunit of the Ku antigen.; Isolation and characterization of cDNA encoding the 80-kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification and characterization of proximal sequence element-binding protein 1, a transcription activating protein related to Ku and TREF that binds the proximal sequence element of the human U1 promoter.; Human DNA helicase II: a novel DNA unwinding enzyme identified as the Ku autoantigen.; Non-histone protein 1 (NHP1) is a member of the Ku protein family which is upregulated in differentiating mouse myoblasts and human promyelocytes.; The autoantigen Ku is indistinguishable from NF IV, a protein forming multimeric protein-DNA complexes.; DNA-dependent ATPase from HeLa cells is related to human Ku autoantigen.; The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium.; Identification of proteins binding to interferon-inducible transcriptional enhancers in hematopoietic cells.; Purification of the sequence-specific transcription factor CTCBF, involved in the control of human collagen IV genes: subunits with homology to Ku antigen.; DNA-dependent protein kinase phosphorylation sites in Ku 70/80 heterodimer.; Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex.; Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86.; DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent manner.; Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.; Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage.; A novel human AP endonuclease with conserved zinc-finger-like motifs involved in DNA strand break responses.; APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; ABH2 couples regulation of ribosomal DNA transcription with DNA alkylation repair.; Identification and functional characterization of a Ku-binding motif in aprataxin polynucleotide kinase/phosphatase-like factor (APLF).; The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins.; Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken ends.; Initial characterization of the human central proteome.; Systematic analysis of protein pools, isoforms, and modifications affecting turnover and subcellular localization.; Deformed epidermal autoregulatory factor-1 (DEAF1) interacts with the Ku70 subunit of the DNA-dependent protein kinase complex.; The E3 ligase RNF8 regulates KU80 removal and NHEJ repair.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1.; XLS (c9orf142) is a new component of mammalian DNA double-stranded break repair.; Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway.; Heat shock factor 1, an inhibitor of non-homologous end joining repair.; Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.; N-terminome analysis of the human mitochondrial proteome.; DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.; The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice.; Specific roles of XRCC4 paralogs PAXX and XLF during V(D)J recombination.; HEXIM1 and NEAT1 Long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.; non-homologous end joining (NHEJ).; ATF7 mediates TNF-alpha-induced telomere shortening.; Ligand binding characteristics of the Ku80 von Willebrand domain.; DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis.; Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair.; Cryo-EM of NHEJ supercomplexes provides insights into DNA repair.; Structural basis of long-range to short-range synaptic transition in NHEJ.; Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.; SETD4-mediated KU70 methylation suppresses apoptosis.",False
PCNA,P12004,Proliferating cell nuclear antigen,MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS,,,"Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins.; Structure of the human gene for the proliferating cell nuclear antigen.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro.; The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21.; Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1.; Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase.; Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta.; Human APE2 protein is mostly localized in the nuclei and to some extent in the mitochondria, while nuclear APE2 is partly associated with proliferating cell nuclear antigen.; Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA.; Terminal deoxynucleotidyltransferase forms a ternary complex with a novel chromatin remodeling protein with 82 kDa and core histone.; Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen.; A defined human system that supports bidirectional mismatch-provoked excision.; Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage.; The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci.; Functional roles of p12, the fourth subunit of human DNA polymerase delta.; Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination.; A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.; Tyrosine phosphorylation controls PCNA function through protein stability.; Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen.; PCNA is ubiquitinated by RNF8.; PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex.; Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity.; Studies with the human cohesin establishment factor, ChlR1. Association of ChlR1 with Ctf18-RFC and Fen1.; CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation.; Role of PCNA-dependent stimulation of 3'-phosphodiesterase and 3'-5' exonuclease activities of human Ape2 in repair of oxidative DNA damage.; Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination.; Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks.; Proliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1.; A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp PCNA.; CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis.; Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells.; DNA polymerase POLN participates in cross-link repair and homologous recombination.; Metnase promotes restart and repair of stalled and collapsed replication forks.; Initial characterization of the human central proteome.; Maintenance of silent chromatin through replication requires SWI/SNF-like chromatin remodeler SMARCAD1.; Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate.; Phosphorylation of the p68 subunit of Pol delta acts as a molecular switch to regulate its interaction with PCNA.; The UNG2 Arg88Cys variant abrogates RPA-mediated recruitment of UNG2 to single-stranded DNA.; Inhibition of homologous recombination by the PCNA-interacting protein PARI.; Spartan/C1orf124, a reader of PCNA ubiquitylation and a regulator of UV-induced DNA damage response.; ZRANB3 is a structure-specific ATP-dependent endonuclease involved in replication stress response.; The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and participates in cellular response to replication stress.; Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass.; Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress.; Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.; A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and Nod2-mediated inflammatory responses.; The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells.; RTEL1 is a replisome-associated helicase that promotes telomere and genome-wide replication.; The ADP-ribosyltransferase PARP10/ARTD10 interacts with proliferating cell nuclear antigen (PCNA) and is required for DNA damage tolerance.; Hypomorphic PCNA mutation underlies a human DNA repair disorder.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components.; CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; Human C6orf211 encodes Armt1, a protein carboxyl methyltransferase that targets PCNA and is linked to the DNA damage response.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; The interaction between ALKBH2 DNA repair enzyme and PCNA is direct, mediated by the hydrophobic pocket of PCNA and perturbed in naturally-occurring ALKBH2 variants.; Bub1 in Complex with LANA Recruits PCNA To Regulate Kaposi's Sarcoma-Associated Herpesvirus Latent Replication and DNA Translesion Synthesis.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; N-terminome analysis of the human mitochondrial proteome.; TRAIP regulates replication fork recovery and progression via PCNA.; R152C DNA Pol beta mutation impairs base excision repair and induces cellular transformation.; PCNA-dependent cleavage and degradation of SDE2 regulates response to replication stress.; Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Removal of RTF2 from Stalled Replisomes Promotes Maintenance of Genome Integrity.; HMCES maintains genome integrity by shielding abasic sites in single-strand DNA.; Fast and efficient DNA replication with purified human proteins.; LncRNA CTBP1-DT-encoded microprotein DDUP sustains DNA damage response signalling to trigger dual DNA repair mechanisms.; Structural and biochemical characterization of the human angiogenin-proliferating cell nuclear antigen interaction.; GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer.; Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA.; Structural basis for recruitment of human flap endonuclease 1 to PCNA.; Crystal structure of human PCNA in complex with the PIP box of DVC1.; TRAIP is a PCNA-binding ubiquitin ligase that protects genome stability after replication stress.; Structure insights into the molecular mechanism of the interaction between UHRF2 and PCNA.; ERCC6L2 mitigates replication stress and promotes centromere stability.",False
FEN1,P39748,Flap endonuclease 1,MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFLIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPVYVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQEVEKFTKRLVKVTKQHNDECKHLLSLMGIPYLDAPSEAEASCAALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLPIQEFHLSRILQELGLNQEQFVDLCILLGSDYCESIRGIGPKRAVDLIQKHKSIEEIVRRLDPNKYPVPENWLHKEAHQLFLEPEVLDPESVELKWSEPNEEELIKFMCGEKQFSEERIRSGVKRLSKSRQGSTQGRLDDFFKVTGSLSSAKRKEPEPKGSTKKKAKTGAAGKFKRGK,,,"Structural and functional conservation of the human homolog of the Schizosaccharomyces pombe rad2 gene, which is required for chromosome segregation and recovery from DNA damage.; Sequence of human FEN-1, a structure-specific endonuclease, and chromosomal localization of the gene (FEN1) in mouse and human.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structural and functional homology between mammalian DNase IV and the 5'-nuclease domain of Escherichia coli DNA polymerase I.; Essential amino acids for substrate binding and catalysis of human flap endonuclease 1.; The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21.; Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1.; Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300.; Arginine residues 47 and 70 of human flap endonuclease-1 are involved in DNA substrate interactions and cleavage site determination.; Studies with the human cohesin establishment factor, ChlR1. Association of ChlR1 with Ctf18-RFC and Fen1.; Nucleolar localization and dynamic roles of flap endonuclease 1 in ribosomal DNA replication and damage repair.; Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A cryptic targeting signal creates a mitochondrial FEN1 isoform with tailed R-loop binding properties.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; R152C DNA Pol beta mutation impairs base excision repair and induces cellular transformation.; Wuho is a new member in maintaining genome stability through its interaction with flap endonuclease 1.; Structural and thermodynamic analysis of human PCNA with peptides derived from DNA polymerase-delta p66 subunit and flap endonuclease-1.; Structural basis for recruitment of human flap endonuclease 1 to PCNA.",False
FAS,P25445,Tumor necrosis factor receptor superfamily member 6,MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV,,,"The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.; Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.; Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation.; Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.; Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.; An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.; Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.; FLICE is activated by association with the CD95 death-inducing signaling complex (DISC).; F1Aalpha, a death receptor-binding protein homologous to the Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase substrate that mediates apoptosis.; LFG: an anti-apoptotic gene that provides protection from fas-mediated cell death.; An unappreciated role for RNA surveillance.; A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway.; Identification of an antiapoptotic protein complex at death receptors.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; Whole-exome-sequencing-based discovery of human FADD deficiency.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD.; Pathogen blocks host death receptor signalling by arginine GlcNAcylation of death domains.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability.; Structural and functional insights into host death domains inactivation by the bacterial arginine GlcNAcyltransferase effector.; NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.; The Fas-FADD death domain complex structure unravels signalling by receptor clustering.; Structural insights into the mechanism of calmodulin binding to death receptors.; Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.; Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.; Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.; Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.; Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.; Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.; The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.; Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.; Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.; Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.; The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.; Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar.; The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.; The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations.",False
TERF2,Q15554,Telomeric repeat-binding factor 2,MAAGAGTAGPASGPGVVRDPAASQPRKRPGREGGEGARRSDTMAGGGGSSDGSGRAAGRRASRSSGRARRGRHEPGLGGPAERGAGEARLEEAVNRWVLKFYFHEALRAFRGSRYGDFRQIRDIMQALLVRPLGKEHTVSRLLRVMQCLSRIEEGENLDCSFDMEAELTPLESAINVLEMIKTEFTLTEAVVESSRKLVKEAAVIICIKNKEFEKASKILKKHMSKDPTTQKLRNDLLNIIREKNLAHPVIQNFSYETFQQKMLRFLESHLDDAEPYLLTMAKKALKSESAASSTGKEDKQPAPGPVEKPPREPARQLRNPPTTIGMMTLKAAFKTLSGAQDSEAAFAKLDQKDLVLPTQALPASPALKNKRPRKDENESSAPADGEGGSELQPKNKRMTISRLVLEEDSQSTEPSAGLNSSQEAASAPPSKPTVLNQPLPGEKNPKVPKGKWNSSNGVEEKETWVEEDELFQVQAAPDEDSTTNITKKQKWTVEESEWVKAGVQKYGEGNWAAISKNYPFVNRTAVMIKDRWRTMKRLGMN,,,"The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2.; Telomeric localization of TRF2, a novel human telobox protein.; The telobox, a Myb-related telomeric DNA binding motif found in proteins from yeast, plants and human.; TRF2 protects human telomeres from end-to-end fusions.; Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres.; TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres.; Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins.; Shelterin: the protein complex that shapes and safeguards human telomeres.; DNA damage-induced phosphorylation of the human telomere-associated protein TRF2.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Apollo, an Artemis-related nuclease, interacts with TRF2 and protects human telomeres in S phase.; The Apollo 5' exonuclease functions together with TRF2 to protect telomeres from DNA repair.; hSnm1B is a novel telomere-associated protein.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Endogenous hSNM1B/Apollo interacts with TRF2 and stimulates ATM in response to ionizing radiation.; The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.; Arginine methylation regulates telomere length and stability.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; TRF2 and Apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structure of the TRFH dimerization domain of the human telomeric proteins TRF1 and TRF2.; How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA: a view from high-resolution crystal structures.; A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins.; NBS1 phosphorylation status dictates repair choice of dysfunctional telomeres.",False
XRCC6,P12956,X-ray repair cross-complementing protein 6,MSGWESYYKTEGDEEAEEEQEENLEASGDYKYSGRDSLIFLVDASKAMFESQSEDELTPFDMSIQCIQSVYISKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVLQELDNPGAKRILELDQFKGQQGQKRFQDMMGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDNPHGNDSAKASRARTKAGDLRDTGIFLDLMHLKKPGGFDISLFYRDIISIAEDEDLRVHFEESSKLEDLLRKVRAKETRKRALSRLKLKLNKDIVISVGIYNLVQKALKPPPIKLYRETNEPVKTKTRTFNTSTGGLLLPSDTKRSQIYGSRQIILEKEETEELKRFDDPGLMLMGFKPLVLLKKHHYLRPSLFVYPEESLVIGSSTLFSALLIKCLEKEVAALCRYTPRRNIPPYFVALVPQEEELDDQKIQVTPPGFQLVFLPFADDKRKMPFTEKIMATPEQVGKMKAIVEKLRFTYRSDSFENPVLQQHFRNLEALALDLMEPEQAVDLTLPKVEAMNKRLGSLVDEFKELVYPPDYNPEGKVTKRKHDNEGSGSKRPKVEYSEEELKTHISKGTLGKFTVPMLKEACRAYGLKSGLKKQELLEALTKHFQD,,,"Cloning and characterization of a cDNA that encodes a 70-kDa novel human thyroid autoantigen.; Molecular cloning of cDNA encoding the p70 (Ku) lupus autoantigen.; Nucleotide sequence and genomic structure analyses of the p70 subunit of the human Ku autoantigen: evidence for a family of genes encoding Ku (p70)-related polypeptides.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of human chromosome 22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of proteins binding to interferon-inducible transcriptional enhancers in hematopoietic cells.; Non-histone protein 1 (NHP1) is a member of the Ku protein family which is upregulated in differentiating mouse myoblasts and human promyelocytes.; The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium.; Purification of the sequence-specific transcription factor CTCBF, involved in the control of human collagen IV genes: subunits with homology to Ku antigen.; Human DNA helicase II: a novel DNA unwinding enzyme identified as the Ku autoantigen.; Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions.; Productive and nonproductive complexes of Ku and DNA-dependent protein kinase at DNA termini.; DNA-dependent protein kinase phosphorylation sites in Ku 70/80 heterodimer.; Ku, a DNA repair protein with multiple cellular functions?; Isolation of Ku70-binding proteins (KUBs).; Defining interactions between DNA-PK and ligase IV/XRCC4.; Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex.; Coordinated assembly of Ku and p460 subunits of the DNA-dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV recruitment.; Proteomic characterization of the human centrosome by protein correlation profiling.; Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; 55K isoform of CDK9 associates with Ku70 and is involved in DNA repair.; ABH2 couples regulation of ribosomal DNA transcription with DNA alkylation repair.; Identification and functional characterization of a Ku-binding motif in aprataxin polynucleotide kinase/phosphatase-like factor (APLF).; The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins.; Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken ends.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Deformed epidermal autoregulatory factor-1 (DEAF1) interacts with the Ku70 subunit of the DNA-dependent protein kinase complex.; HOT1 is a mammalian direct telomere repeat-binding protein contributing to telomerase recruitment.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways.; DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1.; XLS (c9orf142) is a new component of mammalian DNA double-stranded break repair.; Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway.; Heat shock factor 1, an inhibitor of non-homologous end joining repair.; N-terminome analysis of the human mitochondrial proteome.; DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.; Specific roles of XRCC4 paralogs PAXX and XLF during V(D)J recombination.; PAXX is an accessory c-NHEJ factor that associates with Ku70 and has overlapping functions with XLF.; HEXIM1 and NEAT1 Long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.; non-homologous end joining (NHEJ).; ATF7 mediates TNF-alpha-induced telomere shortening.; The three-dimensional structure of the C-terminal DNA-binding domain of human Ku70.; Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair.; Cryo-EM of NHEJ supercomplexes provides insights into DNA repair.; Structural basis of long-range to short-range synaptic transition in NHEJ.; Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.; Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation.; SETD4-mediated KU70 methylation suppresses apoptosis.",False
POLD1,P28340,DNA polymerase delta catalytic subunit,MDGKRRPGPGPGVPPKRARGGLWDDDDAPRPSQFEEDLALMEEMEAEHRLQEQEEEELQSVLEGVADGQVPPSAIDPRWLRPTPPALDPQTEPLIFQQLEIDHYVGPAQPVPGGPPPSRGSVPVLRAFGVTDEGFSVCCHIHGFAPYFYTPAPPGFGPEHMGDLQRELNLAISRDSRGGRELTGPAVLAVELCSRESMFGYHGHGPSPFLRITVALPRLVAPARRLLEQGIRVAGLGTPSFAPYEANVDFEIRFMVDTDIVGCNWLELPAGKYALRLKEKATQCQLEADVLWSDVVSHPPEGPWQRIAPLRVLSFDIECAGRKGIFPEPERDPVIQICSLGLRWGEPEPFLRLALTLRPCAPILGAKVQSYEKEEDLLQAWSTFIRIMDPDVITGYNIQNFDLPYLISRAQTLKVQTFPFLGRVAGLCSNIRDSSFQSKQTGRRDTKVVSMVGRVQMDMLQVLLREYKLRSYTLNAVSFHFLGEQKEDVQHSIITDLQNGNDQTRRRLAVYCLKDAYLPLRLLERLMVLVNAVEMARVTGVPLSYLLSRGQQVKVVSQLLRQAMHEGLLMPVVKSEGGEDYTGATVIEPLKGYYDVPIATLDFSSLYPSIMMAHNLCYTTLLRPGTAQKLGLTEDQFIRTPTGDEFVKTSVRKGLLPQILENLLSARKRAKAELAKETDPLRRQVLDGRQLALKVSANSVYGFTGAQVGKLPCLEISQSVTGFGRQMIEKTKQLVESKYTVENGYSTSAKVVYGDTDSVMCRFGVSSVAEAMALGREAADWVSGHFPSPIRLEFEKVYFPYLLISKKRYAGLLFSSRPDAHDRMDCKGLEAVRRDNCPLVANLVTASLRRLLIDRDPEGAVAHAQDVISDLLCNRIDISQLVITKELTRAASDYAGKQAHVELAERMRKRDPGSAPSLGDRVPYVIISAAKGVAAYMKSEDPLFVLEHSLPIDTQYYLEQQLAKPLLRIFEPILGEGRAEAVLLRGDHTRCKTVLTGKVGGLLAFAKRRNCCIGCRTVLSHQGAVCEFCQPRESELYQKEVSHLNALEERFSRLWTQCQRCQGSLHEDVICTSRDCPIFYMRKKVRKDLEDQEQLLRRFGPPGPEAW,,,"Primary structure of the catalytic subunit of human DNA polymerase delta and chromosomal location of the gene.; Molecular cloning of the cDNA for the catalytic subunit of human DNA polymerase delta.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The human homologue of fission Yeast cdc27, p66, is a component of active human DNA polymerase delta.; Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta.; Reconstitution and characterization of the human DNA polymerase delta four-subunit holoenzyme.; Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen.; Human Werner helicase interacting protein 1 (WRNIP1) functions as a novel modulator for DNA polymerase delta.; Functional roles of p12, the fourth subunit of human DNA polymerase delta.; A novel DNA damage response: rapid degradation of the p12 subunit of dna polymerase delta.; A quantitative atlas of mitotic phosphorylation.; DNA damage alters DNA polymerase delta to a form that exhibits increased discrimination against modified template bases and mismatched primers.; The p12 subunit of human polymerase delta modulates the rate and fidelity of DNA synthesis.; Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells.; Initial characterization of the human central proteome.; Spatiotemporal recruitment of human DNA polymerase delta to sites of UV damage.; Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins.; Human CIA2A-FAM96A and CIA2B-FAM96B Integrate Iron Homeostasis and Maturation of Different Subsets of Cytosolic-Nuclear Iron-Sulfur Proteins.; Dynamics of enzymatic interactions during short flap human Okazaki fragment processing by two forms of human DNA polymerase delta.; A novel function of CRL4(Cdt2): regulation of the subunit structure of DNA polymerase delta in response to DNA damage and during the S phase.; Degradation of p12 subunit by CRL4Cdt2 E3 ligase inhibits fork progression after DNA damage.; An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy.; DNA polymerase delta-interacting protein 2 is a processivity factor for DNA polymerase lambda during 8-oxo-7,8-dihydroguanine bypass.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis.; Break-induced replication repair of damaged forks induces genomic duplications in human cells.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.; New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.; Polymerase delta deficiency causes syndromic immunodeficiency with replicative stress.; Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1.",False
BAX,Q07812,Apoptosis regulator BAX,MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKLVLKALCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG,,,"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.; Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta.; Identification and characterization of baxepsilon, a novel bax variant missing the BH2 and the transmembrane domains.; Characterization of Bax-sigma, a cell death-inducing isoform of Bax.; The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients.; Bax mRNA splice variant lacking exons 2 and 3.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Bax mutations in cell lines derived from hematological malignancies.; A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.; Conformation of the Bax C-terminus regulates subcellular location and cell death.; MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains.; Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax.; E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis.; Humanin peptide suppresses apoptosis by interfering with Bax activation.; JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins.; Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation.; An anti-apoptotic viral protein that recruits Bax to mitochondria.; Clusterin inhibits apoptosis by interacting with activated Bax.; MAP-1 is a mitochondrial effector of Bax.; Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family.; IAN family critically regulates survival and development of T lymphocytes.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation.; Initial characterization of the human central proteome.; Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol.; The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist.; Human Bop is a novel BH3-only member of the Bcl-2 protein family.; Tom70 mediates Sendai virus-induced apoptosis on mitochondria.; N-terminome analysis of the human mitochondrial proteome.; Enterovirus 71 2B induces cell apoptosis by directly inducing the conformational activation of the proapoptotic protein Bax.; PLEKHN1 promotes apoptosis by enhancing Bax-Bak hetero-oligomerization through interaction with Bid in human colon cancer.; Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization.; Deubiquitinating Enzyme USP12 Regulates the Pro-Apoptosis Protein Bax.; Structure of Bax: coregulation of dimer formation and intracellular localization.; Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex.; BAX activation is initiated at a novel interaction site.; Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.; Hematopoietic malignancies demonstrate loss-of-function mutations of BAX.; Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.; Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation.",False
RB1,P06400,Retinoblastoma-associated protein,MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK,,,"The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity.; Human retinoblastoma susceptibility gene: cloning, identification, and sequence.; Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein.; Structure and partial genomic sequence of the human retinoblastoma susceptibility gene.; Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing.; Complete genomic sequence of the human retinoblastoma susceptibility gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genomic organization of the human retinoblastoma gene.; Spectrum of small length germline mutations in the RB1 gene.; Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.; A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity.; Identification of G1 kinase activity for cdk6, a novel cyclin D partner.; SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.; Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79.; The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.; Characterization of the retinoblastoma binding proteins RBP1 and RBP2.; The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing.; Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein.; The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.; Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product.; Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.; Hec1p, an evolutionarily conserved coiled-coil protein, modulates chromosome segregation through interaction with SMC proteins.; Retinoblastoma protein enhances the fidelity of chromosome segregation mediated by hsHec1p.; Rb inhibits the intrinsic kinase activity of TATA-binding protein-associated factor TAFII250.; The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins.; pRB binds to and modulates the transrepressing activity of the E1A-regulated transcription factor p120E4F.; Identification and characterization of a novel human cDNA encoding a 21 kDa pRb-associated protein.; DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.; Rb targets histone H3 methylation and HP1 to promoters.; The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein.; Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb.; Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein.; Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity.; Physical interaction between pRb and cdk9/cyclinT2 complex.; Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.; Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.; Cyclin C/cdk3 promotes Rb-dependent G0 exit.; Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein.; Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity.; LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription.; Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro.; Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.; Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.; Binding of pRB to the PHD protein RBP2 promotes cellular differentiation.; MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.; p600, a unique protein required for membrane morphogenesis and cell survival.; Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells.; Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Targeting the retinoblastoma protein by MC007L, gene product of the molluscum contagiosum virus: detection of a novel virus-cell interaction by a member of the poxviruses.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Methylation of the retinoblastoma tumor suppressor by SMYD2.; Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; BLCAP arrests G(1)/S checkpoint and induces apoptosis through downregulation of pRb1 in HeLa cells.; Structural similarity between the pocket region of retinoblastoma tumour suppressor and the cyclin-box.; Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7.; Structural basis for the specificity of bipartite nuclear localization sequence binding by importin-alpha.; Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.; Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor.; Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture.; Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.; Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype.; Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma.; Frequent constitutional C to T mutations in CGA-arginine codons in the RB1 gene produce premature stop codons in patients with bilateral (hereditary) retinoblastoma.; Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma.; Mutations in the retinoblastoma gene and their expression in somatic and tumor cells of patients with hereditary retinoblastoma.; Germline mutations in the RB1 gene in patients with hereditary retinoblastoma.; Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma.; Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene.; Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma.; Genetics of retinoblastoma: a study.; Twelve novel RB1 gene mutations in patients with hereditary retinoblastoma.; RB1 gene mutations in peripheral blood DNA of patients with isolated unilateral retinoblastoma.; Identification of four novel RB1 germline mutations in Korean retinoblastoma patients.; Diagnostic exome sequencing in persons with severe intellectual disability.",False
EMD,P50402,Emerin,MDNYADLSDTELTTLLRRYNIPHGPVVGSTRRLYEKKIFEYETQRRRLSPPSSSAASSYSFSDLNSTRGDADMYDLPKKEDALLYQSKGYNDDYYEESYFTTRTYGEPESAGPSRAVRQSVTSFPDADAFHHQVHDDDLLSSSEEECKDRERPMYGRDSAYQSITHYRPVSASRSSLDLSYYPTSSSTSFMSSSSSSSSWLTRRAIRPENRAPGAGLGQDRQVPLWGQLLLFLVFVIVLFFIYHFMQAEEGNPF,,,"Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy.; Long-range sequence analysis in Xq28: thirteen known and six candidate genes in 219.4 kb of high GC DNA between the RCP/GCP and G6PD loci.; A novel emerin mutation in a Japanese patient with Emery-Dreifuss muscular dystrophy.; Identification of new mutations in the Emery-Dreifuss muscular dystrophy gene and evidence for genetic heterogeneity of the disease.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Immunocytochemical detection of emerin within the nuclear matrix.; Aberrant intracellular targeting and cell cycle-dependent phosphorylation of emerin contribute to the Emery-Dreifuss muscular dystrophy phenotype.; BAF is required for emerin assembly into the reforming nuclear envelope.; Emerin interacts in vitro with the splicing-associated factor, YT521-B.; Transcriptional repressor germ cell-less (GCL) and barrier to autointegration factor (BAF) compete for binding to emerin in vitro.; Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.; Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy.; Emerin caps the pointed end of actin filaments: evidence for an actin cortical network at the nuclear inner membrane.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus.; The Emery-Dreifuss muscular dystrophy associated-protein emerin is phosphorylated on serine 49 by protein kinase A.; The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity.; A novel role for the nuclear membrane protein emerin in association of the centrosome to the outer nuclear membrane.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Emerin-prelamin A interplay in human fibroblasts.; Involvement of an inner nuclear membrane protein, Nemp1, in Xenopus neural development through an interaction with the chromatin protein BAF.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Samp1 is functionally associated with the LINC complex and A-type lamina networks.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; The NEMP family supports metazoan fertility and nuclear envelope stiffness.; Structural analysis of emerin, an inner nuclear membrane protein mutated in X-linked Emery-Dreifuss muscular dystrophy.; Structural characterization of the LEM motif common to three human inner nuclear membrane proteins.; Changes at P183 of emerin weaken its protein-protein interactions resulting in X-linked Emery-Dreifuss muscular dystrophy.; How does a g993t mutation in the emerin gene cause Emery-Dreifuss muscular dystrophy?",False
GRB2,P62993,Growth factor receptor-bound protein 2,MEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRGDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV,,,"The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.; Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries.; Cloning of a Grb2 isoform with apoptotic properties.; The gene structure of the human growth factor bound protein GRB2.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts.; Insulin stimulates association of insulin receptor substrate-1 with the protein abundant Src homology/growth factor receptor-bound protein 2.; The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.; Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.; p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.; Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein.; Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2.; Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells.; Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.; Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src.; A family of proteins that inhibit signalling through tyrosine kinase receptors.; Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.; Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation.; LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.; Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral.; Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells.; Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins.; Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing adapter protein having similar binding and biological properties to Nck.; Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation.; cbl-b inhibits epidermal growth factor receptor signaling.; NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.; Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral.; Ligand discrimination in signaling through an ErbB4 receptor homodimer.; Interaction of linker for activation of T cells with multiple adapter proteins in platelets activated by the glycoprotein VI-selective ligand, convulxin.; Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control.; Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2-interacting transmembrane adaptor protein).; The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK.; Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2.; Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.; Insulin receptor substrate 4 associates with the protein IRAS.; SKAP55 recruits to lipid rafts and positively mediates the MAPK pathway upon T cell receptor activation.; Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling.; Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling.; Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.; EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis.; LAB: a new membrane-associated adaptor molecule in B cell activation.; TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.; Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.; Signal transduction via the stem cell factor receptor/c-Kit.; The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner.; Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells.; Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream of receptor tyrosine kinase signaling.; Identification of a new transmembrane adaptor protein that constitutively binds Grb2 in B cells.; Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma.; A quantitative atlas of mitotic phosphorylation.; Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages.; An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.; Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.; KIF26A is an unconventional kinesin and regulates GDNF-Ret signaling in enteric neuronal development.; GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, contributes to cellular transformation through the activation of extracellular signal-regulated kinase signaling.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells.; Histidine domain-protein tyrosine phosphatase interacts with Grb2 and GrpL.; Initial characterization of the human central proteome.; FCRL6 receptor: expression and associated proteins.; ACAP4 protein cooperates with Grb2 protein to orchestrate epidermal growth factor-stimulated integrin beta1 recycling in cell migration.; SCIMP, a transmembrane adapter protein involved in major histocompatibility complex class II signaling.; Tespa1 is involved in late thymocyte development through the regulation of TCR-mediated signaling.; Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells.; Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Role of herpes simplex virus VP11/12 tyrosine-based motifs in binding and activation of the Src family kinase Lck and recruitment of p85, Grb2, and Shc.; RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development.; The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module.; N-terminome analysis of the human mitochondrial proteome.; GRB2 Nucleates T Cell Receptor-Mediated LAT Clusters That Control PLC-gamma1 Activation and Cytokine Production.; PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis.; Intersectin-s interaction with DENND2B facilitates recycling of epidermal growth factor receptor.; Grb2 and GRAP connect the B cell antigen receptor to Erk MAP kinase activation in human B cells.; The 11-Kilodalton Nonstructural Protein of Human Parvovirus B19 Facilitates Viral DNA Replication by Interacting with Grb2 through Its Proline-Rich Motifs.; GRB2 enforces homology-directed repair initiation by MRE11.; PEAK1 Y635 phosphorylation regulates cell migration through association with Tensin3 and integrins.; The Grb2 splice variant, Grb3-3, is a negative regulator of RAS activation.; Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis.; GRB2 dimerization mediated by SH2 domain-swapping is critical for T cell signaling and cytokine production.; Regulation of microRNA expression by the adaptor protein GRB2.; RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.; GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer.; GRB2 is a BECN1 interacting protein that regulates autophagy.; Nuclear magnetic resonance solution structure of the growth factor receptor-bound protein 2 Src homology 2 domain.; The three-dimensional solution structure of the Src homology domain-2 of the growth factor receptor-bound protein-2.; Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2.; Crystal structure of the mammalian Grb2 adaptor.; Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.; Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).; Structure-based design, synthesis, and X-ray crystallography of a high- affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.; Dimer formation through domain swapping in the crystal structure of the Grb2-SH2-Ac-pYVNV complex.; Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.; Distinct binding modes of two epitopes in Gab2 that interact with the SH3C domain of Grb2.; High resolution crystal structure of the Grb2 SH2 domain with a phosphopeptide derived from CD28.",False
FOXO3,O43524,Forkhead box protein O3,MAEAPASPAPLSPLEVELDPEFEPQSRPRSCTWPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLEDSARVLAPGGQDPGSGPATAAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIYEWMVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSRFMRVQNEGTGKSSWWIINPDGGKSGKAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPSQLSKWPGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDAPLSPMLYSSSASLSPSVSKPCTVELPRLTDMAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQTQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADGLDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG,,,"Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily.; Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.; Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).; IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.; A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span.; The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor.; Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function.; Initial characterization of the human central proteome.; The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis.; Methylation by Set9 modulates FoxO3 stability and transcriptional activity.; IKK-beta mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death.; Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation.; CHOP potentially co-operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress.; A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels.; CAMKII and Calcineurin regulate the lifespan of Caenorhabditis elegans through the FOXO transcription factor DAF-16.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.; AMBRA1 controls regulatory T-cell differentiation and homeostasis upstream of the FOXO3-FOXP3 axis.; Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification.",False
FOXO1,Q12778,Forkhead box protein O1,MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG,,,"Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.; Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.; Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B.; Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence.; The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site.; Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting.; Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion.; Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding.; Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity.; The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription.; Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.; Gluconeogenesis: re-evaluating the FOXO1-PGC-1alpha connection.; Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt.; A quantitative atlas of mitotic phosphorylation.; Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; C terminus of Hsc70-interacting protein promotes smooth muscle cell proliferation and survival through ubiquitin-mediated degradation of FoxO1.; Regulation of neuronal cell death by MST1-FOXO1 signaling.; Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity.; KRIT1 regulates the homeostasis of intracellular reactive oxygen species.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion.; Cyclophilin A-FoxO1 signaling pathway in endothelial cell apoptosis.; Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification.",False
HSF1,Q00613,Heat shock factor protein 1,MDLPVGPGAAGPSNVPAFLTKLWTLVSDPDTDALICWSPSGNSFHVFDQGQFAKEVLPKYFKHNNMASFVRQLNMYGFRKVVHIEQGGLVKPERDDTEFQHPCFLRGQEQLLENIKRKVTSVSTLKSEDIKIRQDSVTKLLTDVQLMKGKQECMDSKLLAMKHENEALWREVASLRQKHAQQQKVVNKLIQFLISLVQSNRILGVKRKIPLMLNDSGSAHSMPKYSRQFSLEHVHGSGPYSAPSPAYSSSSLYAPDAVASSGPIISDITELAPASPMASPGGSIDERPLSSSPLVRVKEEPPSPPQSPRVEEASPGRPSSVDTLLSPTALIDSILRESEPAPASVTALTDARGHTDTEGRPPSPPPTSTPEKCLSVACLDKNELSDHLDAMDSNLDNLQTMLSSHGFSVDTSALLDLFSPSVTVPDMSLPDLDSSLASIQELLSPQEPPRPPEAENSSPDSGKQLVHYTAQPLFLLDPGSVDTGSNDLPVLFELGEGSYFSEGDGFAEDPTISLLTGSEPPKAKDPTVS,,,"Molecular cloning and expression of a human heat shock factor, HSF1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Isolation of a cDNA for HSF2: evidence for two heat shock factor genes in humans.; Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1.; Heat shock-induced interactions of heat shock transcription factor and the human hsp70 promoter examined by in vivo footprinting.; Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1.; Interaction between heat shock factor and hsp70 is insufficient to suppress induction of DNA-binding activity in vivo.; Activation of the DNA-binding ability of human heat shock transcription factor 1 may involve the transition from an intramolecular to an intermolecular triple-stranded coiled-coil structure.; A heat shock-responsive domain of human HSF1 that regulates transcription activation domain function.; Multiple layers of regulation of human heat shock transcription factor 1.; Evidence for a role of Hsp70 in the regulation of the heat shock response in mammalian cells.; Repression of human heat shock factor 1 activity at control temperature by phosphorylation.; Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1.; Heat shock factor 1 represses Ras-induced transcriptional activation of the c-fos gene.; Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation.; Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1.; Molecular chaperones as HSF1-specific transcriptional repressors.; Transcriptional activation of heat shock factor HSF1 probed by phosphopeptide analysis of factor 32P-labeled in vivo.; Human heat shock factor 1 is predominantly a nuclear protein before and after heat stress.; Rapid and reversible relocalization of heat shock factor 1 within seconds to nuclear stress granules.; Potential targets for HSF1 within the preinitiation complex.; c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity.; Regulation of heat shock transcription factor 1 by stress-induced SUMO-1 modification.; Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex.; Insights into the regulation of heat shock transcription factor 1 SUMO-1 modification.; Transcriptional activity and DNA binding of heat shock factor-1 involve phosphorylation on threonine 142 by CK2.; Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1.; Regulation of molecular chaperone gene transcription involves the serine phosphorylation, 14-3-3 epsilon binding, and cytoplasmic sequestration of heat shock factor 1.; HSF1 modulation of Hsp70 mRNA polyadenylation via interaction with symplekin.; DAXX interacts with heat shock factor 1 during stress activation and enhances its transcriptional activity.; Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress.; Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits transcriptional activity and promotes HSP90 binding.; PDSM, a motif for phosphorylation-dependent SUMO modification.; RNA-mediated response to heat shock in mammalian cells.; Nine-amino-acid transactivation domain: establishment and prediction utilities.; HSF1-TPR interaction facilitates export of stress-induced HSP70 mRNA.; HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential for mitotic progression.; A transcription cofactor required for the heat-shock response.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1.; Protein kinase A binds and activates heat shock factor 1.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Transformation of eEF1Bdelta into heat-shock response transcription factor by alternative splicing.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Interplay of acetyltransferase EP300 and the proteasome system in regulating heat shock transcription factor 1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; BAG3 affects the nucleocytoplasmic shuttling of HSF1 upon heat stress.; HSF1 transcriptional activity is modulated by IER5 and PP2A/B55.; Immediate-early response 5 (IER5) interacts with protein phosphatase 2A and regulates the phosphorylation of ribosomal protein S6 kinase and heat shock factor 1.; Uncoupling stress-inducible phosphorylation of heat shock factor 1 from its activation.; Heat shock factor 1, an inhibitor of non-homologous end joining repair.; Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced HSP90 isoforms and their conformationally restricted mutants.; Heat shock factor 1 is a substrate for p38 mitogen-activated protein kinases.; IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis.; Heat shock factor 1 mediates latent HIV reactivation.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; FOXR1 regulates stress response pathways and is necessary for proper brain development.; Structure of human heat-shock transcription factor 1 in complex with DNA.",False
XPA,P23025,DNA repair protein complementing XP-A cells,MAAADGALPEAAALEQPAELPASVRASIERKRQRALMLRQARLAARPYSATAAAATGGMANVKAAPKIIDTGGGFILEEEEEEEQKIGKVVHQPGPVMEFDYVICEECGKEFMDSYLMNHFDLPTCDNCRDADDKHKLITKTEAKQEYLLKDCDLEKREPPLKFIVKKNPHHSQWGDMKLYLKLQIVKRSLEVWGSQEALEEAKEVRQENREKMKQKKFDKKVKELRRAVRSSVWKRETIVHQHEYGPEENLEDDMYRKTCTMCGHELTYEKM,,,"Analysis of a human DNA excision repair gene involved in group A Xeroderma pigmentosum and containing a zinc-finger domain.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genomic characterization of the human DNA excision repair-controlling gene XPAC.; RPA involvement in the damage-recognition and incision steps of nucleotide excision repair.; Characterization of the human XPA promoter.; Identification and characterization of xpac protein, the gene product of the human XPAC (Xeroderma pigmentosum group A complementing) gene.; Mutational analysis of the structure and function of the Xeroderma pigmentosum group A complementing protein. Identification of essential domains for nuclear localization and DNA excision repair.; Molecular analysis of Xeroderma pigmentosum group A gene.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; UV-dependent interaction between Cep164 and XPA mediates localization of Cep164 at sites of DNA damage and UV sensitivity.; Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA.; Interactions of human nucleotide excision repair protein XPA with DNA and RPA70 Delta C327: chemical shift mapping and 15N NMR relaxation studies.; Structural basis of TFIIH activation for nucleotide excision repair.; Molecular basis of group A Xeroderma pigmentosum: a missense mutation and two deletions located in a zinc finger consensus sequence of the XPAC gene.; Identification of splicing mutations of the last nucleotides of exons, a nonsense mutation, and a missense mutation of the XPAC gene as causes of group A Xeroderma pigmentosum.; Distribution of mutations in the human Xeroderma pigmentosum group A gene and their relationships to the functional regions of the DNA damage recognition protein.",False
MSRA,Q9UJ68,Mitochondrial peptide methionine sulfoxide reductase,MLSATRRACQLLLLHSLFPVPRMGNSASNIVSPQEALPGRKEQTPVAAKHHVNGNRTVEPFPEGTQMAVFGMGCFWGAERKFWVLKGVYSTQVGFAGGYTSNPTYKEVCSEKTGHAEVVRVVYQPEHMSFEELLKVFWENHDPTQGMRQGNDHGTQYRSAIYPTSAKQMEAALSSKENYQKVLSEHGFGPITTDIREGQTFYYAEDYHQQYLSKNPNGYCGLGGTGVSCPVGIKK,,,"Molecular cloning and functional expression of a human peptide methionine sulfoxide reductase (hMsrA).; Heterogeneity and function of mammalian MSRs: enzymes for repair, protection and regulation.; Gene structure, localization and role in oxidative stress of methionine sulfoxide reductase A (MSRA) in the monkey retina.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of a novel human cDNA which shows great homology to Bos taurus methionine sulfoxide reductase (msrA) mRNA.; A novel gene expressed in human hypothalamus.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mitochondrial targeting of the human peptide methionine sulfoxide reductase (MSRA), an enzyme involved in the repair of oxidized proteins.; Dual sites of protein initiation control the localization and myristoylation of methionine sulfoxide reductase A.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.",False
RECQL4,O94761,ATP-dependent DNA helicase Q4,MERLRDVRERLQAWERAFRRQRGRRPSQDDVEAAPEETRALYREYRTLKRTTGQAGGGLRSSESLPAAAEEAPEPRCWGPHLNRAATKSPQSTPGRSRQGSVPDYGQRLKANLKGTLQAGPALGRRPWPLGRASSKASTPKPPGTGPVPSFAEKVSDEPPQLPEPQPRPGRLQHLQASLSQRLGSLDPGWLQRCHSEVPDFLGAPKACRPDLGSEESQLLIPGESAVLGPGAGSQGPEASAFQEVSIRVGSPQPSSSGGEKRRWNEEPWESPAQVQQESSQAGPPSEGAGAVAVEEDPPGEPVQAQPPQPCSSPSNPRYHGLSPSSQARAGKAEGTAPLHIFPRLARHDRGNYVRLNMKQKHYVRGRALRSRLLRKQAWKQKWRKKGECFGGGGATVTTKESCFLNEQFDHWAAQCPRPASEEDTDAVGPEPLVPSPQPVPEVPSLDPTVLPLYSLGPSGQLAETPAEVFQALEQLGHQAFRPGQERAVMRILSGISTLLVLPTGAGKSLCYQLPALLYSRRSPCLTLVVSPLLSLMDDQVSGLPPCLKAACIHSGMTRKQRESVLQKIRAAQVHVLMLTPEALVGAGGLPPAAQLPPVAFACIDEAHCLSQWSHNFRPCYLRVCKVLRERMGVHCFLGLTATATRRTASDVAQHLAVAEEPDLHGPAPVPTNLHLSVSMDRDTDQALLTLLQGKRFQNLDSIIIYCNRREDTERIAALLRTCLHAAWVPGSGGRAPKTTAEAYHAGMCSRERRRVQRAFMQGQLRVVVATVAFGMGLDRPDVRAVLHLGLPPSFESYVQAVGRAGRDGQPAHCHLFLQPQGEDLRELRRHVHADSTDFLAVKRLVQRVFPACTCTCTRPPSEQEGAVGGERPVPKYPPQEAEQLSHQAAPGPRRVCMGHERALPIQLTVQALDMPEEAIETLLCYLELHPHHWLELLATTYTHCRLNCPGGPAQLQALAHRCPPLAVCLAQQLPEDPGQGSSSVEFDMVKLVDSMGWELASVRRALCQLQWDHEPRTGVRRGTGVLVEFSELAFHLRSPGDLTAEEKDQICDFLYGRVQARERQALARLRRTFQAFHSVAFPSCGPCLEQQDEERSTRLKDLLGRYFEEEEGQEPGGMEDAQGPEPGQARLQDWEDQVRCDIRQFLSLRPEEKFSSRAVARIFHGIGSPCYPAQVYGQDRRFWRKYLHLSFHALVGLATEELLQVAR,,,"Cloning of two new human helicase genes of the RecQ family: biological significance of multiple species in higher eukaryotes.; Rothmund-Thomson syndrome responsible gene, RECQL4: genomic structure and products.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome.; Differential regulation of human RecQ family helicases in cell transformation and cell cycle.; Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome.; Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases.; RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes, interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway.; MCM10 mediates RECQ4 association with MCM2-7 helicase complex during DNA replication.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; The N-terminus of the human RecQL4 helicase is a homeodomain-like DNA interaction motif.; The structural and functional characterization of human RecQ4 reveals insights into its helicase mechanism.; Identification of two novel RECQL4exonic SNPs and genomic characterization of the IVS12 minisatellite.; Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome.; Mutation analysis of the RECQL4 gene in sporadic osteosarcomas.; Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene.; Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review.",False
SOD2,P04179,"Superoxide dismutase [Mn], mitochondrial",MLSRAVCGTSRQLAPVLGYLGSRQKHSLPDLPYDYGALEPHINAQIMQLHHSKHHAAYVNNLNVTEEKYQEALAKGDVTAQIALQPALKFNGGGHINHSIFWTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVTERYMACKK,,,"Synthesis and processing of the precursor for human mangano-superoxide dismutase.; Human Mn superoxide dismutase cDNA sequence.; Isolation of cDNAs encoding human manganese superoxide dismutase.; Isolation and characterization of complementary DNAs encoding human manganese-containing superoxide dismutase.; Manganese superoxide dismutase: nucleotide and deduced amino acid sequence of a cDNA encoding a new human transcript.; Complementary DNA encoding human colon cancer manganese superoxide dismutase and the expression of its gene in human cells.; Molecular structure and organization of the human manganese superoxide dismutase gene.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The primary structure of human liver manganese superoxide dismutase.; The human myocardial two-dimensional gel protein database: update 1994.; The major protein expression profile and two-dimensional protein database of human heart.; Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.; Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite.; Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; KRIT1 regulates the homeostasis of intracellular reactive oxygen species.; Initial characterization of the human central proteome.; Protein stability of mitochondrial superoxide dismutase SOD2 is regulated by USP36.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles.; Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface.; Probing the active site of human manganese superoxide dismutase: the role of glutamine 143.; Crystal structure of Y34F mutant human mitochondrial manganese superoxide dismutase and the functional role of tyrosine 34.; Multiple replacements of glutamine 143 in human manganese superoxide dismutase: effects on structure, stability, and catalysis.; Kinetic analysis of product inhibition in human manganese superoxide dismutase.; Contribution of human manganese superoxide dismutase tyrosine 34 to structure and catalysis.; The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients.; The manganese superoxide dismutase Val16Ala polymorphism is associated with decreased risk of diabetic nephropathy in Chinese patients with type 2 diabetes.",False
SOD1,P00441,Superoxide dismutase [Cu-Zn],MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ,,,"Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA.; Architecture and anatomy of the chromosomal locus in human chromosome 21 encoding the Cu/Zn superoxide dismutase.; Human Cu/Zn superoxide dismutase cDNA: isolation of clones synthesising high levels of active or inactive enzyme from an expression library.; Comparison of properties between human recombinant and placental copper-zinc SOD.; Direct sequencing and cloning of superoxide dismutase 1 from peripheral blood.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence of human chromosome 21.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Some sulfhydryl properties and primary structure of human erythrocyte superoxide dismutase.; The complete amino acid sequence of human Cu/Zn superoxide dismutase.; Two novel mutations in the gene for copper zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis.; Superoxide dismutase 1: identification of a novel mutation in a case of familial amyotrophic lateral sclerosis.; The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status.; A quantitative atlas of mitotic phosphorylation.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A ditryptophan cross-link is responsible for the covalent dimerization of human superoxide dismutase 1 during its bicarbonate-dependent peroxidase activity.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Endothelial cell palmitoylproteomic identifies novel lipid-modified targets and potential substrates for protein acyl transferases.; Resveratrol-induced changes of the human adipocyte secretion profile.; SIRT5 desuccinylates and activates SOD1 to eliminate ROS.; Mechanistic aspects of hSOD1 maturation from the solution structure of Cu(I) -loaded hCCS domain 1 and analysis of disulfide-free hSOD1 mutants.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; pLG72 induces superoxide radicals via interaction and aggregation with SOD1.; Copper-zinc superoxide dismutase (Sod1) activation terminates interaction between its copper chaperone (Ccs) and the cytosolic metal-binding domain of the copper importer Ctr1.; SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.; Phenotype in an Infant with SOD1 Homozygous Truncating Mutation.; Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase.; Subunit asymmetry in the three-dimensional structure of a human CuZnSOD mutant found in familial amyotrophic lateral sclerosis.; Solution structure of reduced monomeric Q133M2 copper, zinc superoxide dismutase (SOD). Why is SOD a dimeric enzyme?; The crystal structure of the monomeric human SOD mutant F50E/G51E/E133Q at atomic resolution. The enzyme mechanism revisited.; Solution structure of Apo Cu,Zn superoxide dismutase: role of metal ions in protein folding.; ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization.; Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS.; Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants.; Human SOD1 before harboring the catalytic metal: solution structure of copper-depleted, disulfide-reduced form.; Variable metallation of human superoxide dismutase: atomic resolution crystal structures of Cu-Zn, Zn-Zn and as-isolated wild-type enzymes.; The coupling between disulphide status, metallation and dimer interface strength in Cu/Zn superoxide dismutase.; Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS.; Molecular dynamics using atomic-resolution structure reveal structural fluctuations that may lead to polymerization of human Cu-Zn superoxide dismutase.; Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis.; Crystal structure of human Cu-Zn superoxide dismutase mutant G85R (P21).; Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments.; Structures of mouse SOD1 and human/mouse SOD1 chimeras.; Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.; Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.; A novel mutation in Cu/Zn superoxide dismutase gene in Japanese familial amyotrophic lateral sclerosis.; A new variant Cu/Zn superoxide dismutase (Val7-->Glu) deduced from lymphocyte mRNA sequences from Japanese patients with familial amyotrophic lateral sclerosis.; Identification of a novel SOD1 mutation in an apparently sporadic amyotrophic lateral sclerosis patient and the detection of Ile113Thr in three others.; Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis.; Autosomal dominant amyotrophic lateral sclerosis: a novel mutation in the Cu/Zn superoxide dismutase-1 gene.; Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in Cu/Zn superoxide dismutase gene: a possible new subtype of familial ALS.; 'Sporadic' motoneuron disease due to familial SOD1 mutation with low penetrance.; Identification of a novel exon 4 SOD1 mutation in a sporadic amyotrophic lateral sclerosis patient.; Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis.; A novel point mutation in the Cu/Zn superoxide dismutase gene in a patient with familial amyotrophic lateral sclerosis.; An improved protocol for the analysis of SOD1 gene mutations, and a new mutation in exon 4.; The D90A mutation results in a polymorphism of Cu,Zn superoxide dismutase that is prevalent in northern Sweden and Finland.; Two novel SOD1 mutations in patients with familial amyotrophic lateral sclerosis.; A novel SOD mutant and ALS.; Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase.; Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene.; Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis.; Genetics of amyotrophic lateral sclerosis.; Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis.; A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan.; Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia.; A novel mutation of SOD-1 (Gly 108 Val) in familial amyotrophic lateral sclerosis.; A novel missense point mutation (S134N) of the Cu/Zn superoxide dismutase gene in a patient with familial motor neuron disease.; Novel G16S (GGC-AGC) mutation in the SOD-1 gene in a patient with apparently sporadic young-onset amyotrophic lateral sclerosis.; Familial ALS is associated with mutations in all exons of SOD1: a novel mutation in exon 3 (Gly72Ser).; A missense mutation in the SOD1 gene in patients with amyotrophic lateral sclerosis from the Kii Peninsula and its vicinity, Japan.; A novel SOD1 mutation in an Austrian family with amyotrophic lateral sclerosis.; Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis.; A novel mutation Asp90Val in the SOD1 gene associated with Japanese familial ALS.; Simple and defined method to detect the SOD-1 mutants from patients with familial amyotrophic lateral sclerosis by mass spectrometry.; Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds.; A SOD1 gene mutation in a patient with slowly progressing familial ALS.; A novel SOD1 gene mutation in familial ALS with low penetrance in females.; Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations.; 'True' sporadic ALS associated with a novel SOD-1 mutation.; Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity.; Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis.; Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes.; Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis.; SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization.; Mitochondrial ubiquitin ligase MITOL ubiquitinates mutant SOD1 and attenuates mutant SOD1-induced reactive oxygen species generation.; Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?; A novel L67P SOD1 mutation in an Italian ALS patient.; Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene.; Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.; Oligogenic basis of sporadic ALS: The example of SOD1 p.Ala90Val mutation.",False
FOXM1,Q08050,Forkhead box protein M1,MKTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPAQQESNQAEASKEVAESNSCKFPAGIKIINHPTMPNTQVVAIPNNANIHSIITALTAKGKESGSSGPNKFILISCGGAPTQPPGLRPQTQTSYDAKRTEVTLETLGPKPAARDVNLPRPPGALCEQKRETCADGEAAGCTINNSLSNIQWLRKMSSDGLGSRSIKQEMEEKENCHLEQRQVKVEEPSRPSASWQNSVSERPPYSYMAMIQFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDMFVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQKRPNPELRRNMTIKTELPLGARRKMKPLLPRVSSYLVPIQFPVNQSLVLQPSVKVPLPLAASLMSSELARHSKRVRIAPKVLLAEEGIAPLSSAGPGKEEKLLFGEGFSPLLPVQTIKEEEIQPGEEMPHLARPIKVESPPLEEWPSPAPSFKEESSHSWEDSSQSPTPRPKKSYSGLRSPTRCVSEMLVIQHRERRERSRSRRKQHLLPPCVDEPELLFSEGPSTSRWAAELPFPADSSDPASQLSYSQEVGGPFKTPIKETLPISSTPSKSVLPRTPESWRLTPPAKVGGLDFSPVQTSQGASDPLPDPLGLMDLSTTPLQSAPPLESPQRLLSSEPLDLISVPFGNSSPSDIDVPKPGSPEPQVSGLAANRSLTEGLVLDTMNDSLSKILLDISFPGLDEDPLGPDNINWSQFIPELQ,,,"Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues.; Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope.; Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.; Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Wnt-induced deubiquitination FoxM1 ensures nucleus beta-catenin transactivation.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2.; An intrinsic S/G2 checkpoint enforced by ATR.; Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence.",False
COQ7,Q99807,"NADPH-dependent 3-demethoxyubiquinone 3-hydroxylase, mitochondrial",MSCAGAAAAPRLWRLRPGARRSLSAYGRRTSVRFRSSGMTLDNISRAAVDRIIRVDHAGEYGANRIYAGQMAVLGRTSVGPVIQKMWDQEKDHLKKFNELMVTFRVRPTVLMPLWNVLGFALGAGTALLGKEGAMACTVAVEESIAHHYNNQIRTLMEEDPEKYEELLQLIKKFRDEELEHHDIGLDHDAELAPAYAVLKSIIQAGCRVAIYLSERL,,,"Orthologues of the Caenorhabditis elegans longevity gene clk-1 in mouse and human.; Towards a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging.; Structural and functional conservation of the Caenorhabditis elegans timing gene clk-1.; Initial characterization of the human central proteome.; Aging-associated enzyme human clock-1: substrate-mediated reduction of the diiron center for 5-demethoxyubiquinone hydroxylation.; ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Mitochondrial COQ9 is a lipid-binding protein that associates with COQ7 to enable coenzyme Q biosynthesis.; Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid.; A nuclear role for the respiratory enzyme CLK-1 in regulating mitochondrial stress responses and longevity.; N-terminome analysis of the human mitochondrial proteome.; In vitro construction of the COQ metabolon unveils the molecular determinants of coenzyme Q biosynthesis.; Structure and functionality of a multimeric human COQ7:COQ9 complex.; Pathogenicity of two COQ7 mutations and responses to 2,4-dihydroxybenzoate bypass treatment.; A fatal case of COQ7-associated primary coenzyme Q10 deficiency.; Clinical spectrum in multiple families with primary COQ10 deficiency.; A novel COQ7 mutation causing primarily neuromuscular pathology and its treatment options.; Biallelic variants in the COQ7 gene cause distal hereditary motor neuropathy in two Chinese families.; Phenotypic, molecular, and functional characterization of COQ7-related primary CoQ10 deficiency: Hypomorphic variants and two distinct disease entities.",False
CACNA1A,O00555,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,MARFGDEMPARYGGGGSGAAAGVVVGSGGGRGAGGSRQGGQPGAQRMYKQSMAQRARTMALYNPIPVRQNCLTVNRSLFLFSEDNVVRKYAKKITEWPPFEYMILATIIANCIVLALEQHLPDDDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFAFHKGSYLRNGWNVMDFVVVLTGILATVGTEFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMIPLLQIGLLLFFAILIFAIIGLEFYMGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFAKERERVENRRAFLKLRRQQQIERELNGYMEWISKAEEVILAEDETDGEQRHPFDALRRTTIKKSKTDLLNPEEAEDQLADIASVGSPFARASIKSAKLENSTFFHKKERRMRFYIRRMVKTQAFYWTVLSLVALNTLCVAIVHYNQPEWLSDFLYYAEFIFLGLFMSEMFIKMYGLGTRPYFHSSFNCFDCGVIIGSIFEVIWAVIKPGTSFGISVLRALRLLRIFKVTKYWASLRNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDGIKSQGGVQGGMVFSIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEEEAANQKLALQKAKEVAEVSPLSAANMSIAVKEQQKNQKPAKSVWEQRTSEMRKQNLLASREALYNEMDPDERWKAAYTRHLRPDMKTHLDRPLVVDPQENRNNNTNKSRAAEPTVDQRLGQQRAEDFLRKQARYHDRARDPSGSAGLDARRPWAGSQEAELSREGPYGRESDHHAREGSLEQPGFWEGEAERGKAGDPHRRHVHRQGGSRESRSGSPRTGADGEHRRHRAHRRPGEEGPEDKAERRARHREGSRPARGGEGEGEGPDGGERRRRHRHGAPATYEGDARREDKERRHRRRKENQGSGVPVSGPNLSTTRPIQQDLGRQDPPLAEDIDNMKNNKLATAESAAPHGSLGHAGLPQSPAKMGNSTDPGPMLAIPAMATNPQNAASRRTPNNPGNPSNPGPPKTPENSLIVTNPSGTQTNSAKTARKPDHTTVDIPPACPPPLNHTVVQVNKNANPDPLPKKEEEKKEEEEDDRGEDGPKPMPPYSSMFILSTTNPLRRLCHYILNLRYFEMCILMVIAMSSIALAAEDPVQPNAPRNNVLRYFDYVFTGVFTFEMVIKMIDLGLVLHQGAYFRDLWNILDFIVVSGALVAFAFTGNSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVFNILIVYMLFMFIFAVVAVQLFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYEFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEEYSLEKNERACIDFAISAKPLTRHMPQNKQSFQYRMWQFVVSPPFEYTIMAMIALNTIVLMMKFYGASVAYENALRVFNIVFTSLFSLECVLKVMAFGILNYFRDAWNIFDFVTVLGSITDILVTEFGNNFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIGIDVEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEYVRVWAEYDPAAWGRMPYLDMYQMLRHMSPPLGLGKKCPARVAYKRLLRMDLPVADDNTVHFNSTLMALIRTALDIKIAKGGADKQQMDAELRKEMMAIWPNLSQKTLDLLVTPHKSTDLTVGKIYAAMMIMEYYRQSKAKKLQAMREEQDRTPLMFQRMEPPSPTQEGGPGQNALPSTQLDPGGALMAHESGLKESPSWVTQRAQEMFQKTGTWSPEQGPPTDMPNSQPNSQSVEMREMGRDGYSDSEHYLPMEGQGRAASMPRLPAENQRRRGRPRGNNLSTISDTSPMKRSASVLGPKARRLDDYSLERVPPEENQRHHQRRRDRSHRASERSLGRYTDVDTGLGTDLSMTTQSGDLPSKERDQERGRPKDRKHRQHHHHHHHHHHPPPPDKDRYAQERPDHGRARARDQRWSRSPSEGREHMAHRQGSSSVSGSPAPSTSGTSTPRRGRRQLPQTPSTPRPHVSYSPVIRKAGGSGPPQQQQQQQQQQQQQAVARPGRAATSGPRRYPGPTAEPLAGDRPPTGGHSSGRSPRMERRVPGPARSESPRACRHGGARWPASGPHVSEGPPGPRHHGYYRGSDYDEADGPGSGGGEEAMAGAYDAPPPVRHASSGATGRSPRTPRASGPACASPSRHGRRLPNGYYPAHGLARPRGPGSRKGLHEPYSESDDDWC,,,"Structural elements in domain IV that influence biophysical and pharmacological properties of human alpha1A-containing high-voltage-activated calcium channels.; Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.; Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.; Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function.; The DNA sequence and biology of human chromosome 19.; Expression and antibody inhibition of P-type calcium channels in human small-cell lung carcinoma cells.; Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma.; Characterization of cDNA clones containing CCA trinucleotide repeats derived from human brain.; Differential modulation of Ca(v)2.1 channels by calmodulin and Ca2+-binding protein 1.; Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia.; Crystal structure of the CaV2 IQ domain in complex with Ca2+/calmodulin: high-resolution mechanistic implications for channel regulation by Ca2+.; Progressive ataxia due to a missense mutation in a calcium-channel gene.; Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p.; Detection of a novel missense mutation and second recurrent mutation in the CACNA1A gene in individuals with EA-2 and FHM.; Genetic heterogeneity in Italian families with familial hemiplegic migraine.; A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia.; Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine.; Missense CACNA1A mutation causing episodic ataxia type 2.; The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel.; Loss-of-function EA2 mutations are associated with impaired neuromuscular transmission.; Episodic ataxia type 2. Three novel truncating mutations and one novel missense mutation in the CACNA1A gene.; Functional implications of a novel EA2 mutation in the P/Q-type calcium channel.; A novel R1347Q mutation in the predicted voltage sensor segment of the P/Q-type calcium-channel alpha-subunit in a family with progressive cerebellar ataxia and hemiplegic migraine.; Clusters of non-truncating mutations of P/Q type Ca2+ channel subunit Ca(v)2.1 causing episodic ataxia 2.; Clinical spectrum of episodic ataxia type 2.; Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4.; Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene.; CACNA1A R1347Q: a frequent recurrent mutation in hemiplegic migraine.; Episodic ataxia type 2 showing ictal hyperhidrosis with hypothermia and interictal chronic diarrhea due to a novel CACNA1A mutation.; Late-onset episodic ataxia type 2 associated with a novel loss-of-function mutation in the CACNA1A gene.; The interplay of two single nucleotide polymorphisms in the CACNA1A gene may contribute to migraine susceptibility.; A wide spectrum of clinical, neurophysiological and neuroradiological abnormalities in a family with a novel CACNA1A mutation.; Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2.; New mutation of CACNA1A gene in episodic ataxia type 2.; Congenital ataxia and hemiplegic migraine with cerebral edema associated with a novel gain of function mutation in the calcium channel CACNA1A.; A single amino acid deletion (deltaf1502) in the s6 segment of cav2.1 domain iii associated with congenital ataxia increases channel activity and promotes ca2+ influx.; De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies.; Biallelic CACNA1A mutations cause early onset epileptic encephalopathy with progressive cerebral, cerebellar, and optic nerve atrophy.; Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia.; Cerebellar Atrophy and Changes in Cytokines Associated with the CACNA1A R583Q Mutation in a Russian Familial Hemiplegic Migraine Type 1 Family.; Clinically severe CACNA1A alleles affect synaptic function and neurodegeneration differentially.; Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.; Episodic ataxia type 2 with a novel missense variant (Leu602Arg) in CACNA1A.",False
LRP2,P98164,Low-density lipoprotein receptor-related protein 2,MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEIGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQCIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWVCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENNTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVESQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNKIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLERAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSLIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYATNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIRGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAANRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYLFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFDGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHLKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNEPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECIPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDEKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCLGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFLLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLVASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDRRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALDPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLDYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVMYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNCLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGEIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTLIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEHLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQYEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGLFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHVDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLYFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFLDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTPYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAEVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRSLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTVIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGYLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGINTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERCGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRCDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDRTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQHWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKRHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTCGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDGSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSISGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAPGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKRLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLNGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTIYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLCLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSDGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDCGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCHPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDHYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGAYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSHEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDELGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQHCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQDEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKYVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMFWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYDGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRIFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPPCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGALAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAIDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSEIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV,,,"Cloning and sequencing of human gp330, a Ca(2+)-binding receptor with potential intracellular signaling properties.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1).; A protein involved in calcium sensing of the human parathyroid and placental cytotrophoblast cells belongs to the LDL-receptor protein superfamily.; The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330.; Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin.; Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin.; Functional interaction of megalin with the megalin-binding protein (MegBP), a novel tetratrico peptide repeat-containing adaptor molecule.; Megalin mediates renal uptake of heavy metal metallothionein complexes.; The adaptor disabled-2 binds to the third psi xNPxY sequence on the cytoplasmic tail of megalin.; Role of endocytosis in cellular uptake of sex steroids.; Megalin-mediated endocytosis of cystatin C in proximal tubule cells.; Megalin mediates the transport of leptin across the blood-CSF barrier.; Renal uptake of the antiapoptotic protein survivin is mediated by megalin at the apical membrane of the proximal tubule.; Megalin is predominantly observed in vesicular structures in first and third trimester cytotrophoblasts of the human placenta.; Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the NMR structure of the 10th complement type repeat domain alone and in complex with gentamicin.; The consensus coding sequences of human breast and colorectal cancers.; Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes.; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.; Broadening the phenotype of LRP2 mutations: a new mutation in LRP2 causes a predominantly ocular phenotype suggestive of Stickler syndrome.; Identification of a homozygous missense mutation in LRP2 and a hemizygous missense mutation in TSPYL2 in a family with mild intellectual disability.",False
AIFM1,O95831,"Apoptosis-inducing factor 1, mitochondrial",MFRCGGLAAGALKQKLVPLVRTVCVRSPRQRNRLPGNLFQRWHVPLELQMTRQMASSGASGGKIDNSVLVLIVGLSTVGAGAYAYKTMKEDEKRYNERISGLGLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHED,,,"Molecular characterization of mitochondrial apoptosis-inducing factor.; AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer.; Identification and characterization of AIFsh2, a mitochondrial apoptosis-inducing factor (AIF) isoform with NADH oxidase activity.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space.; Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis.; Apoptosis-inducing factor (AIF) inhibits protein synthesis by interacting with the eukaryotic translation initiation factor 3 subunit p44 (eIF3g).; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Apoptosis-inducing factor is a target for ubiquitination through interaction with XIAP.; A quantitative atlas of mitotic phosphorylation.; Apoptosis-inducing factor plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposed cells.; A brain-specific isoform of mitochondrial apoptosis-inducing factor: AIF2.; Vital function of PRELI and essential requirement of its LEA motif.; Initial characterization of the human central proteome.; Nondegradative ubiquitination of apoptosis inducing factor (AIF) by X-linked inhibitor of apoptosis at a residue critical for AIF-mediated chromatin degradation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Interaction between AIF and CHCHD4 Regulates Respiratory Chain Biogenesis.; N-terminome analysis of the human mitochondrial proteome.; The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis.; DNA binding is required for the apoptogenic action of apoptosis inducing factor.; Structural insights into the coenzyme mediated monomer-dimer transition of the pro-apoptotic apoptosis inducing factor.; Structure/Function Relations in AIFM1 Variants Associated with Neurodegenerative Disorders.; Cowchock syndrome is associated with a mutation in apoptosis-inducing factor.; Defining NADH-Driven Allostery Regulating Apoptosis-Inducing Factor.; Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor.; Early prenatal ventriculomegaly due to an AIFM1 mutation identified by linkage analysis and whole exome sequencing.; Mutations in apoptosis-inducing factor cause X-linked recessive auditory neuropathy spectrum disorder.; From ventriculomegaly to severe muscular atrophy: Expansion of the clinical spectrum related to mutations in AIFM1.; A slowly progressive mitochondrial encephalomyopathy widens the spectrum of AIFM1 disorders.; A novel AIFM1 mutation expands the phenotype to an infantile motor neuron disease.; X-linked hypomyelination with spondylometaphyseal dysplasia (H-SMD) associated with mutations in AIFM1.",False
UCHL1,P09936,Ubiquitin carboxyl-terminal hydrolase isozyme L1,MQLKPMEINPEMLNKVLSRLGVAGQWRFVDVLGLEEESLGSVPAPACALLLLFPLTAQHENFRKKQIEELKGQEVSPKVYFMKQTIGNSCGTIGLIHAVANNQDKLGFEDGSVLKQFLSETEKMSPEDRAKCFEKNEAIQAAHDAVAQEGQCRVDDKVNFHFILFNNVDGHLYELDGRMPFPVNHGASSEDTLLKDAAKVCREFTEREQGEVRFSAVALCKAA,,,"Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The structure of the human gene encoding protein gene product 9.5 (PGP9.5), a neuron-specific ubiquitin C-terminal hydrolase.; Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.; Molecular cloning of cDNA coding for human PGP 9.5 protein. A novel cytoplasmic marker for neurones and neuroendocrine cells.; The ubiquitin pathway in Parkinson's disease.; Neuronal protein gene product 9.5 (IEF SSP 6104) is expressed in cultured human MRC-5 fibroblasts of normal origin and is strongly down-regulated in their SV40 transformed counterparts.; Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes.; Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues.; Cleavage of the C-terminus of NEDD8 by UCH-L3.; The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.; Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1).; Mechanistic studies of ubiquitin C-terminal hydrolase L1.; Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1.; Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.; UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1alpha.; N-terminal proteoforms may engage in different protein complexes.; Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.; Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation.; Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants.; The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease.; Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease.; The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease.; UCHL1 is a Parkinson's disease susceptibility gene.; UCHL-1 is not a Parkinson's disease susceptibility gene.; The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells.; Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts.; Novel UCHL1 mutations reveal new insights into ubiquitin processing.; Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.",False
APP,P05067,Amyloid-beta precursor protein,MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN,,,"The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.; A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors.; The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons.; Genomic organization of the human amyloid beta-protein precursor gene.; Identification and differential expression of a novel alternative splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in leukocytes and brain microglial cells.; A novel method for making nested deletions and its application for sequencing of a 300 kb region of human APP locus.; Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of human chromosome 21.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A cDNA specifying the human amyloid beta precursor protein (ABPP) encodes a 95-kDa polypeptide.; Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene.; Purification of protease nexin II from human fibroblasts.; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease.; Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.; Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer disease brain: coding and noncoding regions of the fetal precursor mRNA are expressed in the cortex.; Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I.; A system for studying the effect(s) of familial Alzheimer disease mutations on the processing of the beta-amyloid peptide precursor.; Alzheimer's disease amyloid peptide is encoded by two exons and shows similarity to soybean trypsin inhibitor.; Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease.; Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels.; Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.; Characterization of beta-amyloid peptide from human cerebrospinal fluid.; Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.; The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient.; Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease.; Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.; An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid.; BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.; A novel mRNA of the A4 amyloid precursor gene coding for a possibly secreted protein.; Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.; Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease.; Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.; The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II.; Protease-specificity of Kunitz inhibitor domain of Alzheimer's disease amyloid protein precursor.; A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease.; Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o).; Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein.; The beta A4 amyloid precursor protein binding to copper.; A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth.; The chondroitin sulfate attachment site of appican is formed by splicing out exon 15 of the amyloid precursor gene.; APP-BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein.; The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein.; Association of a novel human FE65-like protein with the cytoplasmic domain of the amyloid-beta precursor protein.; Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions.; Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease.; An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease.; Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide.; PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein.; Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease.; Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation.; Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress.; Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation.; Interaction of a neuron-specific protein containing PDZ domains with Alzheimer's amyloid precursor protein.; Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42.; Cysteine 144 is a key residue in the copper reduction by the beta-amyloid precursor protein.; Identification of a novel aspartic proteinase (Asp 2) as beta-secretase.; Molecular cloning of human Fe65L2 and its interaction with the Alzheimer's beta-amyloid precursor protein.; Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.; Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.; Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor.; Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins.; Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages.; Beta-amyloid peptide-induced apoptosis regulated by a novel protein containing a G protein activation module.; Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered structure containing superoxide dismutase-like subunits.; Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease.; The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner.; Fibulin-1 binds the amino-terminal head of beta-amyloid precursor protein and modulates its physiological function.; Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II.; Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).; Contrasting species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.; The galvanization of beta-amyloid in Alzheimer's disease.; Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations.; Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2.; A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor.; Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid.; Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.; Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3).; A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing.; Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc.; A cell biological perspective on Alzheimer's disease.; Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1.; Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease.; Amyloid-beta protein precursor (AbetaPP) intracellular domain-associated protein-1 proteins bind to AbetaPP and modulate its processing in an isoform-specific manner.; Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein.; Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.; A peptide zipcode sufficient for anterograde transport within amyloid precursor protein.; SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1.; Regulation of FE65 nuclear translocation and function by amyloid beta-protein precursor in osmotically stressed cells.; BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2.; APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.; Retraction Note: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.; RAGE-mediated signaling contributes to intraneuronal transport of amyloid-{beta} and neuronal dysfunction.; Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol.; Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.; Initial characterization of the human central proteome.; Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.; Quantitative measurements and modeling of cargo-motor interactions during fast transport in the living axon.; MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide and induces its fibrillization.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.; Abeta promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.; Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer's disease mutation.; A single kinase generates the majority of the secreted phosphoproteome.; Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.; X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor.; Sequential NMR resonance assignment and structure determination of the Kunitz-type inhibitor domain of the Alzheimer's beta-amyloid precursor protein.; Solution structure of residues 1-28 of the amyloid beta-peptide.; Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease.; Three-dimensional structures of the amyloid beta peptide (25-35) in membrane-mimicking environment.; Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities.; Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?; Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein.; Substitutions at codon 22 of Alzheimer's Abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells.; The Alzheimer's peptide a beta adopts a collapsed coil structure in water.; Solution structures in aqueous SDS micelles of two amyloid beta peptides of Abeta(1-28) mutated at the alpha-secretase cleavage site.; Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis.; The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain.; Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.; Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution.; Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions.; Molecular basis for passive immunotherapy of Alzheimer's disease.; Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.; Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein.; Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment.; The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol.; Amyloid precursor protein dimerization and synaptogenic function depend on copper binding to the growth factor-like domain.; Interplay of histidine residues of the Alzheimer's disease Abeta peptide governs its Zn-induced oligomerization.; A Binuclear Zinc Interaction Fold Discovered in the Homodimer of Alzheimer's Amyloid-beta Fragment with Taiwanese Mutation D7H.; Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy.; Common fibrillar spines of amyloid-beta and human islet amyloid polypeptide revealed by microelectron diffraction and structure-based inhibitors.; Recognition of the amyloid precursor protein by human gamma-secretase.; Framing beta-amyloid.; Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.; The 717Val-->Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups.; Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease.; Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.; A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.; Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region.; Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene.; A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid.; Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.; Mutation in codon 713 of the beta amyloid precursor protein gene presenting with schizophrenia.; More missense in amyloid gene.; Characterization of amyloid fibril beta-peptide in familial Alzheimer's disease with APP717 mutations.; Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease.; Clinical characteristics in a kindred with early-onset Alzheimer's disease and their linkage to a G-->T change at position 2149 of the amyloid precursor protein gene.; A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease.; Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43).; A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43).; Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala-->Gly mutation.; Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease.; High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.; Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis.; Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene.; Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease.; Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.; Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.; In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease.; The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.; An Iranian family with Alzheimer's disease caused by a novel APP mutation (Thr714Ala).; Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation.; A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene.; A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy.; An African American family with early-onset Alzheimer disease and an APP (T714I) mutation.; Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP.",False
APOE,P02649,Apolipoprotein E,MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH,,,"Synthesis, intracellular processing, and signal peptide of human apolipoprotein E.; Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant.; Nucleotide sequence and structure of the human apolipoprotein E gene.; Genotyping and sequence analysis of apolipoprotein E isoforms.; Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene: PEREC1.; Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A new apolipoprotein E variant (Gln46-->His).; Identification and DNA sequence of a human apolipoprotein E cDNA clone.; Human apolipoprotein E. The complete amino acid sequence.; Cholesteryl ester and apolipoprotein E transfer between human high density lipoproteins and chylomicrons.; Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains.; Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.; Soluble LR11 competes with amyloid beta in binding to cerebrospinal fluid-high-density lipoprotein.; Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.; Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194.; Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins.; Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.; Effects of exogenous apo E-3 and of cholesterol-enriched meals on the cellular metabolism of human chylomicrons and their remnants.; Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.; Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization.; Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.; Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease.; Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.; Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin.; Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein.; Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins.; The HepG2 extracellular matrix contains separate heparinase- and lipid-releasable pools of ApoE. Implications for hepatic lipoprotein metabolism.; Specific regional transcription of apolipoprotein E in human brain neurons.; Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site.; Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.; Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain.; Molecular interactions between apoE and ABCA1: impact on apoE lipidation.; Enrichment of glycopeptides for glycan structure and attachment site identification.; Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E.; Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.; Initial characterization of the human central proteome.; Resveratrol-induced changes of the human adipocyte secretion profile.; Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.; LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.; ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins.; A single kinase generates the majority of the secreted phosphoproteome.; Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment Cells.; ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion.; Regulation of Apolipoprotein E Trafficking by Hepatitis C Virus-Induced Autophagy.; LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.; Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.; Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.; Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein.; Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.; Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding.; Interaction of the N-terminal domain of apolipoprotein E4 with heparin.; Structure of the minimal interface between ApoE and LRP.; Identification of human apolipoprotein E variant gene: apolipoprotein E7 (Glu244,245----Lys244,245).; Molecular cloning of a human apolipoprotein E variant: E5 (Glu-3-->Lys).; Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127.; Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi).; Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.; Apolipoprotein E-4 Philadelphia (Glu-13-->Lys,Arg-145-->Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia.; Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects.; Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3----Lys) and its binding to low density lipoprotein receptors.; Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene.; Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.; Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys, Cys112->Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis.; Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.; Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.; Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA.; Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).; Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis.; Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.; Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease.; A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.; Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.; Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)].; Apolipoprotein E3Basel: new insights into a highly conserved protein region.; Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors.; Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.; APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.; Quantitative detection of single amino acid polymorphisms by targeted proteomics.; Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia.; APOE p.Leu167del mutation in familial hypercholesterolemia.; Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.; Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.; Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.; Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.; Cell-specific production, secretion, and function of apolipoprotein E.; ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response.",False
A2M,P01023,Alpha-2-macroglobulin,MGKNKLLHPSLVLLLLVLLPTDASVSGKPQYMVLVPSLLHTETTEKGCVLLSYLNETVTVSASLESVRGNRSLFTDLEAENDVLHCVAFAVPKSSSNEEVMFLTVQVKGPTQEFKKRTTVMVKNEDSLVFVQTDKSIYKPGQTVKFRVVSMDENFHPLNELIPLVYIQDPKGNRIAQWQSFQLEGGLKQFSFPLSSEPFQGSYKVVVQKKSGGRTEHPFTVEEFVLPKFEVQVTVPKIITILEEEMNVSVCGLYTYGKPVPGHVTVSICRKYSDASDCHGEDSQAFCEKFSGQLNSHGCFYQQVKTKVFQLKRKEYEMKLHTEAQIQEEGTVVELTGRQSSEITRTITKLSFVKVDSHFRQGIPFFGQVRLVDGKGVPIPNKVIFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDRSPCYGYQWVSEEHEEAHHTAYLVFSPSKSFVHLEPMSHELPCGHTQTVQAHYILNGGTLLGLKKLSFYYLIMAKGGIVRTGTHGLLVKQEDMKGHFSISIPVKSDIAPVARLLIYAVLPTGDVIGDSAKYDVENCLANKVDLSFSPSQSLPASHAHLRVTAAPQSVCALRAVDQSVLLMKPDAELSASSVYNLLPEKDLTGFPGPLNDQDNEDCINRHNVYINGITYTPVSSTNEKDMYSFLEDMGLKAFTNSKIRKPKMCPQLQQYEMHGPEGLRVGFYESDVMGRGHARLVHVEEPHTETVRKYFPETWIWDLVVVNSAGVAEVGVTVPDTITEWKAGAFCLSEDAGLGISSTASLRAFQPFFVELTMPYSVIRGEAFTLKATVLNYLPKCIRVSVQLEASPAFLAVPVEKEQAPHCICANGRQTVSWAVTPKSLGNVNFTVSAEALESQELCGTEVPSVPEHGRKDTVIKPLLVEPEGLEKETTFNSLLCPSGGEVSEELSLKLPPNVVEESARASVSVLGDILGSAMQNTQNLLQMPYGCGEQNMVLFAPNIYVLDYLNETQQLTPEIKSKAIGYLNTGYQRQLNYKHYDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARAYIFIDEAHITQALIWLSQRQKDNGCFRSSGSLLNNAIKGGVEDEVTLSAYITIALLEIPLTVTHPVVRNALFCLESAWKTAQEGDHGSHVYTKALLAYAFALAGNQDKRKEVLKSLNEEAVKKDNSVHWERPQKPKAPVGHFYEPQAPSAEVEMTSYVLLAYLTAQPAPTSEDLTSATNIVKWITKQQNAQGGFSSTQDTVVALHALSKYGAATFTRTGKAAQVTIQSSGTFSSKFQVDNNNRLLLQQVSLPELPGEYSMKVTGEGCVYLQTSLKYNILPEKEEFPFALGVQTLPQTCDEPKAHTSFQISLSVSYTGSRSASNMAIVDVKMVSGFIPLKPTVKMLERSNHVSRTEVSSNHVLIYLDKVSNQTLSLFFTVLQDVPVRDLKPAIVKVYDYYETDEFAIAEYNAPCSKDLGNA,,,"Nucleotide sequence of cDNA encoding human alpha 2-macroglobulin and assignment of the chromosomal locus.; Alpha(2) macroglobulin, a PSA-binding protein, is expressed in human prostate stroma.; The full-ORF clone resource of the German cDNA consortium.; The finished DNA sequence of human chromosome 12.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structure of the human alpha-2 macroglobulin gene and its promotor.; Primary structure of human alpha 2-macroglobulin. V. The complete structure.; Primary structure of human alpha 2-macroglobulin. Complete disulfide bridge assignment and localization of two interchain bridges in the dimeric proteinase binding unit.; A genetic polymorphism in a functional domain of human pregnancy zone protein: the bait region. Genomic structure of the bait domains of human pregnancy zone protein and alpha 2 macroglobulin.; Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site.; Human alpha 2-macroglobulin gene is located on chromosome 12.; Proteolytic cleavage sites on alpha 2-macroglobulin resulting in proteinase binding are different for trypsin and Staphylococcus aureus V-8 proteinase.; Primary structure of the 'bait' region for proteinases in alpha 2-macroglobulin. Nature of the complex.; Primary and secondary cleavage sites in the bait region of alpha 2-macroglobulin.; Human neutrophil elastase and cathepsin G cleavage sites in the bait region of alpha 2-macroglobulin. Proposed structural limits of the bait region.; Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.; Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; Initial characterization of the human central proteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Localization of basic residues required for receptor binding to the single alpha-helix of the receptor binding domain of human alpha2-macroglobulin.; Human alpha2-macroglobulin is composed of multiple domains, as predicted by homology with complement component C3.; Sequence polymorphism in the human alpha2-macroglobulin (A2M) gene.",False
SNCG,O76070,Gamma-synuclein,MDVFKKGFSIAKEGVVGAVEKTKQGVTEAAEKTKEGVMYVGAKTKENVVQSVTSVAEKTKEQANAVSEAVVSSVNTVATKTVEEAENIAVTSGVVRKEDLRPSAPQQEGEASKEKEEVAEEAQSGGD,,,"Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing.; Organization, expression and polymorphism of the human persyn gene.; Identification, localization and characterization of the human gamma-synuclein gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Synucleins are a novel class of substrates for G protein-coupled receptor kinases.; Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction.; A quantitative atlas of mitotic phosphorylation.; Initial characterization of the human central proteome.",False
PRDX1,Q06830,Peroxiredoxin-1,MSSGNAKIGHPAPNFKATAVMPDGQFKDISLSDYKGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWVNTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITVNDLPVGRSVDETLRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVQKSKEYFSKQK,,,"A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins.; Cloning and sequence analysis of candidate human natural killer-enhancing factor genes.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha.; A method for detection of overoxidation of cysteines: peroxiredoxins are oxidized in vivo at the active-site cysteine during oxidative stress.; Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation.; Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid.; Regeneration of peroxiredoxins during recovery after oxidative stress: only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress.; Proteomic characterization of the human centrosome by protein correlation profiling.; Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation.; Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.; Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.; HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Tumor suppressor down-regulated in renal cell carcinoma 1 (DRR1) is a stress-induced actin bundling factor that modulates synaptic efficacy and cognition.; Resveratrol-induced changes of the human adipocyte secretion profile.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; N-terminome analysis of the human mitochondrial proteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace.; Protein engineering of the quaternary sulfiredoxin.peroxiredoxin enzyme.substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation.; Crystal structure of dimeric human peroxiredoxin-1 C83S mutant.",False
PON1,P27169,Serum paraoxonase/arylesterase 1,MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIETGSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLELGITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEEKSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGLAWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEKHANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPPASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKALYCEL,,,"Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence.; Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.; Studies on human serum paraoxonase/arylesterase.; Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification.; Structural organization of the human PON1 gene.; Differential expression of a cDNA clone in human liver versus hepatic cancer -- highly homologous to aryl-dialkyl-phosphatase.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of human chromosome 7.; Human chromosome 7: DNA sequence and biology.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase.; Apolipoprotein J is associated with paraoxonase in human plasma.; Purification of rabbit and human serum paraoxonase.; Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.; Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.; Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity.; Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.; Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes.; The molecular basis of the human serum paraoxonase activity polymorphism.; A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM.; New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.; DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.",False
RELA,Q04206,Transcription factor p65,MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQCVKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLSHPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSQADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQISS,,,"Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B.; Genomic organization of the gene encoding the p65 subunit of NF-kappa B: multiple variants of the p65 protein may be generated by alternative splicing.; An alternatively spliced transcript, p65 delta 2, of the gene encoding the p65 subunit of the transcription factor NF-kappa B.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative.; A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene.; I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding.; Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor.; Regulation of intercellular adhesion molecule-1 gene by tumor necrosis factor-alpha is mediated by the nuclear factor-kappaB heterodimers p65/p65 and p65/c-Rel in the absence of p50.; A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription.; IKAP is a scaffold protein of the IkappaB kinase complex.; IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.; NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2.; Yersinia enterocolitica invasin protein triggers IL-8 production in epithelial cells via activation of Rel p65-p65 homodimers.; Inhibition of nuclear factor-kappaB-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats.; Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II.; The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation.; Duration of nuclear NF-kappaB action regulated by reversible acetylation.; A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis.; Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.; The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.; Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).; Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65.; RING finger protein AO7 supports NF-kappaB-mediated transcription by interacting with the transactivation domain of the p65 subunit.; Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability.; Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA.; RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator.; Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB.; Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation.; Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response.; Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways.; The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis.; Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor.; IKKbeta phosphorylates p65 at S468 in transactivation domain 2.; cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B.; COMMD proteins, a novel family of structural and functional homologs of MURR1.; NF-kappaB RelA phosphorylation regulates RelA acetylation.; Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.; Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B.; Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis.; Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB.; Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon.; Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.; Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17.; IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation.; LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB.; Nine-amino-acid transactivation domain: establishment and prediction utilities.; UXT is a novel and essential cofactor in the NF-kappaB transcriptional enhanceosome.; The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment.; Functional characterization of the atopy-associated gene PHF11.; AKIP1 enhances NF-kappaB-dependent gene expression by promoting the nuclear retention and phosphorylation of p65.; Copine-I represses NF-kappaB transcription by endoproteolysis of p65.; The DEAD-box RNA helicase DDX1 interacts with RelA and enhances nuclear factor kappaB-mediated transcription.; Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A novel LZAP-binding protein, NLBP, inhibits cell invasion.; SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310.; Zinc finger protein Gfi1 controls the endotoxin-mediated Toll-like receptor inflammatory response by antagonizing NF-kappaB p65.; The Listeria monocytogenes InlC protein interferes with innate immune responses by targeting the I{kappa}B kinase subunit IKK{alpha}.; Initial characterization of the human central proteome.; TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation.; Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs neutrophil chemotaxis by degrading nuclear p65.; Structural basis of SETD6-mediated regulation of the NF-kB network via methyl-lysine signaling.; NF-kappaB repression by PIAS3 mediated RelA SUMOylation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma.; Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-kappaB activation.; Poxvirus protein MC132 from molluscum contagiosum virus inhibits NF-B activation by targeting p65 for degradation.; Ubiquitination of ECSIT is crucial for the activation of p65/p50 NF-kappaBs in Toll-like receptor 4 signaling.; The DEAD-Box RNA Helicase DDX3 Interacts with NF-kappaB Subunit p65 and Suppresses p65-Mediated Transcription.; Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration.; LRRC25 functions as an inhibitor of NF-kappaB signaling pathway by promoting p65/RelA for autophagic degradation.; Zbtb7a is a transducer for the control of promoter accessibility by NF-kappa B and multiple other transcription factors.; The E3 ubiquitin ligase RNF182 inhibits TLR-triggered cytokine production through promoting p65 ubiquitination and degradation.; Human Cytomegalovirus DNA Polymerase Subunit UL44 Antagonizes Antiviral Immune Responses by Suppressing IRF3- and NF-kappaB-Mediated Transcription.; MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells.; Structure of an IkappaBalpha/NF-kappaB complex.; RELA haploinsufficiency in CD4 lymphoproliferative disease with autoimmune cytopenias.",False
IL6,P05231,Interleukin-6,MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM,,,"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.; Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene.; Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.; Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.; Molecular cloning and expression of hybridoma growth factor in Escherichia coli.; Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells.; Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.; Interleukin 6: identification as a hematopoietic colony-stimulating factor.; Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.; Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium.; Marked cell-type-specific differences in glycosylation of human interleukin-6.; Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond.; Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor.; Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6.; Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.; Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.; IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.; Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system.; IL-6 selectively stimulates fat metabolism in human skeletal muscle.; Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.; A single kinase generates the majority of the secreted phosphoproteome.; A gp130-Src-YAP module links inflammation to epithelial regeneration.; SorLA in Interleukin-6 Signaling and Turnover.; Targeting Interleukin-6 Signaling in Clinic.; Coagulation Factor Xa Induces Proinflammatory Responses in Cardiac Fibroblasts via Activation of Protease-Activated Receptor-1.; Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy.; Solution structure of recombinant human interleukin-6.; 1.9-A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling.; Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.; The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.; An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.; A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density.; Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women.",False
RGN,Q15493,Regucalcin,MSSIKIECVLPENCRCGESPVWEEVSNSLLFVDIPAKKVCRWDSFTKQVQRVTMDAPVSSVALRQSGGYVATIGTKFCALNWKEQSAVVLATVDNDKKNNRFNDGKVDPAGRYFAGTMAEETAPAVLERHQGALYSLFPDHHVKKYFDQVDISNGLDWSLDHKIFYYIDSLSYSVDAFDYDLQTGQISNRRSVYKLEKEEQIPDGMCIDAEGKLWVACYNGGRVIRLDPVTGKRLQTVKLPVDKTTSCCFGGKNYSEMYVTCARDGMDPEGLLRQPEAGGIFKITGLGVKGIAPYSYAG,,,"Isolation of cDNA clone encoding human homologue of senescence marker protein-30 (SMP30) and its location on the X chromosome.; Transcript heterogeneity of the human gene for Ca2+-binding protein regucalcin.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Crystal structure of human senescence marker protein 30: insights linking structural, enzymatic, and physiological functions.; Structural basis of the gamma-lactone-ring formation in ascorbic acid biosynthesis by the senescence marker protein-30/gluconolactonase.",False
ATP5O,P48047,"ATP synthase peripheral stalk subunit OSCP, mitochondrial",MAAPAVSGLSRQVRCFSTSVVRPFAKLVRPPVQVYGIEGRYATALYSAASKQNKLEQVEKELLRVAQILKEPKVAASVLNPYVKRSIKVKSLNDITAKERFSPLTTNLINLLAENGRLSNTQGVVSAFSTMMSVHRGEVPCTVTSASPLEEATLSELKTVLKSFLSQGQVLKLEAKTDPSILGGMIVRIGEKYVDMSVKTKIQKLGRAMREIV,,,"Cloning of the cDNA for the human ATP synthase OSCP subunit (ATP5O) by exon trapping and mapping to chromosome 21q22.1-q22.2.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient and exercise-induced stress.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Stress response silencing by an E3 ligase mutated in neurodegeneration.; Structure of the human ATP synthase.; Variants in Mitochondrial ATP Synthase Cause Variable Neurologic Phenotypes.",False
RAD52,P43351,DNA repair protein RAD52 homolog,MSGTEEAILGGRDSHPAAGGGSVLCFGQCQYTAEEYQAIQKALRQRLGPEYISSRMAGGGQKVCYIEGHRVINLANEMFGYNGWAHSITQQNVDFVDLNNGKFYVGVCAFVRVQLKDGSYHEDVGYGVSEGLKSKALSLEKARKEAVTDGLKRALRSFGNALGNCILDKDYLRSLNKLPRQLPLEVDLTKAKRQDLEPSVEEARYNSCRPNMALGHPQLQQVTSPSRPSHAVIPADQDCSSRSLSSSAVESEATHQRKLRQKQLQQQFRERMEKQQVRVSTPSAEKSEAAPPAPPVTHSTPVTVSEPLLEKDFLAGVTQELIKTLEDNSEKWAVTPDAGDGVVKPSSRADPAQTSDTLALNNQMVTQNRTPHSVCHQKPQAKSGSWDLQTYSADQRTTGNWESHRKSQDMKKRKYDPS,,,"The human and mouse homologs of the yeast RAD52 gene: cDNA cloning, sequence analysis, assignment to human chromosome 12p12.2-p13, and mRNA expression in mouse tissues.; Cloning of human and mouse genes homologous to RAD52, a yeast gene involved in DNA repair and recombination.; Expression of human RAD52 confers resistance to ionizing radiation in mammalian cells.; Identification of novel isoforms of human RAD52.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The finished DNA sequence of human chromosome 12.; Physical interaction between human RAD52 and RPA is required for homologous recombination in mammalian cells.; Regulation of ionizing radiation-induced Rad52 nuclear foci formation by c-Abl-mediated phosphorylation.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RAD51AP1 is an essential mediator of alternative lengthening of telomeres.; RAD51AP1 is an essential mediator of alternative lengthening of telomeres.; Crystal structure of the homologous-pairing domain from the human Rad52 recombinase in the undecameric form.; Structure of the single-strand annealing domain of human RAD52 protein.",False
TOP3B,O95985,DNA topoisomerase 3-beta-1,MKTVLMVAEKPSLAQSIAKILSRGSLSSHKGLNGACSVHEYTGTFAGQPVRFKMTSVCGHVMTLDFLGKYNKWDKVDPAELFSQAPTEKKEANPKLNMVKFLQVEGRGCDYIVLWLDCDKEGENICFEVLDAVLPVMNKAHGGEKTVFRARFSSITDTDICNAMACLGEPDHNEALSVDARQELDLRIGCAFTRFQTKYFQGKYGDLDSSLISFGPCQTPTLGFCVERHDKIQSFKPETYWVLQAKVNTDKDRSLLLDWDRVRVFDREIAQMFLNMTKLEKEAQVEATSRKEKAKQRPLALNTVEMLRVASSSLGMGPQHAMQTAERLYTQGYISYPRTETTHYPENFDLKGSLRQQANHPYWADTVKRLLAEGINRPRKGHDAGDHPPITPMKSATEAELGGDAWRLYEYITRHFIATVSHDCKYLQSTISFRIGPELFTCSGKTVLSPGFTEVMPWQSVPLEESLPTCQRGDAFPVGEVKMLEKQTNPPDYLTEAELITLMEKHGIGTDASIPVHINNICQRNYVTVESGRRLKPTNLGIVLVHGYYKIDAELVLPTIRSAVEKQLNLIAQGKADYRQVLGHTLDVFKRKFHYFVDSIAGMDELMEVSFSPLAATGKPLSRCGKCHRFMKYIQAKPSRLHCSHCDETYTLPQNGTIKLYKELRCPLDDFELVLWSSGSRGKSYPLCPYCYNHPPFRDMKKGMGCNECTHPSCQHSLSMLGIGQCVECESGVLVLDPTSGPKWKVACNKCNVVAHCFENAHRVRVSADTCSVCEAALLDVDFNKAKSPLPGDETQHMGCVFCDPVFQELVELKHAASCHPMHRGGPGRRQGRGRGRARRPPGKPNPRRPKDKMSALAAYFV,,,"A new human topoisomerase III that interacts with SGS1 protein.; One-megabase sequence analysis of the human immunoglobulin lambda gene locus.; A genome annotation-driven approach to cloning the human ORFeome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).",False
ERCC1,P07992,DNA excision repair protein ERCC-1,MDPGKDKEGVPQPSGPPARKKFVIPLDEDEVPPGVAKPLFRSTQSLPTVDTSAQAAPQTYAEYAISQPLEGAGATCPTGSEPLAGETPNQALKPGAKSNSIIVSPRQRGNPVLKFVRNVPWEFGDVIPDYVLGQSTCALFLSLRYHNLHPDYIHGRLQSLGKNFALRVLLVQVDVKDPQQALKELAKMCILADCTLILAWSPEEAGRYLETYKAYEQKPADLLMEKLEQDFVSRVTECLTTVKSVNKTDSQTLLTTFGSLEQLIAASREDLALCPGLGPQKARRLFDVLHEPFLKVP,,,"Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10.; Identification of DNA repair genes in the human genome.; A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.; Human excision repair protein 1, transcript variant, mRNA.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.; ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.; USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.; Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.; The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair.; First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure.; Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia.",False
SIRT1,Q96EB6,NAD-dependent protein deacetylase sirtuin-1,MADEAALALQPGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREVPAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSREPPLADNLYDEDDDDEGEEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS,,,"Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity.; Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.; Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.; Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.; Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.; Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.; Mammalian SIRT1 represses forkhead transcription factors.; FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1).; Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.; Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.; Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.; Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation.; Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.; Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications.; SIRT1 regulates HIV transcription via Tat deacetylation.; Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.; Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1.; Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription.; Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene expression in vivo.; SIRT1 promotes DNA repair activity and deacetylation of Ku70.; SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity.; Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor.; Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity.; SIRT1 deacetylates and positively regulates the nuclear receptor LXR.; SIRT1 regulates the function of the Nijmegen breakage syndrome protein.; An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.; SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation.; SIRT1 regulates circadian clock gene expression through PER2 deacetylation.; Epigenetic control of rDNA loci in response to intracellular energy status.; JNK2-dependent regulation of SIRT1 protein stability.; Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation.; Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation.; SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation.; DBC1 is a negative regulator of SIRT1.; Negative regulation of the deacetylase SIRT1 by DBC1.; Phosphorylation regulates SIRT1 function.; A quantitative atlas of mitotic phosphorylation.; A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2.; Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD.; Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.; Transcriptional corepressor SMILE recruits SIRT1 to inhibit nuclear receptor estrogen receptor-related receptor gamma transactivation.; A c-Myc-SIRT1 feedback loop regulates cell growth and transformation.; hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage.; JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.; Role of SIRT1 in homologous recombination.; SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages.; SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60.; DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.; SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism.; Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha.; SIRT1 regulates UV-induced DNA repair through deacetylating XPA.; SIRT1 deacetylates APE1 and regulates cellular base excision repair.; Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation.; SIRT1 negatively regulates the mammalian target of rapamycin.; SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53.; Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2.; Tumor necrosis factor alpha-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes.; Initial characterization of the human central proteome.; Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation.; EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.; Energy sensing factors PGC-1alpha and SIRT1 modulate PXR expression and function.; Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.; MST1 promotes apoptosis through regulating Sirt1-dependent p53 deacetylation.; Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1.; Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection.; SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities.; SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.; The evolutionarily conserved longevity determinants HCF-1 and SIR-2.1/SIRT1 collaborate to regulate DAF-16/FOXO.; Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1).; The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; 75kDa SirT1 blocks TNFalpha-mediated apoptosis in human osteoarthritic chondrocytes.; SIRT1 links CIITA deacetylation to MHC II activation.; USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development.; PML regulates PER2 nuclear localization and circadian function.; Autoacetylation of the MYST lysine acetyltransferase MOF protein.; The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of breast cancer cells through impaired responses to UV-induced DNA damage.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; SIRT4 represses peroxisome proliferator-activated receptor alpha activity to suppress hepatic fat oxidation.; Deleted in breast cancer 1 (DBC1) protein regulates hepatic gluconeogenesis.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage.; Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced apoptosis.; MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in the cytoplasm.; CCAR2 negatively regulates nuclear receptor LXRalpha by competing with SIRT1 deacetylase.; Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription.; A recurrent de novo PACS2 heterozygous missense variant causes neonatal-onset developmental epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis.; A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity.; Tip60-mediated lipin 1 acetylation and ER translocation determine triacylglycerol synthesis rate.; Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme activity between gluconeogenic and anaplerotic reactions.; Biochemical insight into pseudouridine synthase 7 (PUS7) as a novel interactor of sirtuin, SIRT1.; CCDC84 Acetylation Oscillation Regulates Centrosome Duplication by Modulating HsSAS-6 Degradation.; Dynamic acetylation of the kinetochore-associated protein HEC1 ensures accurate microtubule-kinetochore attachment.; Synergy between SIRT1 and SIRT6 helps recognize DNA breaks and potentiates the DNA damage response and repair in humans and mice.; Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.; Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations.; The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer.",False
HDAC1,Q13547,Histone deacetylase 1,MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSKVMEMFQPSAVVLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLMLGGGGYTIRNVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTNEYLEKIKQRLFENLRMLPHAPGVQMQAIPEDAIPEESGDEDEDDPDKRISICSSDKRIACEEEFSDSEEEGEGGRKNSSNFKKAKRVKTEDEKEKDPEEKKEVTEEEKTKEEKPEAKGVKEEVKLA,,,"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.; Isolation and mapping of a human gene (RPD3L1) that is homologous to RPD3, a transcription factor in Saccharomyces cerevisiae.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; MEF-2 function is modified by a novel co-repressor, MITR.; BCoR, a novel corepressor involved in BCL-6 repression.; HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins.; Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing.; Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.; Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.; NuRD and SIN3 histone deacetylase complexes in development.; Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation.; Sharp, an inducible cofactor that integrates nuclear receptor repression and activation.; Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1.; TGIF2 interacts with histone deacetylase 1 and represses transcription.; ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.; The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase.; SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities.; Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene.; Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1.; A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes.; Acetylated SP3 is a transcriptional activator.; Human MI-ER1 alpha and beta function as transcriptional repressors by recruitment of histone deacetylase 1 to their conserved ELM2 domain.; Identification and characterization of three new components of the mSin3A corepressor complex.; Modulation of p120E4F transcriptional activity by the Gam1 adenoviral early protein.; Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex.; MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.; Site-specific acetylation of the fetal globin activator NF-E4 prevents its ubiquitination and regulates its interaction with the histone deacetylase, HDAC1.; SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1.; ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain.; STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen.; MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing.; Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.; Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex.; INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription.; MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties.; Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription.; Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.; SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus.; CR/periphilin is a transcriptional co-repressor involved in cell cycle progression.; Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line.; Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.; Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.; Regulation of E2F1 function by the nuclear corepressor KAP1.; Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal portion.; Involvement of chromatin and histone deacetylation in SV40 T antigen transcription regulation.; SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1.; The orphan nuclear receptor Rev-erbbeta recruits Tip60 and HDAC1 to regulate apolipoprotein CIII promoter.; Transcription-dependent nucleolar cap localization and possible nuclear function of DExH RNA helicase RHAU.; Nuclear tumor necrosis factor receptor-associated factor 6 in lymphoid cells negatively regulates c-Myb-mediated transactivation through small ubiquitin-related modifier-1 modification.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation.; Protein lysine methyltransferase G9a acts on non-histone targets.; A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression.; A quantitative atlas of mitotic phosphorylation.; Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells.; Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription.; FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4.; Chfr is linked to tumour metastasis through the downregulation of HDAC1.; Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; HDAC3 is negatively regulated by the nuclear protein DBC1.; CDK2AP1/DOC-1 is a bona fide subunit of the Mi-2/NuRD complex.; Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Maintenance of silent chromatin through replication requires SWI/SNF-like chromatin remodeler SMARCAD1.; A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci.; SUMOylation of DEC1 protein regulates its transcriptional activity and enhances its stability.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced transcriptional responses.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Structural and functional characterization of a cell cycle associated HDAC1/2 complex reveals the structural basis for complex assembly and nucleosome targeting.; Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.; De novo mutations in CHD4, an ATP-dependent chromatin remodeler gene, cause an intellectual disability syndrome with distinctive dysmorphisms.; Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality.; A recurrent de novo PACS2 heterozygous missense variant causes neonatal-onset developmental epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis.; NP220 mediates silencing of unintegrated retroviral DNA.; The roles of SMYD4 in epigenetic regulation of cardiac development in zebrafish.; Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex.; ZMYND8 suppresses MAPT213 LncRNA transcription to promote neuronal differentiation.; Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.; The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase.",False
HSPA9,P38646,"Stress-70 protein, mitochondrial",MISASRAAAARLVGAAASRGPTAARHQDSWNGLSHEAFRLVSRRDYASEAIKGAVVGIDLGTTNSCVAVMEGKQAKVLENAEGARTTPSVVAFTADGERLVGMPAKRQAVTNPNNTFYATKRLIGRRYDDPEVQKDIKNVPFKIVRASNGDAWVEAHGKLYSPSQIGAFVLMKMKETAENYLGHTAKNAVITVPAYFNDSQRQATKDAGQISGLNVLRVINEPTAAALAYGLDKSEDKVIAVYDLGGGTFDISILEIQKGVFEVKSTNGDTFLGGEDFDQALLRHIVKEFKRETGVDLTKDNMALQRVREAAEKAKCELSSSVQTDINLPYLTMDSSGPKHLNMKLTRAQFEGIVTDLIRRTIAPCQKAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAVAIGAAIQGGVLAGDVTDVLLLDVTPLSLGIETLGGVFTKLINRNTTIPTKKSQVFSTAADGQTQVEIKVCQGEREMAGDNKLLGQFTLIGIPPAPRGVPQIEVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIENMVKNAEKYAEEDRRKKERVEAVNMAEGIIHDTETKMEEFKDQLPADECNKLKEEISKMRELLARKDSETGENIRQAASSLQQASLKLFEMAYKKMASEREGSGSSGTGEQKEDQKEEKQ,,,"Cloning of the gene encoding peptide-binding protein 74 shows that it is a new member of the heat shock protein 70 family.; Cloning and subcellular localization of human mitochondrial hsp70.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A two-dimensional gel database of human colon carcinoma proteins.; Analysis of proteins from human breast epithelial cells using two-dimensional gel electrophoresis.; Human liver protein map: a reference database established by microsequencing and gel comparison.; Human liver protein map: update 1993.; Proteomic characterization of the human centrosome by protein correlation profiling.; Genetic and structural characterization of the human mitochondrial inner membrane translocase.; Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.; Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones.; The human escort protein Hep binds to the ATPase domain of mitochondrial hsp70 and regulates ATP hydrolysis.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Characterization of the human HSC20, an unusual DnaJ type III protein, involved in iron-sulfur cluster biogenesis.; Initial characterization of the human central proteome.; Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.; The first identification of lysine malonylation substrates and its regulatory enzyme.; MINOS1 is a conserved component of mitofilin complexes and required for mitochondrial function and cristae organization.; Systematic analysis of protein pools, isoforms, and modifications affecting turnover and subcellular localization.; Tespa1 is a novel component of mitochondria-associated endoplasmic reticulum membranes and affects mitochondrial calcium flux.; Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells.; Structural and stability studies of the human mtHsp70-escort protein 1: An essential mortalin co-chaperone.; Human mitochondrial chaperone (mtHSP70) and cysteine desulfurase (NFS1) bind preferentially to the disordered conformation, whereas co-chaperone (HSC20) binds to the structured conformation of the iron-sulfur cluster scaffold protein (ISCU).; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.; N-terminome analysis of the human mitochondrial proteome.; Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia.; Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.; Human mitochondrial Hsp70 (mortalin): shedding light on ATPase activity, interaction with adenosine nucleotides, solution structure and domain organization.; Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-sulfur cluster assembly.; Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone.; Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells.; 2- and N6-functionalized adenosine-5'-diphosphate analogs for the inhibition of mortalin.; Biophysical Consequences of EVEN-PLUS Syndrome Mutations for the Function of Mortalin.",False
GPX1,P07203,Glutathione peroxidase 1,MCAARLAAAAAAAQSVYAFSARPLAGGEPVSLGSLRGKVLLIENVASLUGTTVRDYTQMNELQRRLGPRGLVVLGFPCNQFGHQENAKNEEILNSLKYVRPGGGFEPNFMLFEKCEVNGAGAHPLFAFLREALPAPSDDATALMTDPKLITWSPVCRNDVAWNFEKFLVGPDGVPLRRYSRRFQTIDIEPDIEALLSQGPSCA,,,"cDNA sequence coding for human glutathione peroxidase.; Nucleotide sequence of a human gene for glutathione peroxidase.; Sequence of a cDNA coding for human glutathione peroxidase confirms TGA encodes active site selenocysteine.; Isolation and chromosomal localization of the human glutathione peroxidase gene.; Structure and function of the 5'-flanking sequence of the human cytosolic selenium-dependent glutathione peroxidase gene (hgpx1).; The DNA sequence, annotation and analysis of human chromosome 3.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism.; Initial characterization of the human central proteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Side-by-side comparison of recombinant human glutathione peroxidases identifies overlapping substrate specificities for soluble hydroperoxides.; Crystal structure of the selenocysteine to glycine mutant of human glutathione peroxidase 1.; Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1.; Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer.; Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients.; Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant.",False
GSR,P00390,"Glutathione reductase, mitochondrial",MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAGAVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHSEFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDPKPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAGYIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKKTLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVDEFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPPIGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQGLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR,,,"Cloning and sequencing of mammalian glutathione reductase cDNA.; Structural organization of the human glutathione reductase (GSR) gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence.; Expression of glutathione reductase splice variants in human tissues.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain.; Glutathione reductase from human erythrocytes. Isolation of the enzyme and sequence analysis of the redox-active peptide.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Molecular basis of glutathione reductase deficiency in human blood cells.; Three-dimensional structure of glutathione reductase at 2-A resolution.; Refined structure of glutathione reductase at 1.54-A resolution.; Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: substrate crystal structures at 2 A resolution.; Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor.; Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.; Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers.; A fluoro analogue of the menadione derivative 6-[2'-(3'-methyl)-1',4'-naphthoquinolyl]hexanoic acid is a suicide substrate of glutathione reductase. Crystal structure of the alkylated human enzyme.; Catalytic cycle of human glutathione reductase near 1 A resolution.",False
GSS,P48637,Glutathione synthetase,MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPTSSEVVSYAPFTLFPSLVPSALLEQAYAVQMDFNLLVDAVSQNAAFLEQTLSSTIKQDDFTARLFDIHKQVLKEGIAQTVFLGLNRSDYMFQRSADGSPALKQIEINTISASFGGLASRTPAVHRHVLSVLSKTKEAGKILSNNPSKGLALGIAKAWELYGSPNALVLLIAQEKERNIFDQRAIENELLARNIHVIRRTFEDISEKGSLDQDRRLFVDGQEIAVVYFRDGYMPRQYSLQNWEARLLLERSHAAKCPDIATQLAGTKKVQQELSRPGMLEMLLPGQPEAVARLRATFAGLYSLDVGEEGDQAIAEALAAPSRFVLKPQREGGGNNLYGEEMVQALKQLKDSEERASYILMEKIEPEPFENCLLRPGSPARVVQCISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVAAGVAVLDNPYPV,,,"Sequencing and expression of a cDNA for human glutathione synthetase.; Alternative RNA splicing in expression of the glutathione synthetase gene in human cells.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Initial characterization of the human central proteome.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Molecular basis of glutathione synthetase deficiency and a rare gene permutation event.; Mutations in the glutathione synthetase gene cause 5-oxoprolinuria.; Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction.; Recurrent isolated neonatal hemolytic anemia: think about glutathione synthetase deficiency.",False
GSTA4,O15217,Glutathione S-transferase A4,MAARPKLHYPNGRGRMESVRWVLAAAGVEFDEEFLETKEQLYKLQDGNHLLFQQVPMVEIDGMKLVQTRSILHYIADKHNLFGKNLKERTLIDMYVEGTLDLLELLIMHPFLKPDDQQKEVVNMAQKAIIRYFPVFEKILRGHGQSFLVGNQLSLADVILLQTILALEEKIPNILSAFPFLQEYTVKLSNIPTIKRFLEPGSKKKPPPDEIYVRTVYNIFRP,,,"Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation.; Identification of cDNAs encoding two human alpha class glutathione transferases (GSTA3 and GSTA4) and the heterologous expression of GSTA4-4.; Identification of a novel human glutathione S-transferase using bioinformatics.; The 4-HNE metabolizing GST isozyme hGSTA4-4 is expressed in human heart, pancreas, and skeletal muscle.; Genomic organization, 5'-flanking region and chromosomal localization of the human glutathione transferase A4 gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products.; Substrate specificity combined with stereopromiscuity in glutathione transferase A4-4-dependent metabolism of 4-hydroxynonenal.",False
GSTP1,P09211,Glutathione S-transferase P,MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ,,,"Structure and expression of a human class pi glutathione S-transferase messenger RNA.; The structure of the human glutathione S-transferase pi gene.; Structure of the human genomic glutathione S-transferase-pi gene.; Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.; Human fatty acid ethyl ester synthase III gene: genomic organization, nucleotide sequence, genetic and chromosomal sublocalization.; Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structural evidence for three different types of glutathione transferase in human tissues.; Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties.; Purification and characterization of unique glutathione S-transferases from human muscle.; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; A two-dimensional gel database of human colon carcinoma proteins.; Primary and secondary structural analyses of glutathione S-transferase pi from human placenta.; Tyrosine-7 in human class Pi glutathione S-transferase is important for lowering the pKa of the thiol group of glutathione in the enzyme-glutathione complex.; Tyrosine-7 is an essential residue for the catalytic activity of human class PI glutathione S-transferase: chemical modification and site-directed mutagenesis studies.; Site-directed mutagenesis study on the roles of evolutionally conserved aspartic acid residues in human glutathione S-transferase P1-1.; Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1.; Glutathione S-transferase pi localizes in mitochondria and protects against oxidative stress.; Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Biosynthesis of 14,15-hepoxilins in human l1236 Hodgkin lymphoma cells and eosinophils.; Glutathione-S-transferase P1 is a critical regulator of Cdk5 kinase activity.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Three-dimensional structure of class pi glutathione S-transferase from human placenta in complex with S-hexylglutathione at 2.8-A resolution.; The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate.; Structure and function of the xenobiotic substrate-binding site and location of a potential non-substrate-binding site in a class pi glutathione S-transferase.; The structures of human glutathione transferase P1-1 in complex with glutathione and various inhibitors at high resolution.; Structures of class pi glutathione S-transferase from human placenta in complex with substrate, transition-state analogue and inhibitor.; Structure and function of residue 104 and water molecules in the xenobiotic substrate-binding site in human glutathione S-transferase P1-1.; Solution structure of glutathione bound to human glutathione transferase P1-1: comparison of NMR measurements with the crystal structure.; Rational design of an organometallic glutathione transferase inhibitor.; Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.",False
MT-CO1,P00395,Cytochrome c oxidase subunit 1,MFADRWLFSTNHKDIGTLYLLFGAWAGVLGTALSLLIRAELGQPGNLLGNDHIYNVIVTAHAFVMIFFMVMPIMIGGFGNWLVPLMIGAPDMAFPRMNNMSFWLLPPSLLLLLASAMVEAGAGTGWTVYPPLAGNYSHPGASVDLTIFSLHLAGVSSILGAINFITTIINMKPPAMTQYQTPLFVWSVLITAVLLLLSLPVLAAGITMLLTDRNLNTTFFDPAGGGDPILYQHLFWFFGHPEVYILILPGFGMISHIVTYYSGKKEPFGYMGMVWAMMSIGFLGFIVWAHHMFTVGMDVDTRAYFTSATMIIAIPTGVKVFSWLATLHGSNMKWSAAVLWALGFIFLFTVGGLTGIVLANSSLDIVLHDTYYVVAHFHYVLSMGAVFAIMGGFIHWFPLFSGYTLDQTYAKIHFTIMFIGVNLTFFPQHFLGLSGMPRRYSDYPDAYTTWNILSSVGSFISLTAVMLMIFMIWEAFASKRKVLMVEEPSMNLEWLYGCPPPYHTFEEPVYMKS,,,"Sequence and organization of the human mitochondrial genome.; Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs.; Lineage-specific selection in human mtDNA: lack of polymorphisms in a segment of MTND5 gene in haplogroup J.; Mitochondrial genome variation and the origin of modern humans.; Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines.; Single nucleotide polymorphisms over the entire mtDNA genome that increase the power of forensic testing in Caucasians.; Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing.; Heterogenous point mutations in the mitochondrial tRNA Ser(UCN) precursor coexisting with the A1555G mutation in deaf students from Mongolia.; MITRAC7 acts as a COX1-specific chaperone and reveals a checkpoint during cytochrome c oxidase assembly.; N-terminome analysis of the human mitochondrial proteome.; The mitochondrial TMEM177 associates with COX20 during COX2 biogenesis.; Architecture of human mitochondrial respiratory megacomplex I2III2IV2.; Structure of the intact 14-subunit human cytochrome c oxidase.; Normal variants of human mitochondrial DNA and translation products: the building of a reference data base.; A mitochondrial DNA variant, identified in Leber hereditary optic neuropathy patients, which extends the amino acid sequence of cytochrome c oxidase subunit I.; Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia.; MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase.; Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA.; Metabolic consequences of a novel missense mutation of the mtDNA CO I gene.; Introducing a novel human mtDNA mutation into the Paracoccus denitrificans COX I gene explains functional deficits in a patient.; Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission.; A mitochondrial DNA mutation linked to colon cancer results in proton leaks in cytochrome c oxidase.",False
HSPD1,P10809,"60 kDa heat shock protein, mitochondrial",MLRLPTVFRQMRPVSRVLAPHLTRAYAKDVKFGADARALMLQGVDLLADAVAVTMGPKGRTVIIEQSWGSPKVTKDGVTVAKSIDLKDKYKNIGAKLVQDVANNTNEEAGDGTTTATVLARSIAKEGFEKISKGANPVEIRRGVMLAVDAVIAELKKQSKPVTTPEEIAQVATISANGDKEIGNIISDAMKKVGRKGVITVKDGKTLNDELEIIEGMKFDRGYISPYFINTSKGQKCEFQDAYVLLSEKKISSIQSIVPALEIANAHRKPLVIIAEDVDGEALSTLVLNRLKVGLQVVAVKAPGFGDNRKNQLKDMAIATGGAVFGEEGLTLNLEDVQPHDLGKVGEVIVTKDDAMLLKGKGDKAQIEKRIQEIIEQLDVTTSEYEKEKLNERLAKLSDGVAVLKVGGTSDVEVNEKKDRVTDALNATRAAVEEGIVLGGGCALLRCIPALDSLTPANEDQKIGIEIIKRTLKIPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEKGIIDPTKVVRTALLDAAGVASLLTTAEVVVTEIPKEEKDPGMGAMGGMGGGMGGGMF,,,"Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen.; Nucleotide sequences and novel structural features of human and Chinese hamster hsp60 (chaperonin) gene families.; Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter.; Genetic variation in immune response genes.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Amino-acid sequence homology of a polymorphic cellular protein from human lymphocytes and the chaperonins from Escherichia coli (groEL) and chloroplasts (Rubisco-binding protein).; Development of a database of amino acid sequences for human colon carcinoma proteins separated by two-dimensional polyacrylamide gel electrophoresis.; Complex formation of human T-cell leukemia virus type I p40tax transactivator with cellular polypeptides.; Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.; The human myocardial two-dimensional gel protein database: update 1994.; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Human liver protein map: a reference database established by microsequencing and gel comparison.; Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes.; A two-dimensional gel database of human colon carcinoma proteins.; Mitochondrial import of the human chaperonin (HSP60) protein.; Mammalian mitochondrial chaperonin 60 functions as a single toroidal ring.; The effect of nucleotides and mitochondrial chaperonin 10 on the structure and chaperone activity of mitochondrial chaperonin 60.; Proteomic characterization of the human centrosome by protein correlation profiling.; Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; The first identification of lysine malonylation substrates and its regulatory enzyme.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Resveratrol-induced changes of the human adipocyte secretion profile.; ATAD3B is a human embryonic stem cell specific mitochondrial protein, re-expressed in cancer cells, that functions as dominant negative for the ubiquitous ATAD3A.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.; GTP binding controls complex formation by the human ROCO protein MASL1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Crystal structure of the human mitochondrial chaperonin symmetrical football complex.; Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60.; Mitochondrial Hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy.",False
HSPA1A,P0DMV8,Heat shock 70 kDa protein 1A,MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD,,,"Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70.; Structure and expression of the three MHC-linked HSP70 genes.; Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.; Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human major histocompatibility complex contains genes for the major heat shock protein HSP70.; In vitro transcription of a human hsp 70 heat shock gene by extracts prepared from heat-shocked and non-heat-shocked human cells.; A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.; Interaction between heat shock factor and hsp70 is insufficient to suppress induction of DNA-binding activity in vivo.; Molecular chaperones as HSF1-specific transcriptional repressors.; Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.; Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.; Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.; Human protein phosphatase 5 dissociates from heat-shock proteins and is proteolytically activated in response to arachidonic acid and the microtubule-depolymerizing drug nocodazole.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; The disordered amino-terminus of SIMPL interacts with members of the 70-kDa heat-shock protein family.; The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity.; HDJC9, a novel human type C DnaJ/HSP40 member interacts with and cochaperones HSP70 through the J domain.; Molecular composition of IMP1 ribonucleoprotein granules.; Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase.; Role of the cochaperone Tpr2 in Hsp90 chaperoning.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function.; Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells.; Resveratrol-induced changes of the human adipocyte secretion profile.; The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3.; Identification and characterization of a novel human methyltransferase modulating Hsp70 function through lysine methylation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy.; Hsp70 chaperone dynamics and molecular mechanism.; Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through CHIP/Stub1.; Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro.; The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease.; RING finger protein RNF207, a novel regulator of cardiac excitation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; N-terminome analysis of the human mitochondrial proteome.; A novel nuclear DnaJ protein, DNAJC8, can suppress the formation of spinocerebellar ataxia 3 polyglutamine aggregation in a J-domain independent manner.; The human HSP70 family of chaperones: where do we stand?; HSP70 regulates the function of mitotic centrosomes.; ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation.; BAG3 is a modular, scaffolding protein that physically links heat shock protein 70 (Hsp70) to the small heat shock proteins.; HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.; Structure of a new crystal form of human hsp70 ATPase domain.; Direct inter-subdomain interactions switch between the closed and open forms of the Hsp70 nucleotide-binding domain in the nucleotide-free state.; Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78.; The C-terminal BAG domain of BAG5 induces conformational changes of the Hsp70 nucleotide-binding domain for ADP-ATP exchange.; Biochemical and structural studies on the high affinity of Hsp70 for ADP.",False
HSPA1B,P0DMV9,Heat shock 70 kDa protein 1B,MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD,,,"Structure and expression of the three MHC-linked HSP70 genes.; Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.; Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human major histocompatibility complex contains genes for the major heat shock protein HSP70.; A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.; Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.; Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.; Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.; Human protein phosphatase 5 dissociates from heat-shock proteins and is proteolytically activated in response to arachidonic acid and the microtubule-depolymerizing drug nocodazole.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; The disordered amino-terminus of SIMPL interacts with members of the 70-kDa heat-shock protein family.; The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity.; HDJC9, a novel human type C DnaJ/HSP40 member interacts with and cochaperones HSP70 through the J domain.; Molecular composition of IMP1 ribonucleoprotein granules.; Role of the cochaperone Tpr2 in Hsp90 chaperoning.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function.; Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells.; Resveratrol-induced changes of the human adipocyte secretion profile.; The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3.; Identification and characterization of a novel human methyltransferase modulating Hsp70 function through lysine methylation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy.; Hsp70 chaperone dynamics and molecular mechanism.; Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through CHIP/Stub1.; Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro.; The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; N-terminome analysis of the human mitochondrial proteome.; A novel nuclear DnaJ protein, DNAJC8, can suppress the formation of spinocerebellar ataxia 3 polyglutamine aggregation in a J-domain independent manner.; The human HSP70 family of chaperones: where do we stand?; HSP70 regulates the function of mitotic centrosomes.; ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation.; DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network.; Structure of a new crystal form of human hsp70 ATPase domain.; Direct inter-subdomain interactions switch between the closed and open forms of the Hsp70 nucleotide-binding domain in the nucleotide-free state.; Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78.; The C-terminal BAG domain of BAG5 induces conformational changes of the Hsp70 nucleotide-binding domain for ADP-ATP exchange.; Biochemical and structural studies on the high affinity of Hsp70 for ADP.",False
PCMT1,P22061,Protein-L-isoaspartate(D-aspartate) O-methyltransferase,MAWKSGGASHSELIHNLRKNGIIKTDKVFEVMLATDRSHYAKCNPYMDSPQSIGFQATISAPHMHAYALELLFDQLHEGAKALDVGSGSGILTACFARMVGCTGKVIGIDHIKELVDDSVNNVRKDDPTLLSSGRVQLVVGDGRMGYAEEAPYDAIHVGAAAPVVPQALIDQLKPGGRLILPVGPAGGNQMLEQYDKLQDGSIKMKPLMGVIYVPLTDKEKQWSRWK,,,"Sequence of the D-aspartyl/L-isoaspartyl protein methyltransferase from human erythrocytes. Common sequence motifs for protein, DNA, RNA, and small molecule S-adenosylmethionine-dependent methyltransferases.; Alternative splicing of the human isoaspartyl protein carboxyl methyltransferase RNA leads to the generation of a C-terminal -RDEL sequence in isozyme II.; Characterization of three cDNAs encoding two isozymes of an isoaspartyl protein carboxyl methyltransferase from human erythroid leukemia cells.; Gene expression of carboxyl methyltransferase is altered in Alzheimer's disease and the product is localized to neurofibrillary tangles.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structure of the human gene encoding the protein repair L-isoaspartyl (D-aspartyl) O-methyltransferase.; Purification of homologous protein carboxyl methyltransferase isozymes from human and bovine erythrocytes.; Amino acid polymorphisms of the human L-isoaspartyl/D-aspartyl methyltransferase involved in protein repair.; Distinct C-terminal sequences of isozymes I and II of the human erythrocyte L-isoaspartyl/D-aspartyl protein methyltransferase.; Synthetic peptide substrates for the erythrocyte protein carboxyl methyltransferase. Detection of a new site of methylation at isomerized L-aspartyl residues.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Polymorphic forms of the protein L-isoaspartate (D-aspartate) O-methyltransferase involved in the repair of age-damaged proteins.; Crystal structure of human L-isoaspartyl methyltransferase.; Crystal structure of human L-isoaspartyl-O-methyl-transferase with S-adenosyl homocysteine at 1.6-A resolution and modeling of an isoaspartyl-containing peptide at the active site.; Initial characterization of the human central proteome.",False
MAPK8,P45983,Mitogen-activated protein kinase 8,MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR,,,"JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.; Selective interaction of JNK protein kinase isoforms with transcription factors.; The DNA sequence and comparative analysis of human chromosome 10.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms.; Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7.; The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.; c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity.; JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis.; Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein.; Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26.; Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 induced cell transformation.; GRASP-1 is a neuronal scaffold protein for the JNK signaling pathway.; Prostate-derived sterile 20-like kinase 1-alpha induces apoptosis. JNK- and caspase-dependent nuclear localization is a requirement for membrane blebbing.; Rev7/MAD2B links c-Jun N-terminal protein kinase pathway signaling to activation of the transcription factor Elk-1.; Phosphorylation of two eukaryotic transcription factors, Jun dimerization protein 2 and activation transcription factor 2, in Escherichia coli by Jun N-terminal kinase 1.; JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Crystal structure of SCCA1 and insight about the interaction with JNK1.; Large-scale proteomics analysis of the human kinome.; JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.; JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.; Initial characterization of the human central proteome.; A critical step for JNK activation: isomerization by the prolyl isomerase Pin1.; JNK regulates the photic response of the mammalian circadian clock.; Phosphorylation of Bcl-associated death protein (Bad) by erythropoietin-activated c-Jun N-terminal protein kinase 1 contributes to survival of erythropoietin-dependent cells.; Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis.; JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress.; Phosphorylation of the eukaryotic translation initiation factor 4E-transporter (4E-T) by c-Jun N-terminal kinase promotes stress-dependent P-body assembly.; The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.; JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in response to oxidative stress by recruiting PARP1 to DNA Breaks.; NLRP3 phosphorylation is an essential priming event for inflammasome activation.; MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction.; Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.; Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.; Patterns of somatic mutation in human cancer genomes.",False
YWHAZ,P63104,14-3-3 protein zeta/delta,MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEERNLLSVAYKNVVGARRSSWRVVSSIEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQAESKVFYLKMKGDYYRYLAEVAAGDDKKGIVDQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPEKACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN,,,"Cloning and expression of a human 14-3-3 protein mediating phospholipolysis. Identification of an arachidonoyl-enzyme intermediate during catalysis.; Two unique 5' untranslated regions in mRNAs encoding human 14-3-3 zeta: differential expression in hemopoietic cells.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; ACBD3 interaction with TBC1 domain 22 protein is differentially affected by enteroviral and kobuviral 3A protein binding.; 14-3-3 is phosphorylated by casein kinase I on residue 233. Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction.; Nuclear localization of protein kinase U-alpha is regulated by 14-3-3.; Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis.; Identification of 14-3-3zeta as a protein kinase B/Akt substrate.; The interaction between ADAM 22 and 14-3-3zeta: regulation of cell adhesion and spreading.; The dimeric versus monomeric status of 14-3-3zeta is controlled by phosphorylation of Ser58 at the dimer interface.; Cellular stabilization of the melatonin rhythm enzyme induced by nonhydrolyzable phosphonate incorporation.; Proteomic characterization of the human centrosome by protein correlation profiling.; JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins.; A pathway of neuregulin-induced activation of cofilin-phosphatase Slingshot and cofilin in lamellipodia.; 14-3-3 protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4.; Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin.; Sphingosine activates protein kinase A type II by a novel cAMP-independent mechanism.; JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage.; Melatonin synthesis: 14-3-3-dependent activation and inhibition of arylalkylamine N-acetyltransferase mediated by phosphoserine-205.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon.; Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.; Transgenic mouse proteomics identifies new 14-3-3-associated proteins involved in cytoskeletal rearrangements and cell signaling.; Regulation of Nox1 activity via PKA-mediated phosphorylation of NoxA1 and 14-3-3 binding.; p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor.; Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a phosphorylation-dependent manner.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Suppression of death-associated protein kinase 2 by interaction with 14-3-3 proteins.; N-terminome analysis of the human mitochondrial proteome.; Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.; Herpesvirus deconjugases inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalosome.; 14-3-3 scaffold proteins mediate the inactivation of trim25 and inhibition of the type I interferon response by herpesvirus deconjugases.; Itaconate is a lysosomal inducer that promotes antibacterial innate immunity.; Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding.; Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase complex. a role for scaffolding in enzyme regulation.; Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3.; Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis.; A YWHAZ variant associated with cardiofaciocutaneous syndrome activates the RAF-ERK pathway.",False
PTK2B,Q14289,Protein-tyrosine kinase 2-beta,MSGVSEPLSRVKLGTLRRPEGPAEPMVVVPVDVEKEDVRILKVCFYSNSFNPGKNFKLVKCTVQTEIREIITSILLSGRIGPNIRLAECYGLRLKHMKSDEIHWLHPQMTVGEVQDKYECLHVEAEWRYDLQIRYLPEDFMESLKEDRTTLLYFYQQLRNDYMQRYASKVSEGMALQLGCLELRRFFKDMPHNALDKKSNFELLEKEVGLDLFFPKQMQENLKPKQFRKMIQQTFQQYASLREEECVMKFFNTLAGFANIDQETYRCELIQGWNITVDLVIGPKGIRQLTSQDAKPTCLAEFKQIRSIRCLPLEEGQAVLQLGIEGAPQALSIKTSSLAEAENMADLIDGYCRLQGEHQGSLIIHPRKDGEKRNSLPQIPMLNLEARRSHLSESCSIESDIYAEIPDETLRRPGGPQYGIAREDVVLNRILGEGFFGEVYEGVYTNHKGEKINVAVKTCKKDCTLDNKEKFMSEAVIMKNLDHPHIVKLIGIIEEEPTWIIMELYPYGELGHYLERNKNSLKVLTLVLYSLQICKAMAYLESINCVHRDIAVRNILVASPECVKLGDFGLSRYIEDEDYYKASVTRLPIKWMSPESINFRRFTTASDVWMFAVCMWEILSFGKQPFFWLENKDVIGVLEKGDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVCSLSDVYQMEKDIAMEQERNARYRTPKILEPTAFQEPPPKPSRPKYRPPPQTNLLAPKLQFQVPEGLCASSPTLTSPMEYPSPVNSLHTPPLHRHNVFKRHSMREEDFIQPSSREEAQQLWEAEKVKMRQILDKQQKQMVEDYQWLRQEEKSLDPMVYMNDKSPLTPEKEVGYLEFTGPPQKPPRLGAQSIQPTANLDRTDDLVYLNVMELVRAVLELKNELCQLPPEGYVVVVKNVGLTLRKLIGSVDDLLPSLPSSSRTEIEGTQKLLNKDLAELINKMRLAQQNAVTSLSEECKRQMLTASHTLAVDAKNLLDAVDQAKVLANLAHPPAE,,,"Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions.; Molecular cloning and assignment of FAK2, a novel human focal adhesion kinase, to 8p11.2-p22 by nonisotopic in situ hybridization.; Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily.; Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain.; A calcium-dependent tyrosine kinase splice variant in human monocytes. Activation by a two-stage process involving adherence and a subsequent intracellular signal.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation.; Activation of Pyk2 by stress signals and coupling with JNK signaling pathway.; Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions.; Identification of a new Pyk2 target protein with Arf-GAP activity.; Suppression of Pyk2 kinase and cellular activities by FIP200.; Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers phosphorylation of Pyk2.; The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation and inhibition of the Arf-GTPase-activating protein ASAP1.; Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation.; Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions.; Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.; Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products.; RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner.; Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.; Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.; Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.; Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.; Phosphoproteome of resting human platelets.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; The atypical Rho GTPase Wrch1 collaborates with the nonreceptor tyrosine kinases Pyk2 and Src in regulating cytoskeletal dynamics.; Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in sepsis-induced lung inflammation by activating beta2 integrins.; A Pyk2-Vav1 complex is recruited to beta3-adhesion sites to initiate Rho activation.; Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.; Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and regulates human glomerular mesangial cell adhesion and spreading.; Large-scale proteomics analysis of the human kinome.; Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells.; Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.; The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems.; T cell receptor activation leads to two distinct phases of Pyk2 activation and actin cytoskeletal rearrangement in human T cells.; Initial characterization of the human central proteome.; Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of nephrocystin-1 to control targeting to monocilia.; Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.; Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell activation and function.; Targeting Pyk2 for therapeutic intervention.; Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions.; Redox sensitive Pyk2 as a target for therapeutics in breast cancer.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.; Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2.; Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.; Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.; Structure of protein tyrosine kinase 2 beta (PTK2B) kinase domain.; Patterns of somatic mutation in human cancer genomes.",False
PTK2,Q05397,Focal adhesion kinase 1,MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH,,,"Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK.; Expression of an N-terminally truncated form of human focal adhesion kinase in brain.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.; Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates.; Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions.; Interaction of Hic-5, A senescence-related protein, with focal adhesion kinase.; Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.; Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain.; Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.; Regulation of focal adhesion kinase by a novel protein inhibitor FIP200.; Site-specific phosphorylation of platelet focal adhesion kinase by low-density lipoprotein.; Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway.; The proto-oncogene Fgr regulates cell migration and this requires its plasma membrane localization.; Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.; Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase.; Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.; Cellular characterization of a novel focal adhesion kinase inhibitor.; Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin-5.; Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.; The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription.; Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways.; A novel Cas family member, HEPL, regulates FAK and cell spreading.; Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.; Regulation of estrogen rapid signaling through arginine methylation by PRMT1.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Specific tyrosine phosphorylation of focal adhesion kinase mediated by Fer tyrosine kinase in suspended hepatocytes.; Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.; STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells.; Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).; Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.; EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility.; Large-scale proteomics analysis of the human kinome.; Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.; LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin.; Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.; ZF21 protein regulates cell adhesion and motility.; Comprehensive analysis of phosphorylation sites in Tensin1 reveals regulation by p38MAPK.; CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis.; Signaling through focal adhesion kinase.; Netrin-integrin signaling in epithelial morphogenesis, axon guidance and vascular patterning.; Integrin-regulated FAK-Src signaling in normal and cancer cells.; Focal adhesion kinase: an essential kinase in the regulation of cardiovascular functions.; FERM control of FAK function: implications for cancer therapy.; Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility.; Focal adhesion kinase and cancer.; Focal adhesion kinase and p53 signal transduction pathways in cancer.; The role of focal adhesion kinase in early development.; Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer.; Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions.; Focal adhesion kinase: exploring Fak structure to gain insight into function.; MISP is a novel Plk1 substrate required for proper spindle orientation and mitotic progression.; The Intracranial Aneurysm Gene THSD1 Connects Endosome Dynamics to Nascent Focal Adhesion Assembly.; De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.; The structural basis of localization and signaling by the focal adhesion targeting domain.; Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography.; Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain.; Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.; Structural basis for the interaction between focal adhesion kinase and CD4.; Patterns of somatic mutation in human cancer genomes.",False
IL7,P13232,Interleukin-7,MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH,,,"Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells.; Characterization of the human and murine IL-7 genes.; interleukin7 mRNA,nirs splice variant2.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34.; Disulfide bond assignment in human interleukin-7 by matrix-assisted laser desorption/ionization mass spectroscopy and site-directed cysteine to serine mutational analysis.; Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.; IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors.; Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling.; Recycled IL-7 Can Be Delivered to Neighboring T Cells.; Prediction of the three-dimensional structure of human interleukin-7 by homology modeling.; Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation.; Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.; Generalized verrucosis and HPV-3 susceptibility associated with CD4 T-cell lymphopenia caused by inherited human interleukin-7 deficiency.",False
MAPK14,Q16539,Mitogen-activated protein kinase 14,MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES,,,"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.; Molecular cloning of human p38 MAP kinase.; Mxi2, a mitogen-activated protein kinase that recognizes and phosphorylates Max protein.; Structure and polymorphism of two stress-activated protein kinase genes centromeric of the MHC: SAPK2a and SAPK4.; Exip, a new alternative splicing variant of p38 alpha, can induce an earlier onset of apoptosis in HeLa cells.; Discovery of novel human transcript variants by analysis of intronic single-block EST with polyadenylation site.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.; Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.; Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a hog1 deletion in yeast.; MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway.; Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.; Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6.; RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38alpha mitogen-activated protein kinase (p38alphaMAPK).; Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5.; Regulation of the MEF2 family of transcription factors by p38.; Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors.; Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis.; Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38alpha and its splice isoform Mxi2.; Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase.; Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength.; Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1.; A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs.; The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.; Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.; MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.; Active mutants of the human p38alpha mitogen-activated protein kinase.; Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases.; The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway.; p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation.; p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.; Regulation of the ring finger E3 ligase Siah2 by p38 MAPK.; Nuclear protein NP60 regulates p38 MAPK activity.; p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Phosphoproteome of resting human platelets.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP.; DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization.; Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling complex involved in alpha1-adrenergic receptor-induced p38 activation.; The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa inhibits T cell interferon-gamma production through the p38 mitogen-activated protein kinase pathway.; Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes.; LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1).; In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance.; Mechanisms and functions of p38 MAPK signalling.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction.; ZAKalpha-driven ribotoxic stress response activates the human NLRP1 inflammasome.; Crystal structure of p38 mitogen-activated protein kinase.; A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket.; Structural basis of inhibitor selectivity in MAP kinases.; Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase.; Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.; Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.; Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.; Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.; Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering.; Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase.; Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.; Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.; Fragment-based lead discovery using X-ray crystallography.; Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.; Patterns of somatic mutation in human cancer genomes.",False
FGFR1,P11362,Fibroblast growth factor receptor 1,MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR,,,"The complete amino acid sequence of the shorter form of human basic fibroblast growth factor receptor deduced from its cDNA.; Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.; Diverse forms of a receptor for acidic and basic fibroblast growth factors.; Complete sequence of a human receptor for acidic and basic fibroblast growth factors.; cDNA cloning and expression of a human FGF receptor which binds acidic and basic FGF.; Molecular cloning of a human basic fibroblast growth factor receptor cDNA and expression of a biologically active extracellular domain in a baculovirus system.; Alternative splicing generates at least five different isoforms of the human basic-FGF receptor.; Fibroblast growth factor receptors from liver vary in three structural domains.; K-sam-related gene, N-sam, encodes fibroblast growth factor receptor and is expressed in T-lymphocytic tumors.; A case of Kallmann syndrome carrying a missense mutation in alternatively spliced exon 8A encoding the immunoglobulin-like domain IIIb of fibroblast growth factor receptor 1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization.; Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1.; A novel protein tyrosine kinase gene whose expression is modulated during endothelial cell differentiation.; The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain.; A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes.; A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1.; Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis.; Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis.; Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766.; Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.; Receptor specificity of the fibroblast growth factor family.; Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.; Structure of a heparin-linked biologically active dimer of fibroblast growth factor.; The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.; Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis.; Clinical findings in a patient with FGFR1 P252R mutation and comparison with the literature.; FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).; Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.; The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.; Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.; 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia.; Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.; Factors controlling fibroblast growth factor receptor-1's cytoplasmic trafficking and its regulation as revealed by FRAP analysis.; Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction.; 14-3-3 integrates pro-survival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1 transformed hematopoietic cells.; Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.; Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus.; Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling.; Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis.; Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1.; Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control.; The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations.; A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist.; Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.; Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function.; The structure and function of vertebrate fibroblast growth factor receptor 1.; Cellular signaling by fibroblast growth factor receptors.; Fibroblast growth factor signalling: from development to cancer.; Novel insights in FGFR1 regulation: lessons from Kallmann syndrome.; Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis.; Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.; Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.; Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.; Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.; Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1.; The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.; Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.; A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.; A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome.; An unusual FGFR1 mutation (fibroblast growth factor receptor 1 mutation) in a girl with non-syndromic trigonocephaly.; Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.; Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients.; Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.; Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2).; Gonadotrophin therapy in Kallmann syndrome caused by heterozygous mutations of the gene for fibroblast growth factor receptor 1: report of three families: case report.; Extended mutational analyses of FGFR1 in osteoglophonic dysplasia.; Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia.; Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes.; Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast growth factor receptor 1 (FGFR1).; Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism.; Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis.; Patterns of somatic mutation in human cancer genomes.; Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism.; Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism.; SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.; Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.; FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly.; A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm.; Novel de novo heterozygous FGFR1 mutation in two siblings with Hartsfield syndrome: A case of gonadal mosaicism.; The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients.; Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: evidence for the involvement of an alternatively spliced isoform.",False
SP1,Q8N907,DAN domain family member 5,MLLGQLSTLLCLLSGALPTGSGRPEPQSPRPQSWAAANQTWALGPGALPPLVPASALGSWKAFLGLQKARQLGMGRLQRGQDEVAAVTLPLNPQEVIQGMCKAVPFVQVFSRPGCSAIRLRNHLCFGHCSSLYIPGSDPTPLVLCNSCMPARKRWAPVVLWCLTGSSASRRRVKISTMLIEGCHCSPKA,,,"Cysteine knot protein (SP1).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification and characterization of human CKTSF1B2 and CKTSF1B3 genes in silico.; COCO/DAND5 inhibits developmental and pathological ocular angiogenesis.; A novel biallelic loss-of-function variant in DAND5 causes heterotaxy syndrome.; Whole-exome sequencing reveals a monogenic cause in 56% of individuals with laterality disorders and associated congenital heart defects.",False
FLT1,P17948,Vascular endothelial growth factor receptor 1,MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI,,,"Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.; Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.; Characterization of the VEGF binding site on the Flt-1 receptor.; Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.; A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.; A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells.; A new VEGFR1 receptor transcript coding for the extracellular domains of the protein followed by a C-terminal polyserine tail.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A possible new member of tyrosine kinase family, human frt sequence, is highly conserved in vertebrates and located on human chromosome 13.; Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules.; A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.; Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.; The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma.; Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.; Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells.; Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.; Effect of placenta growth factor-1 on proliferation and release of nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the FLT-1 receptor.; Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers.; Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells.; Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.; The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).; Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.; Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.; A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1.; The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes.; Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.; Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.; RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3-K/Akt pathway.; gamma-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1.; Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis.; Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.; VEGF receptor protein-tyrosine kinases: structure and regulation.; VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.; Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling.; Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).; Signal transduction by vascular endothelial growth factor receptors.; Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.; Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.; Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.; The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1.; Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity.; Patterns of somatic mutation in human cancer genomes.",False
JUN,P05412,Transcription factor Jun,MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF,,,"Structure and chromosomal localization of the functional intronless human JUN protooncogene.; Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.; c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro; definition of the minimal kinase recognition motif.; Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade.; Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene.; A new group of conserved coactivators that increase the specificity of AP-1 transcription factors.; Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription.; SPI-B activates transcription via a unique proline, serine, and threonine domain and exhibits DNA binding affinity differences from PU.1.; Role of the ATFa/JNK2 complex in Jun activation.; Structural and functional characterization of the transforming growth factor-beta -induced Smad3/c-Jun transcriptional cooperativity.; A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300.; Correlation of transcriptional repression by p21(SNFT) with changes in DNA.NF-AT complex interactions.; An unexpected role for FosB in activation-induced cell death of T cells.; Transcriptional repression of MMP-1 by p21SNFT and reduced in vitro invasiveness of hepatocarcinoma cells.; The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling.; Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation.; Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription.; Stress-induced c-Jun activation mediated by Polo-like kinase 3 in corneal epithelial cells.; Activation of Polo-like kinase 3 by hypoxic stresses.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; The forkhead transcription factor FOXK2 promotes AP-1-mediated transcriptional regulation.; Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at 5 threonine sites promotes cell transformation.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.; Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/AP-1 activation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Cancer/testis antigen PAGE4, a regulator of c-Jun transactivation, is phosphorylated by homeodomain-interacting protein kinase 1, a component of the stress-response pathway.; The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation.; A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.; Phosphorylation-induced conformational ensemble switching in an intrinsically disordered cancer/testis antigen.; Synaptonuclear messenger PRR7 inhibits c-Jun ubiquitination and regulates NMDA-mediated excitotoxicity.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.; VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.; Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.; High resolution NMR solution structure of the leucine zipper domain of the c-Jun homodimer.",False
MED1,Q15648,Mediator of RNA polymerase II transcription subunit 1,MKAQGETEESEKLSKMSSLLERLHAKFNQNRPWSETIKLVRQVMEKRVVMSSGGHQHLVSCLETLQKALKVTSLPAMTDRLESIARQNGLGSHLSASGTECYITSDMFYVEVQLDPAGQLCDVKVAHHGENPVSCPELVQQLREKNFDEFSKHLKGLVNLYNLPGDNKLKTKMYLALQSLEQDLSKMAIMYWKATNAGPLDKILHGSVGYLTPRSGGHLMNLKYYVSPSDLLDDKTASPIILHENNVSRSLGMNASVTIEGTSAVYKLPIAPLIMGSHPVDNKWTPSFSSITSANSVDLPACFFLKFPQPIPVSRAFVQKLQNCTGIPLFETQPTYAPLYELITQFELSKDPDPIPLNHNMRFYAALPGQQHCYFLNKDAPLPDGRSLQGTLVSKITFQHPGRVPLILNLIRHQVAYNTLIGSCVKRTILKEDSPGLLQFEVCPLSESRFSVSFQHPVNDSLVCVVMDVQDSTHVSCKLYKGLSDALICTDDFIAKVVQRCMSIPVTMRAIRRKAETIQADTPALSLIAETVEDMVKKNLPPASSPGYGMTTGNNPMSGTTTPTNTFPGGPITTLFNMSMSIKDRHESVGHGEDFSKVSQNPILTSLLQITGNGGSTIGSSPTPPHHTPPPVSSMAGNTKNHPMLMNLLKDNPAQDFSTLYGSSPLERQNSSSGSPRMEICSGSNKTKKKKSSRLPPEKPKHQTEDDFQRELFSMDVDSQNPIFDVNMTADTLDTPHITPAPSQCSTPPTTYPQPVPHPQPSIQRMVRLSSSDSIGPDVTDILSDIAEEASKLPSTSDDCPAIGTPLRDSSSSGHSQSTLFDSDVFQTNNNENPYTDPADLIADAAGSPSSDSPTNHFFHDGVDFNPDLLNSQSQSGFGEEYFDESSQSGDNDDFKGFASQALNTLGVPMLGGDNGETKFKGNNQADTVDFSIISVAGKALAPADLMEHHSGSQGPLLTTGDLGKEKTQKRVKEGNGTSNSTLSGPGLDSKPGKRSRTPSNDGKSKDKPPKRKKADTEGKSPSHSSSNRPFTPPTSTGGSKSPGSAGRSQTPPGVATPPIPKITIQIPKGTVMVGKPSSHSQYTSSGSVSSSGSKSHHSHSSSSSSSASTSGKMKSSKSEGSSSSKLSSSMYSSQGSSGSSQSKNSSQSGGKPGSSPITKHGLSSGSSSTKMKPQGKPSSLMNPSLSKPNISPSHSRPPGGSDKLASPMKPVPGTPPSSKAKSPISSGSGGSHMSGTSSSSGMKSSSGLGSSGSLSQKTPPSSNSCTASSSSFSSSGSSMSSSQNQHGSSKGKSPSRNKKPSLTAVIDKLKHGVVTSGPGGEDPLDGQMGVSTNSSSHPMSSKHNMSGGEFQGKREKSDKDKSKVSTSGSSVDSSKKTSESKNVGSTGVAKIIISKHDGGSPSIKAKVTLQKPGESSGEGLRPQMASSKNYGSPLISGSTPKHERGSPSHSKSPAYTPQNLDSESESGSSIAEKSYQNSPSSDDGIRPLPEYSTEKHKKHKKEKKKVKDKDRDRDRDKDRDKKKSHSIKPESWSKSPISSDQSLSMTSNTILSADRPSRLSPDFMIGEEDDDLMDVALIGN,,,"Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53.; The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Composite co-activator ARC mediates chromatin-directed transcriptional activation.; The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes.; Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex.; Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.; A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation.; Identification of mouse TRAP100: a transcriptional coregulatory factor for thyroid hormone and vitamin D receptors.; Coactivators for the orphan nuclear receptor RORalpha.; Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex.; Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta.; A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression.; Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis.; The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro.; Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo.; An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220.; Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha.; Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor alpha (ERalpha) involves multiple domains of both proteins.; A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology.; Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors.; MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.; Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1.; Mediator modulates Gli3-dependent Sonic hedgehog signaling.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Large-scale proteomics analysis of the human kinome.; The basic helix-loop-helix proteins differentiated embryo chondrocyte (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; CCAR1/CoCoA pair-mediated recruitment of the Mediator defines a novel pathway for GATA1 function.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation.",False
MAPK9,P45984,Mitogen-activated protein kinase 9,MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR,,,"Signal transduction by tumor necrosis factor mediated by JNK protein kinases.; JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.; Selective interaction of JNK protein kinase isoforms with transcription factors.; Molecular cloning and characterization of novel human JNK2 (MAPK9) transcript variants that show different stimulation activities on AP-1.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Role of the ATFa/JNK2 complex in Jun activation.; Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7.; Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein.; The nucleolus as a stress sensor: JNK2 inactivates the transcription factor TIF-IA and down-regulates rRNA synthesis.; Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 induced cell transformation.; The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway.; Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway.; CARMA1-mediated NF-kappaB and JNK activation in lymphocytes.; Large-scale proteomics analysis of the human kinome.; GSK3beta is involved in JNK2-mediated beta-catenin inhibition.; c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.; JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.; Initial characterization of the human central proteome.; JNK regulates the photic response of the mammalian circadian clock.; Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.; The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity.; Patterns of somatic mutation in human cancer genomes.; Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent nephronophthisis.",False
MAPK3,P27361,Mitogen-activated protein kinase 3,MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP,,,"Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1.; Properties of human ERK1b.; Identification of dominant negative Erk1/2 variants in cancer cells.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs.; Heterogeneous expression of four MAP kinase isoforms in human tissues.; Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-activated protein kinase.; Human immunodeficiency virus type 1 Nef binds directly to LCK and mitogen-activated protein kinase, inhibiting kinase activity.; MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates.; MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase.; Phosphorylation by CK2 and MAPK enhances calnexin association with ribosomes.; Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway.; Identification of a cytoplasmic-retention sequence in ERK2.; Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation.; c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity.; IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation.; Insulin receptor substrate 4 associates with the protein IRAS.; Signal transduction via the stem cell factor receptor/c-Kit.; Phosphorylation of Grb10 by mitogen-activated protein kinase: identification of Ser150 and Ser476 of human Grb10zeta as major phosphorylation sites.; Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK.; Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38.; EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2.; Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26.; ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation.; Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.; Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.; Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.; Protein kinase SGK1 enhances MEK/ERK complex formation through the phosphorylation of ERK2: implication for the positive regulatory role of SGK1 on the ERK function during liver regeneration.; Large-scale proteomics analysis of the human kinome.; A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.; The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.; The ERK signaling cascade--views from different subcellular compartments.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; The ERK cascade: distinct functions within various subcellular organelles.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling.; The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically.; TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination.; Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation.; Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells.; Crystal structure of human mono-phosphorylated ERK1 at Tyr204.; Patterns of somatic mutation in human cancer genomes.",False
HMGB1,P09429,High mobility group protein B1,MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFEDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGLSIGDVAKKLGEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEKSKKKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDDE,,,"A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1.; The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13.; Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa.; The genetic variation of the human HMGB1 gene.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.; Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation.; The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.; Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.; Structural basis for the proinflammatory cytokine activity of high mobility group box 1.; Evidence for involvement of HMGB1 protein in human DNA mismatch repair.; Reversing established sepsis with antagonists of endogenous high-mobility group box 1.; Reconstitution of 5'-directed human mismatch repair in a purified system.; The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.; Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products.; Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1.; The extracellular release of HMGB1 during apoptotic cell death.; Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1.; Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion.; Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein.; HMGB1 is a cofactor in mammalian base excision repair.; Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.; HMGB1 develops enhanced proinflammatory activity by binding to cytokines.; High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes.; Proteomic screen defines the hepatocyte nuclear factor 1alpha-binding partners and identifies HMGB1 as a new cofactor of HNF1alpha.; A quantitative atlas of mitotic phosphorylation.; Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis.; Human HMGB1 directly facilitates interactions between nucleotide excision repair proteins on triplex-directed psoralen interstrand crosslinks.; HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic.; CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; HMGB proteins: interactions with DNA and chromatin.; Endogenous HMGB1 regulates autophagy.; A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress.; Initial characterization of the human central proteome.; Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication.; HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells.; HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4.; Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.; Novel role of PKR in inflammasome activation and HMGB1 release.; High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.; HMGB1: The central cytokine for all lymphoid cells.; Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates.; The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Menage a Trois in stress: DAMPs, redox and autophagy.; HMGB1-DNA complex-induced autophagy limits AIM2 inflammasome activation through RAGE.; An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins.; An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.; Role of high mobility group box 1 (HMGB1) in SCA17 pathogenesis.; The role of high mobility group box 1 in innate immunity.; HMGB1 promotes systemic lupus erythematosus by enhancing macrophage inflammatory response.; HMGB1 binds to lipoteichoic acid and enhances TNF-alpha and IL-6 production through HMGB1-mediated transfer of lipoteichoic acid to CD14 and TLR2.; N-terminome analysis of the human mitochondrial proteome.; A core viral protein binds host nucleosomes to sequester immune danger signals.; Serine ADP-ribosylation depends on HPF1.; The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens.; Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.; LPS-induced macrophage HMGB1-loaded extracellular vesicles trigger hepatocyte pyroptosis by activating the NLRP3 inflammasome.; The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression of the EBV lytic switch protein in Burkitt lymphoma cells.; USP13 regulates HMGB1 stability and secretion through its deubiquitinase activity.; High-mobility group box 1 protein promotes dengue virus replication by interacting with untranslated regions of viral genome.; SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and triggers sequential ER stress and inflammatory responses during SARS-CoV-2 infection.; Solution structure of the tandem HMG box domain from human high mobility group protein B1.; HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail.; Redox-sensitive structural change in the A-domain of HMGB1 and its implication for the binding to cisplatin modified DNA.",False
CCNA2,P20248,Cyclin-A2,MLGNSAPGPATREAGSALLALQQTALQEDQENINPEKAAPVQQPRTRAALAVLKSGNPRGLAQQQRPKTRRVAPLKDLPVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPRKPLVPLDYPMDGSFESPHTMDMSIILEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPESLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL,,,"Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma.; Structure and cell cycle-regulated transcription of the human cyclin A gene.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cyclin A is required at two points in the human cell cycle.; SCAPER, a novel cyclin A-interacting protein that regulates cell cycle progression.; Large-scale proteomics analysis of the human kinome.; Initial characterization of the human central proteome.; Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1 (INCA1) regulates proliferation and is repressed by oncogenic signaling.; Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Human cytomegalovirus tegument protein pp150 acts as a cyclin A2-CDK-dependent sensor of the host cell cycle and differentiation state.; The tumor suppressor FBXO31 preserves genomic integrity by regulating DNA replication and segregation through precise control of cyclin A levels.; Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.; Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.; Structural basis of cyclin-dependent kinase activation by phosphorylation.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.",False
HMGB2,P26583,High mobility group protein B2,MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKKCSERWKTMSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAFFLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEKYEKDIAAYRAKGKSEAGKKGPGRPTGSKKKNEPEDEEEEEEEEDEDEEEEDEDEE,,,"Sequence of human HMG2 cDNA.; Structure of a gene coding for human HMG2 protein.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A human HMG2 cDNA with a novel 3'-untranslated region.; Activation of the TFIID-TFIIA complex with HMG-2.; HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.; Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes.; Transient HMGB protein interactions with B-DNA duplexes and complexes.; High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1.; Nucleosome binding properties and Co-remodeling activities of native and in vivo acetylated HMGB-1 and HMGB-2 proteins.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription.; HMGB proteins: interactions with DNA and chromatin.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins.; N-terminome analysis of the human mitochondrial proteome.",False
MAP3K5,Q99683,Mitogen-activated protein kinase kinase kinase 5,MSTEADEGITFSVPPFAPSGFCTIPEGGICRRGGAAAVGEGEEHQLPPPPPGSFWNVESAAAPGIGCPAATSSSSATRGRGSSVGGGSRRTTVAYVINEASQGQLVVAESEALQSLREACETVGATLETLHFGKLDFGETTVLDRFYNADIAVVEMSDAFRQPSLFYHLGVRESFSMANNIILYCDTNSDSLQSLKEIICQKNTMCTGNYTFVPYMITPHNKVYCCDSSFMKGLTELMQPNFELLLGPICLPLVDRFIQLLKVAQASSSQYFRESILNDIRKARNLYTGKELAAELARIRQRVDNIEVLTADIVINLLLSYRDIQDYDSIVKLVETLEKLPTFDLASHHHVKFHYAFALNRRNLPGDRAKALDIMIPMVQSEGQVASDMYCLVGRIYKDMFLDSNFTDTESRDHGASWFKKAFESEPTLQSGINYAVLLLAAGHQFESSFELRKVGVKLSSLLGKKGNLEKLQSYWEVGFFLGASVLANDHMRVIQASEKLFKLKTPAWYLKSIVETILIYKHFVKLTTEQPVAKQELVDFWMDFLVEATKTDVTVVRFPVLILEPTKIYQPSYLSINNEVEEKTISIWHVLPDDKKGIHEWNFSASSVRGVSISKFEERCCFLYVLHNSDDFQIYFCTELHCKKFFEMVNTITEEKGRSTEEGDCESDLLEYDYEYDENGDRVVLGKGTYGIVYAGRDLSNQVRIAIKEIPERDSRYSQPLHEEIALHKHLKHKNIVQYLGSFSENGFIKIFMEQVPGGSLSALLRSKWGPLKDNEQTIGFYTKQILEGLKYLHDNQIVHRDIKGDNVLINTYSGVLKISDFGTSKRLAGINPCTETFTGTLQYMAPEIIDKGPRGYGKAADIWSLGCTIIEMATGKPPFYELGEPQAAMFKVGMFKVHPEIPESMSAEAKAFILKCFEPDPDKRACANDLLVDEFLKVSSKKKKTQPKLSALSAGSNEYLRSISLPVPVLVEDTSSSSEYGSVSPDTELKVDPFSFKTRAKSCGERDVKGIRTLFLGIPDENFEDHSAPPSPEEKDSGFFMLRKDSERRATLHRILTEDQDKIVRNLMESLAQGAEEPKLKWEHITTLIASLREFVRSTDRKIIATTLSKLKLELDFDSHGISQVQVVLFGFQDAVNKVLRNHNIKPHWMFALDSIIRKAVQTAITILVPELRPHFSLASESDTADQEDLDVEDDHEEQPSNQTVRRPQAVIEDAVATSGVSTLSSTVSHDSQSAHRSLNVQLGRMKIETNRLLEELVRKEKELQALLHRAIEEKDQEIKHLKLKSQPIEIPELPVFHLNSSGTNTEDSELTDWLRVNGADEDTISRFLAEDYTLLDVLYYVTRDDLKCLRLRGGMLCTLWKAIIDFRNKQT,,,"Molecular cloning and characterization of a novel protein kinase with a catalytic domain homologous to mitogen-activated protein kinase kinase kinase.; Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.; ASK1 is essential for JNK/SAPK activation by TRAF2.; Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx.; Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins.; Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation.; Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin.; Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.; Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress.; Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation.; Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.; HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell.; Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.; Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation.; Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer.; Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).; AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.; AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3.; Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14-3-3 proteins.; Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation.; AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation.; Negative control of apoptosis signal-regulating kinase 1 through phosphorylation of Ser-1034.; C-terminus of heat shock protein 70-interacting protein facilitates degradation of apoptosis signal-regulating kinase 1 and inhibits apoptosis signal-regulating kinase 1-dependent apoptosis.; Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation.; Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death.; SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation.; Regulation of apoptosis signal-regulating kinase 1 by protein phosphatase 2Cepsilon.; Apoptosis signal-regulating kinase (ASK) 2 functions as a mitogen-activated protein kinase kinase kinase in a heteromeric complex with ASK1.; Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling.; RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical for tumor necrosis factor-induced ASK1-JNK/p38 activation.; Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1.; The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus.; Murine protein serine/threonine kinase 38 activates apoptosis signal-regulating kinase 1 via Thr 838 phosphorylation.; Phosphoproteome of resting human platelets.; A quantitative atlas of mitotic phosphorylation.; Large-scale proteomics analysis of the human kinome.; PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.; Mitochondrial phosphoglycerate mutase 5 uses alternate catalytic activity as a protein serine/threonine phosphatase to activate ASK1.; Apoptosis signal-regulating kinase 1 in stress and immune response.; The roles of ASK family proteins in stress responses and diseases.; Positive regulation of apoptosis signal-regulating kinase 1 by dual-specificity phosphatase 13A.; Arginine methylation-dependent regulation of ASK1 signaling by PRMT1.; The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1 activation by suppressing PP5.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate stress responses.; Cyclophilin A regulates JNK/p38-MAPK signaling through its physical interaction with ASK1.; TRIM48 Promotes ASK1 Activation and Cell Death through Ubiquitination-Dependent Degradation of the ASK1-Negative Regulator PRMT1.; Structural and functional characterization of the human protein kinase ASK1.; Patterns of somatic mutation in human cancer genomes.",False
TAF1,P21675,Transcription initiation factor TFIID subunit 1,MGPGCDLLLRTAATITAAAIMSDTDSDEDSAGGGPFSLAGFLFGNINGAGQLEGESVLDDECKKHLAGLGALGLGSLITELTANEELTGTDGALVNDEGWVRSTEDAVDYSDINEVAEDESRRYQQTMGSLQPLCHSDYDEDDYDADCEDIDCKLMPPPPPPPGPMKKDKDQDSITGVSENGEGIILPSIIAPSSLASEKVDFSSSSDSESEMGPQEATQAESEDGKLTLPLAGIMQHDATKLLPSVTELFPEFRPGKVLRFLRLFGPGKNVPSVWRSARRKRKKKHRELIQEEQIQEVECSVESEVSQKSLWNYDYAPPPPPEQCLSDDEITMMAPVESKFSQSTGDIDKVTDTKPRVAEWRYGPARLWYDMLGVPEDGSGFDYGFKLRKTEHEPVIKSRMIEEFRKLEENNGTDLLADENFLMVTQLHWEDDIIWDGEDVKHKGTKPQRASLAGWLPSSMTRNAMAYNVQQGFAATLDDDKPWYSIFPIDNEDLVYGRWEDNIIWDAQAMPRLLEPPVLTLDPNDENLILEIPDEKEEATSNSPSKESKKESSLKKSRILLGKTGVIKEEPQQNMSQPEVKDPWNLSNDEYYYPKQQGLRGTFGGNIIQHSIPAVELRQPFFPTHMGPIKLRQFHRPPLKKYSFGALSQPGPHSVQPLLKHIKKKAKMREQERQASGGGEMFFMRTPQDLTGKDGDLILAEYSEENGPLMMQVGMATKIKNYYKRKPGKDPGAPDCKYGETVYCHTSPFLGSLHPGQLLQAFENNLFRAPIYLHKMPETDFLIIRTRQGYYIRELVDIFVVGQQCPLFEVPGPNSKRANTHIRDFLQVFIYRLFWKSKDRPRRIRMEDIKKAFPSHSESSIRKRLKLCADFKRTGMDSNWWVLKSDFRLPTEEEIRAMVSPEQCCAYYSMIAAEQRLKDAGYGEKSFFAPEEENEEDFQMKIDDEVRTAPWNTTRAFIAAMKGKCLLEVTGVADPTGCGEGFSYVKIPNKPTQQKDDKEPQPVKKTVTGTDADLRRLSLKNAKQLLRKFGVPEEEIKKLSRWEVIDVVRTMSTEQARSGEGPMSKFARGSRFSVAEHQERYKEECQRIFDLQNKVLSSTEVLSTDTDSSSAEDSDFEEMGKNIENMLQNKKTSSQLSREREEQERKELQRMLLAAGSAASGNNHRDDDTASVTSLNSSATGRCLKIYRTFRDEEGKEYVRCETVRKPAVIDAYVRIRTTKDEEFIRKFALFDEQHREEMRKERRRIQEQLRRLKRNQEKEKLKGPPEKKPKKMKERPDLKLKCGACGAIGHMRTNKFCPLYYQTNAPPSNPVAMTEEQEEELEKTVIHNDNEELIKVEGTKIVLGKQLIESADEVRRKSLVLKFPKQQLPPKKKRRVGTTVHCDYLNRPHKSIHRRRTDPMVTLSSILESIINDMRDLPNTYPFHTPVNAKVVKDYYKIITRPMDLQTLRENVRKRLYPSREEFREHLELIVKNSATYNGPKHSLTQISQSMLDLCDEKLKEKEDKLARLEKAINPLLDDDDQVAFSFILDNIVTQKMMAVPDSWPFHHPVNKKFVPDYYKVIVNPMDLETIRKNISKHKYQSRESFLDDVNLILANSVKYNGPESQYTKTAQEIVNVCYQTLTEYDEHLTQLEKDICTAKEAALEEAELESLDPMTPGPYTPQPPDLYDTNTSLSMSRDASVFQDESNMSVLDIPSATPEKQVTQEGEDGDGDLADEEEGTVQQPQASVLYEDLLMSEGEDDEEDAGSDEEGDNPFSAIQLSESGSDSDVGSGGIRPKQPRMLQENTRMDMENEESMMSYEGDGGEASHGLEDSNISYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRSGPSVLSQVHLSEDEEDSEDFHSIAGDSDLDSDE,,,"The human CCG1 gene, essential for progression of the G1 phase, encodes a 210-kilodalton nuclear DNA-binding protein.; Cloning and expression of human TAFII250: a TBP-associated factor implicated in cell-cycle regulation.; Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism.; The DNA sequence of the human X chromosome.; Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the BHK cell line.; Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism.; Structural and functional analysis of the human TAF1/DYT3 multiple transcript system.; The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle regulatory protein CCG1.; TAFII250 is a bipartite protein kinase that phosphorylates the base transcription factor RAP74.; TAF-like function of SV40 large T antigen.; Interaction of the viral activator protein ICP4 with TFIID through TAF250.; Functional analysis of the human TAFII250 N-terminal kinase domain.; Rb inhibits the intrinsic kinase activity of TATA-binding protein-associated factor TAFII250.; A human homologue of yeast anti-silencing factor has histone chaperone activity.; Taf(II) 250 phosphorylates human transcription factor IIA on serine residues important for TBP binding and transcription activity.; TAFII55 binding to TAFII250 inhibits its acetyltransferase activity.; Identification and characterization of CIA/ASF1 as an interactor of bromodomains associated with TFIID.; Transcription initiation factor IID-interactive histone chaperone CIA-II implicated in mammalian spermatogenesis.; Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression.; Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.; TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7.; X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structure and function of a human TAFII250 double bromodomain module.; Histone recognition and large-scale structural analysis of the human bromodomain family.; Crystal structure of a TAF1-TAF7 complex in human transcription factor IID reveals a promoter binding module.; A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications.; Structure of promoter-bound TFIID and model of human pre-initiation complex assembly.; Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem.; Crystal Structure Analysis of TAF1 Bromodomain.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZ20.; Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to the ATR kinase inhibitor AZD6738.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322.; Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ATR kinase inhibitor AZD6738.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to mTORC1/2 inhibitor AZD3147.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to PLK1 kinase inhibitor BI2536.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to bromosporine.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ATR inhibitor AZ20.; Crystal structure of the unliganded second bromodomain (BD2) of human TAF1.; Crystal structure of the second bromodomain (BD2) of human TAF1 bound to dioxane.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in complex with MES (2-(N-morpholino)ethanesulfonic acid).; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to GNE-371.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-295.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-585.; Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-589.; Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound to ZS1-681.; Structural insights into preinitiation complex assembly on core promoters.; Patterns of somatic mutation in human cancer genomes.; TAF1 Variants Are Associated with Dysmorphic Features, Intellectual Disability, and Neurological Manifestations.; X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes.",False
LMNB1,P20700,Lamin-B1,MATATPVPPRMGSRAGGPTTPLSPTRLSRLQEKEELRELNDRLAVYIDKVRSLETENSALQLQVTEREEVRGRELTGLKALYETELADARRALDDTARERAKLQIELGKCKAEHDQLLLNYAKKESDLNGAQIKLREYEAALNSKDAALATALGDKKSLEGDLEDLKDQIAQLEASLAAAKKQLADETLLKVDLENRCQSLTEDLEFRKSMYEEEINETRRKHETRLVEVDSGRQIEYEYKLAQALHEMREQHDAQVRLYKEELEQTYHAKLENARLSSEMNTSTVNSAREELMESRMRIESLSSQLSNLQKESRACLERIQELEDLLAKEKDNSRRMLTDKEREMAEIRDQMQQQLNDYEQLLDVKLALDMEISAYRKLLEGEEERLKLSPSPSSRVTVSRASSSRSVRTTRGKRKRVDVEESEASSSVSISHSASATGNVCIEEIDVDGKFIRLKNTSEQDQPMGGWEMIRKIGDTSVSYKYTSRYVLKAGQTVTIWAANAGVTASPPTDLIWKNQNSWGTGEDVKVILKNSQGEEVAQRSTVFKTTIPEEEEEEEEAAGVVVEEELFHQQGTPRASNRSCAIM,,,"In vitro posttranslational modification of lamin B cloned from a human T-cell line.; Structural organization of the human gene (LMNB1) encoding nuclear lamin B1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human lamin B contains a farnesylated cysteine residue.; Proteomic characterization of the human centrosome by protein correlation profiling.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Lamin B1 duplications cause autosomal dominant leukodystrophy.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; SEPT12/SPAG4/LAMINB1 complexes are required for maintaining the integrity of the nuclear envelope in postmeiotic male germ cells.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Crystal structures of the coil 2B fragment and the globular tail domain of human lamin B1.; The active site of O-GlcNAc transferase imposes constraints on substrate sequence.; Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.; Beta-strand-mediated dimeric formation of the Ig-like domains of human lamin A/C and B1.; Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis.; LMNB1 mutation causes cerebellar involvement and a genome instability defect.; De Novo Variants in LMNB1 Cause Pronounced Syndromic Microcephaly and Disruption of Nuclear Envelope Integrity.; Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly and define a novel laminopathy.; Structural Variants at the LMNB1 Locus: Deciphering Pathomechanisms in Autosomal Dominant Adult-Onset Demyelinating Leukodystrophy.",False
SDHC,Q99643,"Succinate dehydrogenase cytochrome b560 subunit, mitochondrial",MAALLLRHVGRHCLRAHFSPQLCIRNAVPLGTTAKEEMERFWNKNIGSNRPLSPHITIYSWSLPMAMSICHRGTGIALSAGVSLFGMSALLLPGNFESYLELVKSLCLGPALIHTAKFALVFPLMYHTWNGIRHLMWDLGKGLKIPQLYQSGVVVLVLTVLSSMGLAAM,,,"The cDNA sequence of human CII-3, an integral membrane protein subunit of complex II of the mitochondria electron transport chain.; Cytochrome b in human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of the components in liver mitochondria and chromosome assignment of the genes for the large (SDHC) and small (SDHD) subunits to 1q21 and 11q23.; Characterization of the human SDHC gene encoding one of the integral membrane proteins of succinate-quinone oxidoreductase in mitochondria.; A human succinate-ubiquinone oxidoreductase CII-3 subunit gene ending in a polymorphic dinucleotide repeat is located within the sulfonylurea receptor (SUR) gene.; Homo sapiens succinate dehydrogenase complex, subunit C mRNA, alternative splicing variants.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mutations in SDHC cause autosomal dominant paraganglioma, type 3.; Familial gastrointestinal stromal tumors and germ-line mutations.; Initial characterization of the human central proteome.; N-terminome analysis of the human mitochondrial proteome.; Structure of the human respiratory complex II.",False
FOXO4,P98177,Forkhead box protein O4,MDPGNENSATEAAAIIDLDPDFEPQSRPRSCTWPLPRPEIANQPSEPPEVEPDLGEKVHTEGRSEPILLPSRLPEPAGGPQPGILGAVTGPRKGGSRRNAWGNQSYAELISQAIESAPEKRLTLAQIYEWMVRTVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIKVHNEATGKSSWWMLNPEGGKSGKAPRRRAASMDSSSKLLRGRSKAPKKKPSVLPAPPEGATPTSPVGHFAKWSGSPCSRNREEADMWTTFRPRSSSNASSVSTRLSPLRPESEVLAEEIPASVSSYAGGVPPTLNEGLELLDGLNLTSSHSLLSRSGLSGFSLQHPGVTGPLHTYSSSLFSPAEGPLSAGEGCFSSSQALEALLTSDTPPPPADVLMTQVDPILSQAPTLLLLGGLPSSSKLATGVGLCPKPLEAPGPSSLVPTLSMIAPPPVMASAPIPKALGTPVLTPPTEAASQDRMPQDLDLDMYMENLECDMDNIISDLMDEGEGLDFNFEPDP,,,"AFX1 and p54nrb: fine mapping, genomic structure, and exclusion as candidate genes of X-linked dystonia parkinsonism.; Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23).; An mRNA splice variant of the AFX gene with altered transcriptional activity.; The DNA sequence of the human X chromosome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family.; Direct control of the forkhead transcription factor AFX by protein kinase B.; Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B.; AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1.; The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism.; FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1).; 14-3-3 protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4.; Phenotypic modulation of smooth muscle cells through interaction of Foxo4 and myocardin.; Regulation of intracellular localization and transcriptional activity of FOXO4 by protein kinase B through phosphorylation at the motif sites conserved among the FOXO family.; Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.; FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP.; Oxidative stress-dependent regulation of Forkhead box O4 activity by nemo-like kinase.; Increased proteasome activity in human embryonic stem cells is regulated by PSMD11.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; 1H, 13C and 15N resonance assignments of the DNA binding domain of the human forkhead transcription factor AFX.; Solution structure of the DNA binding domain of the human forkhead transcription factor AFX (FOXO4).",False
HESX1,Q9UBX0,Homeobox expressed in ES cells 1,MSPSLQEGAQLGENKPSTCSFSIERILGLDQKKDCVPLMKPHRPWADTCSSSGKDGNLCLHVPNPPSGISFPSVVDHPMPEERASKYENYFSASERLSLKRELSWYRGRRPRTAFTQNQIEVLENVFRVNCYPGIDIREDLAQKLNLEEDRIQIWFQNRRAKLKRSHRESQFLMAKKNFNTNLLE,,,"Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse.; Anf: a novel class of vertebrate homeobox genes expressed at the anterior end of the main embryonic axis.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis.; Role of conserved salt bridges in homeodomain stability and DNA binding.; Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia.; A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction.; HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism.; A novel mutation in HESX1 causes combined pituitary hormone deficiency without septo optic dysplasia phenotypes.",False
PIK3R1,P27986,Phosphatidylinositol 3-kinase regulatory subunit alpha,MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR,,,"Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases.; Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.; Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor.; Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1.; Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.; p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.; Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.; Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors.; Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes.; Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.; LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.; Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells.; T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane.; KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties.; cbl-b inhibits epidermal growth factor receptor signaling.; Clustering of beta(2)-integrins on human neutrophils activates dual signaling pathways to PtdIns 3-kinase.; Ligand discrimination in signaling through an ErbB4 receptor homodimer.; Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction.; Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.; Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells.; Insulin receptor substrate 4 associates with the protein IRAS.; Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling.; Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV.; Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.; TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.; Signal transduction via the stem cell factor receptor/c-Kit.; The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner.; The proto-oncogene Fgr regulates cell migration and this requires its plasma membrane localization.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; The tyrosine phosphatase CD148 interacts with the p85 regulatory subunit of phosphoinositide 3-kinase.; Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages.; System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.; Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.; A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.; Cellular signaling by fibroblast growth factor receptors.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.; Ligation of CD40 receptor in human B lymphocytes triggers the 5-lipoxygenase pathway to produce reactive oxygen species and activate p38 MAPK.; Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.; Tyrosine phosphorylation of the Galpha-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration.; Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex.; Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Mutations in PIK3R1 cause SHORT syndrome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression.; FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.; A human immunodeficiency caused by mutations in the PIK3R1 gene.; N-terminome analysis of the human mitochondrial proteome.; Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating the stability and activity of BMAL1 and CLOCK.; C1-Ten is a PTPase of nephrin, regulating podocyte hypertrophy through mTORC1 activation.; Insulin resistance and diabetes caused by genetic or diet-induced KBTBD2 deficiency in mice.; Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling.; Crystal structure of P13K SH3 domain at 2.0-A resolution.; Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes.; Crystal structure of the breakpoint cluster region-homology domain from phosphoinositide 3-kinase p85 alpha subunit.; NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex.; Structure of the PI3K SH3 domain and analysis of the SH3 family.; Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase.; Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.; Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.; The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.; A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.; Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3 domain in complex with a peptide ligand: role of the anchor residue in ligand binding.; Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.; Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.; PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.; SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.",False
BSCL2,Q96G97,Seipin,MVNDPPVPALLWAQEVGQVLAGRARRLLLQFGVLFCTILLLLWVSVFLYGSFYYSYMPTVSHLSPVHFYYRTDCDSSTTSLCSFPVANVSLTKGGRDRVLMYGQPYRVTLELELPESPVNQDLGMFLVTISCYTRGGRIISTSSRSVMLHYRSDLLQMLDTLVFSSLLLFGFAEQKQLLEVELYADYRENSYVPTTGAIIEIHSKRIQLYGAYLRIHAHFTGLRYLLYNFPMTCAFIGVASNFTFLSVIVLFSYMQWVWGGIWPRHRFSLQVNIRKRDNSRKEVQRRISAHQPGPEGQEESTPQSDVTEDGESPEDPSGTEGQLSEEEKPDQQPLSGEEELEPEASDGSGSWEDAALLTEANLPAPAPASASAPVLETLGSSEPAGGALRQRPTCSSS,,,"Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.; Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome.; Membrane topology of the human seipin protein.; The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation.; Characterization of seipin/BSCL2, a protein associated with spastic paraplegia 17.; Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy.; Tissue-autonomous function of Drosophila seipin in preventing ectopic lipid droplet formation.; A new seipin-associated neurodegenerative syndrome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Seipin is required for converting nascent to mature lipid droplets.; The ER-Localized Protein DFCP1 Modulates ER-Lipid Droplet Contact Formation.; LDAF1 and Seipin Form a Lipid Droplet Assembly Complex.; Seipin Facilitates Triglyceride Flow to Lipid Droplet and Counteracts Droplet Ripening via Endoplasmic Reticulum Contact.; Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome.; Application of whole exome sequencing in undiagnosed inherited polyneuropathies.; Seipin regulates ER-lipid droplet contacts and cargo delivery.; Promethin Is a Conserved Seipin Partner Protein.; Human SEIPIN Binds Anionic Phospholipids.",False
AGPAT2,O15120,1-acyl-sn-glycerol-3-phosphate acyltransferase beta,MELWPCLAAALLLLLLLVQLSRAAEFYAKVALYCALCFTVSAVASLVCLLRHGGRTVENMSIIGWFVRSFKYFYGLRFEVRDPRRLQEARPCVIVSNHQSILDMMGLMEVLPERCVQIAKRELLFLGPVGLIMYLGGVFFINRQRSSTAMTVMADLGERMVRENLKVWIYPEGTRNDNGDLLPFKKGAFYLAVQAQVPIVPVVYSSFSSFYNTKKKFFTSGTVTVQVLEAIPTSGLTAADVPALVDTCHRAMRTTFLHISKTPQENGATAGSGVQPAQ,,,"Human lysophosphatidic acid acyltransferase. cDNA cloning, expression, and localization to chromosome 9q34.3.; A human cDNA sequence with homology to non-mammalian lysophosphatidic acid acyltransferases.; Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Acquired and inherited lipodystrophies.; Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy.; The microsomal cardiolipin remodeling enzyme acyl-CoA lysocardiolipin acyltransferase is an acyltransferase of multiple anionic lysophospholipids.; Initial characterization of the human central proteome.; Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice.; AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.",False
BMI1,P35226,Polycomb complex protein BMI-1,MHRTTRIKITELNPHLMCVLCGGYFIDATTIIECLHSFCKTCIVRYLETSKYCPICDVQVHKTRPLLNIRSDKTLQDIVYKLVPGLFKNEMKRRRDFYAAHPSADAANGSNEDRGEVADEDKRIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKMDIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMKISHQRDGLTNAGELESDSGSDKANSPAGGIPSTSSCLPSPSTPVQSPHPQFPHISSTMNGTSNSPSGNHQSSFANRPRKSSVNGSSATSSG,,,"Characterization and chromosomal localization of the human proto-oncogene BMI-1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes bmi-1.; Identification and characterization of interactions between the vertebrate polycomb-group protein BMI1 and human homologs of polyhomeotic.; RING1 is associated with the polycomb group protein complex and acts as a transcriptional repressor.; The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans.; Role of histone H2A ubiquitination in Polycomb silencing.; Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing.; Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase.; E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells.; Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus.; Interaction proteomics analysis of polycomb proteins defines distinct PRC1 Complexes in mammalian cells.; BMI1-RING1B is an autoinhibited RING E3 ubiquitin ligase.; Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex.; Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex.; Crystal structure of the PRC1 ubiquitylation module bound to the nucleosome.; BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization.",False
EEF1A1,P68104,Elongation factor 1-alpha 1,MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKKIGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPVLDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPPLGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK,,,"The primary structure of the alpha subunit of human elongation factor 1. Structural aspects of guanine-nucleotide-binding sites.; Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha.; Retropseudogenes constitute the major part of the human elongation factor 1 alpha gene family.; Postnatal expression of a novel mRNA isoform from the human elongation factor-1a gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structure of the amino-terminal end of mammalian elongation factor Tu.; Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells.; Retinol-regulated gene expression in human tracheobronchial epithelial cells. Enhanced expression of elongation factor EF-1 alpha.; Murine elongation factor 1 alpha (EF-1 alpha) is posttranslationally modified by novel amide-linked ethanolamine-phosphoglycerol moieties. Addition of ethanolamine-phosphoglycerol to specific glutamic acid residues on EF-1 alpha.; Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor.; Induction of acute translational response genes by homocysteine. Elongation factors-1alpha, -beta, and -delta.; Exp5 exports eEF1A via tRNA from nuclei and synergizes with other transport pathways to confine translation to the cytoplasm.; Exportin-5-mediated nuclear export of eukaryotic elongation factor 1A and tRNA.; Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.; Male germ cell expression of the PAS domain kinase PASKIN and its novel target eukaryotic translation elongation factor eEF1A1.; Lysyl-tRNA synthetase interacts with EF1alpha, aspartyl-tRNA synthetase and p38 in vitro.; The possible interaction of CDA14 and protein elongation factor 1alpha.; Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity.; The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.; Phosphorylation of eEF1A1 at Ser300 by TbetaR-I results in inhibition of mRNA translation.; Selenium-based S-adenosylmethionine analog reveals the mammalian seven-beta-strand methyltransferase METTL10 to be an EF1A1 lysine methyltransferase.; Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex.; Elongation factor-1A1 is a novel substrate of the protein phosphatase 1-TIMAP complex.; Functional dynamics within the human ribosome regulate the rate of active protein synthesis.; Novel N-terminal and lysine methyltransferases that target translation elongation factor 1A in yeast and human.; The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A).; Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation.; METTL13 methylation of eEF1A increases translational output to promote tumorigenesis.; The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates.; Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.; Didemnin B and ternatin-4 differentially inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes.; Synthesis and single-molecule imaging reveal stereospecific enhancement of binding kinetics by the antitumour eEF1A antagonist SR-A3.; An E3 ligase network engages GCN1 to promote the degradation of translation factors on stalled ribosomes.",False
TFAP2A,P05549,Transcription factor AP-2-alpha,MLWKLTDNIKYEDCEDRHDGTSNGTARLPQLGTVGQSPYTSAPPLSHTPNADFQPPYFPPPYQPIYPQSQDPYSHVNDPYSLNPLHAQPQPQHPGWPGQRQSQESGLLHTHRGLPHQLSGLDPRRDYRRHEDLLHGPHALSSGLGDLSIHSLPHAIEEVPHVEDPGINIPDQTVIKKGPVSLSKSNSNAVSAIPINKDNLFGGVVNPNEVFCSVPGRLSLLSSTSKYKVTVAEVQRRLSPPECLNASLLGGVLRRAKSKNGGRSLREKLDKIGLNLPAGRRKAANVTLLTSLVEGEAVHLARDFGYVCETEFPAKAVAEFLNRQHSDPNEQVTRKNMLLATKQICKEFTDLLAQDRSPLGNSRPNPILEPGIQSCLTHFNLISHGFGSPAVCAAVTALQNYLTEALKAMDKMYLSNNPNSHTDNNAKSSDKEEKHRK,,,"Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements.; An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2.; The genomic structure of the human AP-2 transcription factor.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins.; Analysis of the DNA-binding and activation properties of the human transcription factor AP-2.; Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation.; Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator.; Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2.; Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.; Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.; RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis.; Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor.; A quantitative atlas of mitotic phosphorylation.; The interaction of KCTD1 with transcription factor AP-2alpha inhibits its transactivation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Inhibition of neural crest formation by Kctd15 involves regulation of transcription factor AP-2.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; TFAP2A mutations result in branchio-oculo-facial syndrome.",False
BDNF,P23560,Neurotrophic factor BDNF precursor form,MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVRTHGTLESVNGPKAGSRGLTSLADTFEHVIEELLDEDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR,,,"Molecular cloning of a human gene that is a member of the nerve growth factor family.; Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations.; Characterization of the 5'-flanking region of the human brain-derived neurotrophic factor gene.; Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease.; Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters.; A cDNA clone of human brain-derived neurotrophic factor (HUMBDNFD).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary.; Purification and identification of brain-derived neurotrophic factor from human serum.; Molecular phylogenetics and the origins of placental mammals.; Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor.; Identification of pro- and mature brain-derived neurotrophic factor in human saliva.; SorCS2 regulates dopaminergic wiring and is processed into an apoptotic two-chain receptor in peripheral glia.; Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer.; The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site.; Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations.; Brain-derived neurotrophic factor and obesity in the WAGR syndrome.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Idiopathic congenital central hypoventilation syndrome: evaluation of brain-derived neurotrophic factor genomic DNA sequence variation.; Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder.; The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.; Molecular analysis of congenital central hypoventilation syndrome.; Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type.; Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families.; The BDNF Val66Met Prodomain Disassembles Dendritic Spines Altering Fear Extinction Circuitry and Behavior.",False
CREB1,P16220,Cyclic AMP-responsive element-binding protein 1,MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD,,,"Two distinct forms of active transcription factor CREB (cAMP response element binding protein).; Multiple cDNA clones encoding nuclear proteins that bind to the tax-dependent enhancer of HTLV-1: all contain a leucine zipper structure and basic amino acid domain.; Diversification of cyclic AMP-responsive enhancer binding proteins-generated by alternative exon splicing.; Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA.; Nucleotide and derived amino-acid sequences of the CRE-binding proteins from rat C6 glioma and HeLa cells.; Cloning and expression of a novel CREB mRNA splice variant in human testis.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The promoter of the gene encoding 3',5'-cyclic adenosine monophosphate (cAMP) response element binding protein contains cAMP response elements: evidence for positive autoregulation of gene transcription.; HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions.; Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction.; Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression.; Transcriptional activation of egr-1 by granulocyte-macrophage colony-stimulating factor but not interleukin 3 requires phosphorylation of cAMP response element-binding protein (CREB) on serine 133.; CREB is a regulatory target for the protein kinase Akt/PKB.; Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene.; TORCs: transducers of regulated CREB activity.; Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia.; Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells.; The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector.; TSSK5, a novel member of the testis-specific serine/threonine kinase family, phosphorylates CREB at Ser-133, and stimulates the CRE/CREB responsive pathway.; A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription.; Serum/glucocorticoid-inducible kinase can phosphorylate the cyclic AMP response element binding protein, CREB.; PGC-1-related coactivator: immediate early expression and characterization of a CREB/NRF-1 binding domain associated with cytochrome c promoter occupancy and respiratory growth.; EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271.; TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; A p.D116G mutation in CREB1 leads to novel multiple malformation syndrome resembling CrebA knockout mouse.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Allosteric communication in the KIX domain proceeds through dynamic repacking of the hydrophobic core.",False
ATF2,P15336,Cyclic AMP-dependent transcription factor ATF-2,MKFKLHVNSARQYKDLWNMSDDKPFLCTAPGCGQRFTNEDHLAVHKHKHEMTLKFGPARNDSVIVADQTPTPTRFLKNCEEVGLFNELASPFENEFKKASEDDIKKMPLDLSPLATPIIRSKIEEPSVVETTHQDSPLPHPESTTSDEKEVPLAQTAQPTSAIVRPASLQVPNVLLTSSDSSVIIQQAVPSPTSSTVITQAPSSNRPIVPVPGPFPLLLHLPNGQTMPVAIPASITSSNVHVPAAVPLVRPVTMVPSVPGIPGPSSPQPVQSEAKMRLKAALTQQHPPVTNGDTVKGHGSGLVRTQSEESRPQSLQQPATSTTETPASPAHTTPQTQSTSGRRRRAANEDPDEKRRKFLERNRAAASRCRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTLLRNEVAQLKQLLLAHKDCPVTAMQKKSGYHTADKDDSSEDISVPSSPHTEAIQHSSVSTSNGVSSTSKAEAVATSVLTQMADQSTEPALSQIVMAPSSQSQPSGS,,,"Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain.; Identification of a novel, spliced variant of CREB that is preferentially expressed in the thymus.; Characterization and functional analysis of cAMP response element modulator protein and activating transcription factor 2 (ATF2) isoforms in the human myometrium during pregnancy and labor: identification of a novel ATF2 species with potent transactivation properties.; Homo sapiens activating transcription factor 2 (ATF2) mRNA splice variant.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A cDNA for a human cyclic AMP response element-binding protein which is distinct from CREB and expressed preferentially in brain.; Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade.; Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6.; Characterization of functional domains of an embryonic stem cell coactivator UTF1 which are conserved and essential for potentiation of ATF-2 activity.; ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation.; Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38.; Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK.; ATM-dependent phosphorylation of ATF2 is required for the DNA damage response.; Multiple roles for acetylation in the interaction of p300 HAT with ATF-2.; ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities.; Regulation of TIP60 by ATF2 modulates ATM activation.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Phosphorylation of activation transcription factor-2 at serine 121 by protein kinase c controls c-Jun-mediated activation of transcription.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Hyperosmotic stress-induced ATF-2 activation through Polo-like kinase 3 in human corneal epithelial cells.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria.; Critical role of N-terminal end-localized nuclear export signal in regulation of activating transcription factor 2 (ATF2) subcellular localization and transcriptional activity.; ATF2-at the crossroad of nuclear and cytosolic functions.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Solution structure of the transactivation domain of ATF-2 comprising a zinc finger-like subdomain and a flexible subdomain.; The consensus coding sequences of human breast and colorectal cancers.",False
TBP,P20226,TATA-box-binding protein,MDQNNSLPPYAQGLASPQGAMTPGIPIFSPMMPYGTGLTPQPIQNTNSLSILEEQQRQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQAVAAAAVQQSTSQQATQGTSGQAPQLFHSQTLTTAPLPGTTPLYPSPMTPMTPITPATPASESSGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRIREPRTTALIFSSGKMVCTGAKSEEQSRLAARKYARVVQKLGFPAKFLDFKIQNMVGSCDVKFPIRLEGLVLTHQQFSSYEPELFPGLIYRMIKPRIVLLIFVSGKVVLTGAKVRAEIYEAFENIYPILKGFRKTT,,,"Highly conserved core domain and unique N-terminus with presumptive regulatory motifs in a human TATA factor (TFIID).; Functional domains and upstream activation properties of cloned human TATA binding protein.; Cloning of a transcriptionally active human TATA binding factor.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and analysis of human chromosome 6.; Multiple functional domains of human transcription factor IIB: distinct interactions with two general transcription factors and RNA polymerase II.; ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB.; The RNA polymerase I transcription factor, upstream binding factor, interacts directly with the TATA box-binding protein.; Direct interaction of human TFIID with the HIV-1 transactivator tat.; The zinc finger region of the adenovirus E1A transactivating domain complexes with the TATA box binding protein.; Reconstitution of transcription factor SL1: exclusive binding of TBP by SL1 or TFIID subunits.; Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo.; Characterization of functional domains of an embryonic stem cell coactivator UTF1 which are conserved and essential for potentiation of ATF-2 activity.; Requirement of RSF and FACT for transcription of chromatin templates in vitro.; The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins.; Potential targets for HSF1 within the preinitiation complex.; TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter.; Genomics, evolution, and expression of TBPL2, a member of the TBP family.; SPI-B activates transcription via a unique proline, serine, and threonine domain and exhibits DNA binding affinity differences from PU.1.; A nuclear factor ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo.; Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP).; BRFU, a TFIIB-like factor, is directly recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with TATA-binding protein.; The TFIID components human TAFII140 and Drosophila BIP2 (TAFII155) are novel metazoan homologues of yeast TAFII47 containing a histone fold and a PHD finger.; Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis.; The small nuclear RNA-activating protein 190 Myb DNA binding domain stimulates TATA box-binding protein-TATA box recognition.; HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs.; MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity.; Initial characterization of the human central proteome.; Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4+ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4.; Crystal structure of a human TATA box-binding protein/TATA element complex.; How proteins recognize the TATA box.; Structural basis of preinitiation complex assembly on human pol II promoters.; Crystal structure of negative cofactor 2 recognizing the TBP-DNA transcription complex.; A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?; Different types of repeat expansion in the TATA-binding protein gene are associated with a new form of inherited ataxia.; SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein.; Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus.; Redox signaling by the RNA polymerase III TFIIB-related factor Brf2.; Near-atomic resolution visualization of human transcription promoter opening.; Structure of promoter-bound TFIID and model of human pre-initiation complex assembly.; Structural insights into preinitiation complex assembly on core promoters.",False
APEX1,P27695,DNA repair nuclease/redox regulator APEX1,MPKRGKKGAVAEDGDELRTEPEAKKSKTAAKKNDKEAAGEGPALYEDPPDQKTSPSGKPATLKICSWNVDGLRAWIKKKGLDWVKEEAPDILCLQETKCSENKLPAELQELPGLSHQYWSAPSDKEGYSGVGLLSRQCPLKVSYGIGDEEHDQEGRVIVAEFDSFVLVTAYVPNAGRGLVRLEYRQRWDEAFRKFLKGLASRKPLVLCGDLNVAHEEIDLRNPKGNKKNAGFTPQERQGFGELLQAVPLADSFRHLYPNTPYAYTFWTYMMNARSKNVGWRLDYFLLSHSLLPALCDSKIRSKALGSDHCPITLYLAL,,,"Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants.; Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes.; cDNA cloning, sequencing, expression and possible domain structure of human APEX nuclease homologous to Escherichia coli exonuclease III.; Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme.; Nucleotide sequence of a cDNA for an apurinic/apyrimidinic endonuclease from HeLa cells.; The human gene for apurinic/apyrimidinic endonuclease (HAP1): sequence and localization to chromosome 14 band q12.; Structure of the human DNA repair gene HAP1 and its localisation to chromosome 14q 11.2-12.; Structure, promoter analysis and chromosomal assignment of the human APEX gene.; Large-scale concatenation cDNA sequencing.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A.; Human apurinic endonuclease gene (APE): structure and genomic mapping (chromosome 14q11.2-12).; Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding.; Removal of 3'-phosphoglycolate from DNA strand-break damage in an oligonucleotide substrate by recombinant human apurinic/apyrimidinic endonuclease 1.; The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium.; Asparagine 212 is essential for abasic site recognition by the human DNA repair endonuclease HAP1.; Substrate binding by human apurinic/apyrimidinic endonuclease indicates a Briggs-Haldane mechanism.; AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1.; Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.; Rapid dissociation of human apurinic endonuclease (Ape1) from incised DNA induced by magnesium.; Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals.; Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1.; Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation.; Activation of APE/Ref-1 redox activity is mediated by reactive oxygen species and PKC phosphorylation.; HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.; An exonucleolytic activity of human apurinic/apyrimidinic endonuclease on 3' mispaired DNA.; Human AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor element in the AP-endonuclease 1 promoter.; Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene.; Novel role of tyrosine in catalysis by human AP endonuclease 1.; APE1-dependent repair of DNA single-strand breaks containing 3'-end 8-oxoguanine.; Analysis of nuclear transport signals in the human apurinic/apyrimidinic endonuclease (APE1/Ref1).; Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells.; UVA irradiation induces relocalisation of the DNA repair protein hOGG1 to nuclear speckles.; Nitric oxide controls nuclear export of APE1/Ref-1 through S-nitrosation of cysteines 93 and 310.; Characterization of abasic endonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision.; Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.; Granzyme K degrades the redox/DNA repair enzyme Ape1 to trigger oxidative stress of target cells leading to cytotoxicity.; Evolution of the redox function in mammalian apurinic/apyrimidinic endonuclease.; Enzymatic mechanism of human apurinic/apyrimidinic endonuclease against a THF AP site model substrate.; APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process.; R152C DNA Pol beta mutation impairs base excision repair and induces cellular transformation.; Identification of apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA.; Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Identification and characterization of mitochondrial targeting sequence of human apurinic/apyrimidinic endonuclease 1.; SIRT1 deacetylates APE1 and regulates cellular base excision repair.; Critical lysine residues within the overlooked N-terminal domain of human APE1 regulate its biological functions.; Initial characterization of the human central proteome.; Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain.; Characterization of the endoribonuclease active site of human apurinic/apyrimidinic endonuclease 1.; Transient-state kinetics of apurinic/apyrimidinic (AP) endonuclease 1 acting on an authentic AP site and commonly used substrate analogs: the effect of diverse metal ions and base mismatches.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites.; DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination.; Two divalent metal ions in the active site of a new crystal form of human apurinic/apyrimidinic endonuclease, Ape1: implications for the catalytic mechanism.",False
HBP1,O60381,HMG box-containing protein 1,MVWEVKTNQMPNAVQKLLLVMDKRASGMNDSLELLQCNENLPSSPGYNSCDEHMELDDLPELQAVQSDPTQSGMYQLSSDVSHQEYPRSSWNQNTSDIPETTYRENEVDWLTELANIATSPQSPLMQCSFYNRSSPVHIIATSKSLHSYARPPPVSSSSKSEPAFPHHHWKEETPVRHERANSESESGIFCMSSLSDDDDLGWCNSWPSTVWHCFLKGTRLCFHKGSNKEWQDVEDFARAEGCDNEEDLQMGIHKGYGSDGLKLLSHEESVSFGESVLKLTFDPGTVEDGLLTVECKLDHPFYVKNKGWSSFYPSLTVVQHGIPCCEVHIGDVCLPPGHPDAINFDDSGVFDTFKSYDFTPMDSSAVYVLSSMARQRRASLSCGGPGGQDFARSGFSKNCGSPGSSQLSSNSLYAKAVKNHSSGTVSATSPNKCKRPMNAFMLFAKKYRVEYTQMYPGKDNRAISVILGDRWKKMKNEERRMYTLEAKALAEEQKRLNPDCWKRKRTNSGSQQH,,,"Involvement of retinoblastoma protein and HBP1 in histone H1(0) gene expression.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of human chromosome 7.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human HMG box transcription factor HBP1: a role in hCD2 LCR function.; Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; The multi-subunit GID/CTLH E3 ligase promotes proliferation and targets the transcription factor Hbp1 for degradation.; Solution structure of the HMG box domain from human HMG-box transcription factor 1.",False
BUB1B,O60566,Mitotic checkpoint serine/threonine-protein kinase BUB1 beta,MAAVKKEGGALSEAMSLEGDEWELSKENVQPLRQGRIMSTLQGALAQESACNNTLQQQKRAFEYEIRFYTGNDPLDVWDRYISWTEQNYPQGGKESNMSTLLERAVEALQGEKRYYSDPRFLNLWLKLGRLCNEPLDMYSYLHNQGIGVSLAQFYISWAEEYEARENFRKADAIFQEGIQQKAEPLERLQSQHRQFQARVSRQTLLALEKEEEEEVFESSVPQRSTLAELKSKGKKTARAPIIRVGGALKAPSQNRGLQNPFPQQMQNNSRITVFDENADEASTAELSKPTVQPWIAPPMPRAKENELQAGPWNTGRSLEHRPRGNTASLIAVPAVLPSFTPYVEETARQPVMTPCKIEPSINHILSTRKPGKEEGDPLQRVQSHQQASEEKKEKMMYCKEKIYAGVGEFSFEEIRAEVFRKKLKEQREAELLTSAEKRAEMQKQIEEMEKKLKEIQTTQQERTGDQQEETMPTKETTKLQIASESQKIPGMTLSSSVCQVNCCARETSLAENIWQEQPHSKGPSVPFSIFDEFLLSEKKNKSPPADPPRVLAQRRPLAVLKTSESITSNEDVSPDVCDEFTGIEPLSEDAIITGFRNVTICPNPEDTCDFARAARFVSTPFHEIMSLKDLPSDPERLLPEEDLDVKTSEDQQTACGTIYSQTLSIKKLSPIIEDSREATHSSGFSGSSASVASTSSIKCLQIPEKLELTNETSENPTQSPWCSQYRRQLLKSLPELSASAELCIEDRPMPKLEIEKEIELGNEDYCIKREYLICEDYKLFWVAPRNSAELTVIKVSSQPVPWDFYINLKLKERLNEDFDHFCSCYQYQDGCIVWHQYINCFTLQDLLQHSEYITHEITVLIIYNLLTIVEMLHKAEIVHGDLSPRCLILRNRIHDPYDCNKNNQALKIVDFSYSVDLRVQLDVFTLSGFRTVQILEGQKILANCSSPYQVDLFGIADLAHLLLFKEHLQVFWDGSFWKLSQNISELKDGELWNKFFVRILNANDEATVSVLGELAAEMNGVFDTTFQSHLNKALWKVGKLTSPGALLFQ,,,"Identification of a novel gene -- SSK1 -- in human endothelial cells exposed to shear stress.; The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase.; Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1.; Mutations of mitotic checkpoint genes in human cancers.; The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner.; Human MAD3-like protein kinase (hmad3).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; BUBR1 phosphorylation is regulated during mitotic checkpoint activation.; Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC.; Mad2-independent inhibition of APC/Cdc20 by the mitotic checkpoint protein BubR1.; Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability.; Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss.; Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression.; Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression.; Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1.; Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions.; Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1.; Phosphorylation sites in BubR1 that regulate kinetochore attachment, tension, and mitotic exit.; SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Depletion of BubR1 promotes premature centrosomal localization of cyclin B1 and accelerates mitotic entry.; Defects in chromosome congression and mitotic progression in KIF18A-deficient cells are partly mediated through impaired functions of CENP-E.; BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis.; BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Direct interactions of mitotic arrest deficient 1 (MAD1) domains with each other and MAD2 conformers are required for mitotic checkpoint signaling.; PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent proteasomal degradation.; Premature aging syndrome showing random chromosome number instabilities with CDC20 mutation.; Role of ubiquitin-protein ligase UBR5 in the disassembly of mitotic checkpoint complexes.; Characterization of MAD2B and other mitotic spindle checkpoint genes.; Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B.; Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.; Patterns of somatic mutation in human cancer genomes.",False
PTGS2,P35354,Prostaglandin G/H synthase 2,MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKERSTEL,,,"Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.; Human cyclooxygenase-2 cDNA.; Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2.; Structure of the human cyclo-oxygenase-2 gene.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.; Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2.; Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2.; Mutational analysis of the role of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase catalysis, hydroperoxide reduction, and cyclooxygenase activation.; Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy.; Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.; Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions.; Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2.; Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.; Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2.; Glycosylation regulates turnover of cyclooxygenase-2.; Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.; Prostaglandin H synthase-2-catalyzed oxygenation of 2-arachidonoylglycerol is more sensitive to peroxide tone than oxygenation of arachidonic acid.; COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes.; Inhibition of long-chain acyl-CoA synthetase 4 facilitates production of 5, 11-dihydroxyeicosatetraenoic acid via the cyclooxygenase-2 pathway.; Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections.; Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways.; Cyclooxygenases: structural, cellular, and molecular biology.; The essentiality of arachidonic acid and docosahexaenoic acid.; Aspirin, cyclooxygenase inhibition and colorectal cancer.; Crystal structure of rofecoxib bound to human cyclooxygenase-2.; Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry.; Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone.; Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk.",False
HSPA8,P11142,Heat shock cognate 71 kDa protein,MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD,,,"Structure and expression of a human gene coding for a 71 kd heat shock 'cognate' protein.; Molecular and functional characterization of HSC54, a novel variant of human heat shock cognate protein 70.; Complete coding sequence of human HSC70.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes.; Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes.; A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.; A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins.; Intracellular localization and partial amino acid sequence of a stress-inducible 40-kDa protein in HeLa cells.; BAG-1 modulates the chaperone activity of Hsp70/Hsc70.; Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines.; Molecular chaperones as HSF1-specific transcriptional repressors.; HSC70 interactions with SV40 viral proteins differ between permissive and nonpermissive mammalian cells.; The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors.; A molecular chaperone complex at the lysosomal membrane is required for protein translocation.; A CD14-independent LPS receptor cluster.; Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70.; A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death.; Proteomic characterization of the human centrosome by protein correlation profiling.; Small glutamine-rich tetratricopeptide repeat-containing protein is composed of three structural units with distinct functions.; Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.; Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.; HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome.; Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens.; Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.; HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets.; EWI-2/CD316 is an inducible receptor of HSPA8 on human dendritic cells.; HDJC9, a novel human type C DnaJ/HSP40 member interacts with and cochaperones HSP70 through the J domain.; Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase.; Molecular composition of IMP1 ribonucleoprotein granules.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; The human TPR protein TTC4 is a putative Hsp90 co-chaperone which interacts with CDC6 and shows alterations in transformed cells.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A novel ER J-protein DNAJB12 accelerates ER-associated degradation of membrane proteins including CFTR.; Chaperone-assisted selective autophagy is essential for muscle maintenance.; Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha.; Molecular architecture of the human Prp19/CDC5L complex.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; The endoplasmic reticulum-associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate RMA1 E3-dependent degradation of nascent CFTRDeltaF508.; A novel mammalian ER-located J-protein, DNAJB14, can accelerate ERAD of misfolded membrane proteins.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting.; The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex.; The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3.; Identification and characterization of a novel human methyltransferase modulating Hsp70 function through lysine methylation.; Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/c70 protein and the CHIP E3 ligase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy.; The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress.; Degradation of AF1Q by chaperone-mediated autophagy.; Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro.; RING finger protein RNF207, a novel regulator of cardiac excitation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Expression of DNAJB12 or DNAJB14 causes coordinate invasion of the nucleus by membranes associated with a novel nuclear pore structure.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; Structural and functional analysis of Hikeshi, a new nuclear transport receptor of Hsp70s.; N-terminome analysis of the human mitochondrial proteome.; DNAJC21 mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation.; The human HSP70 family of chaperones: where do we stand?; Salivary protein histatin 3 regulates cell proliferation by enhancing p27(Kip1) and heat shock cognate protein 70 ubiquitination.; Non-canonical interactions between heat shock cognate protein 70 (Hsc70) and Bcl2-associated anthanogene (BAG) co-chaperones are important for client release.; ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation.; The human VGF-derived bioactive peptide TLQP-21 binds heat shock 71 kDa protein 8 (HSPA8)on the surface of SH-SY5Y cells.; Tetrameric assembly of K(+) channels requires ER-located chaperone proteins.; ZMYND10 stabilizes intermediate chain proteins in the cytoplasmic pre-assembly of dynein arms.; The Herpes Simplex Virus 1 Immediate Early Protein ICP22 Is a Functional Mimic of a Cellular J Protein.; DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network.; Loss-of-function mutations in the co-chaperone protein BAG5 cause dilated cardiomyopathy requiring heart transplantation.; Palmitoylation prevents sustained inflammation by limiting NLRP3 inflammasome activation through chaperone-mediated autophagy.; A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation.; Electrostatic interactions of Hsp-organizing protein tetratricopeptide domains with Hsp70 and Hsp90: computational analysis and protein engineering.; Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design.; Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity.",False
SIN3A,Q96ST3,Paired amphipathic helix protein Sin3a,MKRRLDDQESPVYAAQQRRIPGSTEAFPHQHRVLAPAPPVYEAVSETMQSATGIQYSVTPSYQVSAMPQSSGSHGPAIAAVHSSHHHPTAVQPHGGQVVQSHAHPAPPVAPVQGQQQFQRLKVEDALSYLDQVKLQFGSQPQVYNDFLDIMKEFKSQSIDTPGVISRVSQLFKGHPDLIMGFNTFLPPGYKIEVQTNDMVNVTTPGQVHQIPTHGIQPQPQPPPQHPSQPSAQSAPAPAQPAPQPPPAKVSKPSQLQAHTPASQQTPPLPPYASPRSPPVQPHTPVTISLGTAPSLQNNQPVEFNHAINYVNKIKNRFQGQPDIYKAFLEILHTYQKEQRNAKEAGGNYTPALTEQEVYAQVARLFKNQEDLLSEFGQFLPDANSSVLLSKTTAEKVDSVRNDHGGTVKKPQLNNKPQRPSQNGCQIRRHPTGTTPPVKKKPKLLNLKDSSMADASKHGGGTESLFFDKVRKALRSAEAYENFLRCLVIFNQEVISRAELVQLVSPFLGKFPELFNWFKNFLGYKESVHLETYPKERATEGIAMEIDYASCKRLGSSYRALPKSYQQPKCTGRTPLCKEVLNDTWVSFPSWSEDSTFVSSKKTQYEEHIYRCEDERFELDVVLETNLATIRVLEAIQKKLSRLSAEEQAKFRLDNTLGGTSEVIHRKALQRIYADKAADIIDGLRKNPSIAVPIVLKRLKMKEEEWREAQRGFNKVWREQNEKYYLKSLDHQGINFKQNDTKVLRSKSLLNEIESIYDERQEQATEENAGVPVGPHLSLAYEDKQILEDAAALIIHHVKRQTGIQKEDKYKIKQIMHHFIPDLLFAQRGDLSDVEEEEEEEMDVDEATGAVKKHNGVGGSPPKSKLLFSNTAAQKLRGMDEVYNLFYVNNNWYIFMRLHQILCLRLLRICSQAERQIEEENREREWEREVLGIKRDKSDSPAIQLRLKEPMDVDVEDYYPAFLDMVRSLLDGNIDSSQYEDSLREMFTIHAYIAFTMDKLIQSIVRQLQHIVSDEICVQVTDLYLAENNNGATGGQLNTQNSRSLLESTYQRKAEQLMSDENCFKLMFIQSQGQVQLTIELLDTEEENSDDPVEAERWSDYVERYMNSDTTSPELREHLAQKPVFLPRNLRRIRKCQRGREQQEKEGKEGNSKKTMENVDSLDKLECRFKLNSYKMVYVIKSEDYMYRRTALLRAHQSHERVSKRLHQRFQAWVDKWTKEHVPREMAAETSKWLMGEGLEGLVPCTTTCDTETLHFVSINKYRVKYGTVFKAP,,,"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors.; Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression.; Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor, and SF-1, a complex that also participates in repression of transcription.; DACH1 inhibits transforming growth factor-beta signaling through binding Smad4.; Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1.; Identification and characterization of three new components of the mSin3A corepressor complex.; Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus.; CR/periphilin is a transcriptional co-repressor involved in cell cycle progression.; TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Haploinsufficiency of MeCP2-interacting transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical integrity.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Novel SIN3A mutation identified in a Japanese patient with Witteveen-Kolk syndrome.",False
CDK1,P06493,Cyclin-dependent kinase 1,MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM,,,"Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2.; T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement.; Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis.; Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C.; Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15.; The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2.; Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.; RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis.; Proteomic characterization of the human centrosome by protein correlation profiling.; Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region.; Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation.; Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1.; Cks1 regulates cdk1 expression: a novel role during mitotic entry in breast cancer cells.; TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells.; Microtubule deacetylases, SirT2 and HDAC6, in the nervous system.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Rapid cycling and precocious termination of G1 phase in cells expressing CDK1AF.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons.; Human CtIP mediates cell cycle control of DNA end resection and double strand break repair.; Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Mitotic phosphorylation of Aki1 at Ser208 by cyclin B1-Cdk1 complex.; New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses.; The protein kinase Cdelta catalytic fragment is critical for maintenance of the G2/M DNA damage checkpoint.; Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition.; Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.; Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity.; Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance.; CAMP (C13orf8, ZNF828) is a novel regulator of kinetochore-microtubule attachment.; Mammalian cyclin-dependent kinases.; The decision to enter mitosis: feedback and redundancy in the mitotic entry network.; Cell cycle, CDKs and cancer: a changing paradigm.; Cdc2: a monopotent or pluripotent CDK?; Cyclin dependent kinase 1 inhibitors: a review of recent progress.; Checkpoint recovery in cells: how a molecular understanding can help in the fight against cancer.; EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1.; The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation.; Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Ki67 antigen contributes to the timely accumulation of protein phosphatase 1gamma on anaphase chromosomes.; Phosphorylation of the centrosomal protein, Cep169, by Cdk1 promotes its dissociation from centrosomes in mitosis.; Dynamic phosphorylation of CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at centromeres.; N-terminome analysis of the human mitochondrial proteome.; Circadian amplitude regulation via FBXW7-targeted REV-ERBalpha degradation.; Nbs1 converts the human Mre11/Rad50 nuclease complex into an endo/exonuclease machine specific for protein-DNA adducts.; Acetylation of Aurora B by TIP60 ensures accurate chromosomal segregation.; Ska3 Phosphorylated by Cdk1 Binds Ndc80 and Recruits Ska to Kinetochores to Promote Mitotic Progression.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Homozygous Mutations in WEE2 Cause Fertilization Failure and Female Infertility.; An intrinsic S/G2 checkpoint enforced by ATR.; Molecular determinants of the Ska-Ndc80 interaction and their influence on microtubule tracking and force-coupling.; The microtubule-associated protein EML3 regulates mitotic spindle assembly by recruiting the Augmin complex to spindle microtubules.; Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of autophagosome maturation and lipid metabolism.; Phosphorylation of cGAS by CDK1 impairs self-DNA sensing in mitosis.; The Severe Fever with Thrombocytopenia Syndrome Virus NSs Protein Interacts with CDK1 To Induce G2 Cell Cycle Arrest and Positively Regulate Viral Replication.; Multisite phosphorylation determines the formation of Ska-Ndc80 macro-complexes that are essential for chromosome segregation during mitosis.; CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.; ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei.",False
TFDP1,Q14186,Transcription factor Dp-1,MAKDAGLIEANGELKVFIDQNLSPGKGVVSLVAVHPSTVNPLGKQLLPKTFGQSNVNIAQQVVIGTPQRPAASNTLVVGSPHTPSTHFASQNQPSDSSPWSAGKRNRKGEKNGKGLRHFSMKVCEKVQRKGTTSYNEVADELVAEFSAADNHILPNESAYDQKNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSAQECQNLEVERQRRLERIKQKQSQLQELILQQIAFKNLVQRNRHAEQQASRPPPPNSVIHLPFIIVNTSKKTVIDCSISNDKFEYLFNFDNTFEIHDDIEVLKRMGMACGLESGSCSAEDLKMARSLVPKALEPYVTEMAQGTVGGVFITTAGSTSNGTRFSASDLTNGADGMLATSSNGSQYSGSRVETPVSYVGEDDEEDDDFNENDEDD,,,"Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein.; In vivo association of E2F and DP family proteins.; A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells.; Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.",False
DDIT3,P0DPQ6,DDIT3 upstream open reading frame protein,MLKMSGWQRQSQNQSWNLRRECSRRKCIFIHHHT,,,The finished DNA sequence of human chromosome 12.; Deep transcriptome annotation enables the discovery and functional characterization of cryptic small proteins.,False
POLA1,P09884,DNA polymerase alpha catalytic subunit,MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYEVEDFTGVYEEVDEEQYSKLVQARQDDDWIVDDDGIGYVEDGREIFDDDLEDDALDADEKGKDGKARNKDKRNVKKLAVTKPNNIKSMFIACAGKKTADKAVDLSKDGLLGDILQDLNTETPQITPPPVMILKKKRSIGASPNPFSVHTATAVPSGKIASPVSRKEPPLTPVPLKRAEFAGDDVQVESTEEEQESGAMEFEDGDFDEPMEVEEVDLEPMAAKAWDKESEPAEEVKQEADSGKGTVSYLGSFLPDVSCWDIDQEGDSSFSVQEVQVDSSHLPLVKGADEEQVFHFYWLDAYEDQYNQPGVVFLFGKVWIESAETHVSCCVMVKNIERTLYFLPREMKIDLNTGKETGTPISMKDVYEEFDEKIATKYKIMKFKSKPVEKNYAFEIPDVPEKSEYLEVKYSAEMPQLPQDLKGETFSHVFGTNTSSLELFLMNRKIKGPCWLEVKSPQLLNQPVSWCKVEAMALKPDLVNVIKDVSPPPLVVMAFSMKTMQNAKNHQNEIIAMAALVHHSFALDKAAPKPPFQSHFCVVSKPKDCIFPYAFKEVIEKKNVKVEVAATERTLLGFFLAKVHKIDPDIIVGHNIYGFELEVLLQRINVCKAPHWSKIGRLKRSNMPKLGGRSGFGERNATCGRMICDVEISAKELIRCKSYHLSELVQQILKTERVVIPMENIQNMYSESSQLLYLLEHTWKDAKFILQIMCELNVLPLALQITNIAGNIMSRTLMGGRSERNEFLLLHAFYENNYIVPDKQIFRKPQQKLGDEDEEIDGDTNKYKKGRKKAAYAGGLVLDPKVGFYDKFILLLDFNSLYPSIIQEFNICFTTVQRVASEAQKVTEDGEQEQIPELPDPSLEMGILPREIRKLVERRKQVKQLMKQQDLNPDLILQYDIRQKALKLTANSMYGCLGFSYSRFYAKPLAALVTYKGREILMHTKEMVQKMNLEVIYGDTDSIMINTNSTNLEEVFKLGNKVKSEVNKLYKLLEIDIDGVFKSLLLLKKKKYAALVVEPTSDGNYVTKQELKGLDIVRRDWCDLAKDTGNFVIGQILSDQSRDTIVENIQKRLIEIGENVLNGSVPVSQFEINKALTKDPQDYPDKKSLPHVHVALWINSQGGRKVKAGDTVSYVICQDGSNLTASQRAYAPEQLQKQDNLTIDTQYYLAQQIHPVVARICEPIDGIDAVLIATWLGLDPTQFRVHHYHKDEENDALLGGPAQLTDEEKYRDCERFKCPCPTCGTENIYDNVFDGSGTDMEPSLYRCSNIDCKASPLTFTVQLSNKLIMDIRRFIKKYYDGWLICEEPTCRNRTRHLPLQFSRTGPLCPACMKATLQPEYSDKSLYTQLCFYRYIFDAECALEKLTTDHEKDKLKKQFFTPKVLQDYRKLKNTAEQFLSRSGYSEVNLSKLFAGCAVKS,,,"Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases.; Human DNA polymerase alpha gene: sequences controlling expression in cycling and serum-stimulated cells.; Human DNA polymerase alpha catalytic polypeptide binds ConA and RCA and contains a specific labile site in the N-terminus.; DNA polymerase-alpha. Purification and structural characterization of the near homogeneous enzyme from human KB cells.; T-antigen-DNA polymerase alpha complex implicated in simian virus 40 DNA replication.; Interaction of herpes simplex virus 1 origin-binding protein with DNA polymerase alpha.; Role of protein-protein interactions in the function of replication protein A (RPA): RPA modulates the activity of DNA polymerase alpha by multiple mechanisms.; Primase activity of human DNA polymerase alpha-primase. Divalent cations stabilize the enzyme activity of the p48 subunit.; Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication.; A quantitative atlas of mitotic phosphorylation.; Physical interactions between Mcm10, DNA, and DNA polymerase alpha.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; DNA polymerase-alpha regulates the activation of type I interferons through cytosolic RNA:DNA synthesis.; Nuclear magnetic resonance structures of the zinc finger domain of human DNA polymerase-alpha.; Mechanism of Concerted RNA-DNA Primer Synthesis by the Human Primosome.; Defective DNA Polymerase alpha-Primase Leads to X-Linked Intellectual Disability Associated with Severe Growth Retardation, Microcephaly, and Hypogonadism.",False
MAPT,P10636,Microtubule-associated protein tau,MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL,,,"Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.; Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.; The microtubule binding domain of tau protein.; Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.; Structure and novel exons of the human tau gene.; Cloning of tau-related genes.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain.; Molecular interactions of recombinant neural protein tau with recombinant and native PrP proteins in vitro.; Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.; Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262.; A distinct form of tau is selectively incorporated into Alzheimer's paired helical filaments.; A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.; Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer's disease.; The role of tau (MAPT) in frontotemporal dementia and related tauopathies.; Molecular characterization of microtubule-associated proteins tau and MAP2.; The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase.; Characterization of in vitro glycation sites of tau.; Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.; The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.; Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.; Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules.; Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules.; Phosphorylation of tau by fyn: implications for Alzheimer's disease.; Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.; Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.; Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.; Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.; Role for DYRK family kinases on regulation of apoptosis.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.; Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.; Phosphorylation of microtubule-associated protein tau by AMPK-related kinases.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Role of individual MARK isoforms in phosphorylation of tau at Ser262 in Alzheimer's disease.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; LRRK2 Promotes Tau Accumulation, Aggregation and Release.; LRP1 is a master regulator of tau uptake and spread.; 1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides.; A Translocation Pathway for Vesicle-Mediated Unconventional Protein Secretion.; Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease.; Tau is a candidate gene for chromosome 17 frontotemporal dementia.; Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism.; Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.; Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.; A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.; High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.; FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation.; Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.; Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau.; Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits.; A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration.; Mutational analysis of the tau gene in progressive supranuclear palsy.; A distinct familial presenile dementia with a novel missense mutation in the tau gene.; Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation.; Pick's disease is associated with mutations in the tau gene.; Tau gene mutation K257T causes a tauopathy similar to Pick's disease.; Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene.; A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation.; Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells.; Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene.; Pick's disease associated with the novel Tau gene mutation K369I.; Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes.; Clinical and genetic studies of families with the tau N279K mutation (FTDP-17).; A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease.; Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.; An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.; Functional effects of tau gene mutations deltaN296 and N296H.; Early-onset, rapidly progressive familial tauopathy with R406W mutation.; A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology.; An English kindred with a novel recessive tauopathy and respiratory failure.; Tau (MAPT) mutation arg406trp presenting clinically with Alzheimer disease does not share a common founder in western Europe.; Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene.; Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy.; Phenotypic heterogeneity within a new family with the MAPT P301S mutation.; A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy.; A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease.; A thorough assessment of benign genetic variability in GRN and MAPT.; Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance of a unique mutation.; Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.",False
CTGF,P29279,CCN family member 2,MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA,,,"Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.; Connective tissue growth factor.; Human connective tissue growth factor is expressed in advanced atherosclerotic lesions.; Expression, purification and bio-activity of human connective tissue growth factor.; Complete mRNA sequence of human connective tissue growth factor.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and analysis of human chromosome 6.; Differential expression of novH and CTGF in human glioma cell lines.; Identification of human CCN2 (connective tissue growth factor) promoter polymorphisms.; Connective tissue growth factor mRNA is expressed in human keratinocytes as an immediate early gene that responds to serum, EGF, or wounding.; Expression of a gene encoding a novel potential IGF binding protein in human tissues.; Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture.; The heparin-binding 10 kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion.; CCN2/CTGF binds the small leucine rich proteoglycan protein Tsukushi.; A monoallelic variant in CCN2 causes an autosomal dominant spondyloepimetaphyseal dysplasia with low bone mass.; Biallelic variants in CCN2 underlie an autosomal recessive kyphomelic dysplasia.",False
HDAC2,Q92769,Histone deacetylase 2,MAYSQGGGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLPHAPGVQMQAIPEDAVHEDSGDEDGEDPDKRISIRASDKRIACDEEFSDSEDEGEGGRRNVADHKKGAKKARIEEDKKETEDKKTDVKEEDKSKDNSGEKTDTKGTKSEQLSNP,,,"Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular association between ATR and two components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4.; A role for SKIP in EBNA2 activation of CBF1-repressed promoters.; DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci.; NuRD and SIN3 histone deacetylase complexes in development.; Sharp, an inducible cofactor that integrates nuclear receptor repression and activation.; ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.; Isolation and characterization of a novel class II histone deacetylase, HDAC10.; The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2.; Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek.; Acetylation inactivates the transcriptional repressor BCL6.; Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene.; Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1.; A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes.; Identification and characterization of three new components of the mSin3A corepressor complex.; The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains.; Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibition.; MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing.; Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties.; SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation.; CtBP is an essential corepressor for BCL6 autoregulation.; A quantitative atlas of mitotic phosphorylation.; RCS1, a substrate of APC/C, controls the metaphase to anaphase transition.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription.; FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4.; Chfr is linked to tumour metastasis through the downregulation of HDAC1.; Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; CDK2AP1/DOC-1 is a bona fide subunit of the Mi-2/NuRD complex.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.; A BEN-domain-containing protein associates with heterochromatin and represses transcription.; Maintenance of silent chromatin through replication requires SWI/SNF-like chromatin remodeler SMARCAD1.; Nuclear cGMP-dependent kinase regulates gene expression via activity-dependent recruitment of a conserved histone deacetylase complex.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; The subcellular distribution and function of MTA1 in cancer differentiation.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality.; Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation pathway.; The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically.; Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex.; Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.; Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.; Mechanism of assembly, activation and lysine selection by the SIN3B histone deacetylase complex.",False
MAX,P61244,Protein max,MSDNDDIEVESDEEQPRFQSAADKRAHHNALERKRRDHIKDSFHSLRDSVPSLQGEKASRAQILDKATEYIQYMRRKNHTHQQDIDDLKRQNALLEQQVRALEKARSSAQLQTNYPSSDNSLYTNAKGSTISAFDGGSDSSSESEPEEPQSRKKLRMEAS,,,"Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.; Alternative mRNA forms and open reading frames of the max gene.; Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells.; An unappreciated role for RNA surveillance.; Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Max is acetylated by p300 at several nuclear localization residues.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.; Functional and in silico assessment of MAX variants of unknown significance.; Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain.; The crystal structure of an intact human Max-DNA complex: new insights into mechanisms of transcriptional control.; A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes.",False
MXD1,Q05195,Max dimerization protein 1,MAAAVRMNIQMLLEAADYLERREREAEHGYASMLPYNNKDRDALKRRNKSKKNNSSSRSTHNEMEKNRRAHLRLCLEKLKGLVPLGPESSRHTTLSLLTKAKLHIKKLEDCDRKAVHQIDQLQREQRHLKRQLEKLGIERIRMDSIGSTVSSERSDSDREEIDVDVESTDYLTGDLDWSSSSVSDSDERGSMQSLGSDEGYSSTSIKRIKLQDSHKACLGL,,,"Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Multiple tumor suppressor pathways negatively regulate telomerase.; c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1.",False
MDM2,Q00987,E3 ubiquitin-protein ligase Mdm2,MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP,,,"Amplification of a gene encoding a p53-associated protein in human sarcomas.; Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.; A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein.; Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The finished DNA sequence of human chromosome 12.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A functional p53-responsive intronic promoter is contained within the human mdm2 gene.; Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.; Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs.; A MboII polymorphism in exon 11 of the human MDM2 gene occurring in normal blood donors and in soft tissue sarcoma patients: an indication for an increased cancer susceptibility?; Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.; Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.; Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.; Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.; Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.; Identification of a cryptic nucleolar-localization signal in MDM2.; Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.; Hypophosphorylation of Mdm2 augments p53 stability.; A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.; Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.; Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.; A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.; Negative regulation of p53 functions by Daxx and the involvement of MDM2.; A dynamic role of HAUSP in the p53-Mdm2 pathway.; PML regulates p53 stability by sequestering Mdm2 to the nucleolus.; {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.; WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.; MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.; Regulation of p53 and MDM2 activity by MTBP.; A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.; Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.; Critical role for Daxx in regulating Mdm2.; CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway.; The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.; The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.; A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.; PACT is a negative regulator of p53 and essential for cell growth and embryonic development.; CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2.; The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex.; ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.; RYBP stabilizes p53 by modulating MDM2.; MTA1 coregulator regulates p53 stability and function.; Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation.; Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway.; Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.; ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.; Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.; RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.; MdmX is a substrate for the deubiquitinating enzyme USP2a.; Notch1 binds and induces degradation of Snail in hepatocellular carcinoma.; Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2.; The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.; Nucleolar GTP-binding protein-1 (NGP-1) promotes G1 to S phase transition by activating cyclin-dependent kinase inhibitor p21 Cip1/Waf1.; F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress.; A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity.; MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network.; Dysfunction of the MDM2/p53 axis is linked to premature aging.; Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.; Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.; Molecular recognition of p53 and MDM2 by USP7/HAUSP.; Structure of nascent 5S RNPs at the crossroad between ribosome assembly and MDM2-p53 pathways.",False
SUMO1,P63165,Small ubiquitin-related modifier 1,MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV,,,"SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family.; PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia.; UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins.; A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2.; A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex.; Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin.; Identification of immuno-peptidmics that are recognized by tumor-reactive CTL generated from TIL of colon cancer patients.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Preferential modification of nuclear proteins by a novel ubiquitin-like molecule.; Cell cycle regulation of PML modification and ND10 composition.; Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif.; Molecular features of human ubiquitin-like SUMO genes and their encoded proteins.; Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.; The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.; Non-covalent interaction between nucleocapsid protein of Tula hantavirus and small ubiquitin-related modifier-1, SUMO-1.; The intracellular association of the nucleocapsid protein (NP) of hantaan virus (HTNV) with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9).; Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1.; Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Functional modulation of parkin through physical interaction with SUMO-1.; SUMO1 haploinsufficiency leads to cleft lip and palate.; RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia.; Phosphorylation of SUMO-1 occurs in vivo and is conserved through evolution.; Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SUMOylation regulates Kv2.1 and modulates pancreatic beta-cell excitability.; In vivo identification of sumoylation sites by a signature tag and cysteine-targeted affinity purification.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.; SUMOylation of DEC1 protein regulates its transcriptional activity and enhances its stability.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.; PolySUMO-binding proteins identified through a string search.; SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Characterization of nuclear localization and SUMOylation of the ATBF1 transcription factor in epithelial cells.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Transcription Factor hDREF Is a Novel SUMO E3 Ligase of Mi2alpha.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Structure determination of the small ubiquitin-related modifier SUMO-1.; A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex.; Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1.; Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation.; Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex.; Crystal structure of thymine DNA glycosylase conjugated to SUMO-1.; SUMO modification of the ubiquitin-conjugating enzyme E2-25K.; Crystal structure of the SENP1 mutant C603S-SUMO complex reveals the hydrolytic mechanism of SUMO-specific protease.; SUMO protease SENP1 induces isomerization of the scissile peptide bond.",False
H2AFX,P16104,Histone H2AX,MSGRGKTGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGHYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGGVTIAQGGVLPNIQAVLLPKKTSATVGPKAPSGGKKATQASQEY,,,"H2A.X. a histone isoprotein with a conserved C-terminal sequence, is encoded by a novel mRNA with both DNA replication type and polyA 3' processing signals.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.; Megabase chromatin domains involved in DNA double-strand breaks in vivo.; A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.; Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139.; Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress.; NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain.; Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX.; Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.; MDC1 is a mediator of the mammalian DNA damage checkpoint.; DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner.; ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.; Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention.; Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species.; Actinomycin D induces histone gamma-H2AX foci and complex formation of gamma-H2AX with Ku70 and nuclear DNA helicase II.; gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair.; Novel function of beta-arrestin2 in the nucleus of mature spermatozoa.; RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins.; RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly.; DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage.; RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins.; WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity.; Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA Damage signaling.; Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Acetylation of histone H2AX at Lys 5 by the TIP60 histone acetyltransferase complex is essential for the dynamic binding of NBS1 to damaged chromatin.; The proximity ligation assay reveals that at DNA double-strand breaks WRAP53beta associates with gammaH2AX and controls interactions between RNF8 and MDC1.; Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Phosphorylation of the Cajal body protein WRAP53beta by ATM promotes its involvement in the DNA damage response.; VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.; LncRNA CTBP1-DT-encoded microprotein DDUP sustains DNA damage response signalling to trigger dual DNA repair mechanisms.; Specific recognition of phosphorylated tail of H2AX by the tandem BRCT domains of MCPH1 revealed by complex structure.",False
HOXB7,P09629,Homeobox protein Hox-B7,MSSLYYANTLFSKYPASSSVFATGAFPEQTSCAFASNPQRPGYGAGSGASFAASMQGLYPGGGGMAGQSAAGVYAAGYGLEPSSFNMHCAPFEQNLSGVCPGDSAKAAGAKEQRDSDLAAESNFRIYPWMRSSGTDRKRGRQTYTRYQTLELEKEFHYNRYLTRRRRIEIAHTLCLTERQIKIWFQNRRMKWKKENKTAGPGTTGQDRAEAEEEEEE,,,"Two human homeobox genes, c1 and c8: structure analysis and expression in embryonic development.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Lymphoid expression and TATAA binding of a human protein containing an Antennapedia homeodomain.; Lineage-restricted expression of homeobox-containing genes in human hematopoietic cell lines.; Organization of human class I homeobox genes.; Both Pbx1 and E2A-Pbx1 bind the DNA motif ATCAATCAA cooperatively with the products of multiple murine Hox genes, some of which are themselves oncogenes.; The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - evidence for selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements.",False
HOXC4,P09017,Homeobox protein Hox-C4,MIMSSYLMDSNYIDPKFPPCEEYSQNSYIPEHSPEYYGRTRESGFQHHHQELYPPPPPRPSYPERQYSCTSLQGPGNSRGHGPAQAGHHHPEKSQSLCEPAPLSGASASPSPAPPACSQPAPDHPSSAASKQPIVYPWMKKIHVSTVNPNYNGGEPKRSRTAYTRQQVLELEKEFHYNRYLTRRRRIEIAHSLCLSERQIKIWFQNRRMKWKKDHRLPNTKVRSAPPAGAAPSTLSAATPGTSEDHSQSATPPEQQRAEDITRL,,,At least three human homeoboxes on chromosome 12 belong to the same transcription unit.; Complete mutation analysis panel of the 39 human HOX genes.; The finished DNA sequence of human chromosome 12.; Organization of human class I homeobox genes.,False
JAK2,O60674,Tyrosine-protein kinase JAK2,MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKSEADYLTFPSGEYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYFPRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLGMAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQFSQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSRGKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLREALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQTGLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG,,,"Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue.; Cloning and characterization of the human homolog of mouse Jak2.; Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.; DNA sequence and analysis of human chromosome 9.; The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors.; Interaction between the components of the interferon gamma receptor complex.; Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors.; The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity.; STAM2, a new member of the STAM family, binding to the Janus kinases.; A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.; The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.; PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.; The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.; A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.; Janus kinases affect thrombopoietin receptor cell surface localization and stability.; A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.; JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.; Heme controls the regulation of protein tyrosine kinases Jak2 and Src.; Stat1 mediates an auto-regulation of hsp90beta gene in heat shock response.; The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure.; Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control.; Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses.; Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-dependent gene expression?; Janus kinases in immune cell signaling.; Notch-induced Asb2 expression promotes protein ubiquitination by forming non-canonical E3 ligase complexes.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development.; SOCS2 negatively regulates growth hormone action in vitro and in vivo.; The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.; Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.; Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.; A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.; A gain-of-function mutation of JAK2 in myeloproliferative disorders.; Case records of the Massachusetts General Hospital. Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention.; The JAK2 V617F mutation in de novo acute myelogenous leukemias.; The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.; JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.; Patterns of somatic mutation in human cancer genomes.; Germline JAK2 mutation in a family with hereditary thrombocytosis.; Up-regulation of Kv1.3 channels by janus kinase 2.",False
ESR1,P03372,Estrogen receptor,MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV,,,"Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A.; Sequence and expression of human estrogen receptor complementary DNA.; A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7.; The full-ORF clone resource of the German cDNA consortium.; Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor.; Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility.; Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines.; Mechanisms of acquired tamoxifen resistance in a xenotransplanted human breast carcinoma.; Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro.; Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation.; Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II).; Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor.; Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta.; A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action.; Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha.; Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1.; Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain.; Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.; Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells.; A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine.; Functional synergy between the transcription factor Sp1 and the estrogen receptor.; Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action.; Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex.; A nuclear factor ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo.; An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens.; Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2.; Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.; Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins.; Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein.; Characterization of the physical interaction between estrogen receptor alpha and JUN proteins.; Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription.; Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.; CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant.; Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.; Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha.; Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor.; ERAP140, a conserved tissue-specific nuclear receptor coactivator.; A negative coregulator for the human ER.; Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.; BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation.; ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor.; The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell.; An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling.; Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc.; Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription.; Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor kappaB transactivation.; Functional regulation of oestrogen receptor pathway by the dynein light chain 1.; The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1.; Identification of the MLL2 complex as a coactivator for estrogen receptor alpha.; Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells.; MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.; WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors.; ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases.; MTA1, a transcriptional activator of breast cancer amplified sequence 3.; An inherent role of microtubule network in the action of nuclear receptor.; The NMDAR subunit NR3A interacts with microtubule-associated protein 1S in the brain.; CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.; Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor's transcriptional activity.; MS-KIF18A, a kinesin, is associated with estrogen receptor.; PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.; Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1).; Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor alpha.; ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.; ERalpha and AP-1 interact in vivo with a specific sequence of the F promoter of the human ERalpha gene in osteoblasts.; Regulation of estrogen rapid signaling through arginine methylation by PRMT1.; CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor.; MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.; ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells.; SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC pathway.; Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.; Functional interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal pathways in dyslexia.; NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.; OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity.; CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions.; The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.; The regulation of MS-KIF18A expression and cross talk with estrogen receptor.; The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.; Repression of estrogen receptor beta function by putative tumor suppressor DBC1.; Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.; ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.; Modulation of ER alpha transcriptional activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long- and short-form splice variants.; Mammalian MST2 kinase and human Salvador activate and reduce estrogen receptor alpha in the absence of ligand.; Splice isoform estrogen receptors as integral transmembrane proteins.; Multiple sequence-specific DNA-binding proteins mediate estrogen receptor signaling through a tethering pathway.; Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.; DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors.; CBP mediates NF-kappaB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.; CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the transcriptional activity of estrogen receptor-alpha.; DNA homologous recombination factor SFR1 physically and functionally interacts with estrogen receptor alpha.; Modification of ASC1 by UFM1 is crucial for ERalpha transactivation and breast cancer development.; JMJD6 regulates ERalpha methylation on arginine.; The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERalpha.; UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.; Solution structure of the DNA-binding domain of the oestrogen receptor.; The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements.; Molecular basis of agonism and antagonism in the oestrogen receptor.; Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains.; The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.; Homology model for the ligand-binding domain of the human estrogen receptor.; The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties.; Screening for ESR mutations in breast and ovarian cancer patients.; Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women.; G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells.; Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas.; Delayed puberty and estrogen resistance in a woman with estrogen receptor alpha variant.; Familial multiplicity of estrogen insensitivity associated with a loss-of-function ESR1 mutation.",False
LEP,P41159,Leptin,MHWGTLCGFLWLWPYLFYVQAVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC,,,"Positional cloning of the mouse obese gene and its human homologue.; Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue.; Genomic structure and promoter analysis of the human obese gene.; Structural organization and chromosomal assignment of the human obese gene.; Human obese gene: molecular screening in Japanese and Asian Indian NIDDM patients associated with obesity.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.; OB-BP1/Siglec-6. A leptin- and sialic acid-binding protein of the immunoglobulin superfamily.; Leptin secretion and leptin receptor in the human stomach.; Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.; Intralobular ducts of human major salivary glands contain leptin and its receptor.; Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines.; The weight of leptin in immunity.; signaling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1.; Leptin expression in human primary skeletal muscle cells is reduced during differentiation.; leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3.; up-regulation of survivin by leptin/STAT3 signaling in MCF-7 cells.; Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production.; Leptin inhibits glucose intestinal absorption via PKC, p38MAPK, PI3K and MEK/ERK.; 20 years of leptin: connecting leptin signaling to biological function.; Leptin modulates autophagy in human CD4+CD25- conventional T cells.; Leptin is a four-helix bundle: secondary structure by NMR.; Crystal structure of the obese protein leptin-E100.; A novel polymorphism in the leptin gene.; A leptin missense mutation associated with hypogonadism and morbid obesity.; Biologically inactive leptin and early-onset extreme obesity.",False
LEPR,P48357,Leptin receptor,MICQKFCVVLLHWEFIYVITAFNLSYPITPWRFKLSCMPPNSTYDYFLLPAGLSKNTSNSNGHYETAVEPKFNSSGTHFSNLSKTTFHCCFRSEQDRNCSLCADNIEGKTFVSTVNSLVFQQIDANWNIQCWLKGDLKLFICYVESLFKNLFRNYNYKVHLLYVLPEVLEDSPLVPQKGSFQMVHCNCSVHECCECLVPVPTAKLNDTLLMCLKITSGGVIFQSPLMSVQPINMVKPDPPLGLHMEITDDGNLKISWSSPPLVPFPLQYQVKYSENSTTVIREADKIVSATSLLVDSILPGSSYEVQVRGKRLDGPGIWSDWSTPRVFTTQDVIYFPPKILTSVGSNVSFHCIYKKENKIVPSKEIVWWMNLAEKIPQSQYDVVSDHVSKVTFFNLNETKPRGKFTYDAVYCCNEHECHHRYAELYVIDVNINISCETDGYLTKMTCRWSTSTIQSLAESTLQLRYHRSSLYCSDIPSIHPISEPKDCYLQSDGFYECIFQPIFLLSGYTMWIRINHSLGSLDSPPTCVLPDSVVKPLPPSSVKAEITINIGLLKISWEKPVFPENNLQFQIRYGLSGKEVQWKMYEVYDAKSKSVSLPVPDLCAVYAVQVRCKRLDGLGYWSNWSNPAYTVVMDIKVPMRGPEFWRIINGDTMKKEKNVTLLWKPLMKNDSLCSVQRYVINHHTSCNGTWSEDVGNHTKFTFLWTEQAHTVTVLAINSIGASVANFNLTFSWPMSKVNIVQSLSAYPLNSSCVIVSWILSPSDYKLMYFIIEWKNLNEDGEIKWLRISSSVKKYYIHDHFIPIEKYQFSLYPIFMEGVGKPKIINSFTQDDIEKHQSDAGLYVIVPVIISSSILLLGTLLISHQRMKKLFWEDVPNPKNCSWAQGLNFQKPETFEHLFIKHTASVTCGPLLLEPETISEDISVDTSWKNKDEMMPTTVVSLLSTTDLEKGSVCISDQFNSVNFSEAEGTEVTYEDESQRQPFVKYATLISNSKPSETGEEQGLINSSVTKCFSSKNSPLKDSFSNSSWEIEAQAFFILSDQHPNIISPHLTFSEGLDELLKLEGNFPEENNDKKSIYYLGVTSIKKRESGVLLTDKSRVSCPFPAPCLFTDIRVLQDSCSHFVENNINLGTSSKKTFASYMPQFQTCSTQTHKIMENKMCDLTV,,,"Identification and expression cloning of a leptin receptor, OB-R.; A role for leptin and its cognate receptor in hematopoiesis.; Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction.; Structure and sequence variation at the human leptin receptor gene in lean and obese Pima Indians.; Cloning and characterization of a human leptin receptor using a biologically active leptin immunoadhesin.; A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction.; The long terminal repeat of an endogenous retrovirus induces alternative splicing and encodes an additional carboxy-terminal sequence in the human leptin receptor.; Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob receptor.; Human leptin receptor. Determination of disulfide structure and N-glycosylation sites of the extracellular domain.; Leptin secretion and leptin receptor in the human stomach.; Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines.; Leptin expression in human primary skeletal muscle cells is reduced during differentiation.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; 20 years of leptin: connecting leptin signaling to biological function.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Leptin modulates autophagy in human CD4+CD25- conventional T cells.; Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody.; The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations.; Amino acid variants in the human leptin receptor: lack of association to juvenile onset obesity.; Exonic and intronic sequence variation in the human leptin receptor gene (LEPR).; Leptin receptor gene variation and obesity: lack of association in a white British male population.; Transmission disequilibrium and sequence variants at the leptin receptor gene in extremely obese German children and adolescents.; DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.; Seven novel deleterious LEPR mutations found in early-onset obesity: a DeltaExon6-8 shared by subjects from Reunion Island, France, suggests a founder effect.",False
NFKBIA,P25963,NF-kappa-B inhibitor alpha,MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL,,,"Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity.; Clonal deleterious mutations in the IkappaB alpha gene in the malignant cells in Hodgkin's lymphoma.; Homo sapiens IkBa mRNA.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding.; Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli.; Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway.; Signal-induced degradation of IkappaB alpha requires site-specific ubiquitination.; Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation.; Tyrosine phosphorylation of IkappaB-alpha activates NF-kappaB without proteolytic degradation of IkappaB-alpha.; Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.; Site-specific tyrosine phosphorylation of IkappaBalpha negatively regulates its inducible phosphorylation and degradation.; Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation.; Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation.; Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability.; Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences.; IKAP is a scaffold protein of the IkappaB kinase complex.; A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis.; A complex containing betaTrCP recruits Cdc34 to catalyse ubiquitination of IkappaBalpha.; Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha.; Immunosuppressant FK506 activates NF-kappaB through the proteasome-mediated degradation of IkappaBalpha. Requirement for Ikappabalpha n-terminal phosphorylation but not ubiquitination sites.; Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha.; Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination.; IKK epsilon is part of a novel PMA-inducible IkappaB kinase complex.; NAK is an IkappaB kinase-activating kinase.; A subclass of Ras proteins that regulate the degradation of IkappaB.; A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes.; SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.; Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex.; Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis.; Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH).; RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia.; The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment.; Priming and extending: a UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate.; The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism functions.; In silico structural and functional characterization of the RSUME splice variants.; DDRGK1 regulates NF-kappaB activity by modulating IkappaBalpha stability.; FAM76B regulates NF-kappaB-mediated inflammatory pathway by influencing the translocation of hnRNPA2B1.; USP39 Regulates NF-kappaB-Mediated Inflammatory Responses through Deubiquitinating K48-Linked IkappaBalpha.; Structure of an IkappaBalpha/NF-kappaB complex.; The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation.; A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.; A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency.",False
CLU,P10909,Clusterin,MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE,,,"Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.; Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration.; Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-kappaB signaling pathway.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Full-length cDNA libraries and normalization.; The full-ORF clone resource of the German cDNA consortium.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis.; Purification and characterization of apolipoprotein J.; The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.; A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes.; HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing.; Apolipoprotein J: structure and tissue distribution.; Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death.; Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems.; SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges.; Identification of human aging-associated gene.; The apolipoprotein A-I binding protein of placenta and the SP-40,40 protein of human blood are different proteins which both bind to apolipoprotein A-I.; Identification of the disulfide bonds in human plasma protein SP-40,40 (apolipoprotein-J).; Apolipoprotein J is associated with paraoxonase in human plasma.; Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin.; Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.; Identification and characterization of glycosylation sites in human serum clusterin.; Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state.; Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin.; Mildly acidic pH activates the extracellular molecular chaperone clusterin.; Synthesis and functional analyses of nuclear clusterin, a cell death protein.; Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity.; Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.; Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer.; Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Clusterin inhibits apoptosis by interacting with activated Bax.; Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection.; Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.; Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach.; Effects of glycosylation on the structure and function of the extracellular chaperone clusterin.; Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.; Characterization of an eppin protein complex from human semen and spermatozoa.; The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures.; Differential regulation of clusterin and its isoforms by androgens in prostate cells.; The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species.; Clusterin expression in normal mucosa and colorectal cancer.; Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol.; Identification of N-linked glycoproteins in human milk by hydrophilic interaction liquid chromatography and mass spectrometry.; Structural characterization of clusterin-chaperone client protein complexes.; Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; Enrichment of glycopeptides for glycan structure and attachment site identification.; Identification of human plasma proteins as major clients for the extracellular chaperone clusterin.; Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.; Clusterin facilitates in vivo clearance of extracellular misfolded proteins.; Human nuclear clusterin mediates apoptosis by interacting with Bcl-XL through C-terminal coiled coil domain.; GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.; The chaperone activity of clusterin is dependent on glycosylation and redox environment.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway.; Structural basis of soluble membrane attack complex packaging for clearance.",False
MTOR,P42345,Serine/threonine-protein kinase mTOR,MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW,,,"A mammalian protein targeted by G1-arresting rapamycin-receptor complex.; Molecular cloning and expression analysis of five novel genes in chromosome 1p36.; Preparation of a set of expression-ready clones of mammalian long cDNAs encoding large proteins by the ORF trap cloning method.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3.; RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.; Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells.; Characterization of ubiquilin 1, an mTOR-interacting protein.; mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the growth machinery.; Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.; The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase.; Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin.; Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.; FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction.; TSC2 mediates cellular energy response to control cell growth and survival.; GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.; Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.; Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.; FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus.; Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.; Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.; Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.; Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.; The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.; PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.; PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.; mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).; SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth.; Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.; DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.; Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.; Large-scale proteomics analysis of the human kinome.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; mTOR phosphorylated at S2448 binds to raptor and rictor.; Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids.; DAP1, a novel substrate of mTOR, negatively regulates autophagy.; mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.; Activation of mTORC2 by association with the ribosome.; A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability.; Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes.; Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.; mTORC1 directly phosphorylates and regulates human MAF1.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Endoplasmic reticulum is a main localization site of mTORC2.; Initial characterization of the human central proteome.; mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.; MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB.; A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB.; The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis.; 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state.; Phosphorylation of lipin 1 and charge on the phosphatidic acid head group control its phosphatidic acid phosphatase activity and membrane association.; The potential role of BRCA1-associated ATM activator-1 (BRAT1) in regulation of mTOR.; Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a novel mode of TOR inhibition.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6.; Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific domains.; Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis.; Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.; Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.; The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris.; A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces.; Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb.; Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities.; AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation.; Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.; SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1.; Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR.; N-terminome analysis of the human mitochondrial proteome.; Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1.; mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.; WAC regulates mTOR activity by acting as an adaptor for the TTT and Pontin/Reptin complexes.; PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following Engulfment.; Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy.; The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor suppressor FBXO31 and thereby prevents premature cellular senescence.; Mammalian EAK-7 activates alternative mTOR signaling to regulate cell proliferation and migration.; The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.; Transmembrane 4 L six family member 5 senses arginine for mTORC1 signaling.; Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of autophagosome maturation and lipid metabolism.; GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor.; Lipid signalling drives proteolytic rewiring of mitochondria by YME1L.; The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 localization and activity.; Structural basis for the docking of mTORC1 on the lysosomal surface.; mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RICTOR.; A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome.; Leucine regulates autophagy via acetylation of the mTORC1 component raptor.; HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease.; Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway.; SNAT7 regulates mTORC1 via macropinocytosis.; TSPAN8 alleviates high glucose-induced apoptosis and autophagy via targeting mTORC2.; TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to activate dormant ribosomes.; De novo missense variants in RRAGC lead to a fatal mTORopathy of early childhood.; A central role for regulated protein stability in the control of TFE3 and MITF by nutrients.; The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid insufficiency.; Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in cancer cells.; Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.; Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution.; Insights into the domain and repeat architecture of target of rapamycin.; Structure of the human mTOR complex I and its implications for rapamycin inhibition.; mTOR kinase structure, mechanism and regulation.; 4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1.; Architecture of human mTOR complex 1.; Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40.; Cryo-EM structure of human mTOR complex 2.; Architecture of the human mTORC2 core complex.; Architecture of human Rag GTPase heterodimers and their complex with mTORC1.; The 3.2-Aa resolution structure of human mTORC2.; Regulation of human mTOR complexes by DEPTOR.; Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace.; Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt.; Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex.; Patterns of somatic mutation in human cancer genomes.; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.",False
GHRHR,Q02643,Growth hormone-releasing hormone receptor,MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWDGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLAEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVFLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRRAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLFLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPLELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLTSMC,,,Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.; Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone.; Genome-wide discovery and analysis of human seven transmembrane helix receptor genes.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; The DNA sequence of human chromosome 7.; The structure of the gene coding for human growth hormone releasing hormone.; Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse.; Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene.; Crystal structure of the extracellular domain of human growth hormone releasing hormone receptor.; Three new mutations in the gene for the growth hormone (GH)-releasing hormone receptor in familial isolated GH deficiency type IB.; Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene.; A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency.; The consensus coding sequences of human breast and colorectal cancers.,False
CTNNB1,P35222,Catenin beta-1,MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL,,,"E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton.; Functional prediction of the coding sequences of 75 new genes deduced by analysis of cDNA clones from human fetal liver.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence, annotation and analysis of human chromosome 3.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.; Identification of immuno-peptidmics that are recognized by tumor-reactive CTL generated from TIL of colon cancer patients.; Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell adhesion.; Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations.; Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene.; Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration.; ARVCF localizes to the nucleus and adherens junction and is mutually exclusive with p120(ctn) in E-cadherin complexes.; Hot spots in beta-catenin for interactions with LEF-1, conductin and APC.; Beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles.; Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro.; Regulation of beta-catenin structure and activity by tyrosine phosphorylation.; CD43 has a functional NLS, interacts with beta-catenin, and affects gene expression.; The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin.; AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein mediating strong cell-cell adhesion.; Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses.; Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein.; Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.; Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin.; Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.; Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape.; Identification of two novel regulated serines in the N-terminus of beta-catenin.; Protein binding and functional characterization of plakophilin 2. Evidence for its diverse roles in desmosomes and beta -catenin signaling.; Wnt signaling controls the phosphorylation status of beta-catenin.; Regulation of S33/S37 phosphorylated beta-catenin in normal and transformed cells.; The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).; The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.; EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma.; Regulation of beta-catenin signaling in the Wnt pathway.; p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction.; Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway.; Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells.; TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby.; E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus.; MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism.; The Kruppel-like zinc finger protein Glis2 functions as a negative modulator of the Wnt/beta-catenin signaling pathway.; cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal cells.; The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.; beta-Catenin is a Nek2 substrate involved in centrosome separation.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.; CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes.; A quantitative atlas of mitotic phosphorylation.; Chibby forms a homodimer through a heptad repeat of leucine residues in its C-terminal coiled-coil motif.; The kinase TNIK is an essential activator of Wnt target genes.; Down-regulation of death-associated protein kinase-2 is required for beta-catenin-induced anoikis resistance of malignant epithelial cells.; Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation.; The phospholipid-binding protein SESTD1 is a novel regulator of the transient receptor potential channels TRPC4 and TRPC5.; Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the vascular endothelium: evidence for a regulatory TRPC4-beta-catenin interaction.; Characterization of a novel human CDK5 splicing variant that inhibits Wnt/beta-catenin signaling.; Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and regulates insulin internalization.; Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin canonical signalling.; Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor.; Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation.; Defective Wnt-dependent cerebellar midline fusion in a mouse model of Joubert syndrome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The tumor suppressor HINT1 regulates MITF and beta-catenin transcriptional activity in melanoma cells.; Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to enhance Wnt signalling.; Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.; Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris.; Diagnostic exome sequencing in persons with severe intellectual disability.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Simplet/Fam53b is required for Wnt signal transduction by regulating beta-catenin nuclear localization.; beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta-catenin's subcellular localization and transactivator function.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of beta-catenin.; MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in the cytoplasm.; HN1 negatively influences the beta-catenin/E-cadherin interaction, and contributes to migration in prostate cells.; Loss of delta-catenin function in severe autism.; Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and colorectal tumorigenesis.; Cadherin 26 is an alpha integrin-binding epithelial receptor regulated during allergic inflammation.; KSHV vPK inhibits Wnt signaling via preventing interactions between beta-catenin and TCF4.; Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/beta-catenin pathway.; Defects in the cell signaling mediator beta-catenin cause the retinal vascular condition FEVR.; Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL-beta-Catenin Signaling Axis.; SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via Transcriptional and Posttranslational Regulation of beta-Catenin in Lung Cancer.; FLYWCH1, a Novel Suppressor of Nuclear beta-Catenin, Regulates Migration and Morphology in Colorectal Cancer.; DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells.; LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.; beta-Catenin Is Required for the cGAS/STING Signaling Pathway but Antagonized by the Herpes Simplex Virus 1 US3 Protein.; Crystal structure of a beta-catenin/Tcf complex.; Tcf4 can specifically recognize beta-catenin using alternative conformations.; Structure of a human Tcf4-beta-catenin complex.; The crystal structure of the beta-catenin/ICAT complex reveals the inhibitory mechanism of ICAT.; Crystal structure of a beta-catenin/BCL9/Tcf4 complex.; Structural basis of coactivation of liver receptor homolog-1 by beta-catenin.; Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.; Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.; Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma.; Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.; A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene.; A common human skin tumour is caused by activating mutations in beta-catenin.; Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.; APC mutations in sporadic medulloblastomas.; De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum.; Exome sequencing identifies a de novo mutation of CTNNB1 gene in a patient mainly presented with retinal detachment, lens and vitreous opacities, microcephaly, and developmental delay: Case report and literature review.; A mosaic variant in CTNNB1/beta-catenin as a novel cause for osteopathia striata with cranial sclerosis.",False
PSEN1,P49768,Presenilin-1,MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVVVATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWTAWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI,,,"Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.; Identification and characterization of presenilin I-467, I-463 and I-374.; Human presenilin 1 gene encodes an alternative protein-minilin.; Complete sequence of the gene for presenilin 1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 14.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning of Xenopus presenilin-alpha and -beta cDNAs and their differential expression in oogenesis and embryogenesis.; Alzheimer's presenilin 1 gene expression in platelets and megakaryocytes. Identification of a novel splice variant.; Purification and characterization of the human gamma-secretase complex.; Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells.; Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue.; Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C.; Alzheimer's disease associated presenilin-1 holoprotein and its 18-20 kDa C-terminal fragment are death substrates for proteases of the caspase family.; Direct association of presenilin-1 with beta-catenin.; Interaction of presenilins with the filamin family of actin-binding proteins.; Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis.; Identification of a novel PSD-95/Dlg/ZO-1 (PDZ)-like protein interacting with the C terminus of presenilin-1.; Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch.; Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin.; Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.; Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.; Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch.; Identification of the presenilins in hematopoietic cells with localization of presenilin 1 to neutrophil and platelet granules.; A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions.; Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein.; A new splice variant of glial fibrillary acidic protein GFAPepsilon, interacts with the presenilin proteins.; Presenilin 1 is involved in maturation and trafficking of N-cadherin to the plasma membrane.; Reconstitution of gamma-secretase activity.; Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2.; An unappreciated role for RNA surveillance.; A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations.; Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis.; Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins.; Conserved residues within the putative active site of gamma-secretase differentially influence enzyme activity and inhibitor binding.; Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.; C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation.; The presenilin genes: a new gene family involved in Alzheimer disease pathology.; Presenilin mutations in Alzheimer's disease.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Human CRB2 inhibits gamma-secretase cleavage of amyloid precursor protein by binding to the presenilin complex.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Gamma-secretase gene mutations in familial acne inversa.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; G206D mutation of presenilin-1 reduces Pen2 interaction, increases Abeta42/Abeta40 ratio and elevates ER Ca(2+) accumulation.; Solution structure of presenilin-1 CTF subunit.; Three-dimensional structure of human gamma-secretase.; Sampling the conformational space of the catalytic subunit of human gamma-secretase.; An atomic structure of human gamma-secretase.; Structural basis of human gamma-secretase assembly.; Structural basis of Notch recognition by human gamma-secretase.; Recognition of the amyloid precursor protein by human gamma-secretase.; Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3.; Mutations of the presenilin I gene in families with early-onset Alzheimer's disease.; Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.; The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families.; The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.; Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families.; Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation.; E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles.; Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.; A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease.; The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease.; Missense mutation E318G of the presenilin-1 gene appears to be a nonpathogenic polymorphism.; Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease.; Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene.; Missense mutation in exon 11 (codon 378) of the presenilin-1 gene in a French family with early-onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification.; De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases.; A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years.; Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease.; The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease.; Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.; Pathogenic presenilin 1 mutations (P436S and I143F) in early-onset Alzheimer's disease in the UK.; A novel missense mutation (G209R) in exon 8 of the presenilin 1 gene in a Japanese family with presenile familial Alzheimer's disease.; DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: two novel mutations.; A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures.; Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene.; A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease.; High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.; Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy.; The presenilin 1 C92S mutation increases abeta 42 production.; Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation.; Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia.; Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation.; A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families.; Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile).; Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.; Molecular evidence of presenilin 1 mutation in familial early onset dementia.; A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances.; Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.; Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production.; A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease.; Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy.; Early onset familial Alzheimer's disease: Mutation frequency in 31 families.; A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.; A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis.; A presenilin 1 R278I mutation presenting with language impairment.; A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis.; Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life.; One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer's disease.; Mutations of presenilin genes in dilated cardiomyopathy and heart failure.; Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.; Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families.; The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families.; Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.; Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.; Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor.; Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome.; Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta.; Novel PSEN1 mutation in a Bulgarian patient with very early-onset Alzheimer's disease, spastic paraparesis, and extrapyramidal signs.; Presenilin1 G217R mutation linked to Alzheimer disease with cotton wool plaques.; Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation.; A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.; Clinical phenotype of G206D mutation in the presenilin 1 gene in pathologically confirmed familial Alzheimer's disease.; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.; A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease.; Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase.; Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients.; Novel presenilin-1 Y159F sequence variant associated with early-onset Alzheimer's disease.; Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified gamma-secretase complexes.; Trans-dominant negative effects of pathogenic PSEN1 mutations on gamma-secretase activity and Abeta production.; A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease.; Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease.; A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease.; Novel presenilin 1 mutation (p.I83T) in Tunisian family with early-onset Alzheimer's disease.; The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida.; Novel presenilin 1 mutation (Ile408Thr) in an Italian family with late-onset Alzheimer's disease.; A novel PSEN1 K311R mutation discovered in Chinese families with late-onset Alzheimer's disease affects amyloid-beta production and tau phosphorylation.; Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase.; PSEN1 p.Thr116Ile variant in two Korean families with young onset Alzheimer's disease.; Neuropathology and biochemistry of early onset familial Alzheimer's disease caused by presenilin-1 missense mutation Thr116Asn.; Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation.; Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism.; Phenotypic variability in autosomal dominant familial Alzheimer disease due to the S170F mutation of presenilin-1.",False
DLL3,Q9NYJ7,Delta-like protein 3,MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSSVDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK,,,"Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis.; Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome.",False
CDKN2A,P42771,Cyclin-dependent kinase inhibitor 2A,MEPAAGSSMEPSADWLATAAARGRVEEVRALLEAGALPNAPNSYGRRPIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEELGHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD,,,"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.; Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus.; Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia.; Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.; DNA sequence and analysis of human chromosome 9.; Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.; Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.; A cell cycle regulator potentially involved in genesis of many tumor types.; Mutations and altered expression of p16INK4 in human cancer.; Phosphorylation of p16INK4A correlates with Cdk4 association.; Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK 'inhibitors'.; Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.; Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).; Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.; CDKN2 mutations in melanoma.; CDKN2A (p16INK4A) somatic and germline mutations.; Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas.; Germline p16 mutations in familial melanoma.; The MTS1 gene is frequently mutated in primary human esophageal tumors.; Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.; Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.; Mutations associated with familial melanoma impair p16INK4 function.; Novel germline p16 mutation in familial malignant melanoma in southern Sweden.; Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.; Germline mutations of the CDKN2 gene in UK melanoma families.; Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France.; Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas.; Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.; A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.; A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.; Germline mutation of ARF in a melanoma kindred.; CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.; Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.; A novel L94Q mutation in the CDKN2A gene in a melanoma kindred.; Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",False
PPP1CA,P62136,Serine/threonine-protein phosphatase PP1-alpha catalytic subunit,MSDSEKLNLDSIIGRLLEVQGSRPGKNVQLTENEIRGLCLKSREIFLSQPILLELEAPLKICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFLLRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDLQSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVQGWGENDRGVSFTFGAEVVAKFLHKHDLDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPADKNKGKYGQFSGLNPGGRPITPPRNSAKAKK,,,"Cloning and characterization of a human protein phosphatase 1-encoding cDNA.; The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Localization of the gene encoding a type I protein phosphatase catalytic subunit to human chromosome band 11q13.; The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.; Dynamic targeting of protein phosphatase 1 within the nuclei of living mammalian cells.; Growth arrest and DNA damage-inducible protein GADD34 assembles a novel signaling complex containing protein phosphatase 1 and inhibitor 1.; Binding of the concave surface of the Sds22 superhelix to the alpha 4/alpha 5/alpha 6-triangle of protein phosphatase-1.; Protein phosphatase 1 -- targeted in many directions.; The protein phosphatase-1 targeting subunit TIMAP regulates LAMR1 phosphorylation.; A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress.; Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells.; The nuclear PP1 interacting protein ZAP3 (ZAP) is a putative nucleoside kinase that complexes with SAM68, CIA, NF110/45, and HNRNP-G.; Protein phosphatase-1alpha regulates centrosome splitting through Nek2.; Alternative splicing controls nuclear translocation of the cell cycle-regulated Nek2 kinase.; NOM1 targets protein phosphatase I to the nucleolus.; Phosphoproteome of resting human platelets.; A quantitative atlas of mitotic phosphorylation.; Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.; Docking motif-guided mapping of the interactome of protein phosphatase-1.; GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis.; Retraction: GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions.; Identification and characterization of a novel human PP1 phosphatase complex.; SUMOylation of the transcriptional co-repressor KAP1 is regulated by the serine and threonine phosphatase PP1.; Protein phosphatase 1 (PP1) is a post-translational regulator of the mammalian circadian clock.; Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein.; Temporal regulation of EGF signalling networks by the scaffold protein Shc1.; Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis.; Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling.; ATG16L1 phosphorylation is oppositely regulated by CSNK2/casein kinase 2 and PPP1/protein phosphatase 1 which determines the fate of cardiomyocytes during hypoxia/reoxygenation.; Dynamic phosphorylation of CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at centromeres.; N-terminome analysis of the human mitochondrial proteome.; The human SKA complex drives the metaphase-anaphase cell cycle transition by recruiting protein phosphatase 1 to kinetochores.; NBS1 phosphorylation status dictates repair choice of dysfunctional telomeres.; Protein phosphatase 1alpha interacts with Venezuelan equine encephalitis virus capsid protein and regulates viral replication through modulation of capsid phosphorylation.; MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability.; Control of RNA Pol II speed by PNUTS-PP1 and Spt5 dephosphorylation facilitates termination by a 'sitting duck torpedo' mechanism.; WDR82/PNUTS-PP1 prevents transcription-replication conflicts by promoting RNA polymerase II degradation on chromatin.; The phosphatase PP1 sustains global transcription by promoting RNA polymerase II pause release.; The PNUTS phosphatase complex controls transcription pause release.; Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors.; Spinophilin directs protein phosphatase 1 specificity by blocking substrate binding sites.; Understanding the antagonism of retinoblastoma protein dephosphorylation by PNUTS provides insights into the PP1 regulatory code.; Structural and Functional Analysis of the GADD34:PP1 eIF2alpha Phosphatase.; KNL1 Binding to PP1 and Microtubules Is Mutually Exclusive.; Structural basis for SHOC2 modulation of RAS signalling.; Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF activation and Noonan syndrome.; Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase complex.; Structure of the MRAS-SHOC2-PP1C phosphatase complex.; A protein phosphatase 1 specific phosphatase targeting peptide (PhosTAP) to identify the PP1 phosphatome.",False
DBN1,Q16643,Drebrin,MAGVSFSGHRLELLAAYEEVIREESAADWALYTYEDGSDDLKLAASGEGGLQELSGHFENQKVMYGFCSVKDSQAALPKYVLINWVGEDVPDARKCACASHVAKVAEFFQGVDVIVNASSVEDIDAGAIGQRLSNGLARLSSPVLHRLRLREDENAEPVGTTYQKTDAAVEMKRINREQFWEQAKKEEELRKEEERKKALDERLRFEQERMEQERQEQEERERRYREREQQIEEHRRKQQTLEAEEAKRRLKEQSIFGDHRDEEEETHMKKSESEVEEAAAIIAQRPDNPREFFKQQERVASASAGSCDVPSPFNHRPGSHLDSHRRMAPTPIPTRSPSDSSTASTPVAEQIERALDEVTSSQPPPLPPPPPPAQETQEPSPILDSEETRAAAPQAWAGPMEEPPQAQAPPRGPGSPAEDLMFMESAEQAVLAAPVEPATADATEIHDAADTIETDTATADTTVANNVPPAATSLIDLWPGNGEGASTLQGEPRAPTPPSGTEVTLAEVPLLDEVAPEPLLPAGEGCATLLNFDELPEPPATFCDPEEVEGESLAAPQTPTLPSALEELEQEQEPEPHLLTNGETTQKEGTQASEGYFSQSQEEEFAQSEELCAKAPPPVFYNKPPEIDITCWDADPVPEEEEGFEGGD,,,"Molecular cloning of cDNA encoding human drebrin E and chromosomal mapping of its gene.; Human drebrin: cDNA sequence, mRNA tissue distribution and chromosomal localization.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.; Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Phosphoproteome of resting human platelets.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune synapse.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; De Novo ZMYND8 variants result in an autosomal dominant neurodevelopmental disorder with cardiac malformations.; The Structure of the ZMYND8/Drebrin Complex Suggests a Cytoplasmic Sequestering Mechanism of ZMYND8 by Drebrin.; The consensus coding sequences of human breast and colorectal cancers.",False
NOG,Q13253,Noggin,MERCPSLGVTLYALVVVLGLRATPAGGQHYLHIRPAPSDNLPLVDLIEHPDPIFDPKEKDLNETLLRSLLGGHYDPGFMATSPPEDRPGGGGGAAGGAEDLAELDQLLRQRPSGAMPSEIKGLEFSEGLAQGKKQRLSKKLRRKLQMWLWSQTFCPVLYAWNDLGSRFWPRYVKVGSCFSKRSCSVPEGMVCKPSKSVHLTVLRWRCQRRGGQRCGWIPIQYPIISECKCSC,,,"Identification of mammalian noggin and its expression in the adult nervous system.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): mutation within the GDF5 knuckle epitope causes noggin-resistance.; A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.; A New Subtype of Multiple-Synostoses Syndrome is Caused by a Mutation in GDF6 that Decreases its Sensitivity to Noggin and Enhances its Potency as a BMP Signal.; SMAD6 is frequently mutated in nonsyndromic radioulnar synostosis.; Structural basis of BMP signalling inhibition by the cystine knot protein Noggin.; Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis.; Mutations of the NOG gene in individuals with proximal symphalangism and multiple synostosis syndrome.; Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism.; Autosomal dominant stapes ankylosis with broad thumbs and toes, hyperopia, and skeletal anomalies is caused by heterozygous nonsense and frameshift mutations in NOG, the gene encoding noggin.; Identification of a novel NOG gene mutation (P35S) in an Italian family with symphalangism.; The facio-audio-symphalangism syndrome in a four generation family with a nonsense mutation in the NOG-gene.; A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN.; Facioaudiosymphalangism syndrome and growth acceleration associated with a heterozygous NOG mutation.",False
ELN,P15502,Elastin,MAGLTAAAPRPGVLLLLLSILHPSRPGGVPGAIPGGVPGGVFYPGAGLGALGGGALGPGGKPLKPVPGGLAGAGLGAGLGAFPAVTFPGALVPGGVADAAAAYKAAKAGAGLGGVPGVGGLGVSAGAVVPQPGAGVKPGKVPGVGLPGVYPGGVLPGARFPGVGVLPGVPTGAGVKPKAPGVGGAFAGIPGVGPFGGPQPGVPLGYPIKAPKLPGGYGLPYTTGKLPYGYGPGGVAGAAGKAGYPTGTGVGPQAAAAAAAKAAAKFGAGAAGVLPGVGGAGVPGVPGAIPGIGGIAGVGTPAAAAAAAAAAKAAKYGAAAGLVPGGPGFGPGVVGVPGAGVPGVGVPGAGIPVVPGAGIPGAAVPGVVSPEAAAKAAAKAAKYGARPGVGVGGIPTYGVGAGGFPGFGVGVGGIPGVAGVPGVGGVPGVGGVPGVGISPEAQAAAAAKAAKYGAAGAGVLGGLVPGAPGAVPGVPGTGGVPGVGTPAAAAAKAAAKAAQFGLVPGVGVAPGVGVAPGVGVAPGVGLAPGVGVAPGVGVAPGVGVAPGIGPGGVAAAAKSAAKVAAKAQLRAAAGLGAGIPGLGVGVGVPGLGVGAGVPGLGVGAGVPGFGAGADEGVRRSLSPELREGDPSSSQHLPSTPSSPRVPGALAAAKAAKYGAAVPGVLGGLGALGGVGIPGGVVGAGPAAAAAAAKAAAKAAQFGLVGAAGLGGLGVGGLGVPGVGGLGGIPPAAAAKAAKYGAAGLGGVLGGAGQFPLGGVAARPGFGLSPIFPGGACLGKACGRKRK,,,"Alternative splicing of human elastin mRNA indicated by sequence analysis of cloned genomic and complementary DNA.; Cloning of full-length elastin cDNAs from a human skin fibroblast recombinant cDNA library: further elucidation of alternative splicing utilizing exon-specific oligonucleotides.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence of human chromosome 7.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of the complete human elastin gene. Delineation of unusual features in the 5'-flanking region.; Elastin point mutations cause an obstructive vascular disease, supravalvular aortic stenosis.; Isolation and characterization of human elastin cDNAs, and age-associated variation in elastin gene expression in cultured skin fibroblasts.; Identification of genes from a 500-kb region at 7q11.23 that is commonly deleted in Williams syndrome patients.; LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition.; Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN).; Isolated supravalvular aortic stenosis: functional haploinsufficiency of the elastin gene as a result of nonsense-mediated decay.; Fibulin-5 interacts with fibrillin-1 molecules and microfibrils.; Mass spectrometric characterization of human skin elastin peptides produced by proteolytic digestion with pepsin and thermitase.; Characterization of peptides resulting from digestion of human skin elastin with elastase.; Fibulin-5 mutations: mechanisms of impaired elastic fiber formation in recessive cutis laxa.; Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice.; Differential regulation of elastic fiber formation by fibulin-4 and -5.; Fibrillin-1 interactions with fibulins depend on the first hybrid domain and provide an adaptor function to tropoelastin.; An autosomal-recessive form of cutis laxa is due to homozygous elastin mutations, and the phenotype may be modified by a heterozygous fibulin 5 polymorphism.",False
ATR,P20848,Alpha-1-antitrypsin-related protein,MPFSVSWGILLLAGLCCLVPSSLVEDPQEDAAQKTDTSHHDQGDWEDLACQKISYNVTDLAFDLYKELADLSQTSNVLVTPTSVAMAFAMLSLGTKADTRTEILEGLNVNLTETPEAKIHECFQQVLQALSRPDTRLQLTTGSSLFVNKSMKLVDTFLEDTKKLYHSEASSINFRDTEEAKEQINNYVEKRTGRKVVDLVKHLKKDTSLALVDYISFHGKWKDKFKAEHIMVEGFHVDDKTIIRVPMINHLGRFDIHRDRELSSWVLAQHYVGNATAFFILPDPKKMWQLEEKLTYSHLENIQRAFDIRSINLHFPKLSISGTYKLKRVLRNLGITKIFSNEADLSGVSQEAPLKLSKAVHVAVLTIDEKGTEATGAPHLEEKAWSKYQTVMFNRPFLVIIKDDITNFPLFIGKVVNPTQK,,,Molecular structure and sequence homology of a gene related to alpha 1-antitrypsin in the human genome.; SERPINA2 is a novel gene with a divergent function from SERPINA1.; The DNA sequence and analysis of human chromosome 14.; Molecular linkage of the human alpha 1-antitrypsin and corticosteroid-binding globulin genes on chromosome 14q32.1.; Sequence diversity at the proximal 14q32.1 SERPIN subcluster: evidence for natural selection favoring the pseudogenization of SERPINA2.,False
UCP3,P55916,Putative mitochondrial transporter UCP3,MVGLKPSDVPPTMAVKFLGAGTAACFADLVTFPLDTAKVRLQIQGENQAVQTARLVQYRGVLGTILTMVRTEGPCSPYNGLVAGLQRQMSFASIRIGLYDSVKQVYTPKGADNSSLTTRILAGCTTGAMAVTCAQPTDVVKVRFQASIHLGPSRSDRKYSGTMDAYRTIAREEGVRGLWKGTLPNIMRNAIVNCAEVVTYDILKEKLLDYHLLTDNFPCHFVSAFGAGFCATVVASPVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYEQLKRALMKVQMLRESPF,,,"Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression.; The human uncoupling protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts.; UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue.; Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin.; Organisation of the coding exons and mutational screening of the uncoupling protein 3 gene in subjects with juvenile-onset obesity.; The uncoupling protein-3 gene is transcribed from tissue-specific promoters in humans but not in rodents.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Uncoupling proteins 2 and 3 are highly active H(+) transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone).; The basal proton conductance of skeletal muscle mitochondria from transgenic mice overexpressing or lacking uncoupling protein-3.; Activating omega-6 polyunsaturated fatty acids and inhibitory purine nucleotides are high affinity ligands for novel mitochondrial uncoupling proteins UCP2 and UCP3.; Reconstitution of recombinant uncoupling proteins: UCP1, -2, and -3 have similar affinities for ATP and are unaffected by coenzyme Q10.; Uncoupling protein 3 (UCP3) modulates the activity of Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) by decreasing mitochondrial ATP production.; UCP3 is associated with Hax-1 in mitochondria in the presence of calcium ion.; Overexpression of UCP3 decreases mitochondrial efficiency in mouse skeletal muscle in vivo.; Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes.; A novel missense mutation, R70W, in the human uncoupling protein 3 gene in a family with type 2 diabetes.",False
ZMPSTE24,O75844,CAAX prenyl protease 1 homolog,MGMWASLDALWEMPAEKRIFGAVLLFSWTVYLWETFLAQRQRRIYKTTTHVPPELGQIMDSETFEKSRLYQLDKSTFSFWSGLYSETEGTLILLFGGIPYLWRLSGRFCGYAGFGPEYEITQSLVFLLLATLFSALTGLPWSLYNTFVIEEKHGFNQQTLGFFMKDAIKKFVVTQCILLPVSSLLLYIIKIGGDYFFIYAWLFTLVVSLVLVTIYADYIAPLFDKFTPLPEGKLKEEIEVMAKSIDFPLTKVYVVEGSKRSSHSNAYFYGFFKNKRIVLFDTLLEEYSVLNKDIQEDSGMEPRNEEEGNSEEIKAKVKNKKQGCKNEEVLAVLGHELGHWKLGHTVKNIIISQMNSFLCFFLFAVLIGRKELFAAFGFYDSQPTLIGLLIIFQFIFSPYNEVLSFCLTVLSRRFEFQADAFAKKLGKAKDLYSALIKLNKDNLGFPVSDWLFSMWHYSHPPLLERLQALKTMKQH,,,"Identification of a human cDNA encoding a novel protein structurally related to the yeast membrane-associated metalloprotease, Ste24p.; Dual roles for Ste24p in yeast a-factor maturation: NH2-terminal proteolysis and COOH-terminal CAAX processing.; Identification and chromosomal location of two human genes encoding enzymes potentially involved in proteolytic maturation of farnesylated proteins.; Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A quantitative atlas of mitotic phosphorylation.; Initial characterization of the human central proteome.; ZMPSTE24 defends against influenza and other pathogenic viruses.; Comparative influenza protein interactomes identify the role of plakophilin 2 in virus restriction.; Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.; Site specificity determinants for prelamin A cleavage by the zinc metalloprotease ZMPSTE24.; Inhibition of Arenavirus Entry and Replication by the Cell-Intrinsic Restriction Factor ZMPSTE24 Is Enhanced by IFITM Antiviral Activity.; The structural basis of ZMPSTE24-dependent laminopathies.; Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia.; Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy.; Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency.; Severe mandibuloacral dysplasia caused by novel compound heterozygous ZMPSTE24 mutations in two Japanese siblings.; Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24.",False
TP63,Q9H3D4,Tumor protein 63,MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGATNKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPSNTDYPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREFNEGQIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQHTIETYRQQQQQQHQHLLQKQTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGANIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEEGE,,,"A second p53-related protein, p73L, with high homology to p73.; Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16.; p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.; Cloning and functional analysis of human p51, which structurally and functionally resembles p53.; Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.; Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family.; Mutation and expression of the p51 gene in human lung cancer.; Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A new human p53 homologue.; Sequencing of candidate genes for non-syndromic cleft lip and palate.; High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53.; p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.; p63 identifies keratinocyte stem cells.; The p53 family member genes are involved in the Notch signal pathway.; Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.; A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism.; Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains.; SSRP1 functions as a co-activator of the transcriptional activator p63.; WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.; SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase.; NIR, an inhibitor of histone acetyltransferases, regulates transcription factor TAp63 and is controlled by the cell cycle.; Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.; Solution structure of the C-terminal domain of p63.; Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.; Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27.; TP63 gene mutation in ADULT syndrome.; Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63.; p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation.; Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63.; EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma.; The Rapp-Hodgkin syndrome results from mutations of the TP63 gene.; Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin ectodermal dysplasia.; Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are variable expression of a single genetic disorder.; A mutation of the p63 gene in non-syndromic cleft lip.; TP63-truncating variants cause isolated premature ovarian insufficiency.; Novel phenotype of syndromic premature ovarian insufficiency associated with TP63 molecular defect.; Dominant TP63 missense variants lead to constitutive activation and premature ovarian insufficiency.; TP63 gain-of-function mutations cause premature ovarian insufficiency by inducing oocyte apoptosis.",False
UCP2,P55851,Dicarboxylate carrier SLC25A8,MVGFKATDVPPTATVKFLGAGTAACIADLITFPLDTAKVRLQIQGESQGPVRATASAQYRGVMGTILTMVRTEGPRSLYNGLVAGLQRQMSFASVRIGLYDSVKQFYTKGSEHASIGSRLLAGSTTGALAVAVAQPTDVVKVRFQAQARAGGGRRYQSTVNAYKTIAREEGFRGLWKGTSPNVARNAIVNCAELVTYDLIKDALLKANLMTDDLPCHFTSAFGAGFCTTVIASPVDVVKTRYMNSALGQYSSAGHCALTMLQKEGPRAFYKGFMPSFLRLGSWNVVMFVTYEQLKRALMAACTSREAPF,,,"Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression.; Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia.; Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis.; Structure and organization of the human uncoupling protein 2 gene and identification of a common biallelic variant in Caucasian and African-American subjects.; Functional organization of the human uncoupling protein-2 gene, and juxtaposition to the uncoupling protein-3 gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Uncoupling proteins 2 and 3 are highly active H(+) transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone).; Physiological levels of mammalian uncoupling protein 2 do not uncouple yeast mitochondria.; Toward understanding the mechanism of ion transport activity of neuronal uncoupling proteins UCP2, UCP4, and UCP5.; UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation.; A biophysical study on molecular physiology of the uncoupling proteins of the central nervous system.; Mitochondrial proton leaks and uncoupling proteins.; Functional Oligomeric Forms of Uncoupling Protein 2: Strong Evidence for Asymmetry in Protein and Lipid Bilayer Systems.; A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans.",False
POLB,P06746,DNA polymerase beta,MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKKLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKTLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSFRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQLPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPLGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE,,,"Molecular cloning and high-level expression of human polymerase beta cDNA and comparison of the purified recombinant human and rat enzymes.; Polymorphisms in the human DNA polymerase beta gene.; The human DNA polymerase beta gene structure. Evidence of alternative splicing in gene expression.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human beta-polymerase gene. Structure of the 5'-flanking region and active promoter.; Expression of human DNA polymerase beta in Escherichia coli and characterization of the recombinant enzyme.; Sequence of human DNA polymerase beta mRNA obtained through cDNA cloning.; Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.; Catalytic center of DNA polymerase beta for excision of deoxyribose phosphate groups.; Functional analysis of the amino-terminal 8-kDa domain of DNA polymerase beta as revealed by site-directed mutagenesis. DNA binding and 5'-deoxyribose phosphate lyase activities.; Human DNA polymerase beta deoxyribose phosphate lyase. Substrate specificity and catalytic mechanism.; Covalent trapping of human DNA polymerase beta by the oxidative DNA lesion 2-deoxyribonolactone.; Arginine methylation regulates DNA polymerase beta.; The Asp285 variant of DNA polymerase beta extends mispaired primer termini via increased nucleotide binding.; Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.; USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA Polymerase beta.; The E288K colon tumor variant of DNA polymerase beta is a sequence specific mutator.; TCRP1 contributes to cisplatin resistance by preventing Pol beta degradation in lung cancer cells.; R152C DNA Pol beta mutation impairs base excision repair and induces cellular transformation.; Defective nucleotide release by DNA polymerase beta mutator variant E288K is the basis of its low fidelity.; A structural basis for metal ion mutagenicity and nucleotide selectivity in human DNA polymerase beta.; Characterization of the metal ion binding helix-hairpin-helix motifs in human DNA polymerase beta by X-ray structural analysis.; Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism.; Structure of DNA polymerase beta with the mutagenic DNA lesion 8-oxodeoxyguanine reveals structural insights into its coding potential.; Structural insight into the DNA polymerase beta deoxyribose phosphate lyase mechanism.; Revealing an internal stabilization deficiency in the DNA polymerase beta K289M cancer variant through the combined use of chemical biology and X-ray crystallography.; Functional mutation of DNA polymerase beta found in human gastric cancer--inability of the base excision repair in vitro.; A DNA polymerase beta mutant from colon cancer cells induces mutations.; The E295K DNA polymerase beta gastric cancer-associated variant interferes with base excision repair and induces cellular transformation.; The Leu22Pro tumor-associated variant of DNA polymerase beta is dRP lyase deficient.; Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity.; Human Polbeta natural polymorphic variants G118V and R149I affects substrate binding and catalysis.",False
GCLC,P48506,Glutamate--cysteine ligase catalytic subunit,MGLLSQGSPLSWEETKRHADHVRRHGILQFLHIYHAVKDRHKDVLKWGDEVEYMLVSFDHENKKVRLVLSGEKVLETLQEKGERTNPNHPTLWRPEYGSYMIEGTPGQPYGGTMSEFNTVEANMRKRRKEATSILEENQALCTITSFPRLGCPGFTLPEVKPNPVEGGASKSLFFPDEAINKHPRFSTLTRNIRHRRGEKVVINVPIFKDKNTPSPFIETFTEDDEASRASKPDHIYMDAMGFGMGNCCLQVTFQACSISEARYLYDQLATICPIVMALSAASPFYRGYVSDIDCRWGVISASVDDRTREERGLEPLKNNNYRISKSRYDSIDSYLSKCGEKYNDIDLTIDKEIYEQLLQEGIDHLLAQHVAHLFIRDPLTLFEEKIHLDDANESDHFENIQSTNWQTMRFKPPPPNSDIGWRVEFRPMEVQLTDFENSAYVVFVVLLTRVILSYKLDFLIPLSKVDENMKVAQKRDAVLQGMFYFRKDICKGGNAVVDGCGKAQNSTELAAEEYTLMSIDTIINGKEGVFPGLIPILNSYLENMEVDVDTRCSILNYLKLIKKRASGELMTVARWMREFIANHPDYKQDSVITDEMNYSLILKCNQIANELCECPELLGSAFRKVKYSGSKTDSSN,,,"Cloning and nucleotide sequence of a full-length cDNA for human liver gamma-glutamylcysteine synthetase.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a putative antioxidant response element in the 5'-flanking region of the human gamma-glutamylcysteine synthetase heavy subunit gene.; The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency.; Expression and purification of human gamma-glutamylcysteine synthetase.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A missense mutation in the heavy subunit of gamma-glutamylcysteine synthetase gene causes hemolytic anemia.; A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production.",False
GCLM,P48507,Glutamate--cysteine ligase regulatory subunit,MGTDSRAAKALLARARTLHLQTGNLLNWGRLRKKCPSTHSEELHDCIQKTLNEWSSQINPDLVREFPDVLECTVSHAVEKINPDEREEMKVSAKLFIVESNSSSSTRSAVDMACSVLGVAQLDSVIIASPPIEDGVNLSLEHLQPYWEELENLVQSKKIVAIGTSDLDKTQLEQLYQWAQVKPNSNQVNLASCCVMPPDLTAFAKQFDIQLLTHNDPKELLSEASFQEALQESIPDIQAHEWVPLWLLRYSVIVKSRGIIKSKGYILQAKRRGS,,,"Cloning and sequencing of the cDNA for the light subunit of human liver gamma-glutamylcysteine synthetase and relative mRNA levels for heavy and light subunits in human normal tissues.; Homo sapiens GCLM mRNA for glutamate-cysteine ligase, modifier subunit delta2 alternative splicing variant, complete cds.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.",False
SIRT6,Q8N6T7,NAD-dependent protein deacylase sirtuin-6,MSVNYAAGLSPYADKGKCGLPEIFDPPEELERKVWELARLVWQSSSVVFHTGAGISTASGIPDFRGPHGVWTMEERGLAPKFDTTFESARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRDTILDWEDSLPDRDLALADEASRNADLSITLGTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLEIPAWDGPRVLERALPPLPRPPTPKLEPKEESPTRINGSIPAGPKQEPCAQHNGSEPASPKRERPTSPAPHRPPKRVKAKAVPS,,,"Phylogenetic classification of prokaryotic and eukaryotic Sir-2 like proteins.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.; SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span.; Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6.; Human SIRT6 promotes DNA end resection through CtIP deacetylation.; SIRT6 is required for maintenance of telomere position effect in human cells.; SIRT6 promotes DNA repair under stress by activating PARP1.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.; The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis.; Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence.; Multiple regulatory layers of SREBP1/2 by SIRT6.; The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells.; Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling.; The ubiquitin ligase CHIP prevents SirT6 degradation through noncanonical ubiquitination.; SIRT6 exhibits nucleosome-dependent deacetylase activity.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; SIRT6 minor allele genotype is associated with >5-year decrease in lifespan in an aged cohort.; Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion.; The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine.; Reciprocal regulation between SIRT6 and miR-122 controls liver metabolism and predicts hepatocarcinoma prognosis.; JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in response to oxidative stress by recruiting PARP1 to DNA Breaks.; LncPRESS1 is a p53-regulated lncRNA that safeguards pluripotency by disrupting SIRT6-mediated de-acetylation of histone H3K56.; Identifying the functional contribution of the defatty-acylase activity of SIRT6.; SIRT6 deacetylates H3K18ac at pericentric chromatin to prevent mitotic errors and cellular senescence.; A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity.; SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions.; Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6-deficient mice.; SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation.; SIRT6 suppresses pancreatic cancer through control of Lin28b.; SIRT6 is a DNA double-strand break sensor.; Synergy between SIRT1 and SIRT6 helps recognize DNA breaks and potentiates the DNA damage response and repair in humans and mice.; Nitro-fatty acids as activators of hSIRT6 deacetylase activity.; Multivalent interactions drive nucleosome binding and efficient chromatin deacetylation by SIRT6.; The deacetylase SIRT6 promotes the repair of UV-induced DNA damage by targeting DDB2.; Immune evasion strategy involving propionylation by the KSHV interferon regulatory factor 1 (vIRF1).; Structure and biochemical functions of SIRT6.; SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine.; Structural basis of sirtuin 6 activation by synthetic small molecules.; Structural basis of sirtuin 6 inhibition by the hydroxamate trichostatin A: implications for protein deacylase drug development.; Identification of a cellularly active SIRT6 allosteric activator.; Structural basis for the activation and inhibition of Sirtuin 6 by quercetin and its derivatives.; Structural basis for activation of human sirtuin 6 by fluvastatin.; Binding site for activator MDL-801 on SIRT6.; Reply to: Binding site for MDL-801 on SIRT6.; Identification of and molecular basis for SIRT6 loss-of-function point mutations in cancer.; An inactivating mutation in the histone deacetylase SIRT6 causes human perinatal lethality.",False
BUB3,O43684,Mitotic checkpoint protein BUB3,MTGSNEFKLNQPPEDGISSVKFSPNTSQFLLVSSWDTSVRLYDVPANSMRLKYQHTGAVLDCAFYDPTHAWSGGLDHQLKMHDLNTDQENLVGTHDAPIRCVEYCPEVNVMVTGSWDQTVKLWDPRTPCNAGTFSQPEKVYTLSVSGDRLIVGTAGRRVLVWDLRNMGYVQQRRESSLKYQTRCIRAFPNKQGYVLSSIEGRVAVEYLDPSPEVQKKKYAFKCHRLKENNIEQIYPVNAISFHNIHNTFATGGSDGFVNIWDPFNKKRLCQFHRYPTSIASLAFSNDGTTLAIASSYMYEMDDTEHPEDGIFIRQVTDAETKPKSPCT,,,"Phosphorylation of human MAD1 by the BUB1 kinase in vitro.; The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase.; Human BUB3 is a kinetochore protein that interacts with hBUB1 and hBUBR1.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 10.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint.; The human spindle assembly checkpoint protein Bub3 is required for the establishment of efficient kinetochore-microtubule attachments.; A quantitative atlas of mitotic phosphorylation.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A microtubule-associated zinc finger protein, BuGZ, regulates mitotic chromosome alignment by ensuring Bub3 stability and kinetochore targeting.; BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment.; Role of ubiquitin-protein ligase UBR5 in the disassembly of mitotic checkpoint complexes.",False
RAE1,P78406,mRNA export factor RAE1,MSLFGTTSGFGTSGTSMFGSATTDNHNPMKDIEVTSSPDDSIGCLSFSPPTLPGNFLIAGSWANDVRCWEVQDSGQTIPKAQQMHTGPVLDVCWSDDGSKVFTASCDKTAKMWDLSSNQAIQIAQHDAPVKTIHWIKAPNYSCVMTGSWDKTLKFWDTRSSNPMMVLQLPERCYCADVIYPMAVVATAERGLIVYQLENQPSEFRRIESPLKHQHRCVAIFKDKQNKPTGFALGSIEGRVAIHYINPPNPAKDNFTFKCHRSNGTNTSAPQDIYAVNGIAFHPVHGTLATVGSDGRFSFWDKDARTKLKTSEQLDQPISACCFNHNGNIFAYASSYDWSKGHEFYNPQKKNYIFLRNAAEELKPRNKK,,,"The human RAE1 gene is a functional homologue of Schizosaccharomyces pombe rae1 gene involved in nuclear export of poly(A)+ RNA.; mRNA binding protein mrnp 41 localizes to both nucleus and cytoplasm.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Rae1 interaction with NuMA is required for bipolar spindle formation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; N-terminome analysis of the human mitochondrial proteome.; USP11 deubiquitinates RAE1 and plays a key role in bipolar spindle formation.; RAE-1, a novel PHR binding protein, is required for axon termination and synapse formation in Caenorhabditis elegans.; SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.; Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from the nuclear pore complex.; SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98.; Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1.",False
PMCH,P20382,Pro-MCH,MAKMNLSSYILILTFSLFSQGILLSASKSIRNLDDDMVFNTFRLGKGFQKEDTAEKSVIAPSLEQYKNDESSFMNEEENKVSKNTGSKHNFLNHGLPLNLAIKPYLALKGSVAFPAENGVQNTESTQEKREIGDEENSAKFPIGRRDFDMLRCMLGRVYRPCWQV,,,"Structure of the human melanin concentrating hormone mRNA.; Isolation and characterization of the human melanin-concentrating hormone gene and a variant gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals.; The melanin-concentrating hormone gene in human: flanking region analysis, fine chromosome mapping, and tissue-specific expression.",False
MLH1,P40692,DNA mismatch repair protein Mlh1,MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC,,,"Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.; Mutation of a mutL homolog in hereditary colon cancer.; Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations.; Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non-polyposis colorectal cancer (HNPCC).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence, annotation and analysis of human chromosome 3.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.; MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1.; The interaction of DNA mismatch repair proteins with human exonuclease I.; HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutLalpha and hMLH1-hEXO1 complexes.; Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome.; Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA.; The genetic basis of Muir-Torre syndrome includes the hMLH1 locus.; Endonucleolytic function of MutLalpha in human mismatch repair.; Direct visualization of asymmetric adenine nucleotide-induced conformational changes in MutL alpha.; Human mismatch repair: reconstitution of a nick-directed bidirectional reaction.; MutLalpha: at the cutting edge of mismatch repair.; Mechanisms and functions of DNA mismatch repair.; A quantitative atlas of mitotic phosphorylation.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; MCM9 Is Required for Mammalian DNA Mismatch Repair.; HDAC6 regulates DNA damage response via deacetylating MLH1.; The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the stability of DNA mismatch repair protein MLH1.; Crystal structure of MutL protein homolog 1 isoform 1.; Structure of the human MLH1 N-terminus: implications for predisposition to Lynch syndrome.; DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus by a classical nuclear import pathway.; A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.; Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants.; The molecular basis of Turcot's syndrome.; Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16.; CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC mutations.; Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer.; Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary nonpolyposis colorectal cancer.; Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability.; Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients.; Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations.; Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer.; MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis.; Mean age of tumor onset in hereditary nonpolyposis colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes.; Use of SSCP analysis to identify germline mutations in HNPCC families fulfilling the Amsterdam criteria.; Hereditary nonpolyposis colorectal cancer: causative role of a germline missense mutation in the hMLH1 gene confirmed by the independent occurrence of the same somatic mutation in tumour tissue.; Mutational analysis of the hMLH1 gene using an automated two-dimensional DNA typing system.; Molecular basis of HNPCC: mutations of MMR genes.; Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline mutations in hMSH2 or hMLH1 genes.; Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families.; Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer.; A human compound heterozygote for two MLH1 missense mutations.; Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls.; DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in 34 Swedish families with colorectal cancer.; Germline mutations of hMLH1 and hMSH2 genes in patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal cancer.; A novel missense mutation in the DNA mismatch repair gene hMLH1 present among East Asians but not among Europeans.; Four new mutations in the DNA mismatch repair gene MLH1 in colorectal cancers with microsatellite instability.; hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds.; Hereditary nonpolyposis colorectal cancer: identification of novel germline mutations in two kindreds not fulfilling the Amsterdam criteria.; Excess of hMLH1 germline mutations in Swiss families with hereditary non-polyposis colorectal cancer.; Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer.; Neurofibromatosis and early onset of cancers in hMLH1-deficient children.; Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2.; Microsatellite instability, a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer.; Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.; Missense mutations in hMLH1 associated with colorectal cancer.; Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer.; Frequent microsatellite instability and mismatch repair gene mutations in young Chinese patients with colorectal cancer.; Enhanced detection of deleterious and other germline mutations of hMSH2 and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.; Detection of mutations in mismatch repair genes in Portuguese families with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method approach.; Mutational germline analysis of hMSH2 and hMLH1 genes in early onset colorectal cancer patients.; hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer.; Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast.; Extensive somatic microsatellite mutations in normal human tissue.; Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) patients: mutations or polymorphisms?; Functional analysis of human MLH1 and MSH2 missense variants and hybrid human-yeast MLH1 proteins in Saccharomyces cerevisiae.; Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes.; Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer families from Spain.; hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer.; Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach.; Microsatellite instability and mutation analysis of candidate genes in unselected Sardinian patients with endometrial carcinoma.; Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system.; Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing.; Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer.; Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis colorectal cancer.; Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer.; Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.; Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States.; Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.; Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases.; Identification of six novel MSH2 and MLH1 germline mutations in HNPCC.; Genetic analysis of familial colorectal cancer in Israeli Arabs.; Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA.; HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1.; Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families.; Ten novel MSH2 and MLH1 germline mutations in families with HNPCC.; Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden.; Germline epimutation of MLH1 in individuals with multiple cancers.; The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer.; Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.; Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study).; Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies.; Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.; Inheritance of a cancer-associated MLH1 germ-line epimutation.; Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer.; A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.; Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.; Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods.",False
CSNK1E,P49674,Casein kinase I isoform epsilon,MELRVGNKYRLGRKIGSGSFGDIYLGANIASGEEVAIKLECVKTKHPQLHIESKFYKMMQGGVGIPSIKWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFSTYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGAARNPEDVDRERREHEREERMGQLRGSATRALPPGPPTGATANRLRSAAEPVASTPASRIQPAGNTSPRAISRVDRERKVSMRLHRGAPANVSSSDLTGRQEVSRIPASQTSVPFDHLGK,,,"Isolation and characterization of human casein kinase I epsilon (CKI), a novel member of the CKI gene family.; Casein kinase I epsilon from HeLa cell.; Involvement of casein kinase Iepsilon in cytokine-induced granulocytic differentiation.; A genome annotation-driven approach to cloning the human ORFeome.; The DNA sequence of human chromosome 22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Phosphorylation and destabilization of human period I clock protein by human casein kinase I epsilon.; Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin.; Proteomic characterization of the human centrosome by protein correlation profiling.; SCFbeta-TRCP controls clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein.; Dysbindin structural homologue CK1BP is an isoform-selective binding partner of human casein kinase-1.; Negative regulation of LRP6 function by casein kinase I epsilon phosphorylation.; Posttranslational regulation of the mammalian circadian clock by cryptochrome and protein phosphatase 5.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Role of CK1 in GSK3beta-mediated phosphorylation and degradation of snail.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta-catenin signaling.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A CK1 FRET biosensor reveals that DDX3X is an essential activator of CK1epsilon.; The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms.; Structural basis for the potent and selective inhibition of casein kinase 1 epsilon.; Patterns of somatic mutation in human cancer genomes.",False
STUB1,Q9UNE7,E3 ubiquitin-protein ligase CHIP,MKGKEEKEGGARLGAGGGSPEKSPSAQELKEQGNRLFVGRKYPEAAACYGRAITRNPLVAVYYTNRALCYLKMQQHEQALADCRRALELDGQSVKAHFFLGQCQLEMESYDEAIANLQRAYSLAKEQRLNFGDDIPSALRIAKKKRWNSIEERRIHQESELHSYLSRLIAAERERELEECQRNHEGDEDDSHVRAQQACIEAKHDKYMADMDELFSQVDEKRKKRDIPDYLCGKISFELMREPCITPSGITYDRKDIEEHLQRVGHFDPVTRSPLTQEQLIPNLAMKEVIDAFISENGWVEDY,,,"Characterization of human colon cancer antigens recognized by autologous antibodies.; Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions.; Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.; Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16.; Large-scale cDNA transfection screening for genes related to cancer development and progression.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; U box proteins as a new family of ubiquitin-protein ligases.; CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation.; The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins.; Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase.; The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator.; Regulation of the cytoplasmic quality control protein degradation pathway by BAG2.; Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to human myopathy.; Two different classes of E2 ubiquitin-conjugating enzymes are required for the mono-ubiquitination of proteins and elongation by polyubiquitin chains with a specific topology.; MKKS is a centrosome-shuttling protein degraded by disease-causing mutations via CHIP-mediated ubiquitination.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases.; Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.; Functional interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal pathways in dyslexia.; C terminus of Hsc70-interacting protein promotes smooth muscle cell proliferation and survival through ubiquitin-mediated degradation of FoxO1.; Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor.; Chaperone-assisted selective autophagy is essential for muscle maintenance.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Ube2W conjugates ubiquitin to alpha-amino groups of protein N-termini.; The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3.; Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/c70 protein and the CHIP E3 ligase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; The ubiquitin ligase CHIP prevents SirT6 degradation through noncanonical ubiquitination.; Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through CHIP/Stub1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; UBXN2A regulates nicotinic receptor degradation by modulating the E3 ligase activity of CHIP.; N-terminome analysis of the human mitochondrial proteome.; Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.; The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.; ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation.; Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.; Neuronal Preconditioning Requires the Mitophagic Activity of C-terminus of HSC70-Interacting Protein.; PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent proteasomal degradation.; Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48).; CHIP attenuates lipopolysaccharide-induced cardiac hypertrophy and apoptosis by promoting NFATc3 proteasomal degradation.; The uncharacterized protein FAM47E interacts with PRMT5 and regulates its functions.; Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia.; Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP.; Phenotype and frequency of STUB1 mutations: next-generation screenings in Caucasian ataxia and spastic paraplegia cohorts.; Autosomal recessive cerebellar ataxia of adult onset due to STUB1 mutations.; STUB1 mutations in autosomal recessive ataxias - evidence for mutation-specific clinical heterogeneity.; Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.",False
PPM1D,O15297,Protein phosphatase 1D,MAGLYSLGVSVFSDQGGRKYMEDVTQIVVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGPAVAAREARDPLPDAGASPAPSRCCRRRSSVAFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHNGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGEFVVSPEPDTSVHTLDPQKHKYIILGSDGLWNMIPPQDAISMCQDQEEKKYLMGEHGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELYLNLTDSPSYNSQETCVMTPSPCSTPPVKSLEEDPWPRVNSKDHIPALVRSNAFSENFLEVSAEIARENVQGVVIPSKDPEPLEENCAKALTLRIHDSLNNSLPIGLVPTNSTNTVMDQKNLKMSTPGQMKAQEIERTPPTNFKRTLEESNSGPLMKKHRRNGLSRSSGAQPASLPTTSQRKNSVKLTMRRRLRGQKKIGNPLLHQHRKTVCVC,,,"Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.; Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1).; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.; De novo truncating mutations in the last and penultimate exons of PPM1D cause an intellectual disability syndrome.",False
CHEK2,O96017,Serine/threonine-protein kinase Chk2,MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSSQSSHSSSGTLSSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKSCEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKRRPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFERKTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCAAVL,,,"Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.; A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase.; A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage.; Alternative splicing and mutation status of CHEK2 in stage III breast cancer.; A genome annotation-driven approach to cloning the human ORFeome.; Chk2/HuCds1 cell cycle checkpoint protein kinase from human colon carcinoma HT29 cells: regulation by autophosphorylation and DNA-dependent protein kinase and inhibition by cell cycle regulatory drugs.; An alternative spliced Chk2.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Large-scale cDNA transfection screening for genes related to cancer development and progression.; The DNA sequence of human chromosome 22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.; Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.; The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation.; The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.; A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.; Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain.; PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.; 53BP1, a mediator of the DNA damage checkpoint.; The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.; Chk2 activates E2F-1 in response to DNA damage.; MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.; The Chk2 protein kinase.; The stress kinase MRK contributes to regulation of DNA damage checkpoints through a p38gamma-independent pathway.; ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.; Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.; Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.; Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage.; Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456.; Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.; Nek6 is involved in G2/M phase cell cycle arrest through DNA damage-induced phosphorylation.; Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379.; The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage.; Polo-like kinase 4 phosphorylates Chk2.; The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.; Initial characterization of the human central proteome.; A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.; The E3 ligase RNF8 regulates KU80 removal and NHEJ repair.; Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced apoptosis.; The Viral SUMO-Targeted Ubiquitin Ligase ICP0 is Phosphorylated and Activated by Host Kinase Chk2.; ATM-CHK2-TRIM32 axis regulates ATG7 ubiquitination to initiate autophagy under oxidative stress.; Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2.; Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.; Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.; Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling.; Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.; Mutation analysis of the CHK2 gene in families with hereditary breast cancer.; Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.; Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.; CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.; Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.; Mutations in CHEK2 associated with prostate cancer risk.; Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.; CHEK2 variants associate with hereditary prostate cancer.; CHEK2 is a multiorgan cancer susceptibility gene.; Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.; A novel founder CHEK2 mutation is associated with increased prostate cancer risk.; Limited relevance of the CHEK2 gene in hereditary breast cancer.; CHEK2 variant I157T may be associated with increased breast cancer risk.; Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.; Association of two mutations in the CHEK2 gene with breast cancer.; Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.; A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.",False
PCK1,P35558,"Phosphoenolpyruvate carboxykinase, cytosolic [GTP]",MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPVLEAVGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSLLGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM,,,"cDNA sequence and localization of polymorphic human cytosolic phosphoenolpyruvate carboxykinase gene (PCK1) to chromosome 20, band q13.31: PCK1 is not tightly linked to maturity-onset diabetes of the young.; Phosphoenolpyruvate carboxykinase (GTP): characterization of the human PCK1 gene and localization distal to MODY on chromosome 20.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 20.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Structural and functional analysis of the human phosphoenolpyruvate carboxykinase gene promoter.; Regulation of phosphoenolpyruvate carboxykinase (GTP) gene transcription.; Regulation of cellular metabolism by protein lysine acetylation.; Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme activity between gluconeogenic and anaplerotic reactions.; The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.; Crystal structure of human cytosolic phosphoenolpyruvate carboxykinase reveals a new GTP-binding site.; X-ray structures of two xanthine inhibitors bound to PEPCK and N-3 modifications of substituted 1,8-dibenzylxanthines.; C-8 Modifications of 3-alkyl-1,8-dibenzylxanthines as inhibitors of human cytosolic phosphoenolpyruvate carboxykinase.; Three rare diseases in one sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity.; Cytosolic phosphoenolpyruvate carboxykinase deficiency presenting with acute liver failure following gastroenteritis.; Novel homozygous PCK1 mutation causing cytosolic phosphoenolpyruvate carboxykinase deficiency presenting as childhood hypoglycemia, an abnormal pattern of urine metabolites and liver dysfunction.",False
ARHGAP1,Q07960,Rho GTPase-activating protein 1,MDPLSELQDDLTLDDTSEALNQLKLASIDEKNWPSDEMPDFPKSDDSKSSSPELVTHLKWDDPYYDIARHQIVEVAGDDKYGRKIIVFSACRMPPSHQLDHSKLLGYLKHTLDQYVESDYTLLYLHHGLTSDNKPSLSWLRDAYREFDRKYKKNIKALYIVHPTMFIKTLLILFKPLISFKFGQKIFYVNYLSELSEHVKLEQLGIPRQVLKYDDFLKSTQKSPATAPKPMPPRPPLPNQQFGVSLQHLQEKNPEQEPIPIVLRETVAYLQAHALTTEGIFRRSANTQVVREVQQKYNMGLPVDFDQYNELHLPAVILKTFLRELPEPLLTFDLYPHVVGFLNIDESQRVPATLQVLQTLPEENYQVLRFLTAFLVQISAHSDQNKMTNTNLAVVFGPNLLWAKDAAITLKAINPINTFTKFLLDHQGELFPSPDPSGL,,,"Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain.; Characterization of rhoGAP. A GTPase-activating protein for rho-related small GTPases.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification and N-terminal sequence of the p21rho GTPase-activating protein, rho GAP.; Bcr encodes a GTPase-activating protein for p21rac.; BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis.; Exportin 7 defines a novel general nuclear export pathway.; Phosphoproteome of resting human platelets.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; The structure of the GTPase-activating domain from p50rhoGAP.; Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP.",False
CDC42,P60953,Cell division control protein 42 homolog,MQTIKCVVVGDGAVGKTCLLISYTTNKFPSEYVPTVFDNYAVTVMIGGEPYTLGLFDTAGQEDYDRLRPLSYPQTDVFLVCFSVVSPSSFENVKEKWVPEITHHCPKTPFLLVGTQIDLRDDPSTIEKLAKNKQKPITPETAEKLARDLKAVKYVECSALTQKGLKNVFDEAILAALEPPEPKKSRRCVLL,,,"Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDC42.; Molecular cloning of the gene for the human placental GTP-binding protein Gp (G25K): identification of this GTP-binding protein as the human homolog of the yeast cell-division-cycle protein CDC42.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Regulation of the human neutrophil NADPH oxidase by rho-related G-proteins.; Characterization of G25K, a GTP-binding protein containing a novel putative nucleotide binding domain.; Identification of a novel protein with GDP dissociation inhibitor activity for the ras-like proteins CDC42Hs and rac I.; Glucosylation of Rho proteins by Clostridium difficile toxin B.; The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.; Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins.; The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins.; Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas.; SPECs, small binding proteins for Cdc42.; The mammalian homologue of the Caenorhabditis elegans polarity protein PAR-6 is a binding partner for the Rho GTPases Cdc42 and Rac1.; IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling.; Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to atypical protein kinase C.; The integrin cytoplasmic domain-associated protein ICAP-1 binds and regulates Rho family GTPases during cell spreading.; Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins.; Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase.; The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling.; Regulation of dendritic branching and filopodia formation in hippocampal neurons by specific acylated protein motifs.; Ect2 and MgcRacGAP regulate the activation and function of Cdc42 in mitosis.; Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas.; Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease.; The fic domain: regulation of cell signaling by adenylylation.; Requirements for F-BAR proteins TOCA-1 and TOCA-2 in actin dynamics and membrane trafficking during Caenorhabditis elegans oocyte growth and embryonic epidermal morphogenesis.; AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling.; Characterization of hNek6 interactome reveals an important role for its short N-terminal domain and colocalization with proteins at the centrosome.; ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and cell adhesion.; Initial characterization of the human central proteome.; The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42.; Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between beta1 integrins and small GTPases.; The GEF Bcr activates RhoA/MAL signaling to promote keratinocyte differentiation via desmoglein-1.; ARHGDIA: a novel gene implicated in nephrotic syndrome.; A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation of Gq and Gi proteins.; Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins.; Phosphoinositide 3-kinase enables phagocytosis of large particles by terminating actin assembly through Rac/Cdc42 GTPase-activating proteins.; N-terminome analysis of the human mitochondrial proteome.; PLEKHG4B enables actin cytoskeletal remodeling during epithelial cell-cell junction formation.; Recessive NOS1AP variants impair actin remodeling and cause glomerulopathy in humans and mice.; Definition of the switch surface in the solution structure of Cdc42Hs.; Identification of the binding surface on Cdc42Hs for p21-activated kinase.; Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP.; Nucleotide binding to the G12V-mutant of Cdc42 investigated by X-ray diffraction and fluorescence spectroscopy: two different nucleotide states in one crystal.; The structure determination of CDC42Hs and GDP complex.; Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI.; Activation of Rho GTPases by DOCK exchange factors is mediated by a nucleotide sensor.; Structural basis of Fic-mediated adenylylation.; DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses.; Macrothrombocytopenia and developmental delay with a de novo CDC42 mutation: Yet another locus for thrombocytopenia and developmental delay.; Further evidence of a mutation in CDC42 as a cause of a recognizable syndromic form of thrombocytopenia.",False
ARNTL,O00327,Basic helix-loop-helix ARNT-like protein 1,MADQRMDISSTISDFMSPGPTDLLSSSLGTSGVDCNRKRKGSSTDYQESMDTDKDDPHGRLEYTEHQGRIKNAREAHSQIEKRRRDKMNSFIDELASLVPTCNAMSRKLDKLTVLRMAVQHMKTLRGATNPYTEANYKPTFLSDDELKHLILRAADGFLFVVGCDRGKILFVSESVFKILNYSQNDLIGQSLFDYLHPKDIAKVKEQLSSSDTAPRERLIDAKTGLPVKTDITPGPSRLCSGARRSFFCRMKCNRPSVKVEDKDFPSTCSKKKADRKSFCTIHSTGYLKSWPPTKMGLDEDNEPDNEGCNLSCLVAIGRLHSHVVPQPVNGEIRVKSMEYVSRHAIDGKFVFVDQRATAILAYLPQELLGTSCYEYFHQDDIGHLAECHRQVLQTREKITTNCYKFKIKDGSFITLRSRWFSFMNPWTKEVEYIVSTNTVVLANVLEGGDPTFPQLTASPHSMDSMLPSGEGGPKRTHPTVPGIPGGTRAGAGKIGRMIAEEIMEIHRIRGSSPSSCGSSPLNITSTPPPDASSPGGKKILNGGTPDIPSSGLLSGQAQENPGYPYSDSSSILGENPHIGIDMIDNDQGSSSPSNDEAAMAVIMSLLEADAGLGGPVDFSDLPWPL,,,"cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage.; Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway.; JAP3: a novel ARNT-like bHLH-PAS protein.; The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; ARNTL resequence.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Role of the CLOCK protein in the mammalian circadian mechanism.; Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors.; Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2.; Histone acetyltransferase-dependent chromatin remodeling and the vascular clock.; Feedback repression is required for mammalian circadian clock function.; CLOCK/BMAL1 regulates human nocturnin transcription through binding to the E-box of nocturnin promoter.; Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock.; Mechanism of the circadian clock in physiology.; The clock gene brain and muscle Arnt-like protein-1 (BMAL1) is involved in hair growth.; p75 neurotrophin receptor is a clock gene that regulates oscillatory components of circadian and metabolic networks.; Metabolism and the circadian clock converge.; Gene model 129 (Gm129) encodes a novel transcriptional repressor that modulates circadian gene expression.; A meeting of two chronobiological systems: circadian proteins Period1 and BMAL1 modulate the human hair cycle clock.; The E3 ubiquitin ligase UBE3A is an integral component of the molecular circadian clock through regulating the BMAL1 transcription factor.; Molecular architecture of the mammalian circadian clock.; Cancer/testis antigen PASD1 silences the circadian clock.; CLOCK acetylates ASS1 to drive circadian rhythm of ureagenesis.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating the stability and activity of BMAL1 and CLOCK.; Deubiquitinating enzyme USP9X regulates cellular clock function by modulating the ubiquitination and degradation of a core circadian protein BMAL1.; Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-specific circadian networks.; The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.; Intermolecular recognition revealed by the complex structure of human CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA.",False
CLOCK,O15516,Circadian locomoter output cycles protein kaput,MLFTVSCSKMSSIVDRDDSSIFDGLVEEDDKDKAKRVSRNKSEKKRRDQFNVLIKELGSMLPGNARKMDKSTVLQKSIDFLRKHKEITAQSDASEIRQDWKPTFLSNEEFTQLMLEALDGFFLAIMTDGSIIYVSESVTSLLEHLPSDLVDQSIFNFIPEGEHSEVYKILSTHLLESDSLTPEYLKSKNQLEFCCHMLRGTIDPKEPSTYEYVKFIGNFKSLNSVSSSAHNGFEGTIQRTHRPSYEDRVCFVATVRLATPQFIKEMCTVEEPNEEFTSRHSLEWKFLFLDHRAPPIIGYLPFEVLGTSGYDYYHVDDLENLAKCHEHLMQYGKGKSCYYRFLTKGQQWIWLQTHYYITYHQWNSRPEFIVCTHTVVSYAEVRAERRRELGIEESLPETAADKSQDSGSDNRINTVSLKEALERFDHSPTPSASSRSSRKSSHTAVSDPSSTPTKIPTDTSTPPRQHLPAHEKMVQRRSSFSSQSINSQSVGSSLTQPVMSQATNLPIPQGMSQFQFSAQLGAMQHLKDQLEQRTRMIEANIHRQQEELRKIQEQLQMVHGQGLQMFLQQSNPGLNFGSVQLSSGNSSNIQQLAPINMQGQVVPTNQIQSGMNTGHIGTTQHMIQQQTLQSTSTQSQQNVLSGHSQQTSLPSQTQSTLTAPLYNTMVISQPAAGSMVQIPSSMPQNSTQSAAVTTFTQDRQIRFSQGQQLVTKLVTAPVACGAVMVPSTMLMGQVVTAYPTFATQQQQSQTLSVTQQQQQQSSQEQQLTSVQQPSQAQLTQPPQQFLQTSRLLHGNPSTQLILSAAFPLQQSTFPQSHHQQHQSQQQQQLSRHRTDSLPDPSKVQPQ,,,"Molecular cloning and characterization of the human CLOCK gene: expression in the suprachiasmatic nuclei.; Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular cloning of human Clock cDNA 5'-end.; Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors.; Histone acetyltransferase-dependent chromatin remodeling and the vascular clock.; Feedback repression is required for mammalian circadian clock function.; CLOCK/BMAL1 regulates human nocturnin transcription through binding to the E-box of nocturnin promoter.; The transcriptional repressor ID2 can interact with the canonical clock components CLOCK and BMAL1 and mediate inhibitory effects on mPer1 expression.; Biochemical analysis of the canonical model for the mammalian circadian clock.; Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.; A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling.; Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock.; Diurnal expression of the thrombopoietin gene is regulated by CLOCK.; Mechanism of the circadian clock in physiology.; Cyclin-dependent kinase 5 (Cdk5) regulates the function of CLOCK protein by direct phosphorylation.; p75 neurotrophin receptor is a clock gene that regulates oscillatory components of circadian and metabolic networks.; CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the transcriptional activity of estrogen receptor-alpha.; Metabolism and the circadian clock converge.; A meeting of two chronobiological systems: circadian proteins Period1 and BMAL1 modulate the human hair cycle clock.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Molecular architecture of the mammalian circadian clock.; Cancer/testis antigen PASD1 silences the circadian clock.; CLOCK acetylates ASS1 to drive circadian rhythm of ureagenesis.; Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating the stability and activity of BMAL1 and CLOCK.; Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-specific circadian networks.; Intermolecular recognition revealed by the complex structure of human CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA.",False
HIC1,Q14526,Hypermethylated in cancer 1 protein,MTFPEADILLKSGECAGQTMLDTMEAPGHSRQLLLQLNNQRTKGFLCDVIIVVQNALFRAHKNVLAASSAYLKSLVVHDNLLNLDHDMVSPAVFRLVLDFIYTGRLADGAEAAAAAAVAPGAEPSLGAVLAAASYLQIPDLVALCKKRLKRHGKYCHLRGGGGGGGGYAPYGRPGRGLRAATPVIQACYPSPVGPPPPPAAEPPSGPEAAVNTHCAELYASGPGPAAALCASERRCSPLCGLDLSKKSPPGSAAPERPLAERELPPRPDSPPSAGPAAYKEPPLALPSLPPLPFQKLEEAAPPSDPFRGGSGSPGPEPPGRPDGPSLLYRWMKHEPGLGSYGDELGRERGSPSERCEERGGDAAVSPGGPPLGLAPPPRYPGSLDGPGAGGDGDDYKSSSEETGSSEDPSPPGGHLEGYPCPHLAYGEPESFGDNLYVCIPCGKGFPSSEQLNAHVEAHVEEEEALYGRAEAAEVAAGAAGLGPPFGGGGDKVAGAPGGLGELLRPYRCASCDKSYKDPATLRQHEKTHWLTRPYPCTICGKKFTQRGTMTRHMRSHLGLKPFACDACGMRFTRQYRLTEHMRIHSGEKPYECQVCGGKFAQQRNLISHMKMHAVGGAAGAAGALAGLGGLPGVPGPDGKGKLDFPEGVFAVARLTAEQLSLKQQDKAAAAELLAQTTHFLHDPKVALESLYPLAKFTAELGLSPDKAAEVLSQGAHLAAGPDGRTIDRFSPT,,,"p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.; Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1.; The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif.; The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties.; Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.; Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta.; HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies.; A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP.; An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.; Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex.; Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma.; HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A.; Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1).; Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells.; A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.",False
PAPPA,Q13219,Pappalysin-1,MRLWSWVLHLGLLSAALGCGLAERPRRARRDPRAGRPPRPAAGPATCATRAARGRRASPPPPPPPGGAWEAVRVPRRRQQREARGATEEPSPPSRALYFSGRGEQLRLRADLELPRDAFTLQVWLRAEGGQRSPAVITGLYDKCSYISRDRGWVVGIHTISDQDNKDPRYFFSLKTDRARQVTTINAHRSYLPGQWVYLAATYDGQFMKLYVNGAQVATSGEQVGGIFSPLTQKCKVLMLGGSALNHNYRGYIEHFSLWKVARTQREILSDMETHGAHTALPQLLLQENWDNVKHAWSPMKDGSSPKVEFSNAHGFLLDTSLEPPLCGQTLCDNTEVIASYNQLSSFRQPKVVRYRVVNLYEDDHKNPTVTREQVDFQHHQLAEAFKQYNISWELDVLEVSNSSLRRRLILANCDISKIGDENCDPECNHTLTGHDGGDCRHLRHPAFVKKQHNGVCDMDCNYERFNFDGGECCDPEITNVTQTCFDPDSPHRAYLDVNELKNILKLDGSTHLNIFFAKSSEEELAGVATWPWDKEALMHLGGIVLNPSFYGMPGHTHTMIHEIGHSLGLYHVFRGISEIQSCSDPCMETEPSFETGDLCNDTNPAPKHKSCGDPGPGNDTCGFHSFFNTPYNNFMSYADDDCTDSFTPNQVARMHCYLDLVYQGWQPSRKPAPVALAPQVLGHTTDSVTLEWFPPIDGHFFERELGSACHLCLEGRILVQYASNASSPMPCSPSGHWSPREAEGHPDVEQPCKSSVRTWSPNSAVNPHTVPPACPEPQGCYLELEFLYPLVPESLTIWVTFVSTDWDSSGAVNDIKLLAVSGKNISLGPQNVFCDVPLTIRLWDVGEEVYGIQIYTLDEHLEIDAAMLTSTADTPLCLQCKPLKYKVVRDPPLQMDVASILHLNRKFVDMDLNLGSVYQYWVITISGTEESEPSPAVTYIHGSGYCGDGIIQKDQGEQCDDMNKINGDGCSLFCRQEVSFNCIDEPSRCYFHDGDGVCEEFEQKTSIKDCGVYTPQGFLDQWASNASVSHQDQQCPGWVIIGQPAASQVCRTKVIDLSEGISQHAWYPCTISYPYSQLAQTTFWLRAYFSQPMVAAAVIVHLVTDGTYYGDQKQETISVQLLDTKDQSHDLGLHVLSCRNNPLIIPVVHDLSQPFYHSQAVRVSFSSPLVAISGVALRSFDNFDPVTLSSCQRGETYSPAEQSCVHFACEKTDCPELAVENASLNCSSSDRYHGAQCTVSCRTGYVLQIRRDDELIKSQTGPSVTVTCTEGKWNKQVACEPVDCSIPDHHQVYAASFSCPEGTTFGSQCSFQCRHPAQLKGNNSLLTCMEDGLWSFPEALCELMCLAPPPVPNADLQTARCRENKHKVGSFCKYKCKPGYHVPGSSRKSKKRAFKTQCTQDGSWQEGACVPVTCDPPPPKFHGLYQCTNGFQFNSECRIKCEDSDASQGLGSNVIHCRKDGTWNGSFHVCQEMQGQCSVPNELNSNLKLQCPDGYAIGSECATSCLDHNSESIILPMNVTVRDIPHWLNPTRVERVVCTAGLKWYPHPALIHCVKGCEPFMGDNYCDAINNRAFCNYDGGDCCTSTVKTKKVTPFPMSCDLQGDCACRDPQAQEHSRKDLRGYSHG,,,"Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP.; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA.; Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein.; Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein. Disulfide structure and carbohydrate attachment sites.; The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.; Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor.; Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta.; Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues.; Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma.; Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A.; Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene.",False
ADCY5,O95622,Adenylate cyclase type 5,MSGSKSVSPPGYAAQKTAAPAPRGGPEHRSAWGEADSRANGYPHAPGGSARGSTKKPGGAVTPQQQQRLASRWRSDDDDDPPLSGDDPLAGGFGFSFRSKSAWQERGGDDCGRGSRRQRRGAASGGSTRAPPAGGGGGSAAAAASAGGTEVRPRSVEVGLEERRGKGRAADELEAGAVEGGEGSGDGGSSADSGSGAGPGAVLSLGACCLALLQIFRSKKFPSDKLERLYQRYFFRLNQSSLTMLMAVLVLVCLVMLAFHAARPPLQLPYLAVLAAAVGVILIMAVLCNRAAFHQDHMGLACYALIAVVLAVQVVGLLLPQPRSASEGIWWTVFFIYTIYTLLPVRMRAAVLSGVLLSALHLAIALRTNAQDQFLLKQLVSNVLIFSCTNIVGVCTHYPAEVSQRQAFQETRECIQARLHSQRENQQQERLLLSVLPRHVAMEMKADINAKQEDMMFHKIYIQKHDNVSILFADIEGFTSLASQCTAQELVMTLNELFARFDKLAAENHCLRIKILGDCYYCVSGLPEARADHAHCCVEMGMDMIEAISLVREVTGVNVNMRVGIHSGRVHCGVLGLRKWQFDVWSNDVTLANHMEAGGKAGRIHITKATLNYLNGDYEVEPGCGGERNAYLKEHSIETFLILRCTQKRKEEKAMIAKMNRQRTNSIGHNPPHWGAERPFYNHLGGNQVSKEMKRMGFEDPKDKNAQESANPEDEVDEFLGRAIDARSIDRLRSEHVRKFLLTFREPDLEKKYSKQVDDRFGAYVACASLVFLFICFVQITIVPHSIFMLSFYLTCSLLLTLVVFVSVIYSCVKLFPSPLQTLSRKIVRSKMNSTLVGVFTITLVFLAAFVNMFTCNSRDLLGCLAQEHNISASQVNACHVAESAVNYSLGDEQGFCGSPWPNCNFPEYFTYSVLLSLLACSVFLQISCIGKLVLMLAIELIYVLIVEVPGVTLFDNADLLVTANAIDFFNNGTSQCPEHATKVALKVVTPIIISVFVLALYLHAQQVESTARLDFLWKLQATEEKEEMEELQAYNRRLLHNILPKDVAAHFLARERRNDELYYQSCECVAVMFASIANFSEFYVELEANNEGVECLRLLNEIIADFDEIISEDRFRQLEKIKTIGSTYMAASGLNDSTYDKVGKTHIKALADFAMKLMDQMKYINEHSFNNFQMKIGLNIGPVVAGVIGARKPQYDIWGNTVNVASRMDSTGVPDRIQVTTDMYQVLAANTYQLECRGVVKVKGKGEMMTYFLNGGPPLS,,,"Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence, annotation and analysis of human chromosome 3.; Characterization of the human adenylyl cyclase gene family: cDNA, gene structure, and tissue distribution of the nine isoforms.; Cloning and sequence of partial cDNAs encoding the human type V and VI adenylyl cyclases and subsequent RNA-quantification in various tissues.; Raf kinase activation of adenylyl cyclases: isoform-selective regulation.; ADCY5 couples glucose to insulin secretion in human islets.; Adenylyl cyclase 5 regulation by Gbetagamma involves isoform specific use of multiple interaction sites.; Autosomal dominant familial dyskinesia and facial myokymia: single exome sequencing identifies a mutation in adenylyl cyclase 5.; Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia.; ADCY5 mutations are another cause of benign hereditary chorea.; Autosomal recessive inheritance of ADCY5-related generalized dystonia and myoclonus.; Autosomal recessive ADCY5-Related dystonia and myoclonus: Expanding the genetic spectrum of ADCY5-Related movement disorders.; Homozygous ADCY5 mutation causes early-onset movement disorder with severe intellectual disability.; A Novel Homozygous ADCY5 Variant is Associated with a Neurodevelopmental Disorder and Movement Abnormalities.",False
PPARGC1A,Q9UBK2,Peroxisome proliferator-activated receptor gamma coactivator 1-alpha,MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSDQSEIISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGDVTTDNEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHANHNHRIRTNPAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCTSKKKSHTQSQSQHLQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTTPPHKANQDNPFRASPKLKSSCKTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLSKSSVLTGGHEERKTKRPSLRLFGDHDYCQSINSKTEILINISQELQDSRQLENKDVSSDWQGQICSSTDSDQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPSQAVFDDEADKTGELRDSDFSNEQFSKLPMFINSGLAMDGLFDDSEDESDKLSYPWDGTQSYSLFNVSPSCSSFNSPCRDSVSPPKSLFSQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSRSRSPYSRRPRYDSYEEYQHERLKREEYRREYEKRESERAKQRERQRQKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEECTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKSNYADLDSNSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR,,,"Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression.; Cloning and mRNA tissue distribution of human PPARgamma coactivator-1.; A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen.; Characterization of novel peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) isoform in human liver.; A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.; Isoform of PGC-1 generated by alternative splicing.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; Defects in energy homeostasis in Leigh syndrome French Canadian variant through PGC-1alpha/LRP130 complex.; GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha.; Nutrient-dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5.; PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease.; The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis.; RNF34 is a cold-regulated E3 ubiquitin ligase for PGC-1alpha and modulates brown fat cell metabolism.; Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1)- and estrogen-related receptor (ERR)-induced regulator in muscle 1 (Perm1) is a tissue-specific regulator of oxidative capacity in skeletal muscle cells.; Integrated structural modeling of full-length LRH-1 reveals inter-domain interactions contribute to receptor structure and function.; Structure and dynamics of the liver receptor homolog 1-PGC1alpha complex.",False
GPX4,P36969,Phospholipid hydroperoxide glutathione peroxidase GPX4,MSLGRLCRLLKPALLCGALAAPGLAGTMCASRDDWRCARSMHEFSAKDIDGHMVNLDKYRGFVCIVTNVASQUGKTEVNYTQLVDLHARYAECGLRILAFPCNQFGKQEPGSNEEIKEFAAGYNVKFDMFSKICVNGDDAHPLWKWMKIQPKGKGILGNAIKWNFTKFLIDKNGCVVKRYGPMEEPLVIEKDLPHYF,,,"Cloning and sequencing of the cDNA encoding a human testis phospholipid hydroperoxide glutathione peroxidase.; Structural organization of the human selenium-dependent phospholipid hydroperoxide glutathione peroxidase gene (GPX4): chromosomal localization to 19p13.3.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism.; Initial characterization of the human central proteome.; Regulation of ferroptotic cancer cell death by GPX4.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Side-by-side comparison of recombinant human glutathione peroxidases identifies overlapping substrate specificities for soluble hydroperoxides.; FUNDC1 interacts with GPx4 to govern hepatic ferroptosis and fibrotic injury through a mitophagy-dependent manner.; Structural basis for catalytic activity and enzyme polymerization of phospholipid hydroperoxide glutathione peroxidase-4 (GPx4).; Crystal structure of the selenocysteine to glycine mutant of human glutathione peroxidase 4 (GPX4).; Discovery of GPX4 inhibitory peptides from random peptide T7 phage display and subsequent structural analysis.; Genetic variations of gpx-4 and male infertility in humans.; Mutations in the enzyme glutathione peroxidase 4 cause Sedaghatian-type spondylometaphyseal dysplasia.",False
UCP1,P25874,Mitochondrial brown fat uncoupling protein 1,MGGLTASDVHPTLGVQLFSAGIAACLADVITFPLDTAKVRLQVQGECPTSSVIRYKGVLGTITAVVKTEGRMKLYSGLPAGLQRQISSASLRIGLYDTVQEFLTAGKETAPSLGSKILAGLTTGGVAVFIGQPTEVVKVRLQAQSHLHGIKPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMKEAFVKNNILADDVPCHLVSALIAGFCATAMSSPVDVVKTRFINSPPGQYKSVPNCAMKVFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT,,,"Human uncoupling protein gene: structure, comparison with rat gene, and assignment to the long arm of chromosome 4.; Sequence of the cDNA coding for the human uncoupling protein UCP.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Detection of brown adipose tissue uncoupling protein mRNA in adult patients by a human genomic probe.; Expression, folding, and proton transport activity of human uncoupling protein-1 (UCP1) in lipid membranes: evidence for associated functional forms.; The mitochondrial transporter family SLC25: identification, properties and physiopathology.; A polymorphism in the 5' untranslated region and a Met229-->Leu variant in exon 5 of the human UCP1 gene are associated with susceptibility to type II diabetes mellitus.; Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio.; Specific Interaction of the Human Mitochondrial Uncoupling Protein 1 with Free Long-Chain Fatty Acid.",False
FGF23,Q9GZV9,Fibroblast growth factor 23,MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGHVDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTLENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPIPRRHTRSAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGTGPEGCRPFAKFI,,,"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.; Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.; Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.; The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.; The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.; Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.; FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.; FGF23 is processed by proprotein convertases but not by PHEX.; FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.; Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.; Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.; Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro.; Fibroblast growth factor signalling: from development to cancer.; Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.; Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.; A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.; An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.; A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.; A new missense mutation in FGF23 gene in a male with hyperostosis-hyperphosphatemia syndrome (HHS).",False
EFEMP1,Q12805,EGF-containing fibulin-like extracellular matrix protein 1,MLKALFLTMLTLALVKSQDTEETITYTQCTDGYEWDPVRQQCKDIDECDIVPDACKGGMKCVNHYGGYLCLPKTAQIIVNNEQPQQETQPAEGTSGATTGVVAASSMATSGVLPGGGFVASAAAVAGPEMQTGRNNFVIRRNPADPQRIPSNPSHRIQCAAGYEQSEHNVCQDIDECTAGTHNCRADQVCINLRGSFACQCPPGYQKRGEQCVDIDECTIPPYCHQRCVNTPGSFYCQCSPGFQLAANNYTCVDINECDASNQCAQQCYNILGSFICQCNQGYELSSDRLNCEDIDECRTSSYLCQYQCVNEPGKFSCMCPQGYQVVRSRTCQDINECETTNECREDEMCWNYHGGFRCYPRNPCQDPYILTPENRCVCPVSNAMCRELPQSIVYKYMSIRSDRSVPSDIFQIQATTIYANTINTFRIKSGNENGEFYLRQTSPVSAMLVLVKSLSGPREHIVDLEMLTVSSIGTFRTSSVLRLTIIVGPFSF,,,"An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis.; Structure and chromosomal assignment of the human S1-5 gene (FBNL) that is highly homologous to fibrillin.; Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4.; EFEMP1 is not associated with sporadic early onset drusen.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration.; Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations.; EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.; ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain.; Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.; Fibulin-3 negatively regulates chondrocyte differentiation.; Resveratrol-induced changes of the human adipocyte secretion profile.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; A single EFEMP1 mutation associated with both malattia Leventinese and Doyne honeycomb retinal dystrophy.; Dominant radial drusen and Arg345Trp EFEMP1 mutation.; The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice.; Exome sequencing identifies a missense variant in EFEMP1 co-segregating in a family with autosomal dominant primary open-angle glaucoma.; Biallelic variants in EFEMP1 in a man with a pronounced connective tissue phenotype.; Recessive marfanoid syndrome with herniation associated with a homozygous mutation in Fibulin-3.; Loss-of-Function Variants in EFEMP1 Cause a Recognizable Connective Tissue Disorder Characterized by Cutis Laxa and Multiple Herniations.; EFEMP1 rare variants cause familial juvenile-onset open-angle glaucoma.; EFEMP1 rare variants cause familial juvenile-onset open-angle glaucoma.; A loss-of-function cysteine mutant in fibulin-3 (EFEMP1) forms aberrant extracellular disulfide-linked homodimers and alters extracellular matrix composition.",False
ERCC4,Q92889,DNA repair endonuclease XPF,MESGQPARRIAMAPLLEYERQLVLELLDTDGLVVCARGLGADRLLYHFLQLHCHPACLVLVLNTQPAEEEYFINQLKIEGVEHLPRRVTNEITSNSRYEVYTQGGVIFATSRILVVDFLTDRIPSDLITGILVYRAHRIIESCQEAFILRLFRQKNKRGFIKAFTDNAVAFDTGFCHVERVMRNLFVRKLYLWPRFHVAVNSFLEQHKPEVVEIHVSMTPTMLAIQTAILDILNACLKELKCHNPSLEVEDLSLENAIGKPFDKTIRHYLDPLWHQLGAKTKSLVQDLKILRTLLQYLSQYDCVTFLNLLESLRATEKAFGQNSGWLFLDSSTSMFINARARVYHLPDAKMSKKEKISEKMEIKEGEETKKELVLESNPKWEALTEVLKEIEAENKESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEKDSKAEEVWMKFRKEDSSKRIRKSHKRPKDPQNKERASTKERTLKKKKRKLTLTQMVGKPEELEEEGDVEEGYRREISSSPESCPEEIKHEEFDVNLSSDAAFGILKEPLTIIHPLLGCSDPYALTRVLHEVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGRDETNLDLVRGTASADVSTDTRKAGGQEQNGTQQSIVVDMREFRSELPSLIHRRGIDIEPVTLEVGDYILTPEMCVERKSISDLIGSLNNGRLYSQCISMSRYYKRPVLLIEFDPSKPFSLTSRGALFQEISSNDISSKLTLLTLHFPRLRILWCPSPHATAELFEELKQSKPQPDAATALAITADSETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANAKQLYDFIHTSFAEVVSKGKGKK,,,"ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease.; A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.; Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.; Contribution of XPF functional domains to the 5' and 3' incisions produced at the site of a psoralen interstrand cross-link.; Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.; Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases.; Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair.; Drosophila MUS312 and the vertebrate ortholog BTBD12 interact with DNA structure-specific endonucleases in DNA repair and recombination.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.; Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.; The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair.; Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans.; Characterization of molecular defects in Xeroderma pigmentosum group F in relation to its clinically mild symptoms.; Homozygous R788W point mutation in the XPF gene of a patient with xeroderma pigmentosum and late-onset neurologic disease.; Polymorphisms in the human DNA repair gene XPF.; A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis.; Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia.; Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia.; Evaluation of rare variants in the new fanconi anemia gene ERCC4 (FANCQ) as familial breast/ovarian cancer susceptibility alleles.",False
CETP,P11597,Cholesteryl ester transfer protein,MLAATVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQTAFQRASYPDITGEKAMMLLGQVKYGLHNIQISHLSIASSQVELVEAKSIDVSIQNVSVVFKGTLKYGYTTAWWLGIDQSIDFEIDSAIDLQINTQLTCDSGRVRTDAPDCYLSFHKLLLHLQGEREPGWIKQLFTNFISFTLKLVLKGQICKEINVISNIMADFVQTRAASILSDGDIGVDISLTGDPVITASYLESHHKGHFIYKNVSEDLPLPTFSPTLLGDSRMLYFWFSERVFHSLAKVAFQDGRLMLSLMGDEFKAVLETWGFNTNQEIFQEVVGGFPSQAQVTVHCLKMPKISCQNKGVVVNSSVMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKLFLSLLDFQITPKTVSNLTESSSESVQSFLQSMITAVGIPEVMSRLEVVFTALMNSKGVSLFDIINPEIITRDGFLLLQMDFGFPEHLLVDFLQSLS,,,"Cloning and sequencing of human cholesteryl ester transfer protein cDNA.; Organization of the human cholesteryl ester transfer protein gene.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5'-distal sequences. Cis-acting sequences mapped in transgenic mice.; Sequencing of the cholesteryl ester transfer protein 5' regulatory region using artificial transposons.; Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; Cholesteryl ester transfer proteins from different species do not have equivalent activities.; Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.; Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.; A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.; Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay.; Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors.",False
PPARG,P37231,Peroxisome proliferator-activated receptor gamma,MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY,,,"Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.; Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.; Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue.; Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.; No coding mutations are detected in the peroxisome proliferator-activated receptor-gamma gene in Japanese patients with lipoatrophic diabetes.; A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs.; Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human Protein Factory: an infrastructure to convert the human transcriptome into the in vitro-expressed human proteome of versatile utility.; The DNA sequence, annotation and analysis of human chromosome 3.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and characterization of RAP250, a nuclear receptor coactivator.; Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.; Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha.; ERAP140, a conserved tissue-specific nuclear receptor coactivator.; ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor.; Hic-5 regulates an epithelial program mediated by PPARgamma.; Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the DNA-binding domain of peroxisome proliferator-activated receptor gamma.; 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.; Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.; The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.; Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma.; Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}.; Familial focal segmental glomerulosclerosis (FSGS)-linked alpha-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation.; Mycobacterium tuberculosis 19-kDa lipoprotein induces Toll-like receptor 2-dependent peroxisome proliferator-activated receptor gamma expression and promotes inflammatory responses in human macrophages.; Nuclear hormone receptors: Ancient 9aaTAD and evolutionally gained NCoA activation pathways.; Lysine 222 in PPAR gamma1 functions as the key site of MuRF2-mediated ubiquitination modification.; Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma.; Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.; Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.; Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.; Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.; Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.; A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.; Structure-based design of potent retinoid X receptor alpha agonists.; Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.; Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner.; Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.; Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.; Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.; Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR-gamma) gene in diabetic Caucasians: identification of a pro12ala PPAR-gamma-2 missense mutation.; Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.; A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.; Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects.; Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women.; Loss-of-function mutations in PPAR-gamma associated with human colon cancer.; Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension.; PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.; A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.; Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis.; Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.; Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects.",False
AGTR1,P30556,Type-1 angiotensin II receptor,MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE,,,"Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor.; Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor.; Cloning and characterization of a human angiotensin II type 1 receptor.; Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor.; Genetic analysis of the human type-1 angiotensin II receptor.; Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression.; Type 1 angiotensin II receptors of adrenal tumors.; Cloning and sequencing of a human cDNA encoding the angiotensin II receptor type 1.; Rapid identification of polymorphisms in genomic DNA: a high density SNP map of the type I angiotensin II receptor gene locus on chromosome 3q.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The active state of the AT1 angiotensin receptor is generated by angiotensin II induction.; G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor.; beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation.; A strategy for precise and large scale identification of core fucosylated glycoproteins.; G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and Promote Filamin Phosphorylation.; Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.; Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.; Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.; Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody.; Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR.; Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis.",False
CISD2,Q8N5K1,CDGSH iron-sulfur domain-containing protein 2,MVLESVARIVKVQLPAYLKRLPVPESITGFARLTVSEWLRLLPFLGVLALLGYLAVRPFLPKKKQQKDSLINLKIQKENPKVVNEINIEDLCLTKAAYCRCWRSKTFPACDGSHNKHNELTGDNVGPLILKKKEV,,,"A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity.; Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1.; Initial characterization of the human central proteome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; N-terminome analysis of the human mitochondrial proteome.; Crystal structure of Miner1: The redox-active 2Fe-2S protein causative in Wolfram Syndrome 2.",False
EEF1E1,O43324,Eukaryotic translation elongation factor 1 epsilon-1,MAAAAELSLLEKSLGLSKGNKYSAQGERQIPVLQTNNGPSLTGLTTIAAHLVKQANKEYLLGSTAEEKAIVQQWLEYRVTQVDGHSSKNDIHTLLKDLNSYLEDKVYLTGYNFTLADILLYYGLHRFIVDLTVQEKEKYLNVSRWFCHIQHYPGIRQHLSSVVFIKNRLYTNSH,,,"Cloning of cDNA for human p18 from human testis.; Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR.; Dissection of the structural organization of the aminoacyl-tRNA synthetase complex.; Dynamic Organization of Aminoacyl-tRNA Synthetase Complexes in the Cytoplasm of Human Cells.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; Determination of three-dimensional structure and residues of the novel tumor suppressor AIMP3/p18 required for the interaction with ATM.; Assembly of Multi-tRNA Synthetase Complex via Heterotetrameric Glutathione Transferase-homology Domains.",False
EPS8,Q12929,Epidermal growth factor receptor kinase substrate 8,MNGHISNHPSSFGMYPSQMNGYGSSPTFSQTDREHGSKTSAKALYEQRKNYARDSVSSVSDISQYRVEHLTTFVLDRKDAMITVDDGIRKLKLLDAKGKVWTQDMILQVDDRAVSLIDLESKNELENFPLNTIQHCQAVMHSCSYDSVLALVCKEPTQNKPDLHLFQCDEVKANLISEDIESAISDSKGGKQKRRPDALRMISNADPSIPPPPRAPAPAPPGTVTQVDVRSRVAAWSAWAADQGDFEKPRQYHEQEETPEMMAARIDRDVQILNHILDDIEFFITKLQKAAEAFSELSKRKKNKKGKRKGPGEGVLTLRAKPPPPDEFLDCFQKFKHGFNLLAKLKSHIQNPSAADLVHFLFTPLNMVVQATGGPELASSVLSPLLNKDTIDFLNYTVNGDERQLWMSLGGTWMKARAEWPKEQFIPPYVPRFRNGWEPPMLNFMGATMEQDLYQLAESVANVAEHQRKQEIKRLSTEHSSVSEYHPADGYAFSSNIYTRGSHLDQGEAAVAFKPTSNRHIDRNYEPLKTQPKKYAKSKYDFVARNNSELSVLKDDILEILDDRKQWWKVRNASGDSGFVPNNILDIVRPPESGLGRADPPYTHTIQKQRMEYGPRPADTPPAPSPPPTPAPVPVPLPPSTPAPVPVSKVPANITRQNSSSSDSGGSIVRDSQRHKQLPVDRRKSQMEEVQDELIHRLTIGRSAAQKKFHVPRQNVPVINITYDSTPEDVKTWLQSKGFNPVTVNSLGVLNGAQLFSLNKDELRTVCPEGARVYSQITVQKAALEDSSGSSELQEIMRRRQEKISAAASDSGVESFDEGSSH,,,"Evolutionary conservation of the EPS8 gene and its mapping to human chromosome 12q23-q24.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The finished DNA sequence of human chromosome 12.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Molecular interactions of the Src homology 2 domain protein Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 domain proteins.; Overexpression of p97Eps8 leads to cellular transformation: implication of pleckstrin homology domain in p97Eps8-mediated ERK activation.; IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness.; Eps8 controls actin-based motility by capping the barbed ends of actin filaments.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Regulation of cell shape by Cdc42 is mediated by the synergic actin-bundling activity of the Eps8-IRSp53 complex.; Eps8 is increased in pancreatic cancer and required for dynamic actin-based cell protrusions and intercellular cytoskeletal organization.; Eps8 decreases chemosensitivity and affects survival of cervical cancer patients.; A quantitative atlas of mitotic phosphorylation.; Role for EPS8 in squamous carcinogenesis.; Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival.; Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; EPS8, encoding an actin-binding protein of cochlear hair cell stereocilia, is a new causal gene for autosomal recessive profound deafness.; Solution structure of the C-terminal SAM-domain of epidermal growth receptor pathway substrate 8.; Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP.",False
KCNA3,P22001,Potassium voltage-gated channel subfamily A member 3,MDERLSLLRSPPPPSARHRAHPPQRPASSGGAHTLVNHGYAEPAAGRELPPDMTVVPGDHLLEPEVADGGGAPPQGGCGGGGCDRYEPLPPSLPAAGEQDCCGERVVINISGLRFETQLKTLCQFPETLLGDPKRRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRIRRPVNVPIDIFSEEIRFYQLGEEAMEKFREDEGFLREEERPLPRRDFQRQVWLLFEYPESSGPARGIAIVSVLVILISIVIFCLETLPEFRDEKDYPASTSQDSFEAAGNSTSGSRAGASSFSDPFFVVETLCIIWFSFELLVRFFACPSKATFSRNIMNLIDIVAIIPYFITLGTELAERQGNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADDPTSGFSSIPDAFWWAVVTMTTVGYGDMHPVTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQSQYMHVGSCQHLSSSAEELRKARSNSTLSKSEYMVIEEGGMNHSAFPQTPFKTGNSTATCTTNNNPNSCVNIKKIFTDV,,,"Confirmation of the assignment of the gene encoding Kv1.3, a voltage-gated potassium channel (KCNA3) to the proximal short arm of human chromosome 1.; Sequence and functional expression in Xenopus oocytes of a human insulinoma and islet potassium channel.; Cloning, functional expression, and regulation of two K+ channels in human T lymphocytes.; Characterization and functional expression of genomic DNA encoding the human lymphocyte type n potassium channel.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of endogenous Kv1.3 channel isoforms in T cells.",False
SIRT7,Q9NRC8,NAD-dependent protein deacetylase sirtuin-7,MAAGGLSRSERKAAERVRRLREEQQRERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELRGKVRELASAVRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPTLTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTALHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTILCLGSSLKVLKKYPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMRLLMAELGLEIPAYSRWQDPIFSLATPLRAGEEGSHSRKSLCRSREEAPPGDRGAPLSSAPILGGWFGRGCTKRTKRKKVT,,,"Phylogenetic classification of prokaryotic and eukaryotic Sir-2 like proteins.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The full-ORF clone resource of the German cDNA consortium.; Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues.; 'SIRT8' expressed in thyroid cancer is actually SIRT7.; Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.; Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription.; Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis.; Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.; SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation.; Repression of RNA polymerase I upon stress is caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; SIRT7 is activated by DNA and deacetylates histone H3 in the chromatin context.; SIRT7-dependent deacetylation of the U3-55k protein controls pre-rRNA processing.; SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability.; SIRT7 is an RNA-activated protein lysine deacylase.; Regulation of serine-threonine kinase Akt activation by NAD+-dependent deacetylase SIRT7.; SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes.; SIRT7 and the DEAD-box helicase DDX21 cooperate to resolve genomic R loops and safeguard genome stability.; Ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination of the histone deacetylase SIRT7 regulates gluconeogenesis.; SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription.; SIRT7-dependent deacetylation of fibrillarin controls histone H2A methylation and rRNA synthesis during the cell cycle.; Arginine methylation of SIRT7 couples glucose sensing with mitochondria biogenesis.; The epigenetic regulator SIRT7 guards against mammalian cellular senescence induced by ribosomal DNA instability.; SIRT7 regulates the nuclear export of NF-kappaB p65 by deacetylating Ran.; A click chemistry approach reveals the chromatin-dependent histone H3K36 deacylase nature of SIRT7.; Glutarylation of histone H4 lysine 91 regulates chromatin dynamics.; SIRT7 mediates L1 elements transcriptional repression and their association with the nuclear lamina.; Potent Activation of NAD+-Dependent Deacetylase Sirt7 by Nucleosome Binding.; SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair.; E3 ligase adaptor FBXO7 contributes to ubiquitination and proteasomal degradation of SIRT7 and promotes cell death in response to hydrogen peroxide.; Crystal structure of the N-terminal domain of human SIRT7 reveals a three-helical domain architecture.",False
SLC13A1,Q9BZW2,Solute carrier family 13 member 1,MKFFSYILVYRRFLFVVFTVLVLLPLPIVLHTKEAECAYTLFVVATFWLTEALPLSVTALLPSLMLPMFGIMPSKKVASAYFKDFHLLLIGVICLATSIEKWNLHKRIALKMVMMVGVNPAWLTLGFMSSTAFLSMWLSNTSTAAMVMPIAEAVVQQIINAEAEVEATQMTYFNGSTNHGLEIDESVNGHEINERKEKTKPVPGYNNDTGKISSKVELEKNSGMRTKYRTKKGHVTRKLTCLCIAYSSTIGGLTTITGTSTNLIFAEYFNTRYPDCRCLNFGSWFTFSFPAALIILLLSWIWLQWLFLGFNFKEMFKCGKTKTVQQKACAEVIKQEYQKLGPIRYQEIVTLVLFIIMALLWFSRDPGFVPGWSALFSEYPGFATDSTVALLIGLLFFLIPAKTLTKTTPTGEIVAFDYSPLITWKEFQSFMPWDIAILVGGGFALADGCEESGLSKWIGNKLSPLGSLPAWLIILISSLMVTSLTEVASNPATITLFLPILSPLAEAIHVNPLYILIPSTLCTSFAFLLPVANPPNAIVFSYGHLKVIDMVKAGLGVNIVGVAVVMLGICTWIVPMFDLYTYPSWAPAMSNETMP,,,"The human renal sodium sulfate cotransporter (SLC13A1; hNaSi-1) cDNA and gene: organization, chromosomal localization, and functional characterization.; Complete sequencing and characterization of 21,243 full-length human cDNAs.",False
SOCS2,O14508,Suppressor of cytokine signaling 2,MTLRCLEPSGNGGEGTRSQWGTAGSAEEPSPQAARLAKALRELGQTGWYWGSMTVNEAKEKLKEAPEGTFLIRDSSHSDYLLTISVKTSAGPTNLRIEYQDGKFRLDSIICVKSKLKQFDSVVHLIDYYVQMCKDKRTGPEAPRNGTVHLYLTKPLYTSAPSLQHLCRLTINKCTGAIWGLPLPTRLKDYLEEYKFQV,,,"Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3.; Cloning and characterization of novel CIS family genes.; Cloning of a novel human gene coding human suppressor of cytokine signaling-2 (HsSOCS-2).; Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Radiation hybrid and cytogenetic mapping of SOCS1 and SOCS2 to chromosomes 16p13 and 12q, respectively.; Design and application of a cytokine-receptor-based interaction trap.; Initial characterization of the human central proteome.; The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels.; DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).; KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.; Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase.; Structural basis of intersubunit recognition in elongin BC-cullin 5-SOCS box ubiquitin-protein ligase complexes.; Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase.; Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands.; Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2.",False
TPP2,P29144,Tripeptidyl-peptidase 2,MATAATEEPFPFHGLLPKKETGAASFLCRYPEYDGRGVLIAVLDTGVDPGAPGMQVTTDGKPKIVDIIDTTGSGDVNTATEVEPKDGEIVGLSGRVLKIPASWTNPSGKYHIGIKNGYDFYPKALKERIQKERKEKIWDPVHRVALAEACRKQEEFDVANNGSSQANKLIKEELQSQVELLNSFEKKYSDPGPVYDCLVWHDGEVWRACIDSNEDGDLSKSTVLRNYKEAQEYGSFGTAEMLNYSVNIYDDGNLLSIVTSGGAHGTHVASIAAGHFPEEPERNGVAPGAQILSIKIGDTRLSTMETGTGLIRAMIEVINHKCDLVNYSYGEATHWPNSGRICEVINEAVWKHNIIYVSSAGNNGPCLSTVGCPGGTTSSVIGVGAYVSPDMMVAEYSLREKLPANQYTWSSRGPSADGALGVSISAPGGAIASVPNWTLRGTQLMNGTSMSSPNACGGIALILSGLKANNIDYTVHSVRRALENTAVKADNIEVFAQGHGIIQVDKAYDYLVQNTSFANKLGFTVTVGNNRGIYLRDPVQVAAPSDHGVGIEPVFPENTENSEKISLQLHLALTSNSSWVQCPSHLELMNQCRHINIRVDPRGLREGLHYTEVCGYDIASPNAGPLFRVPITAVIAAKVNESSHYDLAFTDVHFKPGQIRRHFIEVPEGATWAEVTVCSCSSEVSAKFVLHAVQLVKQRAYRSHEFYKFCSLPEKGTLTEAFPVLGGKAIEFCIARWWASLSDVNIDYTISFHGIVCTAPQLNIHASEGINRFDVQSSLKYEDLAPCITLKNWVQTLRPVSAKTKPLGSRDVLPNNRQLYEMVLTYNFHQPKSGEVTPSCPLLCELLYESEFDSQLWIIFDQNKRQMGSGDAYPHQYSLKLEKGDYTIRLQIRHEQISDLERLKDLPFIVSHRLSNTLSLDIHENHSFALLGKKKSSNLTLPPKYNQPFFVTSLPDDKIPKGAGPGCYLAGSLTLSKTELGKKADVIPVHYYLIPPPTKTKNGSKDKEKDSEKEKDLKEEFTEALRDLKIQWMTKLDSSDIYNELKETYPNYLPLYVARLHQLDAEKERMKRLNEIVDAANAVISHIDQTALAVYIAMKTDPRPDAATIKNDMDKQKSTLVDALCRKGCALADHLLHTQAQDGAISTDAEGKEEEGESPLDSLAETFWETTKWTDLFDNKVLTFAYKHALVNKMYGRGLKFATKLVEEKPTKENWKNCIQLMKLLGWTHCASFTENWLPIMYPPDYCVF,,,"The DNA sequence and analysis of human chromosome 13.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Nucleotide sequence of cDNA covering the N-terminus of human tripeptidyl peptidase II.; Characterization of cDNA for human tripeptidyl peptidase II: the N-terminal part of the enzyme is similar to subtilisin.; Immunological cross-reactivity between human tripeptidyl peptidase II and fibronectin.; Active site of tripeptidyl peptidase II from human erythrocytes is of the subtilisin type.; A role for nuclear translocation of tripeptidyl-peptidase II in reactive oxygen species-dependent DNA damage responses.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Dual proteolytic pathways govern glycolysis and immune competence.; TPP2 mutation associated with sterile brain inflammation mimicking MS.",False
TP53BP1,Q12888,TP53-binding protein 1,MDPTGSQLDSDFSQQDTPCLIIEDSQPESQVLEDDSGSHFSMLSRHLPNLQTHKENPVLDVVSNPEQTAGEERGDGNSGFNEHLKENKVADPVDSSNLDTCGSISQVIEQLPQPNRTSSVLGMSVESAPAVEEEKGEELEQKEKEKEEDTSGNTTHSLGAEDTASSQLGFGVLELSQSQDVEENTVPYEVDKEQLQSVTTNSGYTRLSDVDANTAIKHEEQSNEDIPIAEQSSKDIPVTAQPSKDVHVVKEQNPPPARSEDMPFSPKASVAAMEAKEQLSAQELMESGLQIQKSPEPEVLSTQEDLFDQSNKTVSSDGCSTPSREEGGCSLASTPATTLHLLQLSGQRSLVQDSLSTNSSDLVAPSPDAFRSTPFIVPSSPTEQEGRQDKPMDTSVLSEEGGEPFQKKLQSGEPVELENPPLLPESTVSPQASTPISQSTPVFPPGSLPIPSQPQFSHDIFIPSPSLEEQSNDGKKDGDMHSSSLTVECSKTSEIEPKNSPEDLGLSLTGDSCKLMLSTSEYSQSPKMESLSSHRIDEDGENTQIEDTEPMSPVLNSKFVPAENDSILMNPAQDGEVQLSQNDDKTKGDDTDTRDDISILATGCKGREETVAEDVCIDLTCDSGSQAVPSPATRSEALSSVLDQEEAMEIKEHHPEEGSSGSEVEEIPETPCESQGEELKEENMESVPLHLSLTETQSQGLCLQKEMPKKECSEAMEVETSVISIDSPQKLAILDQELEHKEQEAWEEATSEDSSVVIVDVKEPSPRVDVSCEPLEGVEKCSDSQSWEDIAPEIEPCAENRLDTKEEKSVEYEGDLKSGTAETEPVEQDSSQPSLPLVRADDPLRLDQELQQPQTQEKTSNSLTEDSKMANAKQLSSDAEAQKLGKPSAHASQSFCESSSETPFHFTLPKEGDIIPPLTGATPPLIGHLKLEPKRHSTPIGISNYPESTIATSDVMSESMVETHDPILGSGKGDSGAAPDVDDKLCLRMKLVSPETEASEESLQFNLEKPATGERKNGSTAVAESVASPQKTMSVLSCICEARQENEARSEDPPTTPIRGNLLHFPSSQGEEEKEKLEGDHTIRQSQQPMKPISPVKDPVSPASQKMVIQGPSSPQGEAMVTDVLEDQKEGRSTNKENPSKALIERPSQNNIGIQTMECSLRVPETVSAATQTIKNVCEQGTSTVDQNFGKQDATVQTERGSGEKPVSAPGDDTESLHSQGEEEFDMPQPPHGHVLHRHMRTIREVRTLVTRVITDVYYVDGTEVERKVTEETEEPIVECQECETEVSPSQTGGSSGDLGDISSFSSKASSLHRTSSGTSLSAMHSSGSSGKGAGPLRGKTSGTEPADFALPSSRGGPGKLSPRKGVSQTGTPVCEEDGDAGLGIRQGGKAPVTPRGRGRRGRPPSRTTGTRETAVPGPLGIEDISPNLSPDDKSFSRVVPRVPDSTRRTDVGAGALRRSDSPEIPFQAAAGPSDGLDASSPGNSFVGLRVVAKWSSNGYFYSGKITRDVGAGKYKLLFDDGYECDVLGKDILLCDPIPLDTEVTALSEDEYFSAGVVKGHRKESGELYYSIEKEGQRKWYKRMAVILSLEQGNRLREQYGLGPYEAVTPLTKAADISLDNLVEGKRKRRSNVSSPATPTASSSSSTTPTRKITESPRASMGVLSGKRKLITSEEERSPAKRGRKSATVKPGAVGAGEFVSPCESGDNTGEPSALEEQRGPLPLNKTLFLGYAFLLTMATTSDKLASRSKLPDGPTGSSEEEEEFLEIPPFNKQYTESQLRAGAGYILEDFNEAQCNTAYQCLLIADQHCRTRKYFLCLASGIPCVSHVWVHDSCHANQLQNYRNYLLPAGYSLEEQRILDWQPRENPFQNLKVLLVSDQQQNFLELWSEILMTGGAASVKQHHSSAHNKDIALGVFDVVVTDPSCPASVLKCAEALQLPVVSQEWVIQCLIVGERIGFKQHPKYKHDYVSH,,,"Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2.; Preparation of a set of expression-ready clones of mammalian long cDNAs encoding large proteins by the ORF trap cloning method.; The full-ORF clone resource of the German cDNA consortium.; Analysis of the DNA sequence and duplication history of human chromosome 15.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Two cellular proteins that bind to wild-type but not mutant p53.; Negative cell cycle regulation and DNA-damage inducible phosphorylation of the BRCT protein 53BP1.; Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways.; 53BP1, a mediator of the DNA damage checkpoint.; Potential role for 53BP1 in DNA end-joining repair through direct interaction with DNA.; MDC1 is a mediator of the mammalian DNA damage checkpoint.; p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.; A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci.; The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity.; 53BP1 oligomerization is independent of its methylation by PRMT1.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; Characterisation of the sites of DNA damage-induced 53BP1 phosphorylation catalysed by ATM and ATR.; ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Protein phosphatase 5 regulates the function of 53BP1 after neocarzinostatin-induced DNA damage.; Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1.; p8/nupr1 regulates DNA-repair activity after double-strand gamma irradiation-induced DNA damage.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Regulation of chromatin architecture by the PWWP domain-containing DNA damage-responsive factor EXPAND1/MUM1.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Protein phosphatase 5 is necessary for ATR-mediated DNA repair.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair.; 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice.; 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.; Msl2 is a novel component of the vertebrate DNA damage response.; Role of 53BP1 oligomerization in regulating double-strand break repair.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Dephosphorylation enables the recruitment of 53BP1 to double-strand DNA breaks.; Uncovering global SUMOylation signaling networks in a site-specific manner.; Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.; SUMO-2 orchestrates chromatin modifiers in response to DNA damage.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; TIRR regulates 53BP1 by masking its histone methyl-lysine binding function.; FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.; GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1.; VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.; Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs.; Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor.; Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.; Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks.; Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair.; Phosphorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1 to control the G1 DNA damage checkpoint.",False
SIRT3,Q9NTG7,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDVSAGLRGSHGARGEPLDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSVGASSVVGSGGSSDKGKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDK,,,"Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Human chromosome 11 DNA sequence and analysis including novel gene identification.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The full-ORF clone resource of the German cDNA consortium.; The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase.; SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria.; Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.; Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2.; The human SIRT3 protein deacetylase is exclusively mitochondrial.; Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5.; A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress.; A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels.; SIRT3 regulates long-chain acyl-coA dehydrogenase by deacetylating conserved lysines near the active site.; Mitochondrial SIRT4-type proteins in Caenorhabditis elegans and mammals interact with pyruvate carboxylase and other acetylated biotin-dependent carboxylases.; SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient and exercise-induced stress.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.; The role of lysine acetylation in the function of mitochondrial ribosomal protein L12.; Crystal structures of human SIRT3 displaying substrate-induced conformational changes.; Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism.; SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth.; Identification of SIRT3 as an eraser of H4K16la.",False
NCOR2,Q9Y618,Nuclear receptor corepressor 2,MSGSTQPVAQTWRATEPRYPPHSLSYPVQIARTHTDVGLLEYQHHSRDYASHLSPGSIIQPQRRRPSLLSEFQPGNERSQELHLRPESHSYLPELGKSEMEFIESKRPRLELLPDPLLRPSPLLATGQPAGSEDLTKDRSLTGKLEPVSPPSPPHTDPELELVPPRLSKEELIQNMDRVDREITMVEQQISKLKKKQQQLEEEAAKPPEPEKPVSPPPIESKHRSLVQIIYDENRKKAEAAHRILEGLGPQVELPLYNQPSDTRQYHENIKINQAMRKKLILYFKRRNHARKQWEQKFCQRYDQLMEAWEKKVERIENNPRRRAKESKVREYYEKQFPEIRKQRELQERMQSRVGQRGSGLSMSAARSEHEVSEIIDGLSEQENLEKQMRQLAVIPPMLYDADQQRIKFINMNGLMADPMKVYKDRQVMNMWSEQEKETFREKFMQHPKNFGLIASFLERKTVAECVLYYYLTKKNENYKSLVRRSYRRRGKSQQQQQQQQQQQQQQQQQPMPRSSQEEKDEKEKEKEAEKEEEKPEVENDKEDLLKEKTDDTSGEDNDEKEAVASKGRKTANSQGRRKGRITRSMANEANSEEAITPQQSAELASMELNESSRWTEEEMETAKKGLLEHGRNWSAIARMVGSKTVSQCKNFYFNYKKRQNLDEILQQHKLKMEKERNARRKKKKAPAAASEEAAFPPVVEDEEMEASGVSGNEEEMVEEAEALHASGNEVPRGECSGPATVNNSSDTESIPSPHTEAAKDTGQNGPKPPATLGADGPPPGPPTPPPEDIPAPTEPTPASEATGAPTPPPAPPSPSAPPPVVPKEEKEEETAAAPPVEEGEEQKPPAAEELAVDTGKAEEPVKSECTEEAEEGPAKGKDAEAAEATAEGALKAEKKEGGSGRATTAKSSGAPQDSDSSATCSADEVDEAEGGDKNRLLSPRPSLLTPTGDPRANASPQKPLDLKQLKQRAAAIPPIQVTKVHEPPREDAAPTKPAPPAPPPPQNLQPESDAPQQPGSSPRGKSRSPAPPADKEAFAAEAQKLPGDPPCWTSGLPFPVPPREVIKASPHAPDPSAFSYAPPGHPLPLGLHDTARPVLPRPPTISNPPPLISSAKHPSVLERQIGAISQGMSVQLHVPYSEHAKAPVGPVTMGLPLPMDPKKLAPFSGVKQEQLSPRGQAGPPESLGVPTAQEASVLRGTALGSVPGGSITKGIPSTRVPSDSAITYRGSITHGTPADVLYKGTITRIIGEDSPSRLDRGREDSLPKGHVIYEGKKGHVLSYEGGMSVTQCSKEDGRSSSGPPHETAAPKRTYDMMEGRVGRAISSASIEGLMGRAIPPERHSPHHLKEQHHIRGSITQGIPRSYVEAQEDYLRREAKLLKREGTPPPPPPSRDLTEAYKTQALGPLKLKPAHEGLVATVKEAGRSIHEIPREELRHTPELPLAPRPLKEGSITQGTPLKYDTGASTTGSKKHDVRSLIGSPGRTFPPVHPLDVMADARALERACYEESLKSRPGTASSSGGSIARGAPVIVPELGKPRQSPLTYEDHGAPFAGHLPRGSPVTTREPTPRLQEGSLSSSKASQDRKLTSTPREIAKSPHSTVPEHHPHPISPYEHLLRGVSGVDLYRSHIPLAFDPTSIPRGIPLDAAAAYYLPRHLAPNPTYPHLYPPYLIRGYPDTAALENRQTIINDYITSQQMHHNAATAMAQRADMLRGLSPRESSLALNYAAGPRGIIDLSQVPHLPVLVPPTPGTPATAMDRLAYLPTAPQPFSSRHSSSPLSPGGPTHLTKPTTTSSSERERDRDRERDRDREREKSILTSTTTVEHAPIWRPGTEQSSGSSGGGGGSSSRPASHSHAHQHSPISPRTQDALQQRPSVLHNTGMKGIITAVEPSTPTVLRSTSTSSPVRPAATFPPATHCPLGGTLDGVYPTLMEPVLLPKEAPRVARPERPRADTGHAFLAKPPARSGLEPASSPSKGSEPRPLVPPVSGHATIARTPAKNLAPHHASPDPPAPPASASDPHREKTQSKPFSIQELELRSLGYHGSSYSPEGVEPVSPVSSPSLTHDKGLPKHLEELDKSHLEGELRPKQPGPVKLGGEAAHLPHLRPLPESQPSSSPLLQTAPGVKGHQRVVTLAQHISEVITQDYTRHHPQQLSAPLPAPLYSFPGASCPVLDLRRPPSDLYLPPPDHGAPARGSPHSEGGKRSPEPNKTSVLGGGEDGIEPVSPPEGMTEPGHSRSAVYPLLYRDGEQTEPSRMGSKSPGNTSQPPAFFSKLTESNSAMVKSKKQEINKKLNTHNRNEPEYNISQPGTEIFNMPAITGTGLMTYRSQAVQEHASTNMGLEAIIRKALMGKYDQWEESPPLSANAFNPLNASASLPAAMPITAADGRSDHTLTSPGGGGKAKVSGRPSSRKAKSPAPGLASGDRPPSVSSVHSEGDCNRRTPLTNRVWEDRPSSAGSTPFPYNPLIMRLQAGVMASPPPPGLPAGSGPLAGPHHAWDEEPKPLLCSQYETLSDSE,,,"Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors.; Unique forms of human and mouse nuclear receptor corepressor SMRT.; SMRTe, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor.; The finished DNA sequence of human chromosome 12.; cDNAs with long CAG trinucleotide repeats from human brain.; A transcriptional co-repressor that interacts with nuclear hormone receptors.; A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness.; Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3.; Sharp, an inducible cofactor that integrates nuclear receptor repression and activation.; ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.; The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2.; Isolation and characterization of a novel class II histone deacetylase, HDAC10.; Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand.; MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.; Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1.; Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; CtBP is an essential corepressor for BCL6 autoregulation.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation.; The basic helix-loop-helix proteins differentiated embryo chondrocyte (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; FBI-1 functions as a novel AR co-repressor in prostate cancer cells.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Structural and functional analysis of the DEAF-1 and BS69 MYND domains.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; TBL1Y: a new gene involved in syndromic hearing loss.; Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.; Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery.; Structure of HDAC3 bound to co-repressor and inositol tetraphosphate.",False
SUN1,O94901,SUN domain-containing protein 1,MDFSRLHMYSPPQCVPENTGYTYALSSSYSSDALDFETEHKLDPVFDSPRMSRRSLRLATTACTLGDGEAVGADSGTSSAVSLKNRAARTTKQRRSTNKSAFSINHVSRQVTSSGVSHGGTVSLQDAVTRRPPVLDESWIREQTTVDHFWGLDDDGDLKGGNKAAIQGNGDVGAAAATAHNGFSCSNCSMLSERKDVLTAHPAAPGPVSRVYSRDRNQKCYFLLQILRRIGAVGQAVSRTAWSALWLAVVAPGKAASGVFWWLGIGWYQFVTLISWLNVFLLTRCLRNICKFLVLLIPLFLLLAGLSLRGQGNFFSFLPVLNWASMHRTQRVDDPQDVFKPTTSRLKQPLQGDSEAFPWHWMSGVEQQVASLSGQCHHHGENLRELTTLLQKLQARVDQMEGGAAGPSASVRDAVGQPPRETDFMAFHQEHEVRMSHLEDILGKLREKSEAIQKELEQTKQKTISAVGEQLLPTVEHLQLELDQLKSELSSWRHVKTGCETVDAVQERVDVQVREMVKLLFSEDQQGGSLEQLLQRFSSQFVSKGDLQTMLRDLQLQILRNVTHHVSVTKQLPTSEAVVSAVSEAGASGITEAQARAIVNSALKLYSQDKTGMVDFALESGGGSILSTRCSETYETKTALMSLFGIPLWYFSQSPRVVIQPDIYPGNCWAFKGSQGYLVVRLSMMIHPAAFTLEHIPKTLSPTGNISSAPKDFAVYGLENEYQEEGQLLGQFTYDQDGESLQMFQALKRPDDTAFQIVELRIFSNWGHPEYTCLYRFRVHGEPVK,,,"Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence of human chromosome 7.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; UNC-84 localizes to the nuclear envelope and is required for nuclear migration and anchoring during C. elegans development.; Nuclear membrane proteins with potential disease links found by subtractive proteomics.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Telomere anchoring at the nuclear periphery requires the budding yeast Sad1-UNC-84 domain protein Mps3.; Characterization of the structures involved in localization of the SUN proteins to the nuclear envelope and the centrosome.; Nuclear envelope localization of human UNC84A does not require nuclear lamins.; Histone acetyltransferase hALP and nuclear membrane protein hsSUN1 function in de-condensation of mitotic chromosomes.; Sun1 forms immobile macromolecular assemblies at the nuclear envelope.; Structural requirements for the assembly of LINC complexes and their function in cellular mechanical stiffness.; A quantitative atlas of mitotic phosphorylation.; Mammalian SUN protein interaction networks at the inner nuclear membrane and their role in laminopathy disease processes.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; LINC complexes promote homologous recombination in part through inhibition of nonhomologous end joining.; Outer nuclear membrane protein Kuduk modulates the LINC complex and nuclear envelope architecture.; Contribution of SUN1 mutations to the pathomechanism in muscular dystrophies.",False
BAK1,Q16611,Bcl-2 homologous antagonist/killer,MASGQGPGPPRQECGEPALPSASEEQVAQDTEEVFRSYVFYRHQQEQEAEGVAAPADPEMVTLPLQPSSTMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATSLFESGINWGRVVALLGFGYRLALHVYQHGLTGFLGQVTRFVVDFMLHHCIARWIAQRGGWVAALNLGNGPILNVLVVLGVVLLGQFVVRRFFKS,,,"Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K.; Induction of apoptosis by the Bcl-2 homologue Bak.; Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Estrogen alters expression of apoptosis-regulators, Bcl-2, Bcl-xL and Bak, as well as susceptibility to therapeutic agents of human breast cancer cells.; A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.; Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak.; Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis.; IAN family critically regulates survival and development of T lymphocytes.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Initial characterization of the human central proteome.; Human Bop is a novel BH3-only member of the Bcl-2 protein family.; Plasminogen kringle 5 induces endothelial cell apoptosis by triggering a voltage-dependent anion channel 1 (VDAC1) positive feedback loop.; N-terminome analysis of the human mitochondrial proteome.; PLEKHN1 promotes apoptosis by enhancing Bax-Bak hetero-oligomerization through interaction with Bid in human colon cancer.; Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.; The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site.; A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak.; Crystal structure of MS0836.",False
IGFBP2,P18065,Insulin-like growth factor-binding protein 2,MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ,,,"Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2).; Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia.; Structure and localization of the human insulin-like growth factor-binding protein 2 gene.; Sequence analysis, expression and chromosomal localization of a gene, isolated from a subtracted human retina cDNA library, that encodes an insulin-like growth factor binding protein (IGFBP2).; Structure of the human insulin-like growth factor binding protein-2 gene.; Full-length cDNA libraries and normalization.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Purification from human cerebrospinal fluid of insulin-like growth factor binding proteins (IGFBPs). Isolation of IGFBP-2, an altered form of IGFBP-3 and a new IGFBP species.; An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility.; Duplication of the IGFBP-2 gene in teleost fish: protein structure and functionality conservation and gene expression divergence.; Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.; Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase beta and the IGF-I receptor to regulate IGF-I-stimulated signaling.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Insulin-Like Growth Factor Binding Protein-2 Promotes Adhesion of Endothelial Progenitor Cells to Endothelial Cells via Integrin alpha5beta1.; Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.; IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin alpha5/FAK in diabetic kidney disease.; Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2).",False
PYCR1,P32322,"Pyrroline-5-carboxylate reductase 1, mitochondrial",MSVGFIGAGQLAFALAKGFTAAGVLAAHKIMASSPDMDLATVSALRKMGVKLTPHNKETVQHSDVLFLAVKPHIIPFILDEIGADIEDRHIVVSCAAGVTISSIEKKLSAFRPAPRVIRCMTNTPVVVREGATVYATGTHAQVEDGRLMEQLLSSVGFCTEVEEDLIDAVTGLSGSGPAYAFTALDALADGGVKMGLPRRLAVRLGAQALLGAAKMLLHSEQHPGQLKDNVSSPGGATIHALHVLESGGFRSLLINAVEASCIRTRELQSMADQEQVSPAAIKKTILDKVKLDSPAGTALSPSGHTKLLPRSLAPAGKD,,,"Cloning human pyrroline-5-carboxylate reductase cDNA by complementation in Saccharomyces cerevisiae.; Novel Human cDNA clones with function of inhibiting cancer cell growth.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Mutations in PYCR1 cause cutis laxa with progeroid features.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Functional specialization in proline biosynthesis of melanoma.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.; N-terminome analysis of the human mitochondrial proteome.; Crystal structure of human pyrroline-5-carboxylate reductase.; Crystal structure of human pyrroline-5-carboxylate reductase.; Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1.; Mutation in pyrroline-5-carboxylate reductase 1 gene in families with cutis laxa type 2.; Compound heterozygous mutations in PYCR1 further expand the phenotypic spectrum of De Barsy syndrome.",False
TP73,O15350,Tumor protein p73,MAQSTATSPDGGTTFEHLWSSLEPDSTYFDLPQSSRGNNEVVGGTDSSMDVFHLEGMTTSVMAQFNLLSSTMDQMSSRAASASPYTPEHAASVPTHSPYAQPSSTFDTMSPAPVIPSNTDYPGPHHFEVTFQQSSTAKSATWTYSPLLKKLYCQIAKTCPIQIKVSTPPPPGTAIRAMPVYKKAEHVTDVVKRCPNHELGRDFNEGQSAPASHLIRVEGNNLSQYVDDPVTGRQSVVVPYEPPQVGTEFTTILYNFMCNSSCVGGMNRRPILIIITLEMRDGQVLGRRSFEGRICACPGRDRKADEDHYREQQALNESSAKNGAASKRAFKQSPPAVPALGAGVKKRRHGDEDTYYLQVRGRENFEILMKLKESLELMELVPQPLVDSYRQQQQLLQRPSHLQPPSYGPVLSPMNKVHGGMNKLPSVNQLVGQPPPHSSAATPNLGPVGPGMLNNHGHAVPANGEMSSSHSAQSMVSGSHCTPPPPYHADPSLVSFLTGLGCPNCIEYFTSQGLQSIYHLQNLTIEDLGALKIPEQYRMTIWRGLQDLKQGHDYSTAQQLLRSSNAATISIGGSGELQRQRVMEAVHFRVRHTITIPNRGGPGGGPDEWADFGFDLPDCKARKQPIKEEFTEAEIH,,,"Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.; Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions.; Two new p73 splice variants, gamma and delta, with different transcriptional activity.; Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta.; Mutational analysis of p73 and p53 in human cancer cell lines.; Human DeltaNp73 regulates a dominant negative feedback loop for TAp73 and p53.; Identification of the p73-specific target sequence present in the deltaNp73 proper promoter.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage.; The emerging p53 gene family.; Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif.; Differential effect of ik3-1/cables on p53- and p73-induced cell death.; Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.; A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity.; Functional association between Wwox tumor suppressor protein and p73, a p53 homolog.; Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells.; Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73.; p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1.; Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.; Regulation of p73 by Hck through kinase-dependent and independent mechanisms.; Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage.; Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation.; The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73.; Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination.; Epstein-Barr virus nuclear antigen 3C interact with p73: Interplay between a viral oncoprotein and cellular tumor suppressor.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism.; Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain.; Mutations in TP73 cause impaired mucociliary clearance and lissencephaly.",False
CNR1,P21554,Cannabinoid receptor 1,MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPLLGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL,,,"Nucleotide sequence of a human cannabinoid receptor cDNA.; Molecular cloning of a human cannabinoid receptor which is also expressed in testis.; An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing.; Identification and characterisation of a novel splice variant of the human CB1 receptor.; cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.; Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.; The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.; CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.; Hemopressin is an inverse agonist of CB1 cannabinoid receptors.; Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling.; The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.; Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.; Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.; Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model.; Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.; Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures of IC3 and a mutant with altered G protein specificity.; Crystal structure of the human cannabinoid receptor CB1.; High-resolution crystal structure of the human CB1 cannabinoid receptor.",False
NFE2L2,Q16236,Nuclear factor erythroid 2-related factor 2,MMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN,,,"Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The full-ORF clone resource of the German cDNA consortium.; Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.; Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2.; Characterization of the interaction between the transcription factors human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2) in the transcriptional regulation of the spermidine/spermine N1-acetyltransferase (SSAT) gene.; BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase.; Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway.; Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.; PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria.; Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational level.; p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Transformation of eEF1Bdelta into heat-shock response transcription factor by alternative splicing.; Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.; The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.; Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.; The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase.; Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.; Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming.; SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.; Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.; Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.; Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder.",False
CDKN1A,P38936,Cyclin-dependent kinase inhibitor 1,MSEPAGDVRQNPCGSKACRRLFGPVDSEQLSRDCDALMAGCIQEARERWNFDFVTETPLEGDFAWERVRGLGLPKLYLPTGPRRGRDELGGGRRPGTSPALLQGTAEEDHVDLSLSCTLVPRSGEQAEGSPGGPGDSQGRKRRQTSMTDFYHSKRRLIFSKRKP,,,"The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.; WAF1, a potential mediator of p53 tumor suppression.; p21 is a universal inhibitor of cyclin kinases.; Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells.; The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells.; Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.; Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer.; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The DNA sequence and analysis of human chromosome 6.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1).; Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding.; New functional activities for the p21 family of CDK inhibitors.; A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome.; Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta.; Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells.; Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.; N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome.; Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex.; The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing.; CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation.; A quantitative atlas of mitotic phosphorylation.; A dual role of Cdk2 in DNA damage response.; Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.; Ionizing radiation induces ATM-independent degradation of p21Cip1 in transformed cells.; Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; TRIM39 regulates cell cycle progression and DNA damage responses via stabilizing p21.; ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21(WAF1.).; A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation.; Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA.",False
PDGFRA,P16234,Platelet-derived growth factor receptor alpha,MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVIISLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSSDLVEDSFL,,,"cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor.; Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes.; Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.; Receptor tyrosine kinases expressed in metastatic colon cancer.; Independent expression of human alpha or beta platelet-derived growth factor receptor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways.; Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors.; Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation.; Tyrosine mutations within the alpha platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signal transduction.; Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor.; Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor.; Demonstration of functionally different interactions between phospholipase C-gamma and the two types of platelet-derived growth factor receptors.; Maximal PDGF-induced lung fibroblast chemotaxis requires PDGF receptor-alpha.; Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis.; Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors.; Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation.; Differential interaction of CrkII adaptor protein with platelet-derived growth factor alpha- and beta-receptors is determined by its internal tyrosine phosphorylation.; Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor regulation of apoptosis.; Platelet-derived-growth-factor-induced signalling in human platelets: phosphoinositide-3-kinase-dependent inhibition of platelet activation.; Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression.; Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.; The role of c-Src in platelet-derived growth factor alpha receptor internalization.; A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.; PDGFRA activating mutations in gastrointestinal stromal tumors.; PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.; PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases.; Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.; The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry.; Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.; The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.; The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.; Signal transduction via platelet-derived growth factor receptors.; PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.; PDGF receptors as targets in tumor treatment.; Role of platelet-derived growth factors in physiology and medicine.; Human cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-alpha as a key for entry.; Structural determinants of the Na+/H+ exchanger regulatory factor interaction with the beta 2 adrenergic and platelet-derived growth factor receptors.; Structures of HCMV Trimer reveal the basis for receptor recognition and cell entry.; PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.; Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.; Patterns of somatic mutation in human cancer genomes.; PDGFRA-mutant syndrome.",False
PIK3CA,P42336,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN,,,"Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene.; Cloning and mutagenesis of the p110 alpha subunit of human phosphoinositide 3'-hydroxykinase.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2.; Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.; Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its protein kinase activity.; Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase alpha that are critical for catalysis and substrate recognition.; Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} regulates invadopodia formation.; Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.; FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.; Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.; Class I PI3K in oncogenic cellular transformation.; Should individual PI3 kinase isoforms be targeted in cancer?; CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype.; Somatic PIK3CA mutations in sporadic cerebral cavernous malformations.; Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition.; The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.; Solution structure of the C2 domain from human PI3-kinase p110 subunit alpha.; A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.; Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.; Mutation of the PIK3CA gene in ovarian and breast cancer.; High frequency of mutations of the PIK3CA gene in human cancers.; PIK3CA mutations in glioblastoma multiforme.; Mutations of PIK3CA in gastric adenocarcinoma.; Functional analysis of PIK3CA gene mutations in human colorectal cancer.; High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.; The prevalence of PIK3CA mutations in gastric and colon cancer.; PIK3CA mutations in advanced ovarian carcinomas.; PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.; PIK3CA mutations in head and neck squamous cell carcinoma.; PIK3CA mutations in nasopharyngeal carcinoma.; PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.; Cancer-specific mutations in PIK3CA are oncogenic in vivo.; Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.; Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.; De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.; Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.; Identification and characterisation of a novel constitutional PIK3CA mutation in a child lacking the typical segmental overgrowth of 'PIK3CA-related overgrowth spectrum' (PROS).",False
C1QA,P02745,Complement C1q subcomponent subunit A,MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIRTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAIRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSRGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFLIFPSA,,,"Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Complete amino acid sequences of the three collagen-like regions present in subcomponent C1q of the first component of human complement.; Completion of the amino acid sequences of the A and B chains of subcomponent C1q of the first component of human complement.; Amino acid sequence of the N-terminal 108 amino acid residues of the B chain of subcomponent C1q of the first component of human complement.; Activation of a complex of C1r and C1s subcomponents of human complement C1 by the third subcomponent C1q.; The Clq receptor site on immunoglobulin G.; The binding properties of human complement component C1q. Interaction with mucopolysaccharides.; The binding site for C1q on IgG.; Ultrastructure of the first component of human complement: electron microscopy of the crosslinked complex.; Molecular modelling of human complement subcomponent C1q and its complex with C1r2C1s2 derived from neutron-scattering curves and hydrodynamic properties.; Complement receptor type 1 (CR1, CD35) is a receptor for C1q.; Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.; Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.; Interaction of human C1q with IgG and IgM: revisited.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; Molecular basis of hereditary C1q deficiency.; The human IgM pentamer is a mushroom-shaped molecule with a flexural bias.; Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway.; Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sites.; Complement is activated by IgG hexamers assembled at the cell surface.; Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression.; C1q and Mannose-Binding Lectin Interact with CR1 in the Same Region on CCP24-25 Modules.; C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.; The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties.; C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition.; C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain.; Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement.",False
CDKN2B,P42772,Cyclin-dependent kinase 4 inhibitor B,MREENKGMPSGGGSDEGLASAAARGLVEKVRQLLEAGADPNGVNRFGRRAIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEERGHRDVAGYLRTATGD,,,"Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.; p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.; Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; DNA sequence and analysis of human chromosome 9.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A cell cycle regulator potentially involved in genesis of many tumor types.; Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.; Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.",False
EIF5A2,Q9GZV4,Eukaryotic translation initiation factor 5A-2,MADEIDFTTGDAGASSTYPMQCSALRKNGFVVLKGRPCKIVEMSTSKTGKHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDYQLICIQDGYLSLLTETGEVREDLKLPEGELGKEIEGKYNAGEDVQVSVMCAMSEEYAVAIKPCK,,,"Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.; Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression.; Expression of eIF5A genes in human cancer cells.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification and characterization of eukaryotic initiation factor 5A-2.; Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Screening the SPO11 and EIF5A2 genes in a population of infertile men.",False
MIF,P03971,Muellerian-inhibiting factor,MRDLPLTSLALVLSALGALLGTEALRAEEPAVGTSGLIFREDLDWPPGSPQEPLCLVALGGDSNGSSSPLRVVGALSAYEQAFLGAVQRARWGPRDLATFGVCNTGDRQAALPSLRRLGAWLRDPGGQRLVVLHLEEVTWEPTPSLRFQEPPPGGAGPPELALLVLYPGPGPEVTVTRAGLPGAQSLCPSRDTRYLVLAVDRPAGAWRGSGLALTLQPRGEDSRLSTARLQALLFGDDHRCFTRMTPALLLLPRSEPAPLPAHGQLDTVPFPPPRPSAELEESPPSADPFLETLTRLVRALRVPPARASAPRLALDPDALAGFPQGLVNLSDPAALERLLDGEEPLLLLLRPTAATTGDPAPLHDPTSAPWATALARRVAAELQAAAAELRSLPGLPPATAPLLARLLALCPGGPGGLGDPLRALLLLKALQGLRVEWRGRDPRGPGRAQRSAGATAADGPCALRELSVDLRAERSVLIPETYQANNCQGVCGWPQSDRNPRYGNHVVLLLKMQVRGAALARPPCCVPTAYAGKLLISLSEERISAHHVPNMVATECGCR,,,"Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment.; Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.; Relationship between serum muellerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.; Anti-Muellerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.; Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.; Variants of the anti-Mullerian hormone gene in a compound heterozygote with the persistent Mullerian duct syndrome and his family.; Molecular genetics of the persistent Mullerian duct syndrome: a study of 19 families.; A 27 base-pair deletion of the anti-Muellerian type II receptor gene is the most common cause of the persistent Muellerian duct syndrome.; Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-beta family.",False
DGAT1,O75907,Diacylglycerol O-acyltransferase 1,MGDRGSSRRRRTGSRPSSHGGGGPAAAEEEVRDAAAGPDVGAAGDAPAPAPNKDGDAGVGSGHWELRCHRLQDSLFSSDSGFSNYRGILNWCVVMLILSNARLFLENLIKYGILVDPIQVVSLFLKDPYSWPAPCLVIAANVFAVAAFQVEKRLAVGALTEQAGLLLHVANLATILCFPAAVVLLVESITPVGSLLALMAHTILFLKLFSYRDVNSWCRRARAKAASAGKKASSAAAPHTVSYPDNLTYRDLYYFLFAPTLCYELNFPRSPRIRKRFLLRRILEMLFFTQLQVGLIQQWMVPTIQNSMKPFKDMDYSRIIERLLKLAVPNHLIWLIFFYWLFHSCLNAVAELMQFGDREFYRDWWNSESVTYFWQNWNIPVHKWCIRHFYKPMLRRGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPLAWFVGRFFQGNYGNAAVWLSLIIGQPIAVLMYVHDYYVLNYEAPAAEA,,,"Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Acyl coenzyme A dependent retinol esterification by acyl coenzyme A: diacylglycerol acyltransferase 1.; Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption.; Synthesis of neutral ether lipid monoalkyl-diacylglycerol by lipid acyltransferases.; DGAT1 mutation is linked to a congenital diarrheal disorder.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme.; Structure and mechanism of human diacylglycerol O-acyltransferase 1.; Autozygome and high throughput confirmation of disease genes candidacy.",False
MT1E,P04732,Metallothionein-1E,MDPNCSCATGGSCTCAGSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCVCKGASEKCSCCA,,,"Structure and expression of two human metallothionein-I isoform genes and a related pseudogene.; Amino acid sequence determination.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Induction by zinc of specific metallothionein isoforms in human monocytes.",False
FGF21,Q9NSA1,Fibroblast growth factor 21,MDSDETGFEHSGLWVSVLAGLLLGACQAHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS,,,"Identification of a novel FGF, FGF-21, preferentially expressed in the liver.; The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Signal peptide prediction based on analysis of experimentally verified cleavage sites.; FGF-21 as a novel metabolic regulator.; Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.; C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors.; Different roles of N- and C- termini in the functional activity of FGF21.; Fibroblast growth factor signalling: from development to cancer.",False
HTRA2,O43464,"Serine protease HTRA2, mitochondrial",MAAPRAGRGAGWSLRAWRALGGIRWGRRPRLTPDLRALLTSGTSDPRARVTYGTPSLWARLSVGVTEPRACLTSGTPGPRAQLTAVTPDTRTREASENSGTRSRAWLAVALGAGGAVLLLLWGGGRGPPAVLAAVPSPPPASPRSQYNFIADVVEKTAPAVVYIEILDRHPFLGREVPISNGSGFVVAADGLIVTNAHVVADRRRVRVRLLSGDTYEAVVTAVDPVADIATLRIQTKEPLPTLPLGRSADVRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGLPQTNVEYIQTDAAIDFGNSGGPLVNLDGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVMMLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNAEDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTE,,,"Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia.; Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response.; Tissue-specific splicing of Omi stress-regulated endoprotease leads to an inactive protease with a modified PDZ motif.; Generation and annotation of the DNA sequences of human chromosomes 2 and 4.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death.; Expression, purification, and functional analysis of the human serine protease HtrA2.; Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase.; THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death.; Initial characterization of the human central proteome.; Identification of a novel anti-apoptotic E3 ubiquitin ligase that ubiquitinates antagonists of inhibitor of apoptosis proteins SMAC, HtrA2, and ARTS.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.; Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi.; Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases.; Structural basis for regulation of apoptosis and autophagy by the BIRC6/SMAC complex.; Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease.; Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease.; Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls.; Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and Parkinson disease.; Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria.; Analysis of protein-coding genetic variation in 60,706 humans.; Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria.",False
GSK3A,P49840,Glycogen synthase kinase-3 alpha,MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS,,,"Glycogen synthase kinase 3 and dorsoventral patterning in Xenopus embryos.; Isolation of cDNA clones for human glycogen synthase kinase 3alpha.; The DNA sequence and biology of human chromosome 19.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.; GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.; GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt.; Glycogen synthase kinase-3: properties, functions, and regulation.; The role of GSK3 in glucose homeostasis and the development of insulin resistance.; Identification of an antiapoptotic protein complex at death receptors.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Glycogen synthase kinase 3: more than a namesake.; GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Initial characterization of the human central proteome.; GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Mycobacterium tuberculosis promotes anti-apoptotic activity of the macrophage by PtpA protein-dependent dephosphorylation of host GSK3alpha.; Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.; Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of autophagosome maturation and lipid metabolism.; LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.; Patterns of somatic mutation in human cancer genomes.",False
NUDT1,P36639,Oxidized purine nucleoside triphosphate hydrolase,MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV,,,"Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis.; Genomic structure and chromosome location of the human mutT homologue gene MTH1 encoding 8-oxo-dGTPase for prevention of A:T to C:G transversion.; Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase. Alternative splicing of transcription products.; Multi-forms of human MTH1 polypeptides produced by alternative translation initiation and single nucleotide polymorphism.; Human chromosome 7: DNA sequence and biology.; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).; The DNA sequence of human chromosome 7.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Intracellular localization of 8-oxo-dGTPase in human cells, with special reference to the role of the enzyme in mitochondria.; The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein.; Functional significance of the conserved residues for the 23-residue module among MTH1 and MutT family proteins.; Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP.; A molecular basis for the selective recognition of 2-hydroxy-dATP and 8-oxo-dGTP by human MTH1.; An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell death caused by oxidative stress.; The GT to GC single nucleotide polymorphism at the beginning of an alternative exon 2C of human MTH1 gene confers an amino terminal extension that functions as a mitochondrial targeting signal.; Initial characterization of the human central proteome.; Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2.; Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2.; Structure of human MTH1, a Nudix family hydrolase that selectively degrades oxidized purine nucleoside triphosphates.; Crystallization and preliminary X-ray analysis of human MTH1 complexed with two oxidized nucleotides, 8-oxo-dGMP and 2-oxo-dATP.; Crystal structure of human MTH1 and the 8-oxo-dGMP product complex.; Crystal Structure of Human 8-oxo-dGTPase (MTH1).; MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.; Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.; MTH1 Substrate Recognition--An Example of Specific Promiscuity.; Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.; Structural and Kinetic Studies of the Human Nudix Hydrolase MTH1 Reveal the Mechanism for Its Broad Substrate Specificity.; MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP.; MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool.; Association study of human MTH1 gene polymorphisms with type 1 diabetes mellitus.; Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk.",False
IKBKB,O14920,Inhibitor of nuclear factor kappa-B kinase subunit beta,MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCTSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS,,,"IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.; IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.; IkappaB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes.; Assignment of IkappaB kinase beta (IKBKB) to human chromosome band 8p12-->p11 by in situ hybridization.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; DNA sequence and analysis of human chromosome 8.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling.; Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase.; IKAP is a scaffold protein of the IkappaB kinase complex.; The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.; Activation of IkappaB kinase beta by protein kinase C isoforms.; Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation.; PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex.; NAK is an IkappaB kinase-activating kinase.; Direct phosphorylation of NF-kappa B1 p105 by the Ikappa B kinase complex on serine 927 is essential for signal-induced p105 proteolysis.; TAK1 is a ubiquitin-dependent kinase of MKK and IKK.; Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases.; Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase.; Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation.; IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.; Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways.; PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages.; Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing.; beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha.; Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation.; NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.; 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling.; Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation.; Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.; Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.; Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation.; Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.; Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.; FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly.; Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.; The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection.; The IkappaB kinase complex: master regulator of NF-kappaB signaling.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.; PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.; Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling.; Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta.; Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Novel cross-talk within the IKK family controls innate immunity.; The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-kappaB signaling.; IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.; SASH1 is a scaffold molecule in endothelial TLR4 signaling.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; A-kinase-anchoring protein-Lbc anchors IkappaB kinase beta to support interleukin-6-mediated cardiomyocyte hypertrophy.; Deficiency of innate and acquired immunity caused by an IKBKB mutation.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Protein kinase IKKbeta-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells.; IFIT5 positively regulates NF-kappaB signaling through synergizing the recruitment of IkappaB kinase (IKK) to TGF-beta-activated kinase 1 (TAK1).; N-terminome analysis of the human mitochondrial proteome.; Dimer of arfaptin 2 regulates NF-kappaB signaling by interacting with IKKbeta/NEMO and inhibiting IKKbeta kinase activity.; FKBP51 employs both scaffold and isomerase functions to promote NF-kappaB activation in melanoma.; LRRC14 attenuates Toll-like receptor-mediated NF-kappa-B signaling through disruption of IKK complex.; Mechanism of vaccinia viral protein B14 mediated inhibition of IkappaB kinase beta activation.; Gain-of-function IKBKB mutation causes human combined immune deficiency.; Novel Functions of IFI44L as a Feedback Regulator of Host Antiviral Responses.; Negative regulation of NEMO signaling by the ubiquitin E3 ligase MARCH2.; Noncanonical STAT1 phosphorylation expands its transcriptional activity into promoting LPS-induced IL-6 and IL-12p40 production.; Threonine phosphorylation of STAT1 restricts interferon signaling and promotes innate inflammatory responses.; Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site.; The consensus coding sequences of human breast and colorectal cancers.; Patterns of somatic mutation in human cancer genomes.",False
SQSTM1,Q13501,Sequestosome-1,MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLSRVAALFPALRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKEKKECRRDHRPPCAQEAPRNMVHPNVICDGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPRPPRAGEARPGPTAESASGPSEDPSVNFLKNVGESVAAALSPLGIEVDIDVEHGGKRSRLTPVSPESSSTEEKSSSQPSSCCSDPSKPGGNVEGATQSLAEQMRKIALESEGRPEEQMESDNCSGGDDDWTHLSSKEVDPSTGELQSLQMPESEGPSSLDPSQEGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL,,,"A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes.; Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genomic structure and promoter analysis of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein.; Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent.; Phosphotyrosine-independent binding of a 62-kDa protein to the src homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of Ser-59 in the lck unique N-terminal region.; p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins.; A p56(lck) ligand serves as a coactivator of an orphan nuclear hormone receptor.; Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62.; The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.; p62 functions as a p38 MAP kinase regulator.; The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway.; The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor.; p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases.; p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4-induced PKCzeta inhibition.; Mallory body -- a disease-associated type of sequestosome.; Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates receptor trafficking and Erk5 signaling.; Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins.; PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62.; p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.; Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease.; Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation.; The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination.; p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death.; Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.; The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex.; Inhibition of sequestosome 1/p62 up-regulation prevents aggregation of ubiquitinated proteins induced by prostaglandin J2 without reducing its neurotoxicity.; Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.; The kinase domain of titin controls muscle gene expression and protein turnover.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; A probability-based approach for high-throughput protein phosphorylation analysis and site localization.; p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.; The globally disseminated M1T1 clone of group A Streptococcus evades autophagy for intracellular replication.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Large-scale proteomics analysis of the human kinome.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy.; Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy.; p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.; Formin follows function: a muscle-specific isoform of FHOD3 is regulated by CK2 phosphorylation and promotes myofibril maintenance.; p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis.; Initial characterization of the human central proteome.; Independent interactions of ubiquitin-binding domains in a ubiquitin-mediated ternary complex.; Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; The deubiquitinating enzyme USP36 controls selective autophagy activation by ubiquitinated proteins.; TRIM13 regulates ER stress induced autophagy and clonogenic ability of the cells.; TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death.; The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; TRAF6 mediates ubiquitination of KIF23/MKLP1 and is required for midbody ring degradation by selective autophagy.; Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis.; The LIR motif - crucial for selective autophagy.; Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites.; Regulation of C1-Ten protein tyrosine phosphatase by p62/SQSTM1-mediated sequestration and degradation.; TRIM proteins regulate autophagy and can target autophagic substrates by direct recognition.; Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1.; Structural determinants in GABARAP required for the selective binding and recruitment of ALFY to LC3B-positive structures.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Disruption of FAT10-MAD2 binding inhibits tumor progression.; SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia.; A phenotype of atypical apraxia of speech in a family carrying SQSTM1 mutation.; ATM functions at the peroxisome to induce pexophagy in response to ROS.; SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles.; Absence of the autophagy adaptor SQSTM1/p62 causes childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy.; An ER-associated pathway defines endosomal architecture for controlled cargo transport.; TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy.; RNF166 Determines Recruitment of Adaptor Proteins during Antibacterial Autophagy.; Keap1/cullin3 modulates p62/SQSTM1 activity via UBA domain ubiquitination.; Ubiquitylation of p62/sequestosome1 activates its autophagy receptor function and controls selective autophagy upon ubiquitin stress.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; Polyubiquitin chain-induced p62 phase separation drives autophagic cargo segregation.; p62 filaments capture and present ubiquitinated cargos for autophagy.; TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy.; LRRC25 inhibits type I IFN signaling by targeting ISG15-associated RIG-I for autophagic degradation.; The BEACH-containing protein WDR81 coordinates p62 and LC3C to promote aggrephagy.; TRIM23 mediates virus-induced autophagy via activation of TBK1.; Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1.; Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease.; Requirement for p62 acetylation in the aggregation of ubiquitylated proteins under nutrient stress.; p62 Negatively Regulates TLR4 Signaling via Functional Regulation of the TRAF6-ECSIT Complex.; CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis.; MOAP-1-mediated dissociation of p62/SQSTM1 bodies releases Keap1 and suppresses Nrf2 signaling.; The ER-embedded UBE2J1/RNF26 ubiquitylation complex exerts spatiotemporal control over the endolysosomal pathway.; The Epstein-Barr virus deubiquitinase BPLF1 targets SQSTM1/p62 to inhibit selective autophagy.; Reconstitution defines the roles of p62, NBR1 and TAX1BP1 in ubiquitin condensate formation and autophagy initiation.; CUL5-ASB6 Complex Promotes p62/SQSTM1 Ubiquitination and Degradation to Regulate Cell Proliferation and Autophagy.; The N-terminal cysteine is a dual sensor of oxygen and oxidative stress.; Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis.; Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox-independent stress response.; S-acylation of p62 promotes p62 droplet recruitment into autophagosomes in mammalian autophagy.; MORG1 limits mTORC1 signaling by inhibiting Rag GTPases.; Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone.; Ubiquitin recognition by the ubiquitin-associated domain of p62 involves a novel conformational switch.; Conformation and dynamics of the three-helix bundle UBA domain of p62 from experiment and simulation.; Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and regulates NF-kappaB signalling.; Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.; Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease.; Three novel mutations in SQSTM1 identified in familial Paget's disease of bone.; Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations.; Identification of SQSTM1 mutations in familial Paget's disease in Australian pedigrees.; Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB).; Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences.; Detection and validation of non-synonymous coding SNPs from orthogonal analysis of shotgun proteomics data.; Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration.",False
CDK7,P50613,Cyclin-dependent kinase 7,MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF,,,"Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase).; Two novel human serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NIMA kinases: cloning and characterization of their expression pattern.; Cloning, expression and subcellular localization of the human homolog of p40MO15 catalytic subunit of cdk-activating kinase.; Molecular cloning of the human CAK1 gene encoding a cyclin-dependent kinase-activating kinase.; Human and Xenopus MO15 mRNA are highly conserved but show different patterns of expression in adult tissues.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase.; p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.; The molecular mechanism of mitotic inhibition of TFIIH is mediated by phosphorylation of CDK7.; Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes.; Regulation of CAK kinase activity by p53.; Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7.; Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins.; The FBP interacting repressor targets TFIIH to inhibit activated transcription.; Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.; Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells.; Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics.; Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.; Recognition of Cdk2 by Cdk7.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; Phosphorylation of steroidogenic factor 1 is mediated by cyclin-dependent kinase 7.; A quantitative atlas of mitotic phosphorylation.; TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II.; SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation.; TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II.; Large-scale proteomics analysis of the human kinome.; Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation.; DNA-Bound peptides control the mRNA transcription through CDK7.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition.; R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.; CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?; Cell cycle, CDKs and cancer: a changing paradigm.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; A history of TFIIH: Two decades of molecular biology on a pivotal transcription/repair factor.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.; Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications.; The crystal structure of human CDK7 and its protein recognition properties.; Patterns of somatic mutation in human cancer genomes.",False
GRN,P28799,Progranulin,MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQLL,,,"Structure and chromosomal location of the human granulin gene.; The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth.; Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains.; PCDGF sequence from lambda phage human Jurkat T cell cDNA library (Clontech).; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair.; Granulins, a novel class of peptide from leukocytes.; Characterisation of UGP and its relationship with beta-core fragment.; Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.; Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.; Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.; Development and application of mass spectrometric methods for the analysis of progranulin N-glycosylation.; Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin.; Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.; Secreted progranulin is a homodimer and is not a component of high density lipoproteins (HDL).; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin.; N-terminome analysis of the human mitochondrial proteome.; Progranulin Recruits HSP70 to beta-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.; Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes.; Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo.; The lysosomal protein cathepsin L is a progranulin protease.; Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations.; Design and solution structure of a well-folded stack of two beta-hairpins based on the amino-terminal fragment of human granulin A.; Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities.; HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.; Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia.; A thorough assessment of benign genetic variability in GRN and MAPT.",False
SERPINE1,P05121,Plasminogen activator inhibitor 1,MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP,,,"Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.; Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns.; cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.; Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1.; The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family.; Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The DNA sequence of human chromosome 7.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.; Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing.; cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell.; Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.; Identification of a PAI-1 binding site in vitronectin.; Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.; Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.; Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.; The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.; The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.; The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.; Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity.; Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence.; Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.; SERPINE1 (PAI-1) is deposited into keratinocyte migration 'trails' and required for optimal monolayer wound repair.; Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1.; Resveratrol-induced changes of the human adipocyte secretion profile.; Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.; Recombinant human plasminogen activator inhibitor-1 promotes cementogenic differentiation of human periodontal ligament stem cells.; Recombinant human plasminogen activator inhibitor-1 accelerates odontoblastic differentiation of human stem cells from apical papilla.; PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells.; A null mutation in SERPINE1 protects against biological aging in humans.; Structural basis of latency in plasminogen activator inhibitor-1.; Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.; Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.; The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.; Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.; Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.; Characterization of single-nucleotide polymorphisms in coding regions of human genes.",False
SPRTN,Q9H040,DNA-dependent metalloprotease SPRTN,MDDDLMLALRLQEEWNLQEAERDHAQESLSLVDASWELVDPTPDLQALFVQFNDQFFWGQLEAVEVKWSVRMTLCAGICSYEGKGGMCSIRLSEPLLKLRPRKDLVETLLHEMIHAYLFVTNNDKDREGHGPEFCKHMHRINSLTGANITVYHTFHDEVDEYRRHWWRCNGPCQHRPPYYGYVKRATNREPSAHDYWWAEHQKTCGGTYIKIKEPENYSKKGKGKAKLGKEPVLAAENKDKPNRGEAQLVIPFSGKGYVLGETSNLPSPGKLITSHAINKTQDLLNQNHSANAVRPNSKIKVKFEQNGSSKNSHLVSPAVSNSHQNVLSNYFPRVSFANQKAFRGVNGSPRISVTVGNIPKNSVSSSSQRRVSSSKISLRNSSKVTESASVMPSQDVSGSEDTFPNKRPRLEDKTVFDNFFIKKEQIKSSGNDPKYSTTTAQNSSSSSSQSKMVNCPVCQNEVLESQINEHLDWCLEGDSIKVKSEESL,,,"The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and biological annotation of human chromosome 1.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Spartan/C1orf124 is important to prevent UV-induced mutagenesis.; Proliferating cell nuclear antigen (PCNA)-binding protein C1orf124 is a regulator of translesion synthesis.; Spartan/C1orf124, a reader of PCNA ubiquitylation and a regulator of UV-induced DNA damage response.; DVC1 (C1orf124) recruits the p97 protein segregase to sites of DNA damage.; DVC1 (C1orf124) is a DNA damage-targeting p97 adaptor that promotes ubiquitin-dependent responses to replication blocks.; Characterization of human Spartan/C1orf124, an ubiquitin-PCNA interacting regulator of DNA damage tolerance.; N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features.; Uncovering global SUMOylation signaling networks in a site-specific manner.; System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.; Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.; SPRTN is a mammalian DNA-binding metalloprotease that resolves DNA-protein crosslinks.; Metalloprotease SPRTN/DVC1 orchestrates replication-coupled DNA-protein crosslink repair.; Mechanism and regulation of DNA-protein crosslink repair by the DNA-dependent metalloprotease SPRTN.; SPRTN protease and checkpoint kinase 1 cross-activation loop safeguards DNA replication.; Tandem deubiquitination and acetylation of SPRTN promotes DNA-protein crosslink repair and protects against aging.; TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.; The FANCJ helicase unfolds DNA-protein crosslinks to promote their repair.; Crystal structure of human PCNA in complex with the PIP box of DVC1.; Structural insight into DNA-dependent activation of human metalloprotease Spartan.",False
RICTOR,Q6R327,Rapamycin-insensitive companion of mTOR,MAAIGRGRSLKNLRVRGRNDSGEENVPLDLTREPSDNLREILQNVARLQGVSNMRKLGHLNNFTKLLCDIGHSEEKLGFHYEDIIICLRLALLNEAKEVRAAGLRALRYLIQDSSILQKVLKLKVDYLIARCIDIQQSNEVERTQALRLVRKMITVNASLFPSSVTNSLIAVGNDGLQERDRMVRACIAIICELALQNPEVVALRGGLNTILKNVIDCQLSRINEALITTILHLLNHPKTRQYVRADVELERILAPYTDFHYRHSPDTAEGQLKEDREARFLASKMGIIATFRSWAGIINLCKPGNSGIQSLIGVLCIPNMEIRRGLLEVLYDIFRLPLPVVTEEFIEALLSVDPGRFQDSWRLSDGFVAAEAKTILPHRARSRPDLMDNYLALILSAFIRNGLLEGLVEVITNSDDHISVRATILLGELLHMANTILPHSHSHHLHCLPTLMNMAASFDIPKEKRLRASAALNCLKRFHEMKKRGPKPYSLHLDHIIQKAIATHQKRDQYLRVQKDIFILKDTEEALLINLRDSQVLQHKENLEWNWNLIGTILKWPNVNLRNYKDEQLHRFVRRLLYFYKPSSKLYANLDLDFAKAKQLTVVGCQFTEFLLESEEDGQGYLEDLVKDIVQWLNASSGMKPERSLQNNGLLTTLSQHYFLFIGTLSCHPHGVKMLEKCSVFQCLLNLCSLKNQDHLLKLTVSSLDYSRDGLARVILSKILTAATDACRLYATKHLRVLLRANVEFFNNWGIELLVTQLHDKNKTISSEALDILDEACEDKANLHALIQMKPALSHLGDKGLLLLLRFLSIPKGFSYLNERGYVAKQLEKWHREYNSKYVDLIEEQLNEALTTYRKPVDGDNYVRRSNQRLQRPHVYLPIHLYGQLVHHKTGCHLLEVQNIITELCRNVRTPDLDKWEEIKKLKASLWALGNIGSSNWGLNLLQEENVIPDILKLAKQCEVLSIRGTCVYVLGLIAKTKQGCDILKCHNWDAVRHSRKHLWPVVPDDVEQLCNELSSIPSTLSLNSESTSSRHNSESESVPSSMFILEDDRFGSSSTSTFFLDINEDTEPTFYDRSGPIKDKNSFPFFASSKLVKNRILNSLTLPNKKHRSSSDPKGGKLSSESKTSNRRIRTLTEPSVDFNHSDDFTPISTVQKTLQLETSFMGNKHIEDTGSTPSIGENDLKFTKNFGTENHRENTSRERLVVESSTSSHMKIRSQSFNTDTTTSGISSMSSSPSRETVGVDATTMDTDCGSMSTVVSTKTIKTSHYLTPQSNHLSLSKSNSVSLVPPGSSHTLPRRAQSLKAPSIATIKSLADCNFSYTSSRDAFGYATLKRLQQQRMHPSLSHSEALASPAKDVLFTDTITMKANSFESRLTPSRFMKALSYASLDKEDLLSPINQNTLQRSSSVRSMVSSATYGGSDDYIGLALPVDINDIFQVKDIPYFQTKNIPPHDDRGARAFAHDAGGLPSGTGGLVKNSFHLLRQQMSLTEIMNSIHSDASLFLESTEDTGLQEHTDDNCLYCVCIEILGFQPSNQLSAICSHSDFQDIPYSDWCEQTIHNPLEVVPSKFSGISGCSDGVSQEGSASSTKSTELLLGVKTIPDDTPMCRILLRKEVLRLVINLSSSVSTKCHETGLLTIKEKYPQTFDDICLYSEVSHLLSHCTFRLPCRRFIQELFQDVQFLQMHEEAEAVLATPPKQPIVDTSAES,,,"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.; The full-ORF clone resource of the German cDNA consortium.; The DNA sequence and comparative analysis of human chromosome 5.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Characterization of size-fractionated cDNA libraries generated by the in vitro recombination-assisted method.; Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.; Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Identification of Protor as a novel Rictor-binding component of mTOR complex-2.; PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.; Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.; Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.; A quantitative atlas of mitotic phosphorylation.; Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.; Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.; Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.; mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.; Rictor is a novel target of p70 S6 kinase-1.; Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.; Initial characterization of the human central proteome.; Endoplasmic reticulum is a main localization site of mTORC2.; ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor.; System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.; Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress.; Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein.; The Bardet-Biedl syndrome-related protein CCDC28B modulates mTORC2 function and interacts with SIN1 to control cilia length independently of the mTOR complex.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific domains.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; Tetraspanin 8-rictor-integrin alpha3 complex is required for glioma cell migration.; Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.; Defining the domain arrangement of the mammalian target of rapamycin complex component Rictor protein.; Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.; PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor.; Poxviruses Evade Cytosolic Sensing through Disruption of an mTORC1-mTORC2 Regulatory Circuit.; The PTH/PTHrP-SIK3 pathway affects skeletogenesis through altered mTOR signaling.; Lysosome positioning influences mTORC2 and AKT signaling.; mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RICTOR.; HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease.; TSPAN8 alleviates high glucose-induced apoptosis and autophagy via targeting mTORC2.; UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established tumorigenic pathway in human colorectal cancer.; GCN5L1-mediated acetylation prevents Rictor degradation in cardiac cells after hypoxic stress.; Architecture of the human mTORC2 core complex.; Cryo-EM structure of human mTOR complex 2.; The 3.2-Aa resolution structure of human mTORC2.; Regulation of human mTOR complexes by DEPTOR.; Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt.",False
CTF1,Q16619,Cardiotrophin-1,MSRREGSLEDPQTDSSVSLLPHLEAKIRQTHSLAHLLTKYAEQLLQEYVQLQGDPFGLPSFSPPRLPVAGLSAPAPSHAGLPVHERLRLDAAALAALPPLLDAVCRRQAELNPRAPRLLRRLEDAARQARALGAAVEALLAALGAANRGPRAEPPAATASAASATGVFPAKVLGLRVCGLYREWLSRTEGDLGQLLPGGSA,,,"Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genetic variants in the promoter (g983G>T) and coding region (A92T) of the human cardiotrophin-1 gene (CTF1) in patients with dilated cardiomyopathy.",False
TRAP1,Q12931,"Heat shock protein 75 kDa, mitochondrial",MARELRALLLWGRRLRPLLRAPALAAVPGGKPILCPRRTTAQLGPRRNPAWSLQAGRLFSTQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDIVVDHYKEEKFEDRSPAAECLSEKETEELMAWMRNVLGSRVTNVKVTLRLDTHPAMVTVLEMGAARHFLRMQQLAKTQEERAQLLQPTLEINPRHALIKKLNQLRASEPGLAQLLVDQIYENAMIAAGLVDDPRAMVGRLNELLVKALERH,,,"A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses.; Complete sequencing and characterization of 21,243 full-length human cDNAs.; The sequence and analysis of duplication-rich human chromosome 16.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor.; A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock.; The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties.; A quantitative atlas of mitotic phosphorylation.; Guidelines for the nomenclature of the human heat shock proteins.; Lysine acetylation targets protein complexes and co-regulates major cellular functions.; Initial characterization of the human central proteome.; The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase.; TRAP1 rescues PINK1 loss-of-function phenotypes.; Toward a comprehensive characterization of a human cancer cell phosphoproteome.; Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.; An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.; N-terminome analysis of the human mitochondrial proteome.",False
TRPV1,Q8NER1,Transient receptor potential cation channel subfamily V member 1,MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK,,,"Cloning and functional expression of a human orthologue of rat vanilloid receptor-1.; The tissue distribution and functional characterization of human VR1.; Pharmacological differences between human and rat vanilloid receptor 1 (VR1).; Isolation and characterization of a human TRPV1 splice variant.; Towards a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.; DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; TRPV3 is a temperature-sensitive vanilloid receptor-like protein.; Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures.; Molecular determinants of vanilloid sensitivity in TRPV1.; A recurrent de novo PACS2 heterozygous missense variant causes neonatal-onset developmental epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis.; Human TRPV1 structure and inhibition by the analgesic SB-366791.",False
NFE2L1,Q14494,Endoplasmic reticulum membrane sensor NFE2L1,MLSLKKYLTEGLLQFTILLSLIGVRVDVDTYLTSQLPPLREIILGPSSAYTQTQFHNLRNTLDGYGIHPKSIDLDNYFTARRLLSQVRALDRFQVPTTEVNAWLVHRDPEGSVSGSQPNSGLALESSSGLQDVTGPDNGVRESETEQGFGEDLEDLGAVAPPVSGDLTKEDIDLIDILWRQDIDLGAGREVFDYSHRQKEQDVEKELRDGGEQDTWAGEGAEALARNLLVDGETGESFPAQVPSGEDQTALSLEECLRLLEATCPFGENAEFPADISSITEAVPSESEPPALQNNLLSPLLTGTESPFDLEQQWQDLMSIMEMQAMEVNTSASEILYSAPPGDPLSTNYSLAPNTPINQNVSLHQASLGGCSQDFLLFSPEVESLPVASSSTLLPLAPSNSTSLNSTFGSTNLTGLFFPPQLNGTANDTAGPELPDPLGGLLDEAMLDEISLMDLAIEEGFNPVQASQLEEEFDSDSGLSLDSSHSPSSLSSSEGSSSSSSSSSSSSSSASSSASSSFSEEGAVGYSSDSETLDLEEAEGAVGYQPEYSKFCRMSYQDPAQLSCLPYLEHVGHNHTYNMAPSALDSADLPPPSALKKGSKEKQADFLDKQMSRDEHRARAMKIPFTNDKIINLPVEEFNELLSKYQLSEAQLSLIRDIRRRGKNKMAAQNCRKRKLDTILNLERDVEDLQRDKARLLREKVEFLRSLRQMKQKVQSLYQEVFGRLRDENGRPYSPSQYALQYAGDGSVLLIPRTMADQQARRQERKPKDRRK,,,"Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast.; Molecular cloning of a putative novel human bZIP transcription factor on chromosome 17q22.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Cloning and functional characterization of LCR-F1: a bZIP transcription factor that activates erythroid-specific, human globin gene expression.; Small Maf proteins interact with the human transcription factor TCF11/Nrf1/LCR-F1.; Interaction of the CNC-bZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription.; The CCAAT enhancer-binding protein (C/EBP)beta and Nrf1 interact to regulate dentin sialophosphoprotein (DSPP) gene expression during odontoblast differentiation.; Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain. Inhibition of nuclear translocation and transacting function.; Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop.; Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.; p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition.; Nrf1 can be processed and activated in a proteasome-independent manner.; Reply to Vangala et al.: Complete inhibition of the proteasome reduces new proteasome production by causing Nrf1 aggregation.; The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.; Nuclear factor erythroid-2 like 1 (NFE2L1): structure, function and regulation.; The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.",False
IFNB1,P01574,Interferon beta,MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,,,"The nucleotide sequence of human fibroblast interferon cDNA.; Isolation and structure of a human fibroblast interferon gene.; Synthesis of human fibroblast interferon by E. coli.; Human fibroblast interferon gene lacks introns.; Structure of a chromosomal gene for human interferon beta.; The complete amino acid sequence of human fibroblast interferon as deduced using synthetic oligodeoxyribonucleotide primers of reverse transcriptase.; On the relationship between human interferon alpha 1 and beta 1 genes.; Human protein factory for converting the transcriptome into an in vitro-expressed proteome.; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; The amino-terminal sequence of human fibroblast interferon as deduced from reverse transcripts obtained using synthetic oligonucleotide primers.; A single amino acid change in IFN-beta1 abolishes its antiviral activity.; Assignment of the disulphide bonds of leukocyte interferon.; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.; Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.; Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein.; Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling.; Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor.; The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein.; Interferon beta treatment for multiple sclerosis: persisting questions.; Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation.; Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.; The crystal structure of human interferon beta at 2.2-A resolution.; The consensus coding sequences of human breast and colorectal cancers.",False
GDF11,O95390,Growth/differentiation factor 11,MVLAAPLLLGFLLLALELRPRGEAAEGPAAAAAAAAAAAAAGVGGERSSRPAPSVAPEPDGCPVCVWRQHSRELRLESIKSQILSKLRLKEAPNISREVVKQLLPKAPPLQQILDLHDFQGDALQPEDFLEEDEYHATTETVISMAQETDPAVQTDGSPLCCHFHFSPKVMFTKVLKAQLWVYLRPVPRPATVYLQILRLKPLTGEGTAGGGGGGRRHIRIRSLKIELHSRSGHWQSIDFKQVLHSWFRQPQSNWGIEINAFDPSGTDLAVTSLGPGAEGLHPFMELRVLENTKRSRRNLGLDCDEHSSESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGQCEYMFMQKYPHTHLVQQANPRGSAGPCCTPTKMSPINMLYFNDKQQIIYGKIPGMVVDRCGCS,,,"A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos.; Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11.; Mutations in GDF11 and the extracellular antagonist, Follistatin, as a likely cause of Mendelian forms of orofacial clefting in humans.; Crystal structure of human GDF11.; Structural basis for potency differences between GDF8 and GDF11.",False
